Selective internal radiation therapies for unresectable early-, intermediate or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation by Walton, Matthew James et al.
This is a repository copy of Selective internal radiation therapies for unresectable early-, 
intermediate or advanced-stage hepatocellular carcinoma: systematic review, network 
meta-analysis and economic evaluation.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/166248/
Version: Published Version
Article:
Walton, Matthew James orcid.org/0000-0003-1932-3689, Wade, Ros 
orcid.org/0000-0002-8666-8110, Claxton, Lindsay orcid.org/0000-0002-1795-7568 et al. (6
more authors) (2020) Selective internal radiation therapies for unresectable early-, 
intermediate or advanced-stage hepatocellular carcinoma: systematic review, network 
meta-analysis and economic evaluation. Health Technology Asssessment. ISSN 
2046-4924 
https://doi.org/10.3310/hta24480
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Journals Library
DOI 10.3310/hta24480
Selective internal radiation therapies  
for unresectable early-, intermediate-  
or advanced-stage hepatocellular 
carcinoma: systematic review, network 
meta-analysis and economic evaluation 
Matthew Walton, Ros Wade, Lindsay Claxton, Sahar Sharif-Hurst, Melissa Harden,  
Jai Patel, Ian Rowe, Robert Hodgson and Alison Eastwood
Health Technology Assessment
Volume 24  Issue 48  September 2020
ISSN 1366-5278
Selective internal radiation therapies for
unresectable early-, intermediate- or
advanced-stage hepatocellular carcinoma:
systematic review, network meta-analysis
and economic evaluation
Matthew Walton ,1 Ros Wade ,1* Lindsay Claxton ,1
Sahar Sharif-Hurst ,1 Melissa Harden ,1 Jai Patel ,2
Ian Rowe ,2 Robert Hodgson 1 and Alison Eastwood 1
1Centre for Reviews and Dissemination, University of York, York, UK
2Leeds Teaching Hospitals NHS Trust, Leeds, UK
*Corresponding author
Declared competing interests of authors: Jai Patel attended a product training course for using
TheraSphere™ [BTG Ltd, London, UK (now Boston Scientific, Marlborough, MA, USA)] in Essen,
Germany, in 2016, which was sponsored by Biocompatibles UK Ltd (Farnham, UK) [acquired by BTG
Ltd], and is a member of the National Institute for Health and Care Excellence Medical Technologies
Advisory Committee (June 2015 to present). Ian Rowe reports personal fees from AbbVie Inc.
(North Chicago, IL, USA) and personal fees from Norgine BV (Amsterdam, the Netherlands),
outside the submitted work.
Published September 2020
DOI: 10.3310/hta24480
This report should be referenced as follows:
Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, et al. Selective internal
radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular
carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technol
Assess 2020;24(48).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.
Health Technology Assessment NICE TAR and DAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 3.370
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science
Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
(www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be
purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme,
and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis
methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can
be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate
any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that
have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote
health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include
any intervention used in the treatment, prevention or diagnosis of disease.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform
National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for
National Screening Committee (NSC) policy decisions.
This report
The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as
project number 17/109/19. The protocol was agreed in March 2019. The assessment report began editorial review in September
2019 and was accepted for publication in January 2020. The authors have been wholly responsible for all data collection,
analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of
the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they
do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions
expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR,
NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this
publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect
those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning
contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation,
Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. 
 Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Senior Clinical 
Professor Andrée Le May
Professor Matthias Beck
Dr Tessa Crilly
Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson
Ms Tara Lamont
Dr Catriona McDaid
Professor William McGuire
Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK
Professor James Raftery
Dr Rob Riemsma
Professor Helen Roberts
Professor Jonathan Ross
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton
Professor Martin Underwood
Please visit the website for a list of editors: 
Editorial contact:  
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Selective internal radiation therapies for unresectable
early-, intermediate- or advanced-stage hepatocellular
carcinoma: systematic review, network meta-analysis and
economic evaluation
Matthew Walton ,1 Ros Wade ,1* Lindsay Claxton ,1
Sahar Sharif-Hurst ,1 Melissa Harden ,1 Jai Patel ,2 Ian Rowe ,2
Robert Hodgson 1 and Alison Eastwood 1
1Centre for Reviews and Dissemination, University of York, York, UK
2Leeds Teaching Hospitals NHS Trust, Leeds, UK
*Corresponding author ros.wade@york.ac.uk
Background: Hepatocellular carcinoma is the most common type of primary liver cancer. Treatment
choice is dependent on underlying liver dysfunction and cancer stage. Treatment options include
conventional transarterial therapies for patients with intermediate-stage disease and systemic therapy
[e.g. sorafenib (Nexavar®; Bayer plc, Leverkusen, Germany)] for patients with advanced-stage disease.
Selective internal radiation therapies deliver radiation to liver tumours via microspheres that are
injected into the hepatic artery. There are three selective internal radiation therapies: TheraSphere™
[BTG Ltd, London, UK (now Boston Scientific, Marlborough, MA, USA)], SIR-Spheres® (Sirtex Medical
Ltd, Woburn, MA, USA) and QuiremSpheres® (Quirem Medical BV, Deventer, the Netherlands).
Objective: To assess the clinical effectiveness and cost-effectiveness of selective internal radiation
therapies for treating patients with unresectable early-, intermediate- or advanced-stage hepatocellular
carcinoma.
Methods: A search was undertaken to identify clinical effectiveness literature relating to selective
internal radiation therapies and relevant comparators for the treatment of hepatocellular carcinoma.
Studies were critically appraised and summarised. The network of evidence was mapped to estimate
the relative effectiveness of the different selective internal radiation therapies and comparator
treatments. An economic analysis evaluated the cost-effectiveness.
Results: Twenty studies were included in the clinical effectiveness review. Two large randomised
controlled trials rated as having a low risk of bias [SARAH: Vilgrain V, Pereira H, Assenat E, Guiu B,
Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90
resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular
carcinoma (SARAH): an open-label randomised controlled Phase 3 trial. Lancet Oncol 2017;18:1624–36;
and SIRveNIB: Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective
internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma.
J Clin Oncol 2018;36:1913–21] found no significant difference in overall survival or progression-free
survival between SIR-Spheres and sorafenib (systemic therapy) in an advanced population, despite
greater tumour response in the SIR-Spheres arm of both trials. There were some concerns regarding
generalisability of the SARAH and SIRveNIB trials to UK practice. All other studies of SIR-Spheres,
TheraSphere or QuiremSpheres were either rated as being at a high risk of bias or caused some concerns
regarding bias. A network meta-analysis was conducted in adults with unresectable hepatocellular
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v
carcinoma who had Child–Pugh class A liver cirrhosis and were ineligible for conventional transarterial
therapies. The analysis included the SARAH and SIRveNIB trials as well as a trial comparing lenvatinib
(Kisplyx®; Eisai Ltd, Tokyo, Japan) (systemic therapy) with sorafenib. There were no meaningful differences
in overall survival between any of the treatments. The base-case economic analysis suggested that
TheraSphere may be cost-saving relative to both SIR-Spheres and QuiremSpheres. However, incremental
cost differences between TheraSphere and SIR-Spheres were small. In a fully incremental analysis, which
included confidential Patient Access Scheme discounts, lenvatinib was the most cost-effective treatment
and dominated all selective internal radiation therapies. In pairwise comparisons of sorafenib with each
selective internal radiation therapy, sorafenib also dominated all selective internal radiation therapies.
Limitations: The existing evidence cannot provide decision-makers with clear guidance on the
comparative effectiveness of treatments in early- and intermediate-stage hepatocellular carcinoma or
on the efficacy of TheraSphere or QuiremSpheres.
Conclusions: In the advanced-stage hepatocellular carcinoma population, two large randomised trials
have shown that SIR-Spheres have similar clinical effectiveness to sorafenib. None of the selective
internal radiation therapies was cost-effective, being more costly and less effective than lenvatinib,
both at list price and with Patient Access Scheme discounts.
Future work: Future studies may wish to include early- and intermediate-stage hepatocellular
carcinoma patients and the low tumour burden/albumin–bilirubin 1 subgroup of advanced-stage
patients. Future high-quality studies evaluating alternative selective internal radiation therapies would
be beneficial.
Study registration: This study is registered as PROSPERO CRD42019128383.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 48. See the NIHR Journals Library website for further project information.
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Glossary
Adverse effect An adverse outcome that occurs during or after exposure to a drug or other
intervention and that may or may not be caused by the intervention.
Assessment Group An independent academic group commissioned by the National Institute for Health
Research on behalf of the National Institute for Health and Care Excellence to appraise the clinical
effectiveness and cost-effectiveness of selective internal radiation therapies.
Confidence interval A measure of uncertainty around the results of a statistical analysis that describes
the range of values within which we can be reasonably sure that the true effect lies. For example, a
95% confidence interval is based on the notion that if a study were repeated many times in other
samples from the same population, 95% of the confidence intervals from those studies would include
the true value of the effect being measured. Wider intervals indicate lower precision; narrow intervals
indicate greater precision.
Conventional transarterial therapies Includes transarterial chemoembolisation, drug-eluting bead
transarterial chemoembolisation and transarterial embolisation without chemotherapy. All three forms
of conventional transarterial therapy work by administering an embolising agent into the hepatic artery
to block blood vessels feeding the tumours in the liver. In the case of transarterial chemoembolisation,
also known as conventional transarterial chemoembolisation, Lipiodol® (Guerbet, Villepinte, France) is
combined with a chemotherapy agent, typically doxorubicin or cisplatin, which is administered directly
to the tumour. In drug-eluting bead transarterial chemoembolisation, drug-eluting beads typically
bound with doxorubicin or epirubicin are administered to the tumour via the hepatic artery.
Transarterial embolisation, or bland transarterial chemoembolisation, involves only the physical
occlusion of blood vessels, with no addition of chemotherapy.
Cost–benefit analysis An economic analysis that converts the effects or consequences of interventions
into the same monetary terms as the costs and compares them using a measure of net benefit or a
cost–benefit ratio.
Cost-effectiveness acceptability curve A graph describing the impact of uncertainty on the result of a
cost-effectiveness model. The graph plots a range of cost-effectiveness thresholds on the horizontal
axis against the probability that the intervention will be cost-effective at that threshold on the vertical
axis. It can usually be drawn directly from the results of a probabilistic sensitivity analysis.
Cost-effectiveness analysis A type of economic analysis that compares the relative costs and
outcomes (effects) of different courses of action. It compares an intervention with another intervention
(s) (or the current standard of care) by estimating how much it costs to gain a unit of a health outcome,
such as a life-year gained or a death prevented.
Cost-effectiveness model A cost-effectiveness or decision model seeks to answer questions about
how to deploy resources in a health-care system. A model is a simplified representation of a real-world
condition and treatment pathway, which aims to estimate the costs and consequences arising from
making a particular policy decision (i.e. whether or not the NHS should fund a new procedure or drug).
All relevant alternative courses of action and their long-term costs and consequences are compared to
inform a decision on which option to adopt.
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Cost-effectiveness threshold This represents the maximum amount a health-care system is willing to
pay to provide a new technology or intervention. National Institute for Health and Care Excellence
guidance typically considers interventions with an incremental cost-effectiveness ratio of between
£20,000 and £30,000 per quality-adjusted life-year to be cost-effective.
Cost–utility analysis The same as a cost-effectiveness analysis, but the effects or consequences of
interventions are expressed in generic units of health gain, usually quality-adjusted life-years.
Credible interval In Bayesian statistics, a credible interval is a posterior probability interval estimation
that incorporates problem-specific contextual information from the prior distribution. Credible
intervals are used for the purposes similar to those of confidence intervals in frequentist statistics.
Cycle The time horizon in a model is split into cycles that represent the smallest period of time
measured in the economic model.
Deterministic sensitivity analysis Explores the impact on model results of varying one or two input
parameters at a time.
Dominance In the field of health economics, a treatment option is said to be ‘dominant’ when it both is
less costly and produces better health outcomes than the comparator strategy. Thus, a treatment that
both is more expensive and results in poorer health outcomes is referred to as ‘dominated’.
EuroQol-5 Dimensions A generic measurement of quality of life used in many clinical trials. This
instrument is easy to use and has been extensively validated across many disease areas. The benefit
of the EuroQol-5 Dimensions is the availability of utility scores (generated through large population
surveys) for each possible combination of questionnaire responses; these can be combined with the
time individuals reside in particular health states to calculate the quality-adjusted life-years associated
with an intervention.
Fixed-effect model A statistical model that stipulates that the units under analysis (e.g. people in a
trial or study in a meta-analysis) are the ones of interest and, thus, constitute the entire population of
units. Only within-study variation is taken to influence the uncertainty of results (as reflected in the
confidence interval) of a meta-analysis using a fixed-effect model.
Heterogeneity In systematic reviews, heterogeneity refers to variability, or differences, between
studies in the estimates of effects. A distinction is sometimes made between ‘statistical heterogeneity’
(differences in the reported effects), ‘methodological heterogeneity’ (differences in study design)
and ‘clinical heterogeneity’ (differences between studies in key characteristics of the participants,
interventions or outcome measures).
Incremental cost-effectiveness ratio A measure that represents the economic value of an intervention
compared with an alternative; it is generally the primary outcome of an economic evaluation. It is
calculated by dividing the difference in costs between two interventions by the difference in
quality-adjusted life-years. It is the cost of generating an additional quality-adjusted life-year
using the intervention we are interested in versus an alternative (usually current clinical practice).
Intention-to-treat analysis An analysis in which all participants enrolled in a trial are analysed
according to the intervention to which they were initially allocated, regardless of whether they went
on to receive it or not.
Network meta-analysis A meta-analysis in which three or more treatments are compared using both
direct comparisons of interventions within trials and indirect comparisons across trials, based on a
common comparator.
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Probabilistic sensitivity analysis Assesses the joint uncertainty across all input parameters in the
model. This is carried out by assigning probability distributions to each input parameter and making
random draws from each of these distributions. This process is then repeated many thousands of times,
resulting in a distribution of outputs that describe the uncertainty in the results of the model.
Quality-adjusted life-year An index of health gain where survival duration is weighted or adjusted
according to the patient’s quality of life over the time they are alive. Quality-adjusted life-years are
based on utilities, which are valuations of quality of life measured on a scale between full health (1)
and death (0). These valuations are multiplied by the number of years that an individual spends in a
health state with that particular utility score, and the quality-adjusted life-years are summed over the
modelled time horizon.
Quality of life A broad concept incorporating all of the factors that might have an impact on an
individual’s physical, mental and social well-being. Health-related quality of life refers to the specific
impact that a medical condition or treatment has on an individual’s functioning and general well-being.
Health-related quality of life is generally measured in clinical trials alongside other outcomes to assess
the impact of an intervention from a patient’s perspective, typically using questionnaires completed by
patients, their families or clinicians, such as the EuroQol-5 Dimensions.
Random-effects model A statistical model sometimes used in meta-analysis in which both within-study
sampling error (variance) and between-study variation are included in the assessment of the uncertainty
(confidence interval) of the results of a meta-analysis.
Randomised controlled trial An experiment in which investigators randomly allocate eligible people
into groups that are each assigned a different intervention in order to compare their relative
effectiveness and safety.
Relative risk (synonym: risk ratio) The ratio of risk in the intervention group to the risk in the control
group. The risk (proportion, probability or rate) is the ratio of people with an event in a group to the
total number in the group. A relative risk of 1 indicates no difference between comparison groups.
For undesirable outcomes, a relative risk of < 1 indicates that the intervention was effective in
reducing the risk of that outcome.
Scenario analysis A process of exploring alternative future outcomes by selection of different assumptions
used in the economic model. Scenarios can represent outcomes ranging from optimistic (where input
variables are changed to their most optimistic value) to pessimistic (where they are changed to their most
pessimistic). These types of analyses test the cost-effectiveness and safety of an intervention in the best and
worst cases, and in other plausible ‘alternative worlds’.
Statistical significance A result is described as statistically significant when the reported p-value falls
below the selected significance level; this value represents the probability that the observed result
could have occurred owing of chance alone if the ‘null hypothesis’ is true (i.e. there was no true
difference between the groups).
Time horizon The time horizon of an economic model is the duration over which costs and health
outcomes are calculated. The choice of time horizon is important, and generally depends on the nature
of the condition for which an intervention is being assessed. A long time horizon is preferred in chronic
or long-term conditions for which there are likely to be important ongoing management costs and
consequences well into the future. The use of a long-term time horizon often involves the extrapolation
of short-term data into the future and the use of assumptions about the persistence of treatment
effects due to a lack of long-term data.
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List of abbreviations
AE adverse event
AG Assessment Group
AIC Akaike information criterion
ALBI albumin–bilirubin
BCLC Barcelona Clinic Liver Cancer
BIC Bayesian information criterion
BNF British National Formulary
BSC best supportive care
CADTH Canadian Agency for Drugs and
Technologies in Health
CE Conformité Européenne
CEAC cost-effectiveness acceptability
curve
CEAF cost-effectiveness acceptability
frontier
CI confidence interval
CINAHL Cumulative Index to Nursing and
Allied Health Literature
CIRT Cardiovascular and Interventional
Radiological Society of Europe
Registry for SIR-Spheres Therapy
CMA cost-minimisation analysis
CRD Centre for Reviews and
Dissemination
CrI credible interval
CT computerised tomography
cTACE conventional transarterial
chemoembolisation
CTT conventional transarterial therapy
DEB-TACE drug-eluting bead transarterial
chemoembolisation
DIC deviance information criterion
DSA deterministic sensitivity analysis
DSU Decision Support Unit
EASL European Association for the
Study of the Liver
ECOG Eastern Cooperative Oncology
Group
eMIT electronic market information tool
ENRY European Network on
Radioembolisation with Yttrium-90
Resin Microspheres
EORTC
QLQ
European Organisation for
Research and Treatment of Cancer
Quality of Life Questionnaire
EQ-5D EuroQol-5 Dimensions
EQ-5D-3L EuroQol-5 Dimensions,
three-level version
FACT-Hep Functional Assessment of Cancer
Therapy Hepatobiliary-Pancreatic
Symptom Index
GP general practitioner
HCC hepatocellular carcinoma
HRG Healthcare Resource Group
HR hazard ratio
HRQoL health-related quality of life
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
INR international normalised ratio
IPD individual patient data
ITT intention to treat
KM Kaplan–Meier
LYG life-years gained
MAA macroaggregated albumin
MELD Model for End-Stage Liver
Disease
MeSH medical subject heading
MRI magnetic resonance imaging
MVI macroscopic vascular invasion
NHS EED NHS Economic Evaluation
Database
NICE National Institute for Health and
Care Excellence
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xxi
NMA network meta-analysis
NMB net monetary benefit
OS overall survival
PAS Patient Access Scheme
PFS progression-free survival
PLLA poly-L-lactic acid
PREMIERE Prospective Randomized study of
chEmoeMbolization versus
radIoEmbolization for the
tReatment of hEpatocellular
carcinoma
PRISMA Preferred Reporting Items for
Systematic Reviews and Meta-
Analyses
PROSPERO international prospective register
of systematic reviews
PSA probabilistic sensitivity analysis
PSS Personal Social Services
PSSRU Personal Social Services Research
Unit
PVI portal vein invasion
PVT portal vein thrombosis
QALY quality-adjusted life-year
RCT randomised controlled trial
RECIST Response Evaluation Criteria in
Solid Tumours
REILD radioembolisation-induced liver
disease
SARAH SorAfenib versus
Radioembolization in Advanced
Hepatocellular Carcinoma
SD standard deviation
SIRT selective internal radiation
therapy
SIRveNIB Selective Internal Radiation
Therapy Versus Sorafenib in
Locally Advanced Hepatocellular
Carcinoma
SmPC summary of product
characteristics
SPECT single-photon emission
computerised tomography
TA technology appraisal
TACE transarterial chemoembolisation
TAE transarterial embolisation
TARE transarterial radioembolisation
TRAE treatment-related adverse event
TTP time to progression
WHO World Health Organization
WTP willingness to pay
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Plain English summary
Hepatocellular carcinoma is the most common type of liver cancer. The choice of treatmentdepends on the extent of the cancer and liver function. Selective internal radiation therapies
deliver radiation directly to liver tumours via tiny beads injected into the main blood vessel into
the liver. There are three selective internal radiation therapies: TheraSphere™ [BTG Ltd, London, UK
(now Boston Scientific, Marlborough, MA, USA)], SIR-Spheres® (Sirtex Medical Ltd, Woburn, MA, USA)
and QuiremSpheres® (Quirem Medical BV, Deventer, the Netherlands).
Our aim was to assess the clinical effectiveness of selective internal radiation therapies for patients
with hepatocellular carcinoma that is not treatable by surgery, and to assess whether or not these
therapies represent good value for money.
There was no meaningful difference between SIR-Spheres and sorafenib (Nexavar®; Bayer plc,
Leverkusen, Germany), which is a cancer drug for advanced hepatocellular carcinoma. Studies of other
selective internal radiation therapies and studies in patients with less advanced disease were generally
of poor quality, so their results may not be reliable. We could not assess whether or not selective
internal radiation therapies are beneficial to patients with early- or intermediate-stage hepatocellular
carcinoma, or whether or not TheraSphere and QuiremSpheres are beneficial.
Compared with sorafenib or lenvatinib (Kisplyx®; Eisai Ltd, Tokyo, Japan) (another systemic cancer
drug), none of the selective internal radiation therapies were good value for money for treating
patients with advanced hepatocellular carcinoma. We found that TheraSphere might be cheaper than
SIR-Spheres and QuiremSpheres, but differences between TheraSphere and SIR-Spheres were small.
There was not enough evidence for patients with early or intermediate disease to say whether or not
selective internal radiation therapy is good value for treating these patients. Future studies in these
populations, alongside any studies comparing the selective internal radiation therapies against each
other, would be helpful.
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Scientific summary
Background
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related
death globally. Hepatocellular carcinoma is the most common type of liver cancer.
Clinical management of hepatocellular carcinoma is complex; there is a range of treatment options
available. The Barcelona Clinic Liver Cancer staging system is used to establish prognosis and enable
the selection of appropriate treatment based on underlying liver dysfunction and cancer stage.
Treatment options include surgery or ablation for early-stage disease, conventional transarterial
therapies for intermediate-stage disease and systemic therapy for advanced-stage disease. Best
supportive care is offered to patients when conventional transarterial therapy or systemic therapy is
not available or appropriate, including patients with terminal-stage disease.
Selective internal radiation therapies deliver radiation to liver tumours via microspheres that are
injected into the hepatic artery. There are three selective internal radiation therapies: TheraSphere™
[BTG Ltd, London, UK (now Boston Scientific, Marlborough, MA, USA)], SIR-Spheres® (Sirtex Medical
Ltd, Woburn, MA, USA) and QuiremSpheres® (Quirem Medical BV, Deventer, the Netherlands).
Objective
To assess the clinical effectiveness and cost-effectiveness of selective internal radiation therapies for
unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma.
Methods
Methods of the clinical effectiveness review
A comprehensive search was undertaken to systematically identify clinical effectiveness literature
relating to TheraSphere, SIR-Spheres and QuiremSpheres compared with each other, conventional
transarterial therapy or established clinical management without selective internal radiation therapy,
in patients with hepatocellular carcinoma. Randomised controlled trials were eligible for inclusion.
Where randomised controlled trial evidence was insufficient to address the decision problem,
non-randomised comparative studies and non-comparative studies were considered. In addition,
a search for randomised controlled trials of comparator therapies was undertaken to strengthen the
network of evidence.
Methods of network meta-analysis
A network meta-analysis was undertaken to estimate the relative effectiveness of the different treatments.
Three network meta-analysis models were produced for the different populations of unresectable
hepatocellular carcinoma patients: patients eligible for a transplant, patients ineligible for a transplant but
eligible for conventional transarterial therapy and patients ineligible for conventional transarterial therapy.
The network meta-analysis in patients eligible for a transplant was not conducted. Clinical advice
confirmed that there are short transplant waiting times in the UK, whereas these were much longer
in the network trials. Therefore, the network may not be generalisable to UK practice. The network
meta-analysis of patients eligible for conventional transarterial therapy was also not conducted
because of the lack of good-quality evidence in this population.
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Several network meta-analyses of patients who are ineligible for conventional transarterial therapy
were conducted for both overall survival and progression-free survival outcomes in the per-protocol
and intention-to-treat populations.
Methods of economic modelling
Owing to the limited clinical evidence in the early and intermediate patient groups, the focus of the
Assessment Group’s economic analysis was on an advanced hepatocellular carcinoma population,
in which high-quality randomised controlled trial evidence was available.
The Assessment Group built a fully probabilistic de novo model, which compared the three selective
internal radiation therapy treatments with the systemic therapies lenvatinib (Kisplyx®; Eisai Ltd, Tokyo,
Japan) and sorafenib (Nexavar®; Bayer plc, Leverkusen, Germany). The model structure comprised a
decision tree representing the outcome of the work-up procedure transitioning into a three-state
partitioned survival model. The main model structure is similar to that adopted in previous appraisals
in advanced hepatocellular carcinoma, consisting of health states representing progression-free
survival, post progression and death. The time horizon was 10 years. Costs and benefits were
discounted at a rate of 3.5% per annum. Costs were valued at 2017/18 prices.
The model drew on data from the SorAfenib versus Radioembolization in Advanced Hepatocellular
Carcinoma (SARAH) [Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and
safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib
in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised
controlled Phase 3 trial. Lancet Oncol 2017;18:1624–36] and Selective Internal Radiation Therapy
Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB) (Chow PKH, Gandhi M,
Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus
sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018;36:1913–21) trials to
estimate the relative effectiveness of selective internal radiation therapy and sorafenib; the base case
assumed equivalence in efficacy for all selective internal radiation therapies. A hazard ratio derived
from the network meta-analysis was applied to the sorafenib survival curve to estimate the efficacy of
lenvatinib. Health state utilities were derived from the per-protocol subgroup of the SARAH trial for
selective internal radiation therapy and systemic therapy patients. Resource use and cost inputs were
derived primarily from the included trials, targeted literature searches, estimates presented in the
companies’ evidence submissions, and previous National Institute for Health and Care Excellence
technology appraisals.
Confidential Patient Access Schemes are available for a number of modelled technologies, including
the comparator therapies lenvatinib and sorafenib and also for QuiremScout® (Quirem Medical BV).
All results in this report are based on list prices; separate analyses that include relevant Patient Access
Scheme discounts are presented in Appendix 17.
Results were presented in terms of incremental net monetary benefit versus the least costly option
in each scenario. Fully incremental cost-effectiveness ratios were also produced. Uncertainty was
accounted for using probabilistic and deterministic sensitivity analyses. The base case was based on
20,000 model iterations using Monte Carlo sampling methods.
Results
Results of the clinical effectiveness review
Seven randomised controlled trials, seven prospective comparative studies, five retrospective
comparative studies and one non-comparative case series were included in the review of
clinical effectiveness.
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Efficacy and safety of SIR-Spheres
Two large randomised controlled trials rated as being at a low risk of bias (SARAH and SIRveNIB)
found no significant difference in overall survival or progression-free survival between SIR-Spheres and
sorafenib, despite a statistically significantly greater tumour response rate in the SIR-Spheres arm of
both trials (SARAH: 19% vs. 12%, p = 0.0421; SIRveNIB: 16.5% vs. 1.7%, p < 0.001). The SARAH trial
reported a significant difference between groups in health-related quality of life, favouring SIR-Spheres;
however, the proportion of patients who completed the questionnaires was low. There was no significant
difference in health-related quality of life between groups in the SIRveNIB trial. Adverse events, particularly
grade ≥ 3 events, were more frequent in the sorafenib group in both trials.
The Sirtex Medical Ltd (hereafter Sirtex) company submission selected a subgroup of patients from
the SARAH trial with ≤ 25% tumour burden and albumin–bilirubin 1 for its base-case analysis in the
economic model; this is not a clinically recognised subgroup and was based on a post hoc analysis.
There were methodological differences between the trials; most notably, SARAH was conducted in
France, whereas SIRveNIB was conducted in the Asia-Pacific region. Hepatocellular carcinoma in
European patients is more likely to be caused by alcohol or hepatitis C, whereas in Asia it is more
likely to be caused by hepatitis B. This has implications for the generalisability of the SIRveNIB trial
results to the UK population, because the natural history of the disease and treatment options differ.
In addition, the SARAH trial included patients with a poor prognosis who would be considered only
for best supportive care in UK practice.
Three other randomised controlled trials of SIR-Spheres were included, comparing SIR-Spheres
with transarterial chemoembolisation, or drug-eluting bead transarterial chemoembolisation and
SIR-Spheres followed by sorafenib with sorafenib alone. Each of these small randomised controlled
trials either were rated as being at a high risk of bias or caused some concerns regarding bias. The
trials comparing SIR-Spheres with transarterial chemoembolisation or drug-eluting bead transarterial
chemoembolisation appeared to favour conventional transarterial therapy over selective internal
radiation therapy in terms of survival outcomes. The addition of SIR-Spheres to sorafenib did not
appear to increase the number of treatment-emergent adverse events.
Efficacy and safety of TheraSphere
There were two small randomised controlled trials and seven prospective comparative studies of
TheraSphere. One of the randomised controlled trials [Prospective Randomized study of chEmoeMbolization
versus radIoEmbolization for the tReatment of hEpatocellular carcinoma (PREMIERE): Salem R,
Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs
time to progression compared with chemoembolization in patients with hepatocellular carcinoma.
Gastroenterology 2016;151:1155–63.e2] and all of the non-randomised controlled trial studies were
rated as being at a high risk of bias, and the other randomised controlled trial caused some concerns
regarding bias. PREMIERE compared TheraSphere with transarterial chemoembolisation as a bridge
to transplant; outcomes were improved in the TheraSphere arm compared with the transarterial
chemoembolisation arm. The other randomised controlled trial compared TheraSphere plus sorafenib
with sorafenib alone as a bridge to transplant; outcomes were similar between treatment groups.
Efficacy and safety of QuiremSpheres
Only one very small case series of QuiremSpheres has been completed in patients with hepatocellular
carcinoma. The available data are too limited to draw any conclusions about the safety or efficacy of
QuiremSpheres.
Direct comparison of different selective internal radiation therapies
Five small retrospective comparative studies, all rated as being at a high or unclear risk of bias, compared
SIR-Spheres with TheraSphere. Two studies included patients who had portal vein thrombosis and appear
to have included some of the same patients. Overall survival was reported in four studies, including the
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two studies of patients with portal vein thrombosis; overall survival was longer in the TheraSphere arm in
three of the studies. One study assessed progression-free survival, which was longer with SIR-Spheres, and
another study assessed time to progression, which was longer with TheraSphere (in patients with portal
vein thrombosis). The tumour response rate was higher in the TheraSphere arm than in the SIR-Spheres
arm in patients with portal vein thrombosis.
Clinical toxicities were generally more frequent with SIR-Spheres than with TheraSphere in one very
small study. In a study of patients with portal vein thrombosis, there was no difference in the
frequency of fatigue, but pain and nausea appeared to be more frequent with SIR-Spheres, and
anorexia appeared to be more frequent with TheraSphere.
No studies that directly compared QuiremSpheres with either SIR-Spheres or TheraSphere were
identified. An addendum was received from Terumo Europe NV (Leuven, Belgium) in August 2019
describing a very small pilot study with several methodological limitations.
Network meta-analysis results
The base-case network meta-analysis was in adults with unresectable hepatocellular carcinoma who
were categorised as Child–Pugh class A and ineligible for conventional transarterial therapy in the
per-protocol population. Three studies were included: two randomised controlled trials comparing
SIR-Spheres with sorafenib (SARAH and SIRveNIB) and one randomised controlled trial comparing
lenvatinib with sorafenib (REFLECT: Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–73). The results provided
no evidence that the random-effects model should be preferred. Therefore, the results of the fixed-
effects model were used for the base-case and scenario analyses.
There were no meaningful differences in overall survival between any of the three treatments in the
per-protocol or intention-to-treat populations. In the per-protocol population, SIR-Spheres showed a
non-significant marginal improvement in overall survival when compared with sorafenib (hazard ratio
0.94, 96% credible interval 0.77 to 1.14), although the credible interval indicates that this result is
uncertain. SIR-Spheres was ranked as the most efficacious therapy, with a probability of being the best
of 0.61. Sorafenib was ranked as the worst treatment, with a probability of being the best of 0.16.
Lenvatinib was ranked as the second best, with a probability of being the best of 0.22.
To produce an efficacy estimate for TheraSphere, a sensitivity analysis included the only study that
directly compared TheraSphere with SIR-Spheres for Child–Pugh class A patients ineligible for
conventional transarterial therapy (Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K,
Schwartz M, et al. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with
portal vein invasion: resin versus glass microspheres. J Vasc Interv Radiol 2016;27:812–21.e2). Adding
this study had a substantial effect on the network meta-analysis results. In the per-protocol population,
TheraSphere showed a significant improvement in overall survival when compared with SIR-Spheres
(hazard ratio 0.44, 95% credible interval 0.20 to 0.84), sorafenib (hazard ratio 0.41, 95% credible
interval 0.20 to 0.77) and lenvatinib (hazard ratio 0.40, 95% credible interval 0.18 to 0.78). However,
these results may be biased and unreliable as the Biederman et al. study is a low-quality retrospective
study reporting a very strong treatment effect on overall survival for TheraSphere compared with
SIR-Spheres (hazard ratio 0.40, 95% credible interval 0.20 to 0.78). A sensitivity analysis excluding the
Asia-Pacific SIRveNIB study from the network meta-analysis had very little impact on the results for
overall survival in the per-protocol and intention-to-treat populations compared with the base case;
there were no significant differences in treatment effects for any comparisons.
Results of economic modelling
The Sirtex and BTG Ltd (hereafter BTG) company submissions each present the methods and results of
two separate economic evaluations that split the population potentially eligible for selective internal
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radiation therapy into two groups: patients eligible for conventional transarterial therapy and patients
ineligible for conventional transarterial therapy. In the corrected version of the BTG conventional
transarterial therapy-eligible population, the probabilistic incremental cost-effectiveness ratio for
selective internal radiation therapy compared with drug-eluting bead transarterial chemoembolisation
was £24,647. In the corrected version of the BTG conventional transarterial therapy-ineligible
population, the probabilistic incremental cost-effectiveness ratio for TheraSphere compared with
regorafenib (Stivarga®, Bayer plc, Leverkusen, Germany) was £69,070. The economic assessment in
the conventional transarterial therapy-eligible population submitted by Sirtex was a cost-minimisation
analysis, and found that the costs of selective internal radiation therapy overlapped significantly
with those of conventional transarterial therapy. The base-case economic analysis submitted for the
conventional transarterial therapy-ineligible population by Sirtex was in a subgroup of patients with
low tumour burden and preserved liver function. The results of the presented probabilistic analysis
predicted that SIR-Spheres dominated sorafenib (lower costs and higher quality-adjusted life-years).
The results of the Assessment Group’s base-case analysis (probabilistic) suggested that TheraSphere
is cost-saving relative to both SIR-Spheres and QuiremSpheres. However, incremental costs between
TheraSphere and SIR-Spheres were small, and pairwise net monetary benefit was close to zero
(–£182). QuiremSpheres was associated with substantial incremental costs of £6615 relative to both
TheraSphere and SIR-Spheres (exclusive of Patient Access Scheme). Pairwise net monetary benefit
between QuiremSpheres and TheraSphere in the Assessment Group’s base case was, therefore,
negative, at –£6599. In analyses presented in Appendix 17, which include available Patient Access
Scheme discounts, QuiremSpheres remained more costly than both TheraSphere and SIR-Spheres;
thus, the pairwise net monetary benefit remained negative.
In a fully incremental analysis at list price, none of the three selective internal radiation therapies
was predicted to be cost-effective at any willingness-to-pay threshold, being more costly and less
effective than lenvatinib. The predicted net monetary benefit for lenvatinib compared with TheraSphere
(the lowest-costing selective internal radiation therapy) was –£2154. In a pairwise comparison of
sorafenib with TheraSphere, the incremental cost-effectiveness ratio for sorafenib was £31,974 per
quality-adjusted life-year gained, with an estimated net monetary benefit of –£150 (implying that
TheraSphere is cost-effective compared with sorafenib at a willingness-to-pay threshold of £30,000).
In a fully incremental analysis conducted including confidential Patient Access Scheme discounts,
lenvatinib remained the most cost-effective therapy and dominated all selective internal radiation
therapies, generating greater health benefits at lower costs. In pairwise comparisons of sorafenib
with each selective internal radiation therapy, sorafenib also dominated all selective internal
radiation therapies.
A number of scenarios were produced to explore the effect of using data from more restrictive but
clinically effective subpopulations, downstaging to potentially curative therapy, different resource use,
cost assumptions and data sources. When the modelled population was limited to only those with
a low tumour burden and preserved liver function, the incremental cost-effectiveness ratios for
TheraSphere and SIR-Spheres were £17,165 and £18,783, respectively, per quality-adjusted life-year
gained versus the most cost-effective systemic therapy at list price. The most optimistic incremental
cost-effectiveness ratios were produced when downstaging to curative therapy was permitted in this
more selective population; incremental cost-effectiveness ratios for TheraSphere and SIR-Spheres
decreased to £1440 and £2339, respectively. However, there was no scenario in which selective
internal radiation therapy was predicted to be cost-effective at a willingness-to-pay threshold of
£30,000 when confidential Patient Access Scheme discounts were included.
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Discussion
The Assessment Group’s analyses predicted lenvatinib to be the most cost-effective treatment in
nearly all scenarios, and sorafenib was generally the most cost-effective alternative, producing more
quality-adjusted life-years at a higher cost. The results of the Assessment Group’s base-case analysis
are robust to changes in a wide range of assumptions and across different scenarios.
Strengths of the Assessment Group model include:
l High-quality randomised controlled trial data were included to model the outcomes of the patient
population most relevant to UK practice.
l Analyses included all appropriate comparators.
l There was independent modelling of the costs and outcomes of patients who receive work-up but
were ineligible to receive selective internal radiation therapy.
l There was preserved randomisation and internal consistency with regard to the use of subsequent
systemic and curative therapies.
Insurmountable limitations in the evidence base meant that the Assessment Group was unable to
address the question of selective internal radiation therapy’s cost-effectiveness in patients with
early- and intermediate-stage hepatocellular carcinoma. The evidence for the use of TheraSphere and
QuiremSpheres in advanced hepatocellular carcinoma patients was extremely limited, and a lack
of head-to-head evidence prevented a meaningful comparison of SIR-Spheres, TheraSphere and
QuiremSpheres with one another. This essentially limits this particular comparison to that of a cost
minimisation, although a full comparison of the cost-effectiveness of selective internal radiation
therapy versus sorafenib and lenvatinib was possible.
Conclusions
Implications for service provision
The existing evidence cannot provide decision-makers with clear guidance on the comparative
effectiveness of treatments in early- and intermediate-stage hepatocellular carcinoma.
In the advanced-stage hepatocellular carcinoma population, two large randomised trials have assessed
the comparative effectiveness of SIR-Spheres with sorafenib, showing that selective internal radiation
therapy has effectiveness similar to that of sorafenib.
None of the selective internal radiation therapies is cost-effective at any willingness-to-pay threshold,
being more costly and less effective than lenvatinib; this is the case both at list price and using Patient
Access Schemes.
Suggested research priorities
No strong conclusions can be drawn in the early- and intermediate-stage hepatocellular carcinoma
populations owing to considerable uncertainty in estimates of effectiveness and high risk of bias.
A priority for further research is, therefore, the conduct of studies in these populations.
The low tumour burden/albumin–bilirubin 1 subgroup potentially represents a group of patients
for whom selective internal radiation therapy may be beneficial when compared with sorafenib.
Future work considering this subgroup may, therefore, be useful.
There is currently very limited evidence on the comparative effectiveness of alternative selective
internal radiation therapies. Future high-quality studies evaluating alternative selective internal
radiation therapies would be beneficial.
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Chapter 1 Background
This report contains reference to confidential information provided as part of the NICE appraisalprocess. This information has been removed from the report and the results, discussions and
conclusions of the report do not include the confidential information. These sections are clearly marked
in the report.
Description of health problem
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related
death globally.1 Hepatocellular carcinoma (HCC) is the most common type of liver cancer, representing
around 90% of primary liver cancers.1 Around 90% of HCCs are associated with a known underlying
aetiology, most frequently chronic viral hepatitis B or C, or overconsumption of alcohol (alcoholic liver
disease). Long periods of chronic liver disease, characterised by hepatic inflammation, fibrosis and
aberrant hepatocyte regeneration, can cause scarring of the liver (cirrhosis).2 One-third of patients with
cirrhosis will develop HCC during their lifetime.1
In the UK, the underlying aetiology of HCC is commonly alcoholic liver disease and non-alcoholic fatty
liver disease, with 50% of cases attributable to these factors. Hepatitis infection (hepatitis B or C) is
also a common cause in the UK but, in contrast with non-Western populations, represents only 15% of
cases. Viral hepatitis is the primary cause of HCC in non-Western populations, with up to 90% of cases
directly attributable to the hepatitis B and C virus.3
Underlying liver cirrhosis and the burden of a growing tumour results in an often substantially reduced
liver function in HCC patients, with consequences for morbidity and mortality. Liver dysfunction associated
with chronic liver disease is commonly assessed using the Child–Pugh scoring system, which classifies
patients into three groups: A, B or C (least severe disease, moderate liver disease and severe/end-stage
liver disease). Treatment options available to HCC patients are in part dictated by liver function, with
choices becoming more limited with increasing liver dysfunction. The Barcelona Clinic Liver Cancer (BCLC)
staging system is used to establish prognosis and enable the selection of appropriate treatment based on
both the underlying liver dysfunction and the cancer stage.1 A modified version of the BCLC staging system
is presented in Table 1. The BCLC staging system classifies patients into five stages (0, A, B, C and D)
according to tumour burden, liver function and Eastern Cooperative Oncology Group (ECOG) performance
status,4 which must all be considered when selecting appropriate treatment.1
Epidemiology
The incidence of HCC is higher in men than in women, with 2128 men and 586 women diagnosed with
HCC in England in 2017.5 The majority of cases occur in adults aged > 60 years.5 The average age of
patients at HCC diagnosis is 66 years, reflecting the long-term nature of most chronic liver disease
underlying HCC.6 Approximately 30% of European patients are diagnosed with early-stage (BCLC
stage 0 or A) HCC, approximately 10% are diagnosed with intermediate-stage (BCLC stage B) HCC,
approximately 50% are diagnosed with advanced-stage (BCLC stage C) HCC and approximately 10%
are diagnosed with terminal (BCLC stage D) HCC.7 The majority of patients are, therefore, diagnosed
with advanced disease, for which treatment options are more limited (see Current service provision).
Prognosis
Prognosis of patients with HCC is heavily dependent on the stage of disease, and is summarised in
Table 1. In very early-stage and early-stage disease, a range of potentially curative treatment options
are typically available and, thus, the long-term prognosis of these patients can be good. In very early-
stage disease, 5-year survival is between 70% and 90%, and it is between 50% and 70% in early-stage
disease.8 In intermediate- and advanced-stage disease, treatment options are more limited and are
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primarily delivered to prolong survival and reduce the burden of symptoms. Length of survival is,
therefore, significantly shorter; prognosis in patients with advanced disease is particularly poor,
with a median survival of < 12 months.8
Current service provision
Clinical management of HCC is complex. There are a range of treatment options available, which
depend on the location and stage of the cancer and liver function. Clinical practice guidelines published
by the European Association for the Study of the Liver (EASL) summarise treatment recommendations
according to BCLC classification.1 These recommendations are presented in Table 1, with some
modifications, reflecting entry criteria to pivotal clinical trials.
The primary aim of therapy in patients diagnosed with early-stage HCC is typically curative, and there
are a number of available treatment options with curative potential. These include radiofrequency
ablation (which uses the heat generated by alternating currents to destroy solid tumour tissue),
resection (in which the tumour-containing portions of the liver are removed) and liver transplantation.1
Owing to the limited availability of suitable donors, liver transplant is typically reserved for patients
with a poor prognosis owing to impaired liver function, and in whom resection is inappropriate, for
example in patients with multifocal tumours. Suitability for transplant is assessed against the Milan
criteria,9 which require patients to have a single lesion of < 5 cm, or up to three lesions of < 3 cm each,
without macroscopic vascular invasion (MVI).1 Typically, patients not meeting these criteria are ineligible
for a transplant, but increasingly patients whose disease has been ‘downstaged’ may be considered for
transplant. Downstaging is when patients whose tumours fall outside the limits permitted by the Milan
criteria9 are brought within the criteria, typically through the use of conventional transarterial therapies
(CTTs) (see below) to reduce tumour burden. Patients waiting for a transplant may also receive CTT as
a ‘bridging therapy’, in which the intent is to control the progression of disease to keep patients within
the Milan criteria.9 However, as transplant waiting times in the UK are typically relatively short, with a
median time for HCC patients of approximately 50 days, the use of bridging therapy is limited.
TABLE 1 Modified BCLC staging system and treatment strategy
Prognostic stage Tumour burden Liver function
Performance
status Recommended treatment Survival
Very early stage
(BCLC 0)
Single < 2-cm
nodule
Preserved
liver function
0 Ablation or resection > 5 years
Early stage
(BCLC A)
1–3 nodules of
< 3 cm in size
Preserved
liver function
0 Ablation, resection or
transplant
> 5 years
Intermediate
stage (BCLC B)
Multinodular,
unresectable
Preserved
liver function
0–1 Conventional transarterial
therapies (TAE, TACE and
DEB-TACE)
> 2.5 years
Advanced stage
(BCLC C)
PVI/extrahepatic
spread
Preserved
liver function
0–2 Systemic therapy [sorafenib,a
lenvatinibb or regorafenibc
(for patients who have
previously had sorafenib)]
≥ 10 months
Terminal stage
(BCLC D)
Non-transplantable
HCC
End-stage
liver function
3–4 Best supportive care 3 months
DEB-TACE, drug-eluting bead transarterial chemoembolisation; PVI, portal vein invasion; TACE, transarterial
chemoembolisation; TAE, transarterial embolisation.
a Nexavar®; Bayer plc, Leverkusen, Germany.
b Kisplyx®; Eisai Ltd, Tokyo, Japan.
c Stivarga®; Bayer plc, Leverkusen, Germany.
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Conventional transarterial therapies are the standard care in intermediate HCC if resection or other
curative treatment modalities are unsuitable. CTT includes transarterial chemoembolisation (TACE),
drug-eluting bead transarterial chemoembolisation (DEB-TACE) and transarterial embolisation (TAE)
without chemotherapy. Blood is primarily supplied to the liver via the hepatic portal vein, whereas
most tumours are supplied by the hepatic artery. All three forms of CTT work by administering an
embolising agent into the hepatic artery to block blood vessels feeding the tumours within the liver.
This process preferentially interrupts the blood supply to the tumours, while allowing blood to
continue to reach the remaining healthy tissue. In the case of TACE, Lipiodol® (Guerbet, Villepinte,
France) is combined with a chemotherapy agent, typically doxorubicin or cisplatin, which is
administered directly to the tumour, allowing for much higher concentrations of the drug to be
achieved than could be tolerated systemically. In DEB-TACE, drug-eluting beads typically bound
with doxorubicin or epirubicin are administered to the tumour via the hepatic artery. This allows the
release of the chemotherapeutic agent over a prolonged period of time, thereby reducing systemic
concentrations (and thus any side effects) compared with TACE.10 TAE, or bland TACE, involves only
the physical occlusion of blood vessels, with no addition of chemotherapy. Because the primary
therapeutic effect of CTT is the embolisation of the hepatic artery, the use of these techniques is
typically limited to patients with good portal vein flow, so as to maintain a good blood supply to the
liver. Therefore, patients with portal vein thrombosis (PVT) or tumour invasion of the portal vein are
typically considered contraindicated to CTT.
In patients who have advanced HCC, or for whom CTT has previously failed, the current standard of
care consists of systemic chemotherapy. Current National Institute for Health and Care Excellence
(NICE) guidance in this population recommends sorafenib (Nexavar®; Bayer plc, Leverkusen, Germany)
as an option for people with Child–Pugh class A liver impairment (TA474).11 Lenvatinib (Kisplyx®,
Eisai Ltd, Tokyo, Japan) is also recommended as an option for people with Child–Pugh class A liver
impairment and an ECOG performance status of 0 or 1 (TA551).12 A recent technology appraisal on
regorafenib (Stivarga®; Bayer plc, Leverkusen, Germany) for treating advanced unresectable HCC
(TA555)13 recommends regorafenib as an option for people who have previously been treated with
sorafenib and have Child–Pugh class A liver impairment and an ECOG performance status of 0 or 1.
Best supportive care (BSC) is offered to patients when CTTs or systemic therapy are not available or
appropriate, including patients with terminal-stage disease.
Description of the technology under assessment
Selective internal radiation therapy (SIRT), also known as transarterial radioembolisation (TARE), is a
complex intervention that delivers radiation directly to liver tumours via microspheres that are injected
into the hepatic artery via a catheter inserted into the femoral artery. The most likely position for SIRT
in the HCC treatment pathway is for patients with intermediate-stage (BCLC stage B) or advanced-
stage (BCLC stage C) HCC as a non-curative option, as the use of SIRT is not precluded by reduced
liver function as strictly as CTTs. However, SIRT is unlikely to be suitable for patients with more limited
liver function (Child–Pugh class ≥ B8) or extrahepatic tumour spread. There may also be a role for SIRT
as a bridging therapy for BCLC stage A patients awaiting transplant (see Current service provision) as an
alternative to CTTs.
The NICE interventional procedures guidance 46014 states that current evidence on the efficacy and
safety of SIRT for primary HCC was adequate to permit routine use of the technology. However,
significant uncertainties remain about its comparative effectiveness relative to conventional transarterial
and systemic therapeutic options.14 Clinicians have been encouraged by NICE to enter eligible patients
into trials comparing the procedure against other forms of treatment and to enrol all patients into the
UK SIRT registry (launched in 2013).14
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The present appraisal concerns three SIRTs: SIR-Spheres® (Sirtex Medical Ltd, Woburn, MA, USA),
TheraSphere™ [BTG Ltd, London, UK (now Boston Scientific, Marlborough, MA, USA)] and QuiremSpheres®
(Quirem Medical BV, Deventer, the Netherlands). SIR-Spheres [manufactured by Sirtex Medical Ltd
(hereafter Sirtex)] is a Conformité Européenne (CE)-marked class III active medical device comprising resin
microspheres containing yttrium-90; SIR-Spheres is indicated for the treatment of inoperable liver tumours.
TheraSphere [manufactured by BTG Ltd (hereafter BTG)] is a CE-marked class III active medical device
comprising glass microspheres containing yttrium-90; TheraSphere is indicated for the treatment of hepatic
neoplasia. QuiremSpheres [manufactured by Quirem Medical BV and distributed by Terumo Europe NV
(Leuven, Belgium)] is a CE-marked class III active medical device comprising poly-L-lactic acid (PLLA)
microspheres containing holmium-166; QuiremSpheres is indicated for the treatment of unresectable
liver tumours.
In preparation for SIRT, patients undergo preliminary angiography of the hepatic artery, and protective
coiling of extrahepatic branches to reduce extrahepatic radiation uptake. For TheraSphere and SIR-
Spheres, technetium-99m-macroaggregated albumin is used as an imaging surrogate and injected into
the hepatic artery using the same catheter position chosen for the scheduled SIRT session. Calculation
of the radiation dose to the tumour and adjacent liver, hepatopulmonary shunt fraction and tracer
distribution are evaluated with single-photon emission computerised tomography (SPECT) imaging.
This is known as the ‘work-up’ procedure, and is ultimately what decides whether or not patients are
eligible to receive SIRT. A high level of lung shunt or extrahepatic uptake contraindicate the SIRT
procedure. When SIRT is not contraindicated following work-up, patients are later readmitted for
the SIRT procedure, which is performed in a lobar, sectorial or segmental approach according to
tumour size and location.1 When tumours are present in both lobes, patients may receive a separate
administration of SIRT to each lobe on separate occasions (often several weeks apart), to allow
clinicians to monitor the liver’s response to radiation and prevent damage.
The work-up procedure for QuiremSpheres exploits the properties of holmium-166 microspheres,
which, unlike yttrium-90, can be visualised with SPECT and magnetic resonance imaging (MRI) even at
low concentrations. Therefore, a lower dose of holmium-166 is used for evaluating dose distribution
[known as QuiremScout® (Quirem Medical BV)], rather than a surrogate, which may allow for a more
accurate assessment of radiation distribution and dosimetry.
Table 2 presents an overview of the main characteristics of each therapy.
TABLE 2 Main characteristics of SIR-Spheres, TheraSphere and QuiremSpheres
Technique SIR-Spheres TheraSphere QuiremSpheres
Radioactive isotope Yttrium-90 Yttrium-90 Holmium-166
Microsphere material Resin Glass PLLA
Therapeutic mode of action Beta radiation Beta radiation Beta radiation
Mean diameter of the microsphere (µm) 32.5 20–30 30
Half-life of the radioactive isotope (hours) 64.1 64.1 26.8
Specific activity per microsphere (Bq) 50 2500 350
Typical administered activity (GBq) 1.4–2.0 – –
Typical number of microspheres administered (millions) 30–40 4 20–30
Time for 90% of dose to be deposited (days) 11 11 4
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Chapter 2 Definition of the decision problem
The decision problem in terms of participants, interventions, comparisons,
outcomes, study design and other key issues
The decision problem relates to the use of the three SIRTs, TheraSphere, SIR-Spheres and QuiremSpheres,
within their approved indications for the treatment of HCC. Relevant comparators are each other, CTTs
(i.e. TAE, TACE and DEB-TACE) or, for people for whom any transarterial therapies are inappropriate,
established clinical management without SIRT, such as systemic therapy (sorafenib, lenvatinib or
regorafenib) or BSC.
Overall aims and objectives of the assessment
This appraisal will assess the clinical effectiveness and cost-effectiveness of the SIRT (TheraSphere,
SIR-Spheres and QuiremSpheres) for treating HCC.
The objectives of the assessment are to evaluate the:
l clinical effectiveness of each intervention
l adverse effect profile of each intervention
l incremental cost-effectiveness of each intervention compared with (1) each other, (2) CTTs,
(3) systemic therapy and (4) BSC.
DOI: 10.3310/hta24480 Health Technology Assessment 2020 Vol. 24 No. 48
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
5
Chapter 3 Assessment of clinical effectiveness
Methods for reviewing clinical effectiveness
A systematic review of the clinical effectiveness evidence on SIRT was undertaken following the
general principles outlined in the Centre for Reviews and Dissemination (CRD)’s guidance on
undertaking systematic reviews15 and reported in accordance with the general principles of the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.16 The
research protocol is registered on PROSPERO, the international prospective register of systematic
reviews in health and social care (registration number CRD42019128383).
Search strategy
A comprehensive search was undertaken to systematically identify clinical effectiveness and
cost-effectiveness literature relating to TheraSphere, SIR-Spheres and QuiremSpheres for HCC.
In addition, a search for randomised controlled trials (RCTs) of comparator therapies was undertaken
to strengthen the network of evidence on SIRT.
Search strategy for selective internal radiation therapy studies
A search strategy was developed in Ovid MEDLINE by an information specialist (MH), with input
from the review team. The strategy consisted of a set of terms for HCC combined with terms for
SIRT, and was limited to studies from 2000 onwards. The 2000 date limit was applied as scoping
searches had identified controlled studies of SIR-Spheres and TheraSphere published after the year
2000; earlier studies were preliminary uncontrolled studies so have limited value for addressing the
decision problem. In addition, clinical advice confirmed that the treatment environment for patients
with HCC was different prior to 2000 in terms of comparator treatment options. The searches were
not limited by language or study design. The MEDLINE strategy was adapted for use in all other
resources searched.
The following databases were searched on 28 January 2019:
l MEDLINE (all) (via Ovid)
l EMBASE (via Ovid)
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus
l Science Citation Index (via Web of Science)
l Cochrane Central Register of Controlled Trials (CENTRAL) (via Wiley)
l Cochrane Database of Systematic Reviews (via Wiley)
l Database of Abstracts of Reviews of Effects (via CRD databases)
l Health Technology Assessment (HTA) database (via CRD databases)
l NHS Economic Evaluation Database (NHS EED) (via CRD databases)
l EconLit (via Ovid).
In addition, information on studies in progress, unpublished research or research reported in grey
literature was sought by searching a range of relevant resources:
l ClinicalTrials.gov
l World Health Organization (WHO) International Clinical Trials Registry portal
l European Union Clinical Trials Register
l PROSPERO
l Conference Proceedings Citation Index – Science (via Web of Science)
l ProQuest Dissertations & Theses A&I (via ProQuest).
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A search of the NICE website and NHS Evidence for relevant guidelines was undertaken on 8 May 2019.
Company submissions and relevant systematic reviews were also hand-searched to identify further
relevant studies. Clinical advisors were consulted for any additional studies.
Search results were imported into EndNote X9 (Clarivate Analytics, Philadelphia, PA, USA) and
de-duplicated. Full search strategies can be found in Appendix 1.
Search strategy for comparator therapies
A search for RCTs of comparator therapies was undertaken to strengthen the network of evidence on
SIRT. In view of time and resource limitations, it was decided to identify RCTs of CTTs (i.e. TAE, TACE
and DEB-TACE) by searching existing relevant systematic reviews and meta-analyses and undertaking
update searches if necessary.
Evidence on systemic therapies for HCC was identified from the recent NICE single technology
appraisals of sorafenib,11 lenvatinib12 and regorafenib.13
The search strategy for systematic reviews and meta-analyses of CTTs was developed in Ovid
MEDLINE by an information specialist (MH), with input from the review team. The strategy consisted
of a set of terms for HCC combined with terms for embolisation or chemoembolisation, and was
limited to studies from 2010 onwards to identify the most recent reviews. A search strategy to limit
retrieval to systematic reviews or meta-analyses was added in MEDLINE and EMBASE.17 The MEDLINE
strategy was adapted for use in all resources searched.
The following databases were searched on 7 May 2019:
l MEDLINE (all) (via Ovid)
l EMBASE (via Ovid)
l Cochrane Database of Systematic Reviews (via Wiley)
l Database of Abstracts of Reviews of Effects (via CRD databases)
l HTA database (via CRD databases).
In addition, PROSPERO was searched to identify any unpublished or ongoing systematic reviews or
meta-analyses.
Search results were imported into EndNote X9 and de-duplicated. Full search strategies can be found
in Appendix 2.
Inclusion criteria
Inclusion criteria were defined in line with the final scope provided by NICE and are outlined below.
Studies were initially assessed for relevance using titles and abstracts. One reviewer examined titles
and abstracts, with a second reviewer checking 10% of records. Full manuscripts of any titles/abstracts
that appeared to be relevant were obtained if possible and the relevance of each study was assessed
independently by two reviewers in accordance with the criteria outlined in the following sections.
Any discrepancies were resolved through consensus and, if necessary, a third reviewer was consulted.
Relevant foreign-language studies were translated and assessed for inclusion in the review. Studies
available only as abstracts were included and attempts were made to contact authors for further data.
Study design
Randomised controlled trials were eligible for inclusion in the clinical effectiveness review. However,
where RCT evidence was insufficient to address the decision problem, non-randomised comparative
studies (including retrospective studies) and non-comparative studies of SIRT were considered for
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inclusion. The evidence was scoped before deciding what level of evidence would be included for data
extraction and quality assessment.
Participants
Studies of people with early-stage HCC in whom curative treatment is contraindicated (BCLC stage A),
and with intermediate-stage (BCLC stage B) or advanced-stage (BCLC stage C) HCC, with or without
PVT/portal vein invasion (PVI), were included in the review. Studies of people with secondary liver
metastases or other types of liver cancer (such as cholangiocarcinoma) were not included unless they
also included people with primary HCC, and results were reported separately for people with HCC.
Interventions
The interventions under consideration were the selective internal radiation therapies TheraSphere,
SIR-Spheres and QuiremSpheres. Studies in which more than one type of SIRT was used were included
only if results were reported separately for the different types of SIRT. Where studies did not state
which type of SIRT or radioembolisation technology was used, authors were contacted to identify the
specific technology used.
Evidence on combined treatments (e.g. SIRT plus sorafenib) was also considered for inclusion, and evidence
was scoped before deciding which trials would be included for data extraction and quality assessment.
Comparators
Relevant comparators were:
l alternative SIRT interventions (i.e. TheraSphere, SIR-Spheres and QuiremSpheres)
l conventional transarterial therapies (i.e. TAE, TACE and DEB-TACE)
l established clinical management without SIRT, such as systemic therapy (i.e. sorafenib, lenvatinib
and regorafenib) or BSC, for people for whom any TAE therapies are inappropriate.
To strengthen the network of evidence on SIRT, we considered undertaking comparisons of CTTs
(i.e. TAE, TACE and DEB-TACE), systemic therapies (i.e. sorafenib, lenvatinib and regorafenib) and BSC,
using RCT evidence. The evidence was scoped and criteria for inclusion were developed. Relevant RCTs
were assessed for quality and key outcome data were extracted, based on requirements for the model.
Outcomes
The outcome measures to be considered included:
l overall survival (OS)
l progression-free survival (PFS)
l time to progression (TTP)
l response rates
l rates of liver transplant or surgical resection
l adverse effects of treatment
l health-related quality of life (HRQoL)
l time on treatment/number of treatments provided.
Data extraction
Data were extracted by one reviewer using a standardised data extraction form and independently
checked for accuracy by a second reviewer. Disagreements were resolved through consensus and, if
necessary, a third reviewer was consulted. If multiple publications of the same study were identified,
data were extracted and reported as a single study.
DOI: 10.3310/hta24480 Health Technology Assessment 2020 Vol. 24 No. 48
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
9
Critical appraisal
The methodological quality of the included studies was assessed using criteria relevant to the study
design. RCTs were assessed using the most recent version of the Cochrane risk-of-bias tool.18 Quality-
assessment tools for other study designs were developed using relevant criteria, such as those outlined
in the CRD’s guidance on undertaking systematic reviews.15 Quality assessment was undertaken by one
reviewer and independently checked by a second reviewer. Any disagreements were resolved through
consensus and, if necessary, a third reviewer was consulted. Details of the quality of the included
studies are presented in descriptive tables and their impact on the reliability of results is discussed.
Methods of data analysis/synthesis
Characteristics of the included SIRT studies (such as participant and intervention characteristics, results
and trial quality) were tabulated and described in a narrative synthesis. Where sufficient clinically and
statistically homogenous data were available, data were pooled using appropriate meta-analytic
techniques using WinBUGS software (Medical Research Council Biostatistics Unit, Cambridge, UK).
Clinical, methodological and statistical heterogeneity were investigated, with sensitivity or subgroup
analyses undertaken where appropriate and where available data permitted.
Where the data allowed, a network meta-analysis (NMA) using Bayesian statistical methods with
WinBUGS software was undertaken to estimate the relative effectiveness of the different treatments.
Results are summarised using point estimates and 95% credible intervals (CrIs) of the effect of each
treatment relative to the reference treatment. Where possible, consistency between direct and indirect
estimates of treatment effect in the NMA was assessed. The results of the NMA are described in
Chapter 4 of this report and were used in the economic model described in Chapter 7.
Clinical effectiveness results
Quantity and quality of research available
Studies of selective internal radiation therapy
The electronic searches for clinical effectiveness evidence on SIRT interventions (i.e. TheraSphere,
SIR-Spheres and QuiremSpheres) identified a total of 4755 records (after de-duplication between
databases). The 4755 records were inserted into an EndNote library. Reviewer 1 (RW) screened 2615
titles and abstracts, and reviewer 2 (SS) screened 2617 titles and abstracts. A total of 477 records
(10% of the library) were double-screened; discrepancies were resolved through consensus or in
consultation with a third reviewer (AE).
Of the 4755 records in the library, 3670 were excluded from the clinical effectiveness review after
title and abstract screening as they did not include patients with unresectable HCC, did not assess
TheraSphere, SIR-Spheres or QuiremSpheres, did not report relevant patient outcomes or were not a
primary study. A total of 1085 records appeared to meet the study selection criteria based on title and
abstract (where an abstract was available).
In view of the large number of potentially eligible records, the evidence was scoped before deciding
which studies to order for full-paper screening. Records were coded, using titles and abstracts (where
available), in terms of the intervention (type of SIRT and whether the study focused on the delivery of
SIRT or the work-up procedure), the study design (prospective or retrospective, comparative or not) and
the number of HCC patients included in the study. A large number of records were conference/meeting
abstracts (n = 603) rather than full publications (n = 482); reviewer 1 (RW) coded the full publications
and reviewer 2 (SS) coded the conference/meeting abstracts. Studies marked as a ‘RCT’ (n = 47;
43 full publications and four conference/meeting abstracts) or as ‘prospective comparative’ (n = 26;
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18 full publications and eight conference/meeting abstracts) or ‘retrospective comparative’ (n = 103;
61 full publications and 42 conference/meeting abstracts) studies were ordered for full-paper screening
as comparative studies (total n = 176) were prioritised over non-comparative studies. However, it was
clear that there were no comparative studies of QuiremSpheres; therefore, all studies considered to
relate to QuiremSpheres (referring to holmium as the intervention) were ordered for full-paper screening
(n = 11). In addition, large non-comparative studies that included > 500 patients were also ordered for
full-paper screening (n = 6). One additional non-comparative study, in which BCLC subgroups and
subsequent treatments were reported and which was considered to be particularly relevant for the
economic model, was ordered. Therefore, a total of 194 records were ordered for full-paper screening.
Of the 194 records ordered, 130 were excluded based on full-paper screening and 64 were considered
to be potentially relevant records to be included in the clinical effectiveness review and/or NMA
(55 studies plus nine associated publications).
A total of 130 records were coded at the title and abstract stage as systematic reviews. Reviewer 1
(RW) screened systematic reviews from 2015 onwards for relevance; there were 25 relevant
systematic reviews (plus one associated erratum). The reference lists of these systematic reviews were
screened to check for additional potentially relevant studies; no additional studies were identified.
Separate searches of guideline databases (the NICE website and NHS Evidence), conducted in May 2019,
identified a total of 23 records after de-duplication against the original library, none of which were
considered relevant for inclusion in the systematic review. The reference lists of relevant guidelines were
screened to check for additional potentially relevant studies; no additional studies were identified.
Clinical advisors were not aware of any additional studies other than those already identified from
electronic searches.
A PRISMA flow diagram is presented in Figure 1. In total, 27 of the 55 studies were prioritised for data
extraction, as they were considered to be the most relevant for the assessment of clinical effectiveness
and/or the proposed NMAs; these studies are summarised in Table 3. One non-comparative study was
included in the clinical effectiveness review because this was the only study of QuiremSpheres;51 the
other 26 studies were comparative studies.
The 28 lower-priority studies are summarised in Appendix 7 along with the reason for not including
them in the systematic review of clinical effectiveness or the proposed NMAs (e.g. consultation with
clinical advisors confirmed that the comparators used were not applicable to current UK practice).52–55
Thirty-four records were coded at the title and abstract stage as potentially relevant economic studies
(seven of which were also coded as includes for the clinical effectiveness review). A separate flow
diagram of the study selection process for these economic studies is presented (see Figure 7).
Studies of comparator therapies
Randomised controlled trials of comparator therapies were sought to strengthen the network of
evidence on SIRT (see Chapter 5). The search for systematic reviews and meta-analyses of CTTs (TAE,
TACE and DEB-TACE) identified 989 records. The records were inserted into an EndNote library and
one reviewer (RW) screened the titles and abstracts. Records were put in reverse date order and
screened started at the year 2019 and worked backwards until no new relevant RCTs were identified
from the reviews and meta-analyses. A total of 319 records were screened, published between 2017
and 2019. Twenty-four of the 319 records were relevant systematic reviews or meta-analyses; full
papers were obtained and reference lists were checked for RCTs comparing TAE, TACE or DEB-TACE
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Records identif ied from searches of
electronic databases
(n = 4755)
Excluded on title/abstract
(n = 3670)
Met broad inclusion criteria
(n = 1085)
Rejected as lower-priority studies
(non-comparative studies of
TheraSphere or SIR-Spheres
with fewer than 500 patients)
(n = 891)
Full papers screened
(n = 194)
Included for data extraction
(n = 27 studies)
• RCTs, n = 7
• Prospective comparative studies, n = 7
• Retrospective comparative studies, n = 12
• Non-comparative studies, n = 1
Excluded
(n = 130)
• Not HCC patients (or mixed population and HCC patients’ results
    not reported separately), n = 15
• Not assessment of TheraSphere, SIR-Spheres or QuiremSpheres,
    n = 9
• SIRT and other intervention results not presented separately, n = 6
• TheraSphere and SIR-Spheres results not presented separately,
    n = 5
• Not a comparative study or large (> 500 patients) non-comparative
    study (higher-quality evidence already identif ied), n = 12
• No relevant patient outcomes, n = 5
• Full paper where type of SIRT not stated (author contacted), n = 9
• Conference abstract where type of SIRT not stated, n = 36
• Duplicate report, n = 7
• Ongoing or terminated study (or protocol), n = 26
Additional studies identified from
systematic reviews, guidelines and
clinical advisors
(n = 0)
Records eligible for inclusion
(n = 64; n = 55 studies + 9 associated publications) 
• RCTs, n = 7
• Prospective comparative studies, n = 11
• Retrospective comparative studies, n = 34
• Large non-comparative studies (> 500 patients) of TheraSphere/SIR-Spheres, n = 2
• Non-comparative studies of QuiremSpheres (in the absence of higher-quality evidence), n = 1
Rejected as lower-priority studies
(less informative for the network of evidence)
(n = 28)
• Prospective comparative studies, n = 4
• Retrospective comparative studies, n = 22
• Non-comparative studies, n = 2
FIGURE 1 The PRISMA flow diagram of the study selection process for the clinical effectiveness review.
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TABLE 3 Studies included in the systematic review of clinical effectiveness or considered for the NMA (n = 27)
Study (first author
and year) Intervention Comparator Location Population
RCTs of SIR-Spheres (n = 5)
Vilgrain 201719 and
Bouattour 201720
SARAH
SIR-Spheres Sorafenib France Adults with locally advanced HCC (BCLC C)
or new HCC not eligible for surgical
resection, transplant or thermal ablation
after a previously cured HCC (cured by
surgery or thermoablative therapy) or HCC
with two unsuccessful rounds of TACE
Chow 201821
SIRveNIB
SIR-Spheres Sorafenib Asia-Pacific
region
Adults with locally advanced HCC (BCLC B
or C) not amenable to curative treatment
Kolligs 201522
SIRTACE
SIR-Spheres TACE Germany
and Spain
Adults with unresectable liver-only HCC
(without portal vein occlusion)
Pitton 201523 SIR-Spheres DEB-TACE Germany Adults with unresectable N0, M0 HCC
(BCLC stage B)
Ricke 201524
SORAMIC
SIR-Spheres plus
sorafenib
Sorafenib alone Germany Adults with unresectable intermediate or
advanced HCC (BCLC stage B or C), with
preserved liver function (Child–Pugh class
≤ B7) and ECOG < 2, who were poor
candidates for TACE (including those failing
TACE)
RCTs of TheraSphere (n = 2)
Salem 2016,25
Gabr 201726 and
Gordon 201627
PREMIERE
TheraSphere TACE USA Adults with BCLC stage A/B unablatable/
unresectable HCC with no vascular
invasion, Child–Pugh class A/B
Kulik 2014,28
Lewandowski
201629 and
Vouche 201330
TheraSphere TheraSphere
plus sorafenib
USA Adults with Child–Pugh class ≤ B8 and
potential candidates for orthotopic liver
transplant
Prospective comparative studies of TheraSphere (n = 7)
Kirchner 201931 TheraSphere TACE/DEB-TACE Germany Adults with unresectable HCC
El Fouly 201532 TheraSphere TACE Germany
and Egypt
Adults with intermediate-stage (BCLC B)
unresectable HCC and good liver function
(Child–Pugh class < B7)
Salem 201333 TheraSphere TACE USA Adults with treatment-naive HCC with
ECOG 0–2
Memon 201334 TheraSphere TACE USA Adults with HCC that progressed after
intra-arterial locoregional therapies
(TACE and SIRT)
Hickey 201635 TheraSphere TACE USA Adults with unresectable HCC and bilirubin
≤ 3.0 mg/dl
Maccauro 201436 TheraSphere
plus sorafenib
TheraSphere
alone
Italy Adults with unresectable HCC (Child–Pugh
class A)
Woodall 200937 TheraSphere BSC USA Adults with unresectable HCC
(including both patients with and patients
without PVT)
continued
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with each other. Eleven relevant RCTs (reported in 12 publications) were identified, which are
summarised in Table 4. In view of the recency of the relevant systematic reviews and meta-analyses
and the age of the RCTs of CTTs (published between 1992 and 2016), it was decided that update
searches were not necessary.
Evidence on systemic therapies for HCC was identified from the recent NICE single technology
appraisals of sorafenib,11 lenvatinib12 and regorafenib.13
Assessment of clinical effectiveness
This section describes the seven RCTs and seven prospective comparative studies of SIR-Spheres and
TheraSphere, the five retrospective comparative studies comparing SIR-Spheres with TheraSphere
and the non-comparative case series of QuiremSpheres. The additional seven retrospective comparative
studies of SIR-Spheres or TheraSphere (see Table 3) and studies of comparator therapies (see Table 4) that
were selected, as they were considered to be potentially relevant for the NMAs, are described in Chapter 5.
TABLE 3 Studies included in the systematic review of clinical effectiveness or considered for the NMA (n = 27)
(continued )
Study (first author
and year) Intervention Comparator Location Population
Retrospective comparative studies of SIR-Spheres vs. TheraSphere (n = 5)
Biederman 201538 SIR-Spheres TheraSphere USA Adults with HCC with PVT
Biederman 201639 SIR-Spheres TheraSphere USA Adults with HCC with PVI
Van Der Gucht
201740
SIR-Spheres TheraSphere Switzerland Adults with unresectable HCC
Bhangoo 201541 TheraSphere SIR-Spheres USA Adults with unresectable HCC
d’Abadie 201842 SIR-Spheres TheraSphere Belgium Adults with HCC
Retrospective comparative studies of SIR-Spheres (n = 4)
Cho 201643 SIR-Spheres Sorafenib Korea Adults with BCLC stage C HCC with PVT
de la Torre 201644 SIR-Spheres Sorafenib Spain Adults with HCC with PVI
Gramenzi 201545 SIR-Spheres Sorafenib Italy Adults with HCC unfit for other effective
therapies, Child–Pugh class A/B,
performance status ≤ 1, no metastases and
no previous systemic chemotherapy
Soydal 201646 TACE SIR-Spheres Turkey Adults with BCLC B or C HCC
Retrospective comparative studies of TheraSphere (n = 3)
Salem 201147 TheraSphere TACE USA Adults with unresectable HCC and bilirubin
3.0 mg/dl
Moreno-Luna
201348
TheraSphere TACE USA Adults with unresectable HCC
Akinwande
201649,50
TheraSphere DEB-TACE USA Adults with unresectable HCC (with or
without PVT)
Non-comparative studies of QuiremSpheres (n = 1)
Radosa 201951 QuiremSpheres N/A Germany Adults with HCC
N/A, not applicable; PREMIERE, Prospective Randomized study of chEmoeMbolization versus radIoEmbolization for the
tReatment of hEpatocellular carcinoma; SARAH, SorAfenib versus Radioembolization in Advanced Hepatocellular
Carcinoma; SIRveNIB, Selective Internal Radiation Therapy Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
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Risk of bias
Results of the risk-of-bias judgements are presented in Appendix 5.
The SorAfenib versus Radioembolization in Advanced Hepatocellular Carcinoma (SARAH) and Selective
Internal Radiation Therapy Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
RCTs were both rated as having a low overall risk of bias.19–21 There were some concerns regarding
bias for the trials undertaken by Pitton et al.23 and Kulik et al.28 Concerns related to the randomisation
process for the study by Pitton et al.23 There were concerns related to the randomisation process,
potential deviations from the intended interventions and measurement of the outcome for the study
by Kulik et al.28 The SIRTACE,22 SORAMIC24 and Prospective Randomized study of chEmoeMbolization
versus radIoEmbolization for the tReatment of hEpatocellular carcinoma (PREMIERE)25–27 trials were all
rated as being at a high overall risk of bias; the SIRTACE trial was rated as being at a high risk of bias
arising from the randomisation process, missing outcome data and measurement of the outcome,22 the
SORAMIC trial was rated as being at a high risk of bias in relation to deviations from the intended
interventions as well as some concerns arising from the randomisation process,24 and the PREMIERE
trial was rated as being at a high risk of bias arising from the randomisation process and concerns
arising from deviations from the intended interventions.25–27
The prospective comparative studies were all rated as being at a high risk of bias.31–37 In particular,
allocation to treatment groups was either inadequately described or inappropriate, resulting in
differences in prognostic factors between treatment groups at baseline. Outcome assessors do not
appear to have been blinded in any of the prospective comparative studies.
TABLE 4 The RCTs of CTTs (n= 11)
Study (first author
and year) Intervention Comparator Population
Lammer 201056
and Vogl 201157
PRECISION V
DEB-TACE TACE Adults with HCC unsuitable for resection or percutaneous ablation
(BCLC A/B without portal invasion or extrahepatic spread)
Golfieri 201458 DEB-TACE TACE Adults with HCC unsuitable for curative treatment or had failed/
recurred after resection/ablation
Sacco 201159 DEB-TACE TACE Adults with previously untreated unresectable HCC not suitable
for ablative treatment, Child–Pugh class A or B and ECOG score
of 0/1, absence of PVT and extrahepatic metastases
van Malenstein
201160
DEB-TACE TACE Adults with HCC who were not candidates for curative
treatments, Child–Pugh class A or B cirrhosis and an ECOG
score of 0 or ECOG score of < 3 if the restriction in status was
not because of the HCC
Llovet 200261 TACE TAE White patients with unresectable HCC not suitable for curative
treatment, or Child–Pugh class A or B and Okuda stage I or II
Kawai 199262 TACE TAE HCC patients
Chang 199463 TACE TAE Untreated patients with inoperable HCC
Meyer 201364 TACE TAE Patients aged ≥ 16 years with HCC not eligible for surgical
resection
Yu 201465 TACE TAE Unresectable HCC
Malagari 201066 DEB-TACE TAE HCC patients unsuitable for curative treatments, with potentially
resectable lesions but at high risk for surgery and patients with
HCC suitable for RFA but of high risk because of location
Brown 201667 DEB-TACE TAE Adults with HCC with ECOG score of 0 to 1 and Okuda stage I
or II
DOI: 10.3310/hta24480 Health Technology Assessment 2020 Vol. 24 No. 48
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
15
Four of the retrospective comparative studies were rated as being at a high risk of bias.38–40,42 The two
studies by Biederman et al.38,39 appear to have included many of the same patients, although one of the
studies was reported only as a conference abstract, with very limited study details.38 Each of the studies
rated as being at a high risk of bias appeared to include patients with different prognostic characteristics
at baseline in the two different treatment groups. It was unclear whether or not outcome assessors were
blinded in any of the studies. The study by Bhangoo et al.41 was rated as being at an unclear risk of bias; it
was unclear whether or not treatment groups were similar at baseline, whether or not outcome assessors
were blinded and whether or not missing outcome data were balanced across treatment groups.
The small case series undertaken by Radosa et al.51 should be considered to be at a high risk of bias;
it is unclear whether or not patients were representative of all those who would be eligible for SIRT
in clinical practice, outcome assessors were not blinded to the participants’ intervention and outcome
measures were not consistently assessed.
Efficacy and safety of SIR-Spheres
As discussed in Study design, RCTs were eligible for inclusion in the clinical effectiveness review, with
non-randomised comparative studies and non-comparative studies considered for inclusion, in the
absence of sufficient RCT evidence. Five RCTs of SIR-Spheres were identified, comparing SIR-Spheres
with established therapies available to patients with intermediate (TACE/DEB-TACE) and advanced
(sorafenib) HCC. Other studies of SIR-Spheres identified also compared with sorafenib or TACE
(see Table 3); therefore, they were not included in the review.
This section focuses on the two large good-quality RCTs (SARAH and SIRveNIB) and also presents a
brief summary of the three lower-quality RCTs of SIR-Spheres.
The SARAH and SIRveNIB randomised controlled trials
Two large RCTs compared SIR-Spheres with sorafenib in patients who were not suitable for curative
treatments: the SARAH trial was conducted in France19,20 and the SIRveNIB trial was conducted in the
Asia-Pacific region.21 Both trials were considered to have a low overall risk of bias (see Appendix 5).
Further details of these trials are presented in Table 5.
As shown in Table 5, there were methodological differences between the SARAH and the SIRveNIB
trials. In the SIRveNIB trial, patients could receive only one SIRT delivery, whereas in the SARAH trial
patients could receive more than one delivery of SIRT; 69 out of 184 (37.5%) patients who received
SIRT received more than one delivery to either the ipsilateral or the contralateral lobe.
The SARAH trial was conducted in France and the SIRveNIB trial was conducted in the Asia-Pacific
region. This has implications for the generalisability of the SIRveNIB trial results to the UK population.
HCC in European patients is more likely to be caused by alcohol or hepatitis C, whereas in Asia it is
more likely to be caused by hepatitis B. The natural history of these diseases is different. Treatment
options are also different, as hepatitis B-related liver disease is often less advanced than in alcohol-
related or hepatitis C-related disease; therefore, patients may have had more treatment prior to
receiving systemic therapy.
The Sirtex submission stated that patient selection in the SARAH trial did not reflect UK clinical
practice, as the trial included patients with a poor survival prognosis who would be considered for only
systemic therapy or BSC [e.g. because of a high tumour burden, main PVT or impaired liver function
(Child–Pugh class B)]. Therefore, this has implications for the generalisability of the SARAH trial results
to the UK population who would be eligible for SIRT in clinical practice.
In both trials, patients were assessed for suitability of SIRT after randomisation. In the SARAH trial,
53 out of 237 (22.4%) patients allocated to SIR-Spheres did not receive SIRT, 26 of whom were
treated with sorafenib. In the SIRveNIB trial, 52 out of 182 (28.6%) patients allocated to SIR-Spheres
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TABLE 5 Details of the SARAH and SIRveNIB RCTs
Characteristic SARAH19 SIRveNIB21
Trial characteristic
Study design Multicentre open-label RCT Multicentre open-label RCT
Location France (25 centres) Asia-Pacific region (11 countries)
Source of funding Sirtex Sirtex
Inclusion criteria Locally advanced HCC (BCLC stage C) or new HCC
not eligible for surgery/ablation after previously
cured HCC (cured by surgery or thermoablative
therapy) or HCC with two unsuccessful rounds
of TACE. Life expectancy of > 3 months, ECOG
performance status 0 or 1, Child–Pugh class A or B
score of ≤ 7
Locally advanced HCC (BCLC stage B
or C without extrahepatic disease)
with or without PVT, not amenable
to curative treatment modalities
Intervention SIR-Spheres (n = 237)
Patients underwent angiography, protective coiling
and MAA-SPECT/computerised tomography scan
and were readmitted for SIRT 1 or 2 weeks later. In
bilobar tumours, the first treatment was delivered
to the hemiliver with the greatest tumour burden
and the contralateral hemiliver was scheduled for
treatment 30–60 days after the first treatment. If
the tumour progressed, SIRT could be repeated
184/237 patients received SIR-Spheres:
l One (unilobar) treatment = 115 patients
l Two (ipsilateral) treatments = 17 patients
l Two (contralateral) treatments = 41 patients
l Three (ipsilateral) treatments = two patients
l Three (contralateral) treatments = nine patients
53/237 (22%) patients did not receive SIRT
SIR-Spheres (n = 182)
Patients underwent angiographic and
MAA assessment of suitability for
SIRT. Eligible patients received a
single delivery of SIRT
52/182 (28.6%) patients did not
receive SIRT
Comparator Sorafenib (n = 222)
Continuous oral sorafenib (400 mg twice daily)
Sorafenib (n = 178)
Continuous oral sorafenib (400 mg
twice daily)
Primary outcome OS OS
Secondary outcomes l PFS
l Tumour response
l Adverse events
l Quality of life (EORTC QLQ-C30 version 3 and
the specific HCC module QLQ-HCC18)
l PFS
l Tumour response
l Adverse events
l Quality of life (EQ-5D)
Baseline patient characteristic (ITT population)
SIR-Spheres Sorafenib SIR-Spheres Sorafenib
Number of patients 237 (ITT)
174 (per protocol)
222 (ITT)
206 (per protocol)
182 (ITT)
130 (per
protocol)
178 (ITT)
162 (per
protocol)
Median/mean age
(years)
66 (IQR 60–72) 65 (IQR 58–73) 59.5 (SD 12.9) 57.7 (SD 10.6)
Proportion male (%) 89 91 80.8 84.8
continued
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TABLE 5 Details of the SARAH and SIRveNIB RCTs (continued )
Characteristic SARAH19 SIRveNIB21
Cirrhosis present,
n (%)
211 (89) 201 (91) NR NR
Cause of HCC, n (%)
Alcohol 147 (62)a 124 (56)a NR NR
Non-alcoholic
steatohepatitis
49 (21)a 60 (27)a NR NR
Hepatitis B 13 (5)a 15 (7)a 93 (51.1) 104 (58.4)
Hepatitis C 55 (23)a 49 (22)a 26 (14.3) 19 (10.7)
Hepatitis B and C NR NR 4 (2.2) 5 (2.8)
Other/unknown 45 (19)a 41 (18)a NR NR
BCLC classification, n (%)
Stage A 9 (4) 12 (5) 0 1 (0.6)
Stage B 66 (28) 61 (27) 93 (51.1) 97 (54.5)
Stage C 162 (68) 149 (67) 88 (48.4) 80 (44.9)
Child–Pugh
classification, n (%)
A5 +A6: 196 (83)
B7: 39 (16)
Unknown: 2 (1)
A5 +A6: 187 (84)
B7: 35 (16)
Unknown: 0 (0)
A: 165 (90.7)
B: 14 (7.7)
A: 160 (89.9)
B: 16 (9.0)
ECOG performance status, n (%)
0 145 (61) 139 (63) 135 (74.2) 141 (79.2)
1 92 (39) 83 (37) 47 (25.8) 37 (20.8)
Tumours, n (%)
Single 110 (46) 96 (43) NR NR
Multiple 127 (54) 126 (57)
Tumour involvement, n (%)
Unilobar 187 (79) 187 (84) NR NR
Bilobar 50 (21) 35 (16)
MVI, n (%) 149 (63) 128 (58) NR NR
PVT, n (%) NR NR 56 (30.8) 54 (30.3)
Portal venous invasion, n/N (%)
Main portal vein 49/143 (34) 38/118 (32) NR NR
Main portal branch
(right or left)
65/143 (46) 59/118 (50)
Segmental 29/143 (20) 21/118 (18)
Portal vein occlusion, n/N (%)
Complete 18/48 (38) 18/38 (47) NR NR
Incomplete 30/48 (62) 20/38 (53)
Previously received
TACE, n (%)
106/237 (45) 94/222 (42) NR NR
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did not receive SIRT, three of whom were treated with sorafenib (where reported; subsequent
treatments were not reported for 31/52 patients). Results were presented for both the intention-to-
treat (ITT) and the per-protocol populations; patients who did not receive their allocated treatment
were excluded from the per-protocol analysis (those who received sorafenib instead of SIRT were not
included in the sorafenib arm in the per-protocol analysis).
TABLE 5 Details of the SARAH and SIRveNIB RCTs (continued )
Characteristic SARAH19 SIRveNIB21
Trial results
Median OS (months) 8.0 (95% CI 6.7 to 9.9) 9.9 (95% CI 8.7 to 11.4) 8.8 10.0
HR 1.15, 95% CI 0.94 to 1.41; p = 0.18 (ITT)
HR 0.99, 95% CI 0.79 to 1.24 (per protocol)
HR 1.12, 95% CI 0.9 to 1.4; p = 0.36
(ITT)
HR 0.86, 95% CI 0.7 to 1.1; p = 0.27
(per protocol)
Median PFS (months) 4.1 (95% CI 3.8 to 4.6) 3.7 (95% CI 3.3 to 5.4) 5.8 5.1
HR 1.03, 95% CI 0.85 to 1.25; p = 0.76 (ITT) HR 0.89, 95% CI 0.7 to 1.1; p = 0.31
(ITT)
HR 0.73, 95% CI 0.6 to 0.9;
p = 0.0128 (per protocol)
TTP (months) NR 6.1 5.4
Tumour response rate 36/190 (19%) evaluable
patients achieved a
complete (n = 5) or
partial (n = 31) response
23/198 (12%) evaluable
patients achieved a
complete (n= 2) or
partial (n = 21) response
16.5% (all partial
response, 0%
achieved a
complete
response)
1.7% (all partial
response, 0%
achieved a
complete
response)
Rates of subsequent
liver transplantation
or resection
6/237 (2.5%) had
tumour ablationb
3/237 (1.3%) had liver
surgeryb
2/237 (0.8%) had liver
transplantation
2/222 (0.9%) had
tumour ablation
1/222 (0.5) had liver
transplantation
1/182 (0.5%) had
radiofrequency
ablation
2/182 (1.1%) had
surgery
2/178 (1.1%) had
radiofrequency
ablation
1/178 (0.6%)
had surgery
HRQoLc Global health status subscore was significantly
better in the SIRT group than in the sorafenib group
(group effect p = 0.0048; time effect p < 0.0001) and
the between-group difference tended to increase
with time (group × time interaction p = 0.0447)
There were no statistically significant
differences in the EQ-5D index
between the SIRT and sorafenib groups
throughout the study in either the ITT
or the per-protocol populations
Number of patients
reporting treatment-
related adverse
events, n/N (%)
173/226 (77) 203/216 (94) 78/130 (60) 137/162 (84.6)
Number of patients
reporting grade
≥ 3 adverse events,
n/N (%)
92/226 (41) 136/216 (63) 36/130 (27.7) 82/162 (50.6)
CI, confidence interval; EORTC QLQ, European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire; EQ-5D, EuroQol-5 Dimensions; HR, hazard ratio; IQR, interquartile range; ITT, intention to treat;
MAA, macroaggregated albumin; NR, not reported; SD, standard deviation.
a The same patient could have several causes of disease.
b Further information provided by Sirtex in response to clarification questions stated that 7/237 patients had
radiofrequency ablation and 4/237 patients had resection.
c HRQoL assessment had missing values for a high proportion of patients at most time points for SARAH and at some
time points for SIRveNIB.
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The SARAH and SIRveNIB trial publications reported baseline characteristics for both the ITT and the
per-protocol populations.19,21 The SIR-Spheres and sorafenib groups were generally similar at baseline
in the ITT populations (see Table 5). However, in the per-protocol population, patients in the sorafenib
arm appeared to have slightly worse disease characteristics than those in the SIR-Spheres arm in the
SARAH trial (BCLC stage C: 69.4% vs. 65.5%; Child–Pugh class B7: 14.6% vs. 11.5%; median tumour
burden: 20% vs. 12.5%, respectively) and in the SIRveNIB trial (BCLC stage C: 45.1% vs. 38.5%;
PVT: 29.6% vs. 23.1%; tumour size > 50% of liver: 21.6% vs. 17.7%, respectively).
Overall survival Neither trial found a statistically significant difference in OS between SIR-Spheres
and sorafenib in either the ITT or the per-protocol analyses, as shown in Table 5.
Both trials undertook subgroup analyses according to baseline characteristics. The SIRveNIB trial
reported a statistically significant difference in OS favouring SIR-Spheres in the subgroup of patients
with BCLC stage C disease in the per-protocol analysis [median 9.2 vs. 5.8 months, hazard ratio (HR)
0.67, 95% confidence interval (CI) 0.4 to 1.0; p = 0.0475]. The SARAH trial demonstrated a statistically
significant difference in OS favouring sorafenib in the subgroup of patients with complete occlusion
in the main portal vein in the per-protocol analysis (HR 2.44, 95% CI 1.01 to 5.88); however, the
number of patients included in this subgroup analysis was very small, so the result should be interpreted
with caution.
Progression-free survival In the SARAH trial, PFS was defined as the time from the closest date of
radiological examination before first administration of study treatment to disease progression, in
accordance with Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria,68 or death. In the
SIRveNIB trial, PFS was defined as the time from the date of randomisation to tumour progression at
any site in the body, or death, whichever is earlier. Tumour progression was assessed in accordance
with RECIST 1.1 criteria.68
Progression-free survival was not statistically significantly different between treatment groups in
the ITT analyses of either the SARAH or the SIRveNIB trials. However, in the SIRveNIB trial, PFS was
statistically significantly improved with SIR-Spheres in the per-protocol analysis (HR 0.73, 95% CI
0.6 to 0.9; p = 0.0128).
Tumour response rate Tumour response was statistically significantly greater in the SIR-Spheres arm
than in the sorafenib arm in both the SARAH and the SIRveNIB trials (SARAH: 19% vs. 12%, p = 0.0421;
SIRveNIB: 16.5% vs. 1.7%, p < 0.001). However, in the SARAH trial, only 190 SIR-Spheres patients and
198 sorafenib patients were evaluable and included in the analysis.
Rate of liver transplantation or resection A very small proportion of patients in both treatment
arms of the SARAH and the SIRveNIB trials went on to have subsequent liver transplantation (< 1%),
liver surgery (0.6–1.3%) or tumour ablation (0.5–2.5%).
Quality of life The SARAH trial reported statistically significantly better HRQoL in the SIR-Spheres
treatment group than in the sorafenib group for both the ITT and the per-protocol populations, assessed
using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ)-C30. However, the proportion of patients who completed questionnaires was 71% in
the SIR-Spheres group (169/237) and 84% (186/222) in the sorafenib group at baseline, reducing with
time to only 29% (26/90 patients at risk) in the SIR-Spheres group and 32% (29/92 patients at risk) in
the sorafenib group at 12-month follow-up. There was no statistically significant difference in HRQoL
between the treatment groups in the SIRveNIB trial, assessed using the EuroQol-5 Dimensions
(EQ-5D) index.
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Adverse events The proportion of patients reporting at least one treatment-related adverse event
(TRAE) and the proportion reporting at least one grade ≥ 3 adverse event (AE) was higher in the
sorafenib group than in the SIR-Spheres group in both trials, as shown in Table 5.
In the SARAH trial, the most frequent grade ≥ 3 AEs were fatigue (SIR-Spheres 9% vs. sorafenib 19%),
liver dysfunction (11% vs. 13%), increased laboratory liver values (9% vs. 7%), haematological abnormalities
(10% vs. 14%), diarrhoea (1% vs. 14%), abdominal pain (3% vs. 6%), increased creatinine (2% vs. 6%)
and hand–foot skin reaction (< 1% vs. 6%).
In the SIRveNIB trial, the most frequent grade ≥ 3 AEs of interest were anaemia (SIR-Spheres 0% vs.
sorafenib 2.5%), fatigue (0% vs. 3.7%), diarrhoea (0% vs. 3.7%), abdominal pain (2.3% vs. 1.2%), ascites
(3.8% vs. 2.5%), hypertension (0% vs. 1.2%), upper gastrointestinal haemorrhage (0.8% vs. 1.9%),
jaundice (0.8% vs. 1.2%), radiation hepatitis (1.5% vs. 0%) and hand–foot skin reaction (0% vs. 16.7%).
The AE profiles of SIRT and sorafenib are very different. Sorafenib is a continuous treatment, whereas
most patients receive only one delivery of SIRT [37.5% patients in the SARAH trial received more than
one delivery, either to the ipsilateral or to the contralateral lobe (primarily because of bilobar tumours
or a large central tumour requiring bilateral treatment), whereas in the SIRveNIB trial patients received
only one delivery]. AE rates were not reported separately for patients who received more than one
delivery of SIRT; therefore, it is not possible to compare AE rates for patients who received one delivery
with those who received more than one delivery. In the SARAH trial, patients with bilobar tumours
received the first treatment in the hemiliver with the greatest tumour burden, and treatment of the
contralateral hemiliver was scheduled 30–60 days after the first treatment. No patient had a whole-liver
treatment approach in one session. Clinical advisors confirmed that this is reflective of their experience;
patients would not receive whole-liver treatment in one session to reduce the risk of radioembolisation-
induced liver disease (REILD). However, the Sirtex submission states that SIR-Spheres can be administered
to both lobes of the liver during the same procedure [based on observational data in which 95.9%
patients in the European Network on Radioembolisation with Yttrium-90 Resin Microspheres (ENRY)
register received whole-liver treatments in a single session69]; neither the SARAH trial nor the SIRveNIB
trial administered SIR-Spheres to both lobes during the same procedure. This variance is probably
because of the clinical indication for SIRT; the ENRY register is likely to include a majority of patients
with colorectal cancer liver metastases, who do not have underlying cirrhosis, whereas in HCC patients
the cirrhotic liver is likely to be more susceptible to REILD.
A relatively large proportion of patients who undergo work-up for SIRT, to assess their suitability for
the procedure, are unable to receive SIRT (e.g. owing to liver-to-lung shunting or unfavourable hepatic
arterial anatomy) [42/226 (18.6%) in SARAH and 37/182 (20.3%) in SIRveNIB]. The work-up of patients
who are unable to undergo SIRT delivery has cost implications.
The SARAH randomised controlled trial subgroup analysis (low tumour burden/low
albumin–bilirubin grade)
The Sirtex company submission selected a subgroup of patients from the SARAH trial with ≤ 25%
tumour burden and albumin–bilirubin (ALBI) 1 for their base-case analysis in the economic model; the
company stated that these patients are considered the most appropriate candidates for SIR-Spheres
in clinical practice, as they are the most likely to benefit from SIRT. This is not a clinically recognised
subgroup and was based on a post hoc analysis; therefore, these results should be prospectively
validated before being considered relevant for clinical practice.
This subgroup included 37 (16%) patients in the SIRT group and 48 (22%) patients in the sorafenib
group; 92% of those allocated to SIRT received treatment after work-up. Baseline characteristics were
relatively well balanced between treatment groups, although more patients in the SIRT arm had BCLC
stage B disease, single tumours and received previous TACE (these patients generally have a better
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prognosis than patients who are diagnosed at a later stage and are not eligible for TACE) than in the
sorafenib arm. More patients in the sorafenib arm had an ECOG performance status of 0 and unilobar
liver involvement. Table 6 presents the baseline characteristics and results for the full ITT population
and the low tumour burden/low ALBI grade subgroup of the SARAH trial.
TABLE 6 Details of the ITT population and the low tumour burden/low ALBI grade subgroup of SARAH
Characteristic
ITT population
Low tumour burden/
low ALBI grade subgroup
SIR-Spheres Sorafenib SIR-Spheres Sorafenib
Baseline patient characteristic
Number of patients 237 222 37 48
Median age (years) 66 65 NR NR
Age group (years) (%)
≥ 65 NR NR 43 48
< 65 NR NR 57 52
BCLC classification (%)
Stage A 4 5 3 6
Stage B 28 27 43 35
Stage C 68 67 54 58
Child–Pugh
classification (%)
A5 +A6: 83
B7: 16
Unknown: 1
A5 +A6: 84
B7: 16
Unknown: 0
A: 95
B: 5
A: 98
B: 2
ECOG performance status (%)
0 61 63 62 79
1 39 37 38 21
Tumours (%)
Single 46 43 43 33
Multiple 54 57 57 67
Tumour involvement (%)
Unilobar 79 84 76 85
Bilobar 21 16 24 15
MVI (%) 63 58 54 52
Portal venous invasion, n/N (%)
Main portal vein 49/143 (34) 38/118 (32) 11 10
Main portal
branch
65/143 (46) 59/118 (50)
Segmental 29/143 (20) 21/118 (18)
Previously received
TACE (%)
45 42 51 44
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As shown in Table 6, median OS and PFS appeared to be better in the SIR-Spheres arm than in the
sorafenib arm in the post hoc subgroup analysis, although the difference between treatment groups
was not statistically significant. The proportion of patients who went on to have potentially curative
therapy was higher in the SIR-Spheres arm than in the sorafenib arm, although numbers were very
low (five and one patients, respectively). Tumour response rate, HRQoL and AEs were not reported
separately for the low tumour burden/low ALBI grade subgroup.
Prespecified and post hoc subgroup analysis results were presented in the SARAH trial publication for
OS.19 Tumour burden was included as a post hoc subgroup. However, neither the ALBI grade nor the
combination of low tumour burden and low ALBI grade was presented.
The SIRveNIB trial did not report subgroup analysis results for the subgroup of low tumour burden/low
ALBI grade patients. However, ALBI grade was included in the OS subgroup analysis. Results favoured
TABLE 6 Details of the ITT population and the low tumour burden/low ALBI grade subgroup of SARAH (continued )
Characteristic
ITT population
Low tumour burden/
low ALBI grade subgroup
SIR-Spheres Sorafenib SIR-Spheres Sorafenib
Trial results
Median OS
(months)
8.0 (95% CI 6.7 to 9.9) 9.9 (95% CI 8.7 to 11.4) 21.9 (95% CI
15.2 to 32.5)
17.0 (95% CI
11.6 to 20.8)
HR 1.15, 95% CI 0.94 to 1.41; p = 0.18 HR 0.73, 95% CI 0.44 to
1.21; p = 0.22
Median PFS
(months)
4.1 (95% CI 3.8 to 4.6) 3.7 (95% CI 3.3 to 5.4) NR NR
HR 1.03, 95% CI 0.85 to 1.25; p = 0.76 HR 0.65, 95% CI 0.41 to
1.02; p = 0.06
Tumour response
rate
36/190 (19%) evaluable
patients achieved a complete
(n = 5) or partial (n= 31)
response
23/198 (12%) evaluable
patients achieved a complete
(n = 2) or partial (n = 21)
response
NR NR
Rates of
subsequent liver
transplantation or
resection
6/237 (2.5%) had tumour
ablationa
3/237 (1.3%) had liver
surgerya
2/237 (0.8%) had liver
transplantation
2/222 (0.9%) had tumour
ablation
1/222 (0.5%) had liver
transplantation
14%
(subsequent
curative
therapy)
2%
(subsequent
curative
therapy)
HRQoLb Global health status subscore was significantly better in
the SIRT group than in the sorafenib group (group effect
p = 0.0048; time effect p < 0.0001) and the between-group
difference tended to increase with time (group*time interaction
p = 0.0447)
NR
Number of patients
reporting TRAEs,
n/N (%)
173/226 (77) 203/216 (94) NR NR
Number of patients
reporting grade
≥ 3 AEs, n/N (%)
92/226 (41) 136/216 (63) NR NR
NR, not reported.
a Further information provided by Sirtex in response to clarification questions stated that 7/237 patients had
radiofrequency ablation and 4/237 patients had resection.
b HRQoL assessment had missing values for a high proportion of patients at most time points for SARAH and at some
time points for SIRveNIB.
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SIR-Spheres in the subgroup of ALBI 1 patients (HR 0.89, 95% CI 0.6 to 1.4; p = 0.58), whereas results
favoured sorafenib for the subgroup of patients with ALBI 2/3 (HR 1.24, 95% CI 0.9 to 1.7; p = 0.14).
Other randomised controlled trials of SIR-Spheres
The SIRTACE is a small RCT rated as being at a high risk of bias that compared SIR-Spheres (n = 13)
with TACE (n = 15) in patients with unresectable HCC without portal vein occlusion.22 A higher
proportion of patients in the SIRT group had BCLC stage A disease (38.5% vs. 26.7%) and Child–Pugh
liver function class A (92.3% vs. 86.7%) than in the TACE group. The average number of tumour
nodules was higher in the TACE group (5.0 vs. 3.5). Therefore, patients in the SIR-Spheres treatment
arm had a better prognosis than those in the TACE arm.
At 6 months, 69.2% of SIRT patients and 86.7% of TACE patients were still alive. At 12 months,
46.2% of SIRT patients and 66.7% of TACE patients were still alive. PFS, disease control rate and
the proportion of patients who went on to have potentially curative therapy were similar between
treatment groups. The proportion of patients with a partial response was higher in the SIRT group than
in the TACE group (30.8% vs. 13.3%), although patient numbers were very small.
There were no statistically significant differences between treatment groups in HRQoL by week 12,
despite Functional Assessment of Cancer Therapy Hepatobiliary-Pancreatic Symptom Index (FACT-Hep)
scores being lower in the SIRT group at baseline (indicating lower quality of life). However, 10 out of
28 patients had missing baseline data and were excluded from HRQoL analyses. The proportion of
patients reporting TRAEs was higher in the TACE group than in the SIRT group (33.3% vs. 23.1%),
although the proportion of patients reporting at least one AE was higher in the SIRT group (92.3% vs.
66.7%), as was the number of patients with grade ≥ 3 AEs (three vs. two patients) and serious AEs
requiring hospitalisation (seven vs. five patients).
A small RCT by Pitton et al.,23 with some concerns regarding bias, compared SIR-Spheres (n = 12) with
DEB-TACE (n = 12) in patients with unresectable intermediate (BCLC stage B) HCC with preserved
liver function (Child–Pugh class A–B7). Treatment groups appeared reasonably similar at baseline,
although more patients in the SIRT group had received prior local ablation (four vs. one) and more
patients in the DEB-TACE group had received prior resection (five vs. three). Median OS and PFS were
longer in the DEB-TACE arm than in the SIR-Spheres arm (788 days vs. 592 days and 216 days vs.
180 days, respectively), although the difference between groups was not statistically significant. Median
TTP was 371 days in the SIRT arm and 336 days in the DEB-TACE arm. AEs were not reported.
The SORAMIC RCT compared SIR-Spheres followed by sorafenib with sorafenib alone in patients
with unresectable intermediate or advanced (BCLC stage B or C) HCC with preserved liver function
(Child–Pugh class ≤ B7) and ECOG performance status of < 2, who were poor candidates for TACE.
Only safety and tolerability data for the first 40 patients have been published to date, rated as being
at a high risk of bias.24 More patients in the sorafenib-alone group had PVT (35% vs. 15%) and BCLC
stage C disease (70% vs. 60%), indicating poorer prognosis in this group. There were 196 treatment-
emergent AEs reported in the SIRT plus sorafenib arm and 222 events in the sorafenib-alone arm, of
which 21.9% and 21.2%, respectively, were considered to be grade ≥ 3. The most common grade 3 or 4
AEs (hypertension, hand–foot skin reaction and diarrhoea) were reported in a similar number of patients
in both treatment arms. Grade 3 or 4 fatigue appeared more common in patients receiving SIRT plus
sorafenib (20% vs. 10%). Grade 3 or 4 infection and anorexia appeared more common in patients receiving
sorafenib alone (20% vs. 5% and 0% vs. 10%, respectively). Grade 3 or 4 laboratory-related events were
more common in patients receiving sorafenib alone (elevated gamma-glutamyltransferase level 45% vs.
30%, elevated aspartate aminotransferase level 15% vs. 0% and elevated alanine aminotransferase level
10% vs. 0%). One patient experienced a grade 3 gastric ulcer that was probably (but not proven to be)
related to SIRT microspheres deposition.
Further details of each of these trials are presented in Appendix 6.
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Ongoing studies
There are three ongoing studies of SIR-Spheres including patients with HCC: the Austrian Cardiovascular
and Interventional Radiological Society of Europe Registry for SIR-Spheres Therapy (CIRT),70 the RESIN
tumour registry in the USA71 and the RESIN tumour registry in Taiwan.72 The CIRT study was completed
in January 2020, the RESIN tumour registry study in the USA is due to be completed in August 2022 and
the RESIN tumour registry study in Taiwan was due to be completed in December 2019.
There is also an ongoing individual patient data prospective meta-analysis of patients from the
SIRveNIB and SARAH trials: VESPRO.73
Efficacy and safety of TheraSphere
As discussed in Study design, RCTs were eligible for inclusion in the clinical effectiveness review.
Non-randomised comparative studies (including retrospective studies) and non-comparative studies
were considered for inclusion in the absence of sufficient RCT evidence. Only two small RCTs of
TheraSphere were identified. Therefore, prospective non-randomised comparative studies were also
included in the clinical effectiveness review; seven non-RCTs were included, most of which compared
TheraSphere with TACE/DEB-TACE. The retrospective comparative studies of TheraSphere that were
identified also compared against TACE/DEB-TACE (see Table 3); therefore, they were not included in
the review as they were considered to be lower quality than the prospective comparative studies.
One small RCT rated as being at a high risk of bias (PREMIERE) compared TheraSphere (n = 24) with
TACE (n = 21) as a bridge to transplant in patients with BCLC stage A or B unresectable HCC with
no vascular invasion and Child–Pugh liver function class A or B.25–27 The proportion of patients with
Child–Pugh class A was much higher in the TACE arm than in the TheraSphere arm (71% vs. 50%) and
the proportion of patients with portal hypertension was much lower in the TACE arm (52% vs. 83%),
suggesting better prognosis in the TACE arm. OS was slightly longer in the TheraSphere arm (18.6 months
vs. 17.7 months) and the rate of liver transplant/resection was also higher in the TheraSphere arm (87% vs.
70% of ‘listed patients’), although time to transplant/resection was slightly longer in the TheraSphere arm
(8.8 months vs. 7.6 months). TTP was significantly longer in the TheraSphere arm: overall median TTP was
not reached in the TheraSphere arm (> 26 months) and was 6.8 months in the TACE arm (HR 0.112,
95% CI 0.027 to 0.557; p= 0.007); TTP in the non-transplanted patients was also significantly longer in the
TheraSphere arm (median > 26 months vs. 4.8 months). AEs and HRQoL were not reported.
One small RCT by Kulik et al.,28–30 which caused some concerns regarding bias, compared TheraSphere
plus sorafenib (n = 10) with sorafenib alone (n = 10) as a bridge to transplant in patients with
Child–Pugh liver function class ≤ B8 HCC who were potential candidates for liver transplant. A higher
proportion of patients in the TheraSphere plus sorafenib arm were male (80% vs. 50%) and had BCLC
stage A disease (70% vs. 50%), with more patients in the TheraSphere-alone arm having BCLC stage C
disease (40% vs. 20%). More patients in the TheraSphere plus sorafenib arm had ECOG performance
status 0 (80% vs. 60%) and Child–Pugh liver function class A (80% vs. 60%). Three patients died in the
TheraSphere arm, compared with two patients in the TheraSphere plus sorafenib arm. The proportion
of patients receiving liver transplant or resection was 90% in each treatment arm. Most AEs were
more common in the TheraSphere-alone arm (fatigue 90% vs. 40%, diarrhoea 20% vs. 10%, pain 50%
vs. 0%, nausea 70% vs. 20% and vomiting 20% vs. 0%), although grade ≥ 3 hand–foot skin reaction was
more common in the TheraSphere plus sorafenib arm (20% vs. 0%).
Five prospective comparative studies, all rated as being at a high risk of bias, compared TheraSphere
with TACE/DEB-TACE in patients with HCC.31–35 Two studies assessed OS. In one small study (n = 86),
OS appeared slightly longer with TACE than with TheraSphere in patients with intermediate-stage
disease (median 18 months vs. 16.4 months).32 In a much larger study (n = 765) in which survival
outcomes were stratified by BCLC stage and Child–Pugh liver function class, survival was longer in the
TACE arm for patients with early- and intermediate-stage disease but longer in the TheraSphere arm
for patients with advanced-stage disease.35 Two small studies (n = 86 and n = 96) assessed TTP, which
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was longer with TheraSphere than with TACE (median 13.3 months vs. 6.8 months and median 13.3
months vs. 8.4 months).32,34 Two small studies (n = 67 and n = 86) assessed complete or partial response
rate; results were conflicting, with one study31 favouring TACE (2.3% vs. 0%, using RECIST criteria68)
and the other32 favouring TheraSphere (75% vs. 50%, using modified RECIST criteria68). Two small
studies (n = 67 and n = 56) assessed HRQoL, both favouring TheraSphere.31,33 Only one study (n = 86)
reported AEs; the most commonly reported AE (unspecific abdominal pain) was more frequent in TACE
patients than in SIRT patients (83% vs. 5%).32
One small prospective matched case–control study by Maccauro et al.,36 rated as being at a high risk of
bias, compared TheraSphere plus sorafenib (n = 15) with TheraSphere alone (n = 30) in patients with
predominantly BCLC stage C (due to PVT) unresectable HCC with Child–Pugh liver function class A.
The study was published only as a conference abstract; therefore, very limited data are available.
Results were similar between treatment groups for OS (median 10 months in each treatment arm),
PFS (median 6 months vs. 7 months in the TheraSphere plus sorafenib and TheraSphere-alone arms,
respectively) and response rate, using modified RECIST criteria68 (45.5% vs. 42.8%). However, response
rate using EASL criteria1 was better in the TheraSphere-alone arm (40% vs. 10%).
One small prospective comparative study by Woodall et al.,37 rated as being at a high risk of bias,
compared TheraSphere in HCC patients without PVT (n = 20) with TheraSphere in HCC patients with
PVT (n = 15) and a no-treatment control (BSC) in HCC patients who were not eligible for SIRT owing
to substantial extrahepatic disease or hepatopulmonary shunt or underlying liver insufficiency (n = 17).
OS was significantly longer in patients without PVT who received TheraSphere (median 13.9 months)
than in patients with PVT who received TheraSphere (median 3.2 months) and patients who received
BSC (median 5.2 months). AEs were more common in TheraSphere patients who had PVT than in those
who did not have PVT (33% vs. 25%). No other outcomes were reported.
Further details of each of these studies are presented in Appendix 6.
Ongoing studies
There is one ongoing RCT of TheraSphere in patients with HCC: STOP-HCC, which has an
estimated study completion date of February 2020; final results are not anticipated before at least
December 2020.74
The BTG submission presents 12 additional ongoing or planned studies of TheraSphere.
Efficacy and safety of QuiremSpheres
Only one study of QuiremSpheres has been completed in patients with HCC: a small case series
undertaken by Radosa et al.51 Nine patients with HCC were retrospectively identified from a
prospectively maintained database of patients who received QuiremSpheres between March 2017 and
April 2018 at a single centre. It is unclear whether or not patients were representative of all those
who would be eligible for SIRT in clinical practice. The available data are too limited to draw any
conclusions about the safety or efficacy of QuiremSpheres. Study details are presented in Appendix 6.
Ongoing studies
There are three ongoing studies of QuiremSpheres including patients with HCC: HEPAR Primary,75
HORA EST HCC76 and Hope166.77 All three studies are currently recruiting patients.
Direct comparisons of different selective internal radiation therapies
Five small retrospective comparative studies, all rated as being at a high or unclear risk of bias, compared
SIR-Spheres with TheraSphere. No studies were identified that directly compared QuiremSpheres with
either SIR-Spheres or TheraSphere. Further details of each of the five studies are presented in Appendix 6.
The two studies by Biederman et al. (n = 9738 and n = 9039) included patients who all had PVT and
appear to have included some of the same patients, although one of the studies was published only
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as a conference abstract,38 so it is unclear how much overlap there was. The study by d’Abadie et al.42
(n = 58 procedures) aimed to investigate the difference in efficacy per Gy of resin versus glass spheres
and whether or not the difference could result from the different degrees of heterogeneity in sphere
distribution; limited patient outcomes were reported.
Overall survival was reported in four studies [n = 97,38 n = 90 (possibly with some overlap),39 n = 7740
and n = 1741]. OS was longer in the TheraSphere arm in three of the studies,38,39,41 two of which
included patients who all had PVT.38,39 Median OS in the SIR-Spheres arm ranged from 3.7 to 7.7 months.
Median OS in the TheraSphere arm ranged from 7.0 to 15 months.
Progression-free survival was reported in only one study (n = 77), in which it was longer in the
SIR-Spheres arm (6.1 months vs. 5.0 months).40 However, TTP was reported for the two treatment
arms separately in one other study (n = 90 patients with PVT), in which it was longer in the
TheraSphere arm (5.9 months vs. 2.8 months).39
Tumour response rate was reported for the two treatment arms separately in only one study (n = 90
patients with PVT), in which a higher proportion of evaluable patients had a complete (8.8% vs. 0%) or
partial (31.6% vs. 13.3%) response in the TheraSphere arm.39
None of the studies reported HRQoL outcomes.
Adverse events were reported separately for the two treatment arms in two studies. The study by
Biederman et al.39 (n = 90 patients with PVT) reported no significant difference in pain (41.2% vs.
30.8%), fatigue (17.6% vs. 18.5%), nausea (17.6% vs. 3.1%) or anorexia (0% vs. 9.2%) between the
SIR-Spheres and TheraSphere arms, respectively. In the very small study by Bhangoo et al.41 (n = 17),
all clinical toxicities reported were more frequent in the SIR-Spheres arm than in the TheraSphere arm
(fatigue 67% vs. 45%, abdominal pain 33% vs. 27%, nausea/vomiting 67% vs. 55%, anorexia/weight loss
33% vs. 9%, diarrhoea 17% vs. 0% and gastric ulcer 17% vs. 0%).
An addendum, in the form of an academic-in-confidence manuscript, was received from Terumo Europe NV
(hereafter Terumo) in August 2019. The manuscript described a retrospective pilot study of (confidential
information has been removed) patients treated with QuiremSpheres, TheraSphere or SIR-Spheres at
two centres in Germany and the Netherlands. OS and response were assessed at 6 months for all three
interventions and at 12 months for QuiremSpheres and SIR-Spheres. Median OS was similar between the
treatment groups at 6 months (confidential information has been removed) and 12 months (confidential
information has been removed). The most commonly reported AEs were (confidential information has been
removed) abdominal pain, fatigue and nausea; other AEs were rarely reported. This was a very small pilot
study with unclear patient selection; patients in the TheraSphere group had poorer prognosis at baseline
than did the other two treatment groups. The authors acknowledge that the study carries several
methodological limitations.78
Clinical effectiveness summary and conclusions
SIR-Spheres
There are two large good-quality RCTs comparing SIR-Spheres with sorafenib (SARAH19,20 and SIRveNIB21).
There was no statistically significant difference in OS (HR 1.15, 95% CI 0.94 to 1.41 SARAH, and
HR 1.12, 95% CI 0.9 to 1.4 SIRveNIB) or PFS (HR 1.03, 95% CI 0.85 to 1.25 SARAH, and HR 0.89,
95% CI 0.7 to 1.1 SIRveNIB) in the SARAH or SIRveNIB trials in the ITT populations. However, tumour
response rate was significantly greater in the SIR-Spheres arm than in the sorafenib arm in both trials
(of patients who were evaluable and included in the analyses). The SARAH trial reported significantly
better HRQoL in the SIR-Spheres arm than in the sorafenib arm, assessed using the EORTC QLQ-C30,
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although the proportion of patients who completed the questionnaires was low, particularly at later
time points. The SIRveNIB trial found no significant difference in HRQoL assessed using the EQ-5D
index. The AE profiles of SIR-Spheres and sorafenib are very different, although the most common AEs
generally occurred more frequently in the sorafenib arm in both trials.
There are some concerns regarding the generalisability of the SARAH and SIRveNIB trials to patients
who would be eligible for SIRT in UK practice. The SIRveNIB trial was conducted in the Asia-Pacific
region, where the aetiology of HCC differs from that in European patients; HCC is predominantly
caused by hepatitis B in Asia, whereas it is predominantly caused by alcohol or hepatitis C in Europe.
The SARAH trial included patients with a poorer prognosis than those who would be considered for
SIRT in UK practice (e.g. high tumour burden, main PVT or impaired liver function).
Around one-fifth of patients in the SARAH and SIRveNIB trials were not suitable for SIRT after
work-up (e.g. due to liver-to-lung shunting or unfavourable hepatic arterial anatomy); a proportion of
patients assessed for suitability for SIRT in clinical practice would also be considered unsuitable, with
associated cost implications.
Patients with bilobar disease may require more than one administration of SIRT. In the SARAH trial,
patients with bilobar tumours received the first treatment in the hemiliver with the greatest tumour
burden, and treatment of the contralateral hemiliver was scheduled 30–60 days after the first treatment.
However, the Sirtex submission states that SIR-Spheres can be administered to both lobes of the liver
during the same procedure; neither the SARAH trial nor the SIRveNIB trial administered SIR-Spheres to
both lobes during the same procedure. Clinical advisors confirmed that this is reflective of their experience,
in which patients would not receive whole-liver treatment in one session to reduce the risk of REILD.
The Sirtex company submission selected a subgroup of patients from the SARAH trial with ≤ 25% tumour
burden and ALBI 1 for its base-case analysis in the economic model; the company stated that these
patients are considered the most appropriate candidates for SIR-Spheres in clinical practice, as they are
the most likely to benefit from SIRT. This is not a clinically recognised subgroup and was based on a post
hoc analysis; therefore, these results should be prospectively validated before being considered relevant
to clinical practice. Median OS (HR 0.73, 95% CI 0.44 to 1.21) and PFS (HR 0.65, 95% CI 0.41 to 1.02)
appeared better in the SIR-Spheres arm than in the sorafenib arm in the subgroup analysis, although the
difference between treatment groups was not statistically significant. The proportion of patients who
went on to have potentially curative therapy was higher in the SIR-Spheres arm than in the sorafenib arm,
although numbers were very low (five and one patients, respectively).
Three very small poorer-quality RCTs compared SIR-Spheres with TACE,22 DEB-TACE23 or SIR-Spheres
plus sorafenib versus sorafenib alone.24 The trials comparing SIR-Spheres with TACE or DEB-TACE
appeared to favour the chemoembolisation procedure over SIRT in terms of survival outcomes.22,23 The
addition of SIR-Spheres to sorafenib did not appear to increase the number of treatment-emergent AEs.24
TheraSphere
Two small RCTs25–30 and seven prospective comparative studies31–37 of TheraSphere were included in the
clinical effectiveness review; one of the RCTs (PREMIERE) and all of the non-RCT studies were rated as
being at a high risk of bias, and the other RCT caused some concerns regarding bias. Therefore, all of
these results should be interpreted with caution.
Both RCTs assessed TheraSphere as a bridge to transplant. The PREMIERE RCT reported longer TTP,
a higher proportion of patients undergoing transplant and slightly longer OS in the TheraSphere arm
than in the TACE arm.25–27 Kulik et al.28–30 reported similar survival and transplant/resection rates
between patients receiving TheraSphere plus sorafenib or sorafenib alone.
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Five prospective comparative studies compared TheraSphere with TACE or DEB-TACE; OS appeared
better with TheraSphere in patients with early- and intermediate-stage disease.32,35 TTP was longer
with TheraSphere than with TACE.32,34 Results relating to response rates were conflicting.31,32 HRQoL
appeared better with TheraSphere.31,33 One study reported that the most common AE was more
frequent with TACE than with SIRT.32
One prospective comparative study compared TheraSphere plus sorafenib with TheraSphere alone,
with similar results between treatment groups.36 The other study compared TheraSphere in patients
with or without PVT with no treatment in patients unsuitable for TheraSphere; OS was significantly
longer in patients without PVT who received TheraSphere compared with those with PVT who
received TheraSphere and those who received only BSC.37
QuiremSpheres
Only one study of QuiremSpheres has been completed in patients with HCC: a small case series
undertaken by Radosa et al.51 The available data are too limited to draw any conclusions about the
safety or efficacy of QuiremSpheres.
Direct comparison of different selective internal radiation therapies
Five small retrospective comparative studies, all rated as being at a high or unclear risk of bias,
compared SIR-Spheres with TheraSphere. Two of the studies included patients who all had PVT and
appear to have included some of the same patients.38,39 OS was reported in four studies, including the
two studies of patients with PVT; OS was longer in the TheraSphere arm in three of the studies.38,39,41
One study assessed PFS, which was longer with SIR-Spheres,40 and another study assessed TTP, which
was longer with TheraSphere (in patients with PVT).39 Tumour response rate was higher in the
TheraSphere arm than in the SIR-Spheres arm in patients with PVT.39 One very small study reported
more frequent clinical toxicities in the SIR-Spheres arm than in the TheraSphere arm.41 In patients with
PVT, there was no difference in the frequency of fatigue, but pain and nausea appeared more frequent
with SIR-Spheres, and anorexia appeared more frequent with TheraSphere.39
No studies were identified that directly compared QuiremSpheres with either SIR-Spheres or TheraSphere.
The BTG submission described a systematic review by Kallini et al.,79 supported by funding from
BTG, which aimed to compare the AE profiles of TheraSphere and SIR-Spheres for the treatment of
unresectable HCC. Twenty-two observational studies of TheraSphere and nine observational studies
of SIR-Spheres were included in the review and the number of AEs and number of patients across
studies were summed to calculate the proportion of patients experiencing each AE. No studies directly
comparing TheraSphere with SIR-Spheres were included in the review. AE reporting appears to have
been variable between studies, with many AEs being reported by very few of the included studies
(e.g. hepatobiliary and respiratory AEs). Baseline characteristics of patients were poorly reported in
many of the included studies. Gastric ulcers were reported more frequently with SIR-Spheres than with
TheraSphere [3.1% (six studies) vs. 0.1% (nine studies)], but the proportion of patients reporting ascites
was higher with TheraSphere than with SIR-Spheres [9.2% (10 studies) vs. 4.7% (5 studies)]. Nausea
(13 studies in total), fatigue (16 studies in total) and abdominal pain (18 studies in total) occurred in
similar proportions of patients for both interventions.79
An addendum, in the form of an academic-in-confidence manuscript, was received from Terumo in August
2019. OS and response were similar between the treatment groups. The most commonly reported AEs
were (confidential information has been removed) abdominal pain, fatigue and nausea; other AEs were
rarely reported. This was a very small pilot study with several methodological limitations.78
Conclusions
There is a large body of evidence on the clinical effectiveness and safety of SIRT compared with
sorafenib or TACE. Only two studies were considered to have a low risk of bias: SARAH19,20 and
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SIRveNIB,21 which both compared SIR-Spheres with sorafenib. However, there are some concerns
regarding the generalisability of the results of these two RCTs to the UK HCC population, particularly
the SIRveNIB trial, which was conducted in the Asia-Pacific region where the aetiology of HCC differs
from that in Europe.
Both RCTs found no significant difference in OS or PFS between SIR-Spheres and sorafenib, despite
statistically significantly greater tumour response rate in the SIR-Spheres arm of both trials. The
SARAH trial reported a significant difference between groups in HRQoL, favouring SIR-Spheres;
however, the proportion of patients who completed the questionnaires was low. AEs, particularly
grade ≥ 3 events, were more frequent in the sorafenib group in both trials.
The Sirtex company submission selected a subgroup of patients from the SARAH trial with ≤ 25%
tumour burden and ALBI 1 for its base-case analysis in the economic model. Although results appeared
more promising in this subgroup of patients with a better prognosis, these post hoc subgroup analysis
results should be prospectively validated before being considered relevant to clinical practice.
In studies comparing the different SIRT, patients with PVT appeared to have better survival outcomes
with TheraSphere than with SIR-Spheres; however, this result was from a small retrospective comparative
study rated as being at a high risk of bias and, therefore, may not be reliable. Other studies comparing
TheraSphere with SIR-Spheres that did not include only patients with PVT had conflicting results. The
only study that compared QuiremSpheres with SIR-Spheres and TheraSphere was provided by Terumo
as an addendum in August 2019. Clinical outcomes appeared to be similar between treatment groups;
however, this was a very small pilot study with several methodological limitations.
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Chapter 4 Evidence synthesis to inform
the relative efficacy of the interventions
Overview
Studies assessing the clinical effectiveness of SIRT for patients with unresectable HCC have been
discussed and summarised in Chapter 3. The PRISMA flow diagram describing the selection process is
shown in Figure 1. Treatment options vary greatly for patients with unresectable HCC according to
the stage and severity of cancer and liver disease, as described in Chapter 1, Current service provision.
Therefore, three NMA models were produced to represent the different populations of unresectable
HCC patients. The 26 comparative studies and RCTs included in the systematic review of clinical
effectiveness (see Table 3) and the 11 RCTs of CTTs (see Table 4) were screened for inclusion in each
of the three NMA models. Alongside this, two studies of systemic therapies were identified from
recent NICE single technology appraisals of sorafenib and lenvatinib: Llovet et al.80 and Kudo et al.81
Therefore, 39 studies were screened for inclusion in each of the three NMAs.
Network meta-analysis of adults with unresectable hepatocellular
carcinoma who are eligible for transplant and of those eligible for
conventional transarterial therapies
Meta-analysis using mixed treatment comparisons enables the estimation of different parameters
when direct evidence on comparisons of interest is absent or sparse. The statistical synthesis method
of NMA enables the comparison of multiple treatment options using both direct comparisons of
interventions from RCTs and indirect comparisons across trials based on a common comparator.82
As suggested by the term, NMA needs a ‘network of evidence’ to be established between all the
interventions of interest.
Network 1: adults with unresectable hepatocellular carcinoma who are eligible for transplant
The first model (network 1) included patients with early/intermediate-stage unresectable HCC who
were eligible for transplant. SIRT could potentially be used as a bridging treatment for patients awaiting
transplant as described in Chapter 1, Description of the technology under assessment. These patients are
generally classed as BCLC stage A patients, with preserved liver function and performance status 0–1.
To ensure consistency in the compared studies, studies were included only if ≥ 70% of the recruited
population had early-stage HCC or if results were split by disease stage. Only 2 out of 39 studies were
selected for network 1. This included two small RCTs: PREMIERE25 and Kulik et al.28 The main reason for
the exclusion of studies was patients having advanced-stage disease and, therefore, not being eligible for
transplant. The reasons for including and excluding each study are reported in Table 7.
However, clinical advice was that there are short transplant waiting times in the UK (< 2 months),
whereas the two trials in the network had transplant waiting times of roughly 7–9 months (mean
7.8 months in Kulik et al.28 and median 8.8 months in Salem et al.25). Therefore, the network may not be
generalisable to the UK and there may be limited opportunity for benefit in the UK given the short
waiting times. Clinicians advised that, in the UK, bridging treatment is also used during the work-up
phase, before the patient goes on to the waiting list. However, TACE rather than SIRT is more
commonly used in this context. Furthermore, the two RCTs included in the network have very small
sample sizes and, therefore, any efficacy estimates produced would be highly uncertain. Therefore,
network 1, of patients with early/intermediate-stage HCC, was not conducted as it was deemed
unsuitable for decision-making.
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TABLE 7 Network 1: adults with unresectable HCC who are potentially eligible for transplant
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Studies included in the network (n = 2)
Salem 201625–27
(PREMIERE)
45 TheraSphere TACE RCT Patients with early/intermediate
HCC with no vascular invasion.
The intent of therapy was
bridge to transplant
Kulik 201428 20 TheraSphere TheraSphere
plus sorafenib
RCT Adults with Child–Pugh class
≤ B8 and potential candidates
for orthotopic liver transplant.
BCLC stage C patients (30%)
were symptomatic only
Studies excluded from this network (n = 37)
Kolligs 201522
(SIRTACE)
28 SIR-Spheres TACE RCT Mixed population of early- and
intermediate-stage patients,
without portal vein occlusion.
Pilot trial funded by Sirtex.
Results split for transplantable
patients were requested but not
provided
Chow 201821
(SIRveNIB)
360 SIR-Spheres Sorafenib RCT Adults with locally advanced
HCC (BCLC B or C) not
amenable to curative treatment
Vilgrain 201719,84
(SARAH)
459 SIR-Spheres Sorafenib RCT Adults with locally advanced
HCC (BCLC C) or new HCC not
eligible for surgery/ablation
after previously cured HCC or
HCC with two unsuccessful
rounds of TACE. Only a few
patients received curative
therapy
Pitton 201523 24 SIR-Spheres DEB-TACE RCT Adults with intermediate-stage
HCC (BCLC stage B). Patients
eligible for curative therapy
were excluded
Ricke 201524
(SORAMIC)
40 SIR-Spheres
plus sorafenib
Sorafenib RCT Adults with unresectable
intermediate or advanced HCC
(BCLC stage B or C). No
patients received transplant
Kudo 201881
(REFLECT)
289 (subgroup
of 954 patients)
Lenvatinib Sorafenib RCT Subgroup of adults with
advanced-stage HCC, majority
had PVI or extrahepatic spread –
ineligible for transplant
Llovet 200880
(SHARP)
602 Sorafenib Placebo RCT Adults with intermediate- and
advanced-stage HCC, majority
had extrahepatic spread/
vascular invasion. Patients
ineligible for transplant
Malagari 201066 87 DEB-TACE TAE RCT Patients unsuitable for curative
treatments with potentially
resectable lesions but at high
risk for surgery
Brown 201667 101 DEB-TACE TAE RCT Mixed population and some
patients with PVI, ineligible for
transplant
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TABLE 7 Network 1: adults with unresectable HCC who are potentially eligible for transplant (continued )
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Lammer 201056,57
(PRECISION)
212 DEB-TACE TACE RCT No relevant outcomes reported
Golfieri 201458 177 DEB-TACE TACE RCT Adults with early-, intermediate-
and advanced-stage HCC
without PVT. The population is
too varied to include
Sacco 201159 67 DEB-TACE TACE RCT Patients with early- and
intermediate-stage HCC,
ineligible for transplant
van Malenstein
201160
30 DEB-TACE TACE RCT No relevant outcomes reported
Llovet 200261 112 TACE TAE RCT Adults with intermediate- and
advanced-stage HCC, ineligible
for transplant
Kawai 199262 289 TACE TAE RCT Patients with early/
intermediate-stage HCC but no
relevant transplant results
reported
Chang 199463 46 TACE TAE RCT Patients with inoperable HCC
Meyer 201364 86 TACE TAE RCT Patients with early-,
intermediate- and advanced-
stage HCC, ineligible for
transplant
Yu 201465 98 TACE TAE RCT Adults with early-, intermediate-
and advanced-stage HCC,
ineligible for transplant
Kirchner 201931 94 TheraSphere TACE/
DEB-TACE
Prospective
comparative
No relevant outcomes reported
Hickey 201635 765 TheraSphere TACE Prospective
comparative
Includes patients potentially
eligible for transplant, but no
transplant outcomes were
reported
El Fouly 201532 86 TheraSphere TACE Prospective
comparative
Adults with intermediate-stage
(BCLC B) unresectable HCC.
Patients eligible for curative
therapy were excluded
Salem 201333 56 TheraSphere TACE Prospective
comparative
No relevant outcomes were
reported
Woodall 200937 52 TheraSphere BSC Prospective
comparative
Patients with advanced-stage
HCC, ineligible for transplant
Memon 201483 96 TheraSphere TACE Prospective
comparative
No relevant outcomes reported
Maccauro 201436 45 TheraSphere
plus sorafenib
TheraSphere Matched
case–control
study
Patients with intermediate/
advanced HCC with PVT, not
appropriate for transplant
Salem 201147 245 TheraSphere TACE Retrospective
comparative
Majority of patients had early/
intermediate-stage HCC (88.1%)
and 39% were within Milan
transplant criteria (T2) but there
were no relevant outcomes
reported
continued
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Network 2: adults with unresectable hepatocellular carcinoma who are eligible for
conventional transarterial therapies
The second model was for patients with unresectable HCC who are eligible for CTTs. Patients in this
population tend to have intermediate-stage HCC (BCLC B); however, patients with advanced-stage HCC
(BCLC C) can also be eligible if they do not have PVT/PVI or extrahepatic spread. Studies in which the
majority of patients had intermediate-stage HCC (BCLC B) and ≤ 30% of patients had advanced disease
(BCLC C) were included. If studies reported results split by disease stage, they were included. A small
proportion of patients in this population may also be eligible for downstaging to transplant; however,
there was very little evidence to inform this. Furthermore, clinicians advised that the role of downstaging
HCC for liver transplantation is currently under evaluation in the UK and SIRT is not specifically required
for downstaging as this can be achieved using existing therapies, most commonly TACE.
TABLE 7 Network 1: adults with unresectable HCC who are potentially eligible for transplant (continued )
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Bhangoo 201541 17 TheraSphere SIR-Spheres Retrospective
comparative
Patients with intermediate/
advanced unresectable HCC
who either failed or had disease
not amenable to alternative
locoregional therapies
Cho 201643 63 SIR-Spheres Sorafenib Retrospective
comparative
Patients with BCLC stage C
HCC with PVT, not appropriate
for transplant
de la Torre 201644 73 SIR-Spheres Sorafenib Retrospective
comparative
Patients with HCC with PVI, not
appropriate for curative therapy
Van Der Gucht
201740
77 SIR-Spheres TheraSphere Retrospective
comparative
Patients with early, intermediate
and advanced HCC, not
appropriate for curative therapy
Biederman 201639 90 SIR-Spheres TheraSphere Retrospective
comparative
Patients with unresectable HCC
with main or lobar PVT, not
appropriate for curative therapy
Akinwande
201649,50
96 (matched
cohort of
358 patients)
TheraSphere DEB-TACE Retrospective
comparative
Adults with unresectable HCC
(with or without PVT), unlikely
transplant intent
Soydal 201646 80 SIR-Spheres TACE Retrospective
comparative
Patients with intermediate/
advanced-stage HCC, some
patients with extrahepatic
metastases
Gramenzi 201545 137 SIR-Spheres Sorafenib Retrospective
comparative
Patients with intermediate/
advanced HCC, not appropriate
for curative therapy
Moreno-Luna
201348
116 TheraSphere TACE Retrospective
comparative
Excluded patients eligible for
curative therapy
Biederman 201538 97 TheraSphere SIR-Spheres Retrospective
comparative
Adults with advanced HCC with
PVT, not eligible for curative
therapy
d’Abadie 201842 45 SIR-Spheres TheraSphere Retrospective
comparative
Unclear population
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After screening the 39 studies described in the previous section, seven studies were identified as relevant
for the population of patients who are eligible for CTT: six RCTs and one retrospective comparative study.
The reasons for inclusion and exclusion are listed in Table 8. The main reason for exclusion was the
population being substantially mixed in terms of stage of HCC disease or patients having advanced-stage
disease, which made them ineligible for CTT. SIRTACE,22 which is a RCT comparing SIR-Spheres and TACE
described in Chapter 3, Efficacy and safety of SIR-Spheres, included a mixed population of patients with
early-, intermediate- and advanced-stage HCC. The trial was funded by Sirtex; therefore, data split by
disease stage were requested. However, Sirtex was unable to provide the data as it did not have access to
them, so the trial could not be included in the NMA.
TABLE 8 Network 2: adults with unresectable HCC who are eligible for CTTs
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Studies included in this network (n = 7)
Pitton 201523 24 SIR-Spheres DEB-TACE RCT Patients with intermediate-
stage HCC (BCLC stage B)
Yu 201465 98 TACE TAE RCT Patients with unresectable HCC,
Child–Pugh class A or B,
ECOG < 2
Malagari 201066 87 DEB-TACE TAE RCT Patients unsuitable for curative
treatments with potentially
resectable lesions but at high
risk for surgery
Sacco 201159 67 DEB-TACE TACE RCT Patients with untreated HCC,
Child–Pugh class A or B,
ECOG 0–1
Chang 199463 46 TACE TAE RCT Patients with inoperable HCC,
Child–Pugh class A or B
Meyer 201364 86 TACE TAE RCT Patients with untreated,
unresectable HCC, Child–Pugh
class A or B, ECOG 0–2
Van Der Gucht
201740
35 (subgroup of
77 patients)
SIR-Spheres TheraSphere Retrospective
comparative
Subgroup of early/intermediate-
HCC patients
Studies excluded from this network (n = 32)
Kolligs 201522
(SIRTACE)
28 SIR-Spheres TACE RCT Mixed population of early- and
intermediate-stage patients,
without portal vein occlusion.
Pilot trial funded by Sirtex. Data
for intermediate patients were
requested but not provided
Vilgrain 201719,84
(SARAH)
459 SIR-Spheres Sorafenib RCT Patients with locally advanced
HCC or new HCC not eligible for
surgery/ablation after previously
cured HCC or HCC with two
unsuccessful rounds of TACE.
Poor candidates for TACE
Salem 201625
(PREMIERE)
45 TheraSphere TACE RCT Patients with early/intermediate-
HCC with no vascular invasion.
The intent of therapy was bridge
to transplant
continued
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TABLE 8 Network 2: adults with unresectable HCC who are eligible for CTTs (continued )
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Kulik 201428 20 TheraSphere TheraSphere
plus sorafenib
RCT Intent of therapy was bridge to
transplant
Chow 201821
(SIRveNIB)
360 SIR-Spheres Sorafenib RCT Sorafenib is an irrelevant
comparator in this population
Lammer 201056,57
(PRECISION)
212 DEB-TACE TACE RCT No relevant outcomes reported
Ricke 201524
(SORAMIC)
40 SIR-Spheres
plus sorafenib
Sorafenib RCT Poor candidates for TACE
van Malenstein
201160
30 DEB-TACE TACE RCT No relevant outcomes reported
Brown 201667 101 DEB-TACE TAE RCT Mixed population and some
patients have PVI
Golfieri 201458 177 DEB-TACE TACE RCT Patients with early-,
intermediate- and advanced-
stage HCC without PVT. The
population is too varied to
include
Llovet 200261 112 TACE TAE RCT Patients with intermediate/
advanced-stage HCC without
PVI/extrahepatic disease but no
relevant outcomes reported
Kawai 199262 289 TACE TAE RCT Patients with early/
intermediate-stage HCC but no
relevant outcomes reported
Kudo 201881
(REFLECT)
289 (subgroup
of 954 patients)
Lenvatinib Sorafenib RCT Subgroup of patients with
advanced-stage HCC, majority
had PVI or extrahepatic
spread – ineligible for TACE
Llovet 200880
(SHARP)
602 Sorafenib Placebo RCT Adults with intermediate/
advanced-stage HCC, majority
had extrahepatic spread/MVI.
Patients ineligible for TACE
Hickey 201635 765 TheraSphere TACE Prospective
comparative
Adults with early-, intermediate-
and advanced-stage HCC but
significant baseline imbalances
in age, PVI, number of lesions
and CP class
Kirchner 201931 94 TheraSphere TACE/DEB-
TACE
Prospective
comparative
No relevant outcomes reported
Memon 201334 96 TheraSphere TACE Prospective
comparative
No relevant outcomes reported
Salem 201333 56 TheraSphere TACE Prospective
comparative
No relevant outcomes reported
El Fouly 201532 86 TheraSphere TACE Prospective
comparative
Patients with intermediate-stage
HCC but systematic selection
bias and baseline imbalances in
age, tumour size and tumour
number were detected
Woodall 200937 52 TheraSphere BSC Prospective
comparative
Patients with advanced-stage
HCC, ineligible for TACE
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The studies included in network 2 were a RCT directly comparing SIR-Spheres with DEB-TACE,23 five
RCTs comparing different CTTs59,63–66 and one retrospective comparative study comparing SIR-Spheres
with TheraSphere.40 The RCT that compared SIR-Spheres with DEB-TACE23 included only 24 patients
(described in more detail in Chapter 3, Efficacy and safety of SIR-Spheres) and was the only direct
evidence between SIR-Spheres and CTT. There were no studies comparing TheraSphere with CTT.
The retrospective study comparing SIR-Spheres with TheraSphere40 was rated as being at a high risk of
bias, as described in Chapter 3, Efficacy and safety of SIR-Spheres.
TABLE 8 Network 2: adults with unresectable HCC who are eligible for CTTs (continued )
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Maccauro 201436 45 TheraSphere
plus sorafenib
TheraSphere Matched
case–control
study
Patients with intermediate/
advanced HCC, poor candidates
for TACE
Akinwande 201649 96 (subgroup of
358 patients)
TheraSphere DEB-TACE Retrospective
comparative
Mixed population of patients
with unresectable HCC with or
without PVT, results not split by
disease stage
Bhangoo 201541 17 TheraSphere SIR-Spheres Retrospective
comparative
Patients ineligible for TACE
(patients had either failed or
were not amenable to other
locoregional therapies)
Moreno-Luna
201348
116 TheraSphere TACE Retrospective
comparative
Patients with unresectable HCC
not eligible for transplant but
significant baseline imbalances
between groups in ECOG
status, Child–Pugh class,
number of tumours and
BCLC stage
Cho 201643 63 SIR-Spheres Sorafenib Retrospective
comparative
Patients ineligible for TACE
de la Torre 201644 73 SIR-Spheres Sorafenib Retrospective
comparative
Patients ineligible for TACE
Biederman 201639 90 SIR-Spheres TheraSphere Retrospective
comparative
Patients ineligible for TACE
Gramenzi 201545 137 SIR-Spheres Sorafenib Retrospective
comparative
Patients were ineligible or
unsuitable for TACE
Biederman 201538 97 SIR-Spheres TheraSphere Retrospective
comparative
Patients with unresectable,
advanced-stage HCC with PVT,
poor candidates for TACE
d’Abadie 201842 45 SIR-Spheres TheraSphere Retrospective
comparative
Population unclear. Appears to
include both patients eligible
and non-eligible for TACE
Salem 201147 245 TheraSphere TACE Retrospective
comparative
Mixed population of patients
with HCC without PVT or
extrahepatic metastases but
results not stratified by
BCLC stage
Soydal 201646 80 TACE SIR-Spheres Retrospective
comparative
Patients with intermediate/
advanced-stage HCC, some
patients with extrahepatic
metastases
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The five RCTs comparing different CTTs, which were deemed relevant for this population, were included to
inform the network. This includes three RCTs comparing TACE and TAE.63–65 The risk-of-bias assessment
reported some concerns regarding bias in the randomisation process for all three trials. The assessment
also highlighted concerns regarding protocol deviations from the intended interventions for Chang et al.63
Both Yu et al.65 and Meyer et al.64 showed no significant differences in OS or PFS. Chang et al.63 reported
only survival rates between groups but did not find any significant differences.
There was one RCT comparing DEB-TACE and TAE: Malagari et al.66 The risk-of-bias assessment
reported some concerns with this study regarding bias in the randomisation process and in protocol
deviations from the intended interventions. The trial was conducted in 95 patients and found that TTP
was significantly longer in the DEB-TACE arm (42.4± 9.5 weeks) than in the TAE arm (36.2 ± 9.0 weeks).
The remaining RCT compared DEB-TACE and TACE: Sacco et al.59 This trial was rated as being at a high
overall risk of bias owing to an open randomisation process. The trial found no significant differences
in survival rates or other relevant outcomes between the two groups. Full results of the risk-of-bias
judgements are presented in Appendix 9 and the study details and results are presented in Appendix 10.
The network diagram representing the model is shown in Figure 2. There are missing direct comparisons
and there is no common comparator in the evidence base for both OS and PFS outcomes in this
population; therefore, it forms a ‘disconnected network’. Implementing a NMA in this population would
produce very uncertain results as it relies on a single small trial by Pitton et al.23 to connect SIR-Spheres
in the network. Furthermore, it would not provide reliable evidence on TheraSphere comparisons with
CTT as there is only one small, retrospective, low-quality study connecting TheraSphere in the network.
Therefore, network 2, of patients with unresectable HCC who are eligible for CTT, was not conducted as
it was deemed unsuitable for decision-making.
Network 3: adults with unresectable hepatocellular carcinoma who are ineligible for
conventional transarterial therapies
The third model was for patients with unresectable HCC who are ineligible for CTT. Patients in this
population tend to have advanced-stage HCC (BCLC C) with or without PVT/PVI. This population may,
however, include some patients with intermediate-stage disease (BCLC B) who are ineligible for CTT or
who have previously failed CTT.
DEB-TACE
TACE
TAE
SIR-
Spheres
TheraSphere
Van Der Gucht40
(35)
Pitton23
(24)
Sacco59
(67)
Malagari66
(87)
Yu65
(98)
Chang63
(46)
Meyer64
(86)
RCT
Retrospective study
FIGURE 2 Network 2: patients eligible for CTTs.
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There were 26 comparative studies included in the systematic review of clinical effectiveness, which
were identified as potentially eligible for the third network; the 11 RCTs comparing different CTTs
were not screened as they are not relevant for this population. A further two studies of systemic
therapies identified from previous technology appraisals were additionally screened for inclusion in
this network. Out of 28 studies, three RCTs and five retrospective comparative studies were initially
selected as relevant for this population. Twenty studies were excluded, mainly because of irrelevant
comparisons or not reporting relevant outcomes. The NMA diagram is illustrated in Figure 3.
The network includes robust direct evidence between SIR-Spheres and sorafenib from the two large
RCTs SARAH84 and SIRveNIB,21 which are described in more detail in Chapter 3, Efficacy and safety of
SIR-Spheres. There are also three smaller retrospective comparative studies comparing SIR-Spheres and
sorafenib.44,45,85 On closer examination, all three of these studies were rated as being at a high risk of
bias owing to an imbalance in baseline characteristics, unclear reporting of missing data and unblinded
outcome assessors (see Appendix 8). Therefore, owing to already having identified high-quality RCTs
comparing SIR-Spheres and sorafenib, these three retrospective studies were removed. Including
low-quality studies where there is already reliable evidence may invalidate the NMA and consequently
the results. Furthermore, the two retrospective studies, Biederman et al.39 and Van Der Gucht et al.,40
were also considered to have a high risk of bias, as described in Chapter 3, Direct comparisons of
different selective internal radiation therapies. However, these studies were included as a sensitivity
analysis as they are the only studies with direct evidence between TheraSphere and SIR-Spheres.
The network was updated and the final NMA of patients ineligible for CTT includes two RCTs comparing
SIR-Spheres and sorafenib,19,21 one RCT comparing lenvatinib and sorafenib81 and two retrospective
comparative studies comparing SIR-Spheres and TheraSphere (included as a sensitivity analysis)
(Figure 4).38,40 The decisions for including and excluding each study are detailed in Table 9. The study
selection process for this NMA (updated network 3) is illustrated in Figure 5.
RCT
Retrospective study
Kudo81
(289)
SIRveNIB22
(360)
SARAH20
(459)
de la Torre44
(73)
Lenvatinib
Sorafenib SIR-Spheres
TheraSphere
Gramenzi45
(137)
Cho43
(32)
Biederman39
(90)
Van Der Gucht40
(42)
FIGURE 3 Network 3: adults with unresectable HCC who are ineligible for CTTs.
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RCT
Retrospective study
Kudo81
(289)
SIRveNIB22
(360)
SARAH20
(459)
Lenvatinib
Sorafenib SIR-Spheres
TheraSphere
Biederman39
(90)
Van Der Gucht40
(42)
FIGURE 4 Updated network 3: adults with unresectable HCC who are ineligible for CTTs.
TABLE 9 Network 3: adults with unresectable HCC who are ineligible for CTTs
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Studies included in this network (n = 5)
Chow 201821
(SIRveNIB)
360 SIR-Spheres Sorafenib RCT Patients with locally advanced
HCC
Vilgrain 201719,84
(SARAH)
459 SIR-Spheres Sorafenib RCT Adults with locally advanced
HCC (BCLC C) or new HCC not
eligible for surgery/ablation
after previously cured HCC or
HCC with two unsuccessful
rounds of TACE
Kudo 201881
(REFLECT)
289 (subgroup
of 954 patients)
Lenvatinib Sorafenib RCT Subgroup of adults with
advanced-stage HCC, majority
had PVI or extrahepatic spread
Van Der Gucht
201740
42 (subgroup of
77 patients)
SIR-Spheres TheraSphere Retrospective
comparative
Subgroup of advanced-stage
HCC patients
Biederman 201639 90 SIR-Spheres TheraSphere Retrospective
comparative
Patients with unresectable HCC
and main or lobar PVT
Studies excluded from this network (n = 23)
Ricke 201524
(SORAMIC)
40 SIR-Spheres
plus sorafenib
Sorafenib RCT Adults with unresectable
intermediate or advanced HCC,
poor candidate for TACE. Only
safety analyses are published.
Data were requested from
company but, as this is an
investigator-initiated trial, the
data were not available
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TABLE 9 Network 3: adults with unresectable HCC who are ineligible for CTTs (continued )
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Llovet 200880
(SHARP)
602 Sorafenib Placebo RCT Adults with intermediate/
advanced-stage HCC, majority
had extrahepatic spread/
vascular invasion. This study
was not required for the NMA
as it did not provide any extra
information and was not needed
for the cost-effectiveness model
Salem 201625
(PREMIERE)
45 TheraSphere TACE RCT Compared TACE – irrelevant
comparison in this population
Kolligs 201522
(SIRTACE)
28 SIR-Spheres TACE RCT Compared TACE – irrelevant
comparison in this population
Pitton 201523 24 SIR-Spheres DEB-TACE RCT Compared DEB-TACE –
irrelevant comparison in this
population
Kulik 201428 20 TheraSphere TheraSphere
plus sorafenib
RCT Mixed population with the
intent to bridge to transplant
Kirchner 201931 94 TheraSphere TACE/
DEB-TACE
Prospective
comparative
Compared TACE – irrelevant
comparison in this population
Hickey 201635 765 TheraSphere TACE Prospective
comparative
Compared TACE – irrelevant
comparison in this population
El Fouly 201532 86 TheraSphere TACE Prospective
comparative
Compared TACE – irrelevant
comparison in this population
Woodall 200937 52 TheraSphere BSC Prospective
comparative
Patients with advanced-stage
HCC. Excluded owing to
systematic selection bias and
significant baseline imbalances
Memon 201334 96 TheraSphere TACE Prospective
comparative
No relevant outcomes reported
Salem 201333 56 TheraSphere TACE Prospective
comparative
No relevant outcomes reported
and compared TACE –
irrelevant comparison in this
population
Maccauro 201436 45 TheraSphere
plus sorafenib
TheraSphere Matched
case–control
study
Patients with intermediate/
advanced-stage HCC. No
relevant outcomes reported
Cho 201643 63 SIR-Spheres Sorafenib Retrospective
comparative
Patients with BCLC stage C
HCC and PVI. However, study
of low quality and high risk of
bias, and therefore excluded
from updated network
de la Torre 201644 73 SIR-Spheres Sorafenib Retrospective
comparative
Patients with unresectable HCC
and PVI. However, study of low
quality and high risk of bias and
therefore excluded from
updated network
Gramenzi 201545 137 SIR-Spheres Sorafenib Retrospective
comparative
Patients with intermediate/
advanced-stage HCC unfit for
other effective therapies.
However, study of low quality and
high risk of bias, and therefore
excluded from updated network
continued
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TABLE 9 Network 3: adults with unresectable HCC who are ineligible for CTTs (continued )
Study (first author
and year) n Intervention Comparator Study design Reason for inclusion/exclusion
Akinwande 201649 96 TheraSphere DEB-TACE Retrospective
comparative
Compared TACE – irrelevant
comparison in this population
Moreno-Luna
201348
116 TheraSphere TACE Retrospective
comparative
Compared TACE – irrelevant
comparison in this population
Salem 201147 245 TheraSphere TACE Retrospective
comparative
Compared TACE – irrelevant
comparison in this population
d’Abadie 201842 45 SIR-Spheres TheraSphere Retrospective
comparative
Population unclear. Appears to
include patients both eligible
and non-eligible for TACE
Bhangoo 201541 17 TheraSphere SIR-Spheres Retrospective
comparative
Mixed population of patients
with unresectable HCC, who
had either failed or were not
amenable to other locoregional
therapies. No relevant outcomes
reported
Biederman 201538 97 SIR-Spheres TheraSphere Retrospective
comparative
Adults with unresectable HCC
with PVT. No relevant outcomes
reported
Soydal 201646 80 TACE SIR-Spheres Retrospective
comparative
Compared TACE – irrelevant
comparison
• Comparative studies included in systematic review of
    clinical effectiveness, n = 26
• RCTs of systemic therapies, n = 2
• RCTs comparing conventional transarterial therapies, n = 11
Excluded RCTs comparing
conventional transarterial therapies as
they are not relevant for this population
(n = 11)
Studies screened for inclusion in network
(n = 28)
Excluded
(n = 20)
• Relevant results not reported/data
    not available, n = 7
• Irrelevant comparison, n = 9
• Mixed or unclear population, n = 2
• High risk of bias, n = 1
• Non-informative study, n = 1
Retrospective studies comparing
SIR-Spheres and sorafenib excluded
as low-quality evidence
(n = 3)
Studies included in NMA
(n = 5)
FIGURE 5 Flow diagram of the study selection process for the NMA of adults ineligible for CTTs.
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Methods of data analysis
This section describes a NMA of all relevant RCTs (Table 10) and a NMA of RCTs that included only
patients with Child–Pugh class A liver function. Currently, in the UK, systemic therapy, such as
sorafenib and lenvatinib, is licensed for only Child–Pugh class A patients with unresectable HCC.
However, results for all patients in the ITT population are reported in Appendix 12, Tables 39 and 40.
In the SARAH19 and SIRveNIB21 trials, 22.4% and 28.6% of patients allocated to SIR-Spheres did not
receive SIRT. Patients who did not receive their allocated treatment were excluded from the per-
protocol analysis. Therefore, the NMA of Child–Pugh class A patients with unresectable HCC who are
ineligible for CTT in the per-protocol population is the base-case scenario. However, the ITT results are
used for the REFLECT trial.12 Therefore, the results for the ITT population are also reported. Both OS
and PFS were assessed as outcomes. However, PFS in Child–Pugh class A patients was not reported
for the SIRveNIB study21 or for patients in the Biederman et al.39 study. Therefore, PFS could not be
assessed in the base-case population or in the sensitivity analyses.
The NMA was estimated using Bayesian Markov chain Monte Carlo techniques in WinBUGS, using
code obtained from the NICE Decision Support Unit (DSU)’s Technical Support Document.86 An initial
burn-in of at least 50,000 simulations was used, and convergence was confirmed through visual
inspection of the Brook–Gelman–Rubin diagnostic and history plots. This was followed by 100,000
simulations on three chains to estimate the sampled parameters. Where available, Kaplan–Meier (KM)
data were extracted using methods reported by Guyot et al.87 When KM data were not available,
HRs and their variance were extracted, and log-hazard ratios synthesised. To synthesise HRs across
studies, it is required that the proportional hazards assumption holds. Therefore, the deviation from
proportional hazards was tested and the Schoenfeld residuals, survival curves and piecewise hazards
visually inspected. It was decided to conduct more complex time-varying models only if simple models
TABLE 10 Summary of studies included in the NMA
Study (first author
and year) Treatment n
Median age
(years) Male, n (%)
PVT/PVI,
n (%)
BCLC classification, n (%)
A B C
Vilgrain 201719
(SARAH)
SIR-Spheres 174 66.3 ± 9.4 158 (90.8) 29 (16.7)a 7 (4.0) 53 (30.5) 114 (65.5)
Sorafenib 206 64.6 ± 9.5 186 (90.3) 37 (18.0)a 9 (4.4) 54 (26.2) 143 (69.4)
Chow 201821
(SIRveNIB)
SIR-Spheres 130 60.9 (SD 11.5) 107 (82.3) 30 (23.1)b 0 (0) 79 (60.8) 50 (38.5)
Sorafenib 162 57.5 (SD 10.6) 138 (85.2) 48 (29.6)b 1 (0.6) 88 (54.3) 73 (45.1)
NICE 201812
(REFLECT)c
Lenvatinib 369 – – 0 (0) – – –
Sorafenib 386 – – 0 (0) – – –
Retrospective comparative studies
Biederman 201639 SIR-Spheres 21 60 ± 11.5 20 (95.2) 100%d – – –
TheraSphere 69 65.6 ± 11.3 54 (78.3) 100%d – – –
eVan Der Gucht
201740
SIR-Spheres 24 – – – 0 (0) 0 (0) 24 (100)
TheraSphere 18 – – – 0 (0) 0 (0) 18 (100)
SD, standard deviation.
a Main PVI.
b PVT.
c Subgroup of patients with no extrahepatic spread or macroscopic PVI.
d Main and lobar PVT.
e Subgroup of patients with advanced-stage HCC.
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were not a good fit to the data. A model was chosen by visually inspecting the development of the
hazard over time for the different trials and then by comparing deviance information criterion (DIC)
values for the competing models. It was decided that a hierarchical model with classes of treatments
composed of individual treatments, which would allow each treatment effect to be estimated as well as
the overall class mean, was not possible owing to the small number of studies in the NMA.86 Finally,
both fixed- and random-effects models were evaluated and between-trial heterogeneity was assessed
using the between-study standard deviation (SD). Inconsistency did not need to be examined, as there
were no loops in the network.
Model selection
A Bayesian evidence synthesis approach was employed. With a Bayesian framework, prior belief about
a treatment effect is combined with a likelihood distribution that summarises the data to obtain a
posterior distribution reflecting the belief about the treatment effect after incorporating the evidence.
Normal identity link models were used for this NMA.86 The Schoenfeld residuals were visually
inspected and statistically tested for each survival curve except for the REFLECT study because only a
subgroup of the data were used, for which there was no KM curve (see Appendix 11). Although the KM
curves for each study cross over, which suggests that there are some concerns about the proportional
hazards assumption, there is no clear statistical evidence that the assumption is violated for all of the
included studies.12 The viability of the network depends on the proportional hazards assumption.
Therefore, HRs were synthesised across studies. The choice of prior distributions for the between-
study variance was explored. A half-normal (0, 0.192) prior was chosen as a uniform (0, 3) prior was too
influential. The justification for the half-normal prior is that it expresses the prior belief that 95% of
trials will give HRs within a factor of 2 from the estimated median HR. However, owing to the small
number of studies, there was little evidence to inform the between-study heterogeneity. The half-
normal prior was also influential, although less so than the uniform prior. According to DIC and total
residual deviance statistics, the fixed-effects model provided a better fit to the data than did the
random-effects counterpart. The fixed-effects model had both a lower DIC and fewer parameters. This
is again because of the small number of studies and the influence of the prior on the between-study
heterogeneity. Owing to both models having similar results, the fixed-effects model was chosen as it is
a simpler model. Results from both are presented for comparison.
Scenario and subgroup analyses
Scenario analyses including the two low-quality retrospective studies, by Biederman et al.39 and
Van Der Gucht et al.,40 were carried out, as discussed in Chapter 3, Network 3: adults with unresectable
hepatocellular carcinoma who are ineligible for conventional transarterial therapies. For the first scenario,
the Biederman et al.39 study was added to the base-case NMA: adults with unresectable HCC who are
Child–Pugh class A and ineligible for CTT in both the per-protocol population and the ITT population.
There were no available data on Child–Pugh class A patients in the Van Der Gucht et al.40 study;
therefore, it was not included. For the second scenario, which is reported in Appendix 12, both the
Biederman et al.39 and Van Der Gucht et al.40 studies were added to the NMA of all adults who are
ineligible for CTT in the ITT population. Biederman et al.39 did not report PFS outcomes; therefore,
the second scenario was used for the OS outcome only.
A sensitivity analysis that excluded the RCT SIRveNIB21 was conducted. Patients in the SIRveNIB trial
are from the Asia-Pacific region and, thus, have different HCC disease aetiology and consequently
differing treatments to those from Europe. This is discussed in more detail in Chapter 3, Efficacy and
safety of SIR-Spheres. Therefore, a scenario was conducted in which SIRveNIB was excluded from the
base-case NMA.
It was not possible to conduct a subgroup analysis in Child–Pugh class A patients with PVT or in
patients with PVI. The only available data for this subgroup of patients were from the two RCTs
comparing SIR-Spheres and sorafenib: SARAH19,20 and SIRveNIB.21 However, SIRveNIB reported results
for only the subgroup of patients with PVT, and SARAH reported results for only patients with PVI.
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Results
Results of the base-case network meta-analysis in the per-protocol population: adults with
unresectable hepatocellular carcinoma who are Child–Pugh class A and ineligible for
conventional transarterial therapy
Three studies were included in the base-case analysis: two RCTs comparing SIR-Spheres and sorafenib and
one RCT comparing lenvatinib and sorafenib. The baseline characteristics of these studies are detailed in
Table 10. The REFLECT trial,81 which compares lenvatinib and sorafenib, included patients with extrahepatic
spread (61% in the lenvatinib arm and 62% in the sorafenib arm). All the other trials excluded patients with
extrahepatic spread; therefore, the subgroup of patients without extrahepatic spread or PVI was used for
the REFLECT trial. A more appropriate subgroup was not reported.
The results of both the fixed-effects analysis and the random-effects analysis are shown in Table 11.
The results provide no evidence that the random-effects model should be preferred. The DIC is
marginally higher (–0.40 for the random-effects model, compared with –1.38 for the fixed-effects
model; lower DIC values are preferred, with differences of 2–5 considered important).86 In addition,
the high level of uncertainty around the random-effects CrI indicates that there is little information to
inform the random-effects parameter. Therefore, the results of the fixed-effects model will be used for
the base-case and all scenario analyses. Both fixed-effects and random-effects results are reported in
Appendix 13, Tables 43–46, for comparison.
There were no meaningful differences in OS in the per-protocol population between any of the three
treatments and all treatments appear to have a similar effect. SIR-Spheres shows a marginal improvement
in OS when compared with sorafenib (HR 0.94, 95% CrI 0.77 to 1.14) and lenvatinib (HR 0.91, 95% CrI
0.63 to 1.26); however, the treatment effects are uncertain as the CrI crosses 1. Lenvatinib shows a
marginal reduction in OS when compared with sorafenib (HR 1.06, 95% CrI 0.79 to 1.40), although again
the CrI crosses 1 (Table 12). Figure 6 presents the cumulative ranking curves for each treatment, with rank 1
being the best and rank 3 being the worst. SIR-Spheres was ranked as the most efficacious therapy, with a
TABLE 12 Hazard ratio estimates (95% CrIs) for OS for each treatment comparison for the base-case NMA in the
per-protocol population
Sorafenib 1.07 (0.88 to 1.29) 0.96 (0.72 to 1.27)
0.94 (0.77 to 1.14) SIR-Spheres 0.91 (0.63 to 1.26)
1.06 (0.79 to 1.40) 1.14 (0.79 to 1.58) Lenvatinib
TABLE 11 Overall survival results for the base-case NMA in the per-protocol population
Intervention Comparator
HR (95% CrI)
Fixed effects Random effects
SIR-Spheres Sorafenib 0.94 (0.77 to 1.14) 0.94 (0.68 to 1.26)
SIR-Spheres Lenvatinib 0.91 (0.63 to 1.26) 0.92 (0.52 to 1.51)
Lenvatinib Sorafenib 1.06 (0.79 to 1.40) 1.08 (0.68 to 1.64)
SD – 0.13 (0.005 to 0.380)
DIC –1.38 0.40
pD 2.0 2.5
pD, number of parameters.
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probability of being the best of 0.61. Lenvatinib was ranked as the worst treatment, with a probability of
being best of 0.22. Sorafenib was ranked as the second best, with a probability of being best of 0.16.
Results of the base-case network meta-analysis in the intention-to-treat population: adults
with unresectable hepatocellular carcinoma who are Child–Pugh class A and ineligible for
conventional transarterial therapy
Similar to the per-protocol population, there were no significant differences between treatments in the
base-case NMA in the ITT population (Table 13).
SIR-Spheres appears to increase mortality when compared with sorafenib and lenvatinib (HR 1.13,
95% CrI 0.96 to 1.32 and 1.09, 95% CrI 0.77 to 1.48, respectively). However, the CrIs indicate that
these results are uncertain. Lenvatinib also shows a reduction in OS when compared with sorafenib
(1.06, 95% CrI 0.79 to 1.40); however, the 95% CrI crosses 1, indicating that there is not a significant
treatment effect.
The HRs for all patients in the ITT population for OS and PFS are shown in Appendix 12, Tables 41
and 42, respectively.
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FIGURE 6 Cumulative ranking probability plots for each treatment in the base-case NMA for the per-protocol population.
TABLE 13 Overall survival results for the base-case NMA in the ITT population
Intervention Comparator
HR (95% CrI)
Fixed effects Random effects
SIR-Spheres Sorafenib 1.13 (0.96 to 1.32) 1.13 (0.86 to 1.47)
SIR-Spheres Lenvatinib 1.09 (0.77 to 1.48) 1.10 (0.66 to 1.74)
Lenvatinib Sorafenib 1.06 (0.79 to 1.40) 1.07 (0.70 to 1.59)
SD – 0.11 (0.004 to 0.352)
DIC –3.04 –0.86
pD 2.00 2.00
pD, number of parameters.
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Scenario 1: inclusion of Biederman et al. into the base-case network meta-analysis
The Biederman et al.39 study was added to the base-case NMA in a scenario analysis, which allowed for
a comparison to be made against TheraSphere. Biederman et al.39 reports a very strong treatment
effect on OS with TheraSphere compared with SIR-Spheres (HR 0.40, 95% CrI 0.20 to 0.78). However,
as discussed earlier, Biederman et al.39 is a retrospective, poor-quality study; therefore, these results
may either in part or in full reflect the impact of bias. Furthermore, all patients in the Biederman et al.39
study have PVT, which is much higher than the proportion of patients who have PVT/PVI in the other
included studies. Adding this study has a substantial effect on the NMA results. In the per-protocol
population, TheraSphere shows a substantial significant improvement in OS when compared with
SIR-Spheres (HR 0.44, 95% CrI 0.20 to 0.84), sorafenib (HR 0.41, 95% CrI 0.20 to 0.77) and lenvatinib
(HR 0.40, 95% CrI 0.18 to 0.78). There were no significant differences in OS between any of the other
treatments (Table 14).
Similarly, in the ITT population, there was a significant improvement in OS with TheraSphere compared
with sorafenib (HR 0.47, 95% CrI 0.21 to 0.88), SIR-Spheres (HR 0.41, 95% CrI 0.20 to 0.77) and
lenvatinib (HR 0.45, 95% CrI 0.20 to 0.89). There were no significant differences in OS between
SIR-Spheres, sorafenib and lenvatinib (see Table 14).
Sensitivity analysis
Exclusion of the SIRveNIB study from the base-case network meta-analysis
The SIRveNIB trial,21 which compares SIR-Spheres and sorafenib, was conducted in the Asia-Pacific
region. This has implications for the generalisability of the SIRveNIB trial results to the UK population.
The aetiology of HCC and the consequent treatment in the Asia-Pacific region are different, as
described in more detail in Chapter 3, Efficacy and safety of SIR-Spheres. A sensitivity analysis was
therefore implemented, in which the SIRveNIB study was excluded from the base-case NMA. Excluding
SIRveNIB had very little impact on the results for OS in the ITT population compared with the base-
case NMA. All treatment effects for all comparisons were similar to the base-case NMA (Table 15). The
OS results in the per-protocol population, however, showed a slight change after excluding SIRveNIB.
The treatment effect estimate for SIR-Spheres versus sorafenib increased (1.02, 95% CrI 0.79 to 1.29)
compared with the base-case NMA (0.94, 95% CrI 0.77 to 1.14). This showed a reduction in OS with
SIR-Spheres rather than an improvement, as seen in the base-case per-protocol population, although
neither were statistically significant.
TABLE 14 Overall survival results adding Biederman et al. to the base-case NMA
Intervention Comparator
HR (95% CrI) (fixed effects)
Per-protocol population ITT population
SIR-Spheres Sorafenib 0.94 (0.77 to 1.13) 1.13 (0.96 to 1.32)
SIR-Spheres Lenvatinib 0.91 (0.63 to 1.26) 1.09 (0.77 to 1.48)
TheraSphere SIR-Spheres 0.44 (0.20 to 0.84) 0.41 (0.20 to 0.77)
TheraSphere Sorafenib 0.41 (0.20 to 0.77) 0.47 (0.21 to 0.88)
TheraSphere Lenvatinib 0.40 (0.18 to 0.78) 0.45 (0.20 to 0.89)
Lenvatinib Sorafenib 1.06 (0.79 to 1.40) 1.06 (0.79 to 1.40)
DIC 0.30 –1.32
pD 3.00 3.00
pD, number of parameters.
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Summary of findings of relative efficacy from network meta-analysis
Treatment options and outcomes vary greatly for patients with unresectable HCC according to the
severity of cancer and liver disease. Therefore, three NMA models were produced to represent the
different populations of unresectable HCC patients: patients eligible for transplant, patients ineligible
for transplant but eligible for CTT and patients ineligible for CTT.
The NMA in patients eligible for transplant was not conducted. Clinical advice was that there are
short transplant waiting times in the UK, whereas these were much longer in the trials in the NMA.
Therefore, the network may not be generalisable to the UK and there may be limited opportunity for
benefit, given the short waiting times. Furthermore, the two RCTs included in the network have very
small sample sizes and, therefore, any efficacy estimates produced would be highly uncertain. The NMA
of patients eligible for CTT was also not conducted because of the lack of good-quality evidence in this
population. There was only one RCT of 24 patients directly comparing SIR-Spheres and the comparator
therapies of interest. There were no studies comparing TheraSphere and CTT. Therefore, with missing
direct comparisons and only one small study to connect the network, results produced would be very
uncertain and unsuitable for decision-making.
Several NMAs of patients who are ineligible for CTT were conducted for both OS outcomes and PFS
outcomes in the per-protocol and ITT populations.
The base-case NMA was in adults with unresectable HCC who have Child–Pugh class A liver disease
and are ineligible for CTT in the per-protocol population. Three studies were included in the base-case
analysis: two RCTs comparing SIR-Spheres and sorafenib and one RCT comparing lenvatinib and
sorafenib. The results provided no evidence that the random-effects model should be preferred. In
addition, the high level of uncertainty around the random-effects CrI indicated that there is little
information to inform the random-effect parameter. Therefore, the results of the fixed-effects model
were used for the base-case and scenario analyses.
There were no meaningful differences in OS between any of the three treatments in the per-protocol
or ITT populations. All treatments appear to have a similar effect. In the per-protocol population,
SIR-Spheres showed a non-significant marginal improvement in OS when compared with sorafenib
(HR 0.94, 95% CrI 0.77 to 1.14), although the CrI indicates that this result is uncertain. SIR-Spheres
was ranked as the most efficacious therapy, with a probability of being the best of 0.61. Lenvatinib was
ranked as the worst treatment, with a probability of being best of 0.22. Sorafenib was ranked as the
second best, with a probability of being best of 0.16.
To produce an efficacy estimate for TheraSphere, the only two studies that directly compared TheraSphere
and SIR-Spheres for patients ineligible for CTT, Biederman et al.39 and Van Der Gucht et al.,40 were included
as a sensitivity analysis. Both are low-quality retrospective studies, which reported strong treatment effects
TABLE 15 Results of the base-case NMA excluding the SIRveNIB study
Intervention Comparator
OS HR (95% CrI)
ITT population Per-protocol population
SIR-Spheres Sorafenib 1.14 (0.90 to 1.41) 1.02 (0.79 to 1.29)
SIR-Spheres Lenvatinib 1.09 (0.75 to 1.55) 0.98 (0.66 to 1.40)
Lenvatinib Sorafenib 1.06 (0.79 to 1.40) 1.06 (0.79 to 1.40)
DIC –0.52 –0.34
pD 2.0 2.0
pD, number of parameters.
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on OS with TheraSphere compared with SIR-Spheres (HR 0.40, 95% CrI 0.20 to 0.78, and HR 0.77,
95% CrI 0.27 to 2.18, respectively). Adding these studies had a substantial effect on the NMA results.
In the per-protocol population, TheraSphere showed a substantial and statistically significant improvement
in OS when compared with SIR-Spheres (HR 0.44, 95% CrI 0.20 to 0.84), sorafenib (HR 0.41, 95% CrI 0.20
to 0.77) and lenvatinib (HR 0.40, 95% CrI 0.18 to 0.78). In the ITT population, there was also a significant
improvement in OS with TheraSphere when compared with sorafenib (HR 0.53, 95% CrI 0.31 to 0.84),
SIR-Spheres (HR 0.46, 95% CrI 0.28 to 0.72) and lenvatinib (HR 0.51, 95% CrI 0.28 to 0.86). A sensitivity
analysis, which excluded the SIRveNIB study from the base-case NMA was also conducted. The SIRveNIB
trial, which compared SIR-Spheres and sorafenib, was conducted in the Asia-Pacific region. This has
implications for the generalisability of the SIRveNIB trial results to the UK population. Excluding SIRveNIB,
however, had very little impact on the results for OS and PFS in the per-protocol and ITT populations
compared with the base-case NMA. There were no significant differences in treatment effects for
any comparisons.
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Chapter 5 Assessment of existing
cost-effectiveness evidence
Systematic review of existing cost-effectiveness evidence
This section presents a systematic review of previous economic evaluations of SIRT and provides an
overview of these assessments and a discussion of their relevance to the UK NHS. The findings from
the review were used to help inform the development of a new decision-analytic model, which is
reported in Chapter 7.
Methods
Systematic searches for relevant literature were completed as part of the search used to identify
clinical effectiveness studies. These searches included a broad set of terms aimed at identifying any
evidence relating to SIRT, including studies evaluating the cost-effectiveness of SIRT. Details of the
searches undertaken are reported in Chapter 3, Search strategy, and the full search strategy is reported
in Appendix 1.
Study selection was conducted in two stages: (1) titles and abstracts identified by the search strategy
were examined and screened as part of the clinical effectiveness review for any study potentially
relevant to the cost-effectiveness review, and (2) full texts were then obtained and screened for
inclusion. Screening of titles and abstracts, therefore, aligned with the selection approach outlined in
Chapter 3, Search strategy; a single reviewer screened all studies, with 10% checked by a second
reviewer. Full-text screening was conducted independently by two reviewers, with disagreements
resolved by consensus. All studies meeting the inclusion criteria were summarised and used to
identify potential structural issues, assumptions and key drivers of cost-effectiveness. The quality
of the cost-effectiveness studies was assessed using a modified version of the Philips checklist88
(see Appendix 14, Table 47).
Studies were included in the review if they assessed the cost-effectiveness of a SIRT versus any other
therapy in a HCC population. A broad range of studies were considered for inclusion in the review,
including economic evaluations conducted alongside trials, modelling studies and analyses of
administrative databases. Only full economic evaluations comparing two or more options including
both costs and consequences (cost-effectiveness, cost–utility or cost–benefit analyses) were included.
Results of the review of existing cost-effectiveness evidence
As described in Chapter 3, Quantity and quality of research available, a total of 34 records were identified
as being potentially relevant to cost-effectiveness. The full-text articles of these records were assessed
for eligibility, with a total of seven studies (eight publications) found to meet the inclusion criteria.
Three studies were reported as full papers and four were reported as abstracts only. A PRISMA flow
diagram of the review of studies identified in the main systematic review is presented in Figure 7.
The following sections provide a summary of the Assessment Group (AG)’s critique of the three studies
reported in full-paper format,89–92 including an assessment of the studies’ quality and relevance to an
NHS perspective. Details of the quality assessment implemented are included in Appendix 14, Table 47.
For the four studies identified that were reported only as conference abstracts,93–96 a brief overview is
presented along with reported results. Given the limited nature of the reporting of study details, no
formal quality assessment of the abstracts was undertaken.
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Review of Rognoni et al. (2017 and 2018)90,97
Overview
Two studies by Rognoni et al.90,97 reported on the cost-effectiveness of SIRT in HCC from an Italian
heath service perspective. Both studies used the same basic model design and inputs, but investigated
different treatment strategies. One study97 compared SIRT with sorafenib in two HCC subpopulations:
intermediate (BCLC B) and intermediate-advanced (BCLC C) disease. The other study90 compared SIRT
followed by TACE and possibly sorafenib with SIRT followed by sorafenib in patients with intermediate
disease (BCLC B).
Both studies presented a probabilistic Markov model consisting of up to five health states: stable
disease, progression, posttransplant, death from disease and death from other causes. The post-
transplant health state was used only for the comparison of SIRT with sorafenib in patients with
intermediate disease. Transition probabilities were drawn from three Italian oncology centres, which
were compared using propensity score matching. HRQoL measures were not reported in this cohort;
utilities were, therefore, derived from cost-effectiveness analysis registries. Utilities were assumed to
be the same across the patient populations. Italy-specific costs were used in the model, and were
derived primarily from official local tariffs and reference costs.
For intermediate-stage patients, the estimated incremental cost-effectiveness ratio (ICER) for SIRT
compared with sorafenib was €3302 per quality-adjusted life-year (QALY) gained. In advanced-stage
patients, SIRT was found to dominate sorafenib. These results appear to be driven primarily by the
relatively low costs of the SIRT procedure relative to the acquisition costs of sorafenib, combined with
significant clinical benefits of SIRT resulting in additional life-years gained (LYG). In the comparison of
SIRT followed by TACE and possibly sorafenib, with SIRT followed by sorafenib, SIRT-TACE-sorafenib
was found to dominate SIRT-sorafenib.
Commentary
The two studies appear to be comprehensive and well implemented, accounting for all major sources of
costs and benefits, including long-term benefits in patients receiving liver transplant. However, the
fitting and selection of parametric functions to survival data were poorly described and explored.
Variability in cost-effectiveness estimates was explored using a one-way sensitivity analysis, showing
that the results were robust to a wide range of assumptions.
Records identif ied as potentially relevant
to cost-effectiveness review
(n = 34)
Full papers screened
(n = 18)
Excluded on title/abstract
(n = 16)
Excluded
(n = 10)
• Economic analysis type did not
    meet inclusion criteria, n = 10
Included for data extraction
(n = 7; eight records)
• Conference abstracts, n = 4 (five records)
• Full cost-effectiveness analysis, n = 3
FIGURE 7 Flow diagram of the study selection process for the cost-effectiveness review.
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However, the two studies suffered from a number of potential limitations. Foremost among these is
the use of non-randomised data to produce estimates of relative effectiveness. Although propensity
scoring was used to adjust for baseline imbalances, this process may have affected the results.
The comparison between SIRT and sorafenib in the BCLC C subgroup is of particular concern, as a
significant survival benefit was predicted for patients receiving SIRT. This is inconsistent with the
results of the SARAH19 and SIRveNIB21 trials reported in Chapter 3, Efficacy and safety of SIR-Spheres,
which show no such benefit. The HRQoL values used were generally not reflective of the population
under consideration, and matched poorly with those used in previous NICE technology appraisals (TAs)
in this indication. The study was also limited in its capacity to inform the present appraisal as the costs
and resource use evidence reflected an Italian health-care setting, and the choice of comparators does
not represent current UK practice.
Review of Rostambeigi et al. (2014)91,92
Overview
The study by Rostambeigi et al.91,92 (also presented as a conference abstract) sought to assess the
cost-effectiveness of SIRT versus conventional TACE in three subgroups (BCLC A, B and C) of patients
with HCC from a US Medicare perspective.
The model presented was a patient simulation that followed 750 patients (split evenly between
BCLC A, B and C) through a treatment pathway comprising treatment with either SIRT or TACE.
The simulation was repeated for each treatment type and patient subgroup over a time horizon of
3 or 5 years. The model structure adopted is not clearly reported, but appeared to allow for disease
recurrence, mortality and liver transplant.
Probabilities for each outcome were drawn from the literature for each patient subgroup according to
BCLC stage. Exponential curves were used to estimate survival based on reported survival rates, with a
10% increase in mortality for 1 month following recurrence of HCC and re-treatment. Transplant rates
of 29%, 16% and 5% were applied for patients in BCLC stages A, B and C, respectively, although is it
unclear how this affected model outcomes. The model assumed disease ‘recurrence’ rates of 40%, 60%
and 80% every 10 months for SIRT patients, whereas TACE patients had a recurrence rate of 60%, and
could receive 4 to 10 procedures. An assumed probability of 0.5 was used for SIRT re-treatment at the
beginning of every 10-month treatment interval, and patients were assumed to receive a maximum of
two or three SIRT treatments depending on the scenario. Costs applied in the model were obtained
from Medicare reimbursement costs; HRQoL was not considered.
The ICERs presented were estimated using an unconventional approach, calculated by dividing the
incremental mean cost per month of survival (i.e. total costs divided by OS in months) by the overall
incremental survival in months. The authors did not account for dominance in their calculations,
presenting a number of negative ICERs without sufficient interpretation of their different meanings.
ICERs in which SIRT was less costly and less effective, less costly and more effective, and more costly
but less effective than TACE were presented without further distinction.
In the main analysis in which each procedure could be repeated every 10 months for up to 5 years,
the AG calculated SIRT to increase mean survival by 3.80 months in BCLC C patients at a reduced
cost. In the scenario in which procedures are repeated every 6 months for up to 3 years, SIRT was
more effective (2.90 months incremental survival), with reduced costs compared with TACE in
BCLC C patients. In all other patient groups and treatment regimens, SIRT was dominated by TACE.
Commentary
The limited reporting of the model structure and assumptions adopted prevents a detailed critique or
discussion of the appropriateness of the model to estimate the relative costs and benefits of SIRT and
sorafenib. A number of key structural assumptions appear to have been made arbitrarily, and poor
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reporting of model inputs limits the generalisability of this study to other settings. As the resource use
and costs are specific to the USA, they are unlikely to be relevant to an NHS setting. The choice of
comparators and outcome measures (e.g. LYG) further limits comparison with UK practice.
Review of Marqueen et al. (2018)93
Marqueen et al.93 (conference abstract only) estimated the cost-effectiveness of SIRT with yttrium-90
resin microspheres versus sorafenib in patients with advanced HCC, from a US Medicare perspective.
The authors constructed a multistate Markov model (health states not reported) to estimate incremental
costs and QALYs over a 5-year time horizon. Hazard rates for disease progression and death were based
on a pooled analysis of individual patient data (IPD) from the SARAH19 and SIRveNIB21 RCTs. The clinical
data used in the model were not summarised in the abstract, although the authors stated that there was
no statistically significant difference in OS, and SIRT was better tolerated and with a higher quality of life
than sorafenib. Trial data were also used to inform the parameter values for AEs, treatment adherence
and quality-of-life utility weights.
Costs were US$135,256 versus US$90,911 and QALYs were 0.63 versus 0.60 for sorafenib versus
SIRT, respectively. The resulting ICER of sorafenib was US$1,479,020 per QALY gained. A probabilistic
sensitivity analysis (PSA) demonstrated that the likelihood that sorafenib would be cost-effective did
not exceed 1% in cost-effectiveness thresholds up to US$200,000 per QALY. If the monthly price of
sorafenib decreased from US$16,390 to US$7250, the ICER of sorafenib fell below US$200,000, and
an ICER of <US$100,000 was reached if the monthly price fell below US$6500. Similar results were
found using SARAH and SIRveNIB results separately.
Review of Chaplin et al. (2015)94
Chaplin et al.94 (conference abstract only) conducted a cost-effectiveness analysis of TheraSphere versus
sorafenib in patients with advanced HCC in the UK.94 The authors constructed a Markov model comprising
stable disease, progression and death health states, estimating incremental costs and QALYs over a 10-year
time horizon. Clinical outcomes for TheraSphere and sorafenib were drawn from two separate RCTs. For
TheraSphere, clinical outcomes were based on Salem et al.,47 a non-randomised comparative effectiveness
analysis of radioembolisation with TheraSphere (n= 123) versus chemoembolisation (n= 122). The study
enrolled a range of patients, including 39% who were BCLC A, 50% who were BCLC B and 9% who were
BCLC C. For sorafenib, outcomes were based on Llovet et al.,98 a Phase III RCT that included 299 sorafenib
patients and 303 patients on placebo, who had not received previous systemic treatment: 82% patients
were BCLC C and 18% were BCLC B. Details of data synthesis were not reported in the abstract, but a
comparison of median PFS and OS reported in the trial manuscripts with the model predictions suggests
that the authors undertook adjustments to account for population differences.
The model estimated that TheraSphere increased TTP (6.2 vs. 4.9 months) and median survival
(13.8 vs. 9.7 months). Yttrium-90 was associated with higher QALYs than sorafenib (1.12 vs. 0.85),
with lower lifetime costs (£21,441 vs. £34,050). The model also included a scenario in which OS and
TTP were assumed to be equivalent, in which TheraSphere remained a dominant treatment option.
Review of Parikh et al. (2018)95
Parikh et al.95 (conference abstract only) estimated the cost-effectiveness of SIRT with SIR-Spheres
versus sorafenib in patients with unresectable HCC and Child–Pugh class A cirrhosis, from a US payer
perspective. The authors constructed a Markov simulation model. Clinical inputs for survival and AEs
were derived from the SARAH19 and SIRveNIB21 trials. Costs were derived from a literature review,
Red Book pharmacy data99 and SEER - Medicare data.100 Although methods for estimating clinical
outcomes were not reported, the authors stated that both trials failed to demonstrate a survival
difference between SIRT and sorafenib, although patient-reported outcomes were superior in the SIRT
groups. The authors reported results of the model using data from the SARAH trial only, data from the
SIRveNIB trial only and an analysis in which data from both studies were pooled.
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In all scenarios, SIRT was associated with lower total QALYs than sorafenib was. Using data from
SARAH,19 SIRT was associated with increased costs compared with sorafenib and, therefore, sorafenib
was the dominant treatment option. Using data from SIRveNIB,21 sorafenib was associated with an
ICER of >US$100,000, owing to lower SIRT costs. When combining data from both trials, sorafenib
was cost-effective compared with SIRT, with an ICER of US$19,534 per QALY gained. In the combined
scenario, lifetime costs were US$63,333 for sorafenib and US$61,897 for SIRT, and there were 0.88
QALYs gained for sorafenib and 0.81 QALYs gained for SIRT. The authors concluded that sorafenib is
cost-effective compared with SIRT for patients with unresectable HCC, and that SIRT should not be
used as first-line therapy in patients with advanced HCC who are eligible for sorafenib.
Review of Palmer et al. (2017)96
Palmer et al.96 (conference abstract only) built a cost-minimisation model to evaluate the cost-
effectiveness of SIR-Spheres versus sorafenib for patients with BCLC C HCC. This model assumed
equal efficacy between SIR-Spheres and sorafenib based on data from the SARAH RCT.19 AE data were
collected from Llovet et al.98 for sorafenib and Sangro et al.69 for SIR-Spheres. Costs were derived from
‘standard UK sources’ and data from a UK hospital.
SIR-Spheres dominated sorafenib in this analysis, generating 0.0079 (95% CI 0.0046 to 0.0111) more
QALYs than sorafenib, and providing a cost saving of £8909 (95% CI £3257 to £14,570). One-way
sensitivity analyses showed that the primary drivers were time on treatment for sorafenib and
the costs of work-up and administration for SIR-Spheres. The authors concluded that SIRT using
SIR-Spheres is a cost-effective option for BCLC C HCC patients in the UK.
Discussion
The review of existing cost-effectiveness evidence identified three full studies along with four evaluations
reported only in abstract form. The three studies reported as full texts compared SIRTwith TACE, SIRT
with sorafenib, and two alternative treatment sequences: SIRT followed by TACE and possibly sorafenib
against SIRT followed by sorafenib. All studies reported in abstract form compared SIRTwith sorafenib.
Selective internal radiation therapy versus sorafenib
Only one study comparing SIRT with sorafenib was reported as a full text (i.e. Rognoni et al.89,90), with
the remainder reported as conference abstracts (i.e. Chaplin et al.,94 Marqueen et al.,93 Palmer et al.96
and Parikh et al.95).
The Rognoni et al.89,90 study has a number of important limitations, most notably the use of non-randomised
evidence to estimate the relative effectiveness of SIRT and sorafenib. The survival gains achieved on SIRT
in this study were not reflected in the much larger SARAH19 and SIRveNIB21 trials. A further limitation of
the Rognoni et al.89,90 study was the questionable source of utility values, which do not reflect HRQoL
values used in a number of previous TAs in advanced HCC. The Rognoni et al.89,90 study also adopts a
non-UK perspective, which further limits the relevance of the model results to UK decision-makers.
Except for Chaplin et al.,94 which used non-randomised sources of efficacy data, the conference
abstracts drew data from the SARAH and/or SIRveNIB trials. This may mean that these studies are
more relevant to NHS decision-making. However, their results were inconsistent. Marqueen et al.93
and Palmer et al.96 both reported small QALY gains in favour of SIRT with lower incremental costs.
Parikh et al.,95 in contrast, reported sorafenib to be more clinically effective with higher costs for
sorafenib. The source of this inconsistency is unclear given that all three studies derived clinical
effectiveness data from the same trials, but this may be reflective of differences in cost and HRQoL
assumptions. In these three models, the differences in incremental QALYs between sorafenib and SIRT
are small, suggesting that the results may be very sensitive to different assumptions around survival or
HRQoL. Marqueen et al.93 and Palmer et al.96 noted that model predictions were sensitive to treatment
cost assumptions. Palmer et al.96 specifically highlighted SIRT work-up costs and time on treatment for
sorafenib as particular drivers of cost-effectiveness.
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Because of these inconsistencies, it is difficult to draw conclusions on the cost-effectiveness of SIRT
based on existing analysis of the SARAH and SIRveNIB trials. Limited reporting also prevents
meaningful validation of the assumptions and input parameters used in each model, and only
Palmer et al.96 was conducted from a UK perspective.
Selective internal radiation therapy versus transarterial chemoembolisation
One study, reported as a full text by Rostambeigi et al.,91,92 evaluated the cost-effectiveness of SIRT
versus TACE. However, the model structure and inputs used in the analysis were inadequately
reported and justified. This is reflected in the AG’s quality assessment (see Appendix 5), in which the
majority of elements were scored as unclear. In particular, the source of the clinical effectiveness data
used to populate the model is unclear. The evidence identified in the systematic review presented
in Chapter 3, however, suggests that it was probably based on non-randomised comparative studies,
as little RCT evidence was identified in a CTT-eligible population.
Previous National Institute for Health and Care Excellence guidance
There have been three previous NICE TAs in HCC, although none was for SIRT. These include the
evaluations of sorafenib (TA47411), lenvatinib (TA55112) and regorafenib (TA55513). These appraisals
are all for systemic therapies for the treatment of advanced unresectable HCC, which forms a
subpopulation of that outlined in the scope of the present appraisal of SIRT. This section discusses the
key issues and sources of data in each appraisal.
A summary of relevant NICE technology appraisals completed prior to July 2019 is presented in Table 16.
TABLE 16 Summary of previous technology appraisals in HCC
Characteristic Sorafenib (TA474)11 Lenvatinib (TA551)12 Regorafenib (TA555)13
Model structure Markov model, using three
health states: progression free,
progressed and dead
A partitioned survival model,
using three health states:
progression free, progressed
and dead
A partitioned survival model,
using three health states:
progression free, progressed and
dead. Cycle length of 28 days
Population Patients with advanced-stage
HCC, who have failed or are
unsuitable for surgical or
locoregional therapies
Untreated, advanced or
unresectable HCC patients who
had Child–Pugh class A status.
This was in line with the NICE
scope for this appraisal. The
ERG evaluated efficacy results
for the Western subgroup, but
ultimately used the full
population results
Adults with advanced,
unresectable HCC who had
previously received sorafenib
Intervention and
comparators
Sorafenib, administered orally
at a dose of 400 mg twice daily
The comparator was BSC
Dosing based on mean dose
received in the SHARP trial,69
assuming no wastage
The intervention was lenvatinib,
which is orally administered.
The starting dose was 12 mg for
patients weighing > 60 kg, and
8mg for patients weighing
< 60 kg
Dosing was based on mean
dose received by the Western
subgroup of the REFLECT trial,12
assuming no wastage. The ERG
implemented dosing based on
full pack usage (no wastage)
The comparator was sorafenib,
administered orally at a daily
dose of 800 mg
Regorafenib, administered orally
at a dose of 160 mg once daily
for the first 21 days of each
28-day treatment cycle
The comparator was BSC,
consisting of symptomatic
therapies only
The company used mean doses
from RESORCE101 to estimate
regorafenib usage. The ERG
implemented dosing based on
full-pack usage (no wastage)
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TABLE 16 Summary of previous technology appraisals in HCC (continued )
Characteristic Sorafenib (TA474)11 Lenvatinib (TA551)12 Regorafenib (TA555)13
Perspective,
time horizon and
discounting
NHS perspective (PSS in
sensitivity analysis). Time
horizon of 14 years; discount
rate of 3.5% applied to both
costs and QALYs
NHS and PSS perspective. Time
horizon of 20 years; discount
rate of 3.5% applied to both
costs and QALYs
NHS and PSS perspective. Time
horizon of 15 years; discount
rate of 3.5% was applied to both
costs and QALYs
Source of clinical
outcomes data
SHARP trial.69 A Phase III trial
comparing sorafenib with BSC,
enrolling patients with an
ECOG score of 0–2 and
Child–Pugh class A liver disease
REFLECT trial.12 A Phase III trial
comparing lenvatinib with
sorafenib enrolling patients
with unresectable BCLC stage B
(those who were ineligible for
TACE) or BCLC stage C HCC,
and Child–Pugh class A liver
disease
RESORCE trial.101 A Phase III
trial comparing regorafenib with
BSC. This study excluded
patients who discontinued
treatment with sorafenib due to
toxicity, those with Child–Pugh
class B liver disease, and those
with an ECOG performance
score of ≥ 2
Effectiveness
extrapolation
For PFS, the company fit a
log-normal model
For OS, the company fit a
log-normal model. Weibull was
considered equally plausible by
the committee
For PFS, the company fit a
log-normal model to each
treatment group independently.
The ERG applied a gamma
distribution for PFS in its
base-case analysis
For OS, a log-logistic function
was fitted to each treatment
group independently. The ERG
preferred adjusted OS analyses,
controlling for rates of
subsequent therapy
For PFS, observed KM curves
were used directly
For OS, the company used a
log-normal function fitted to
IPD for regorafenib group in
RESORCE,101 with the relative
effect for BSC modelled using
a HR
The ERG preferred independent
Weibull functions to model OS
HRQoL Mapping from FACT-G
collected during the SHARP69
study to a set of time trade-off
utility values using a published
algorithm
A treatment effect was not
included
Estimated based on EQ-5D-3L
data collected in the REFLECT
trial12
A linear mixed model was
used to generate health state
utilities from the EQ-5D data,
controlling for prior treatment,
age, sex, geographical region,
baseline EQ-5D score and
baseline ECOG performance
status. A treatment effect
was not included. Disutilities
associated with AEs were not
explicitly modelled
Estimated based on EQ-5D-3L
data collected in the RESORCE
trial101
A tobit regression model was
fitted to the data: progression
status and TEAEs were included
as covariates. Treatment effect
was not included as a covariate
Resources and
costs
Costs and health-care resource
use considered included
drug acquisition, disease
management and AEs
Disease management costs
were estimated from pooling
two surveys used in the
sorafenib appraisals
(2007 and 2015)
Costs and health-care resource
use considered included
drug acquisition, disease
management, AEs and
end-of-life costs
Unit costs were from national
sources. Disease management
costs were estimated from
pooling two surveys used
in the sorafenib appraisals
(2007 and 2015)
The company’s model included
costs of (1) drug acquisition for
regorafenib, (2) health state
resource use and (3) the
management of AEs. Unit costs
were from national sources
Resource use consisted of visits,
tests and hospitalisations,
and was estimated from the
sorafenib resource use survey
conducted in 2015, as no further
sources of medical resource use
data were identified
The ERG preferred the use of
combined 2007 and 2015
survey costs
continued
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The modelling approach taken across all three appraisals was similar, with each using a model based on
three health states: progression free, progressed disease and death. The sorafenib appraisal differed
slightly in its approach and used a Markov model, whereas a partitioned survival modelling approach
was used in the other two appraisals.
Clinical data for TA47411 (sorafenib), TA55112 (lenvatinib) and TA55513 (regorafenib) were drawn
respectively from the relevant pivotal trials SHARP,69 REFLECT12 and RESORCE.101 Because of the
availability of directly relevant RCT data, no meta-analysis was undertaken in any of the three
appraisals. Modelling of clinical effectiveness was, therefore, undertaken by extrapolating available KM
data. The committee’s preferred approach in all three appraisals was to independently fit parametric
functions to each of the treatment arms on the grounds that proportional hazards did not hold.
The parametric function adopted varied across appraisals, with the log-normal and Weibull functions
considered the best fitting and most clinically plausible in the appraisal of sorafenib, and the log-logistic
function was considered the most appropriate in the lenvatinib appraisal. In the regorafenib appraisal,
the Weibull function was considered the best fit, with the exponential and Gompertz functions being
plausible alternatives.
TABLE 16 Summary of previous technology appraisals in HCC (continued )
Characteristic Sorafenib (TA474)11 Lenvatinib (TA551)12 Regorafenib (TA555)13
Time on
treatment and
subsequent
therapies
The cost of post-progression
sorafenib treatment was
removed from the model,
but the analysis submitted
for Cancer Drugs Fund
reconsideration included
these costs
Patients received BSC after
treatment discontinuation
Time to treatment
discontinuation KM data were
used directly in the model to
estimate the proportion of
patients on treatment at a
given time
Subsequent therapies applied
after discontinuation in the
company model included
sorafenib and regorafenib. The
REFLECT trial12 included other
therapies post progression.
The ERG preferred a scenario
whereby post-progression
therapy costs were removed;
however, the committee
concluded that it was
reasonable to apply these
costs as the benefits of post-
progression treatment was
reflected in the OS model
Discontinuation probability
applied for patients while
progression free and post
progression, from RESORCE.101
Progression-free: based on
proportion of patients
discontinuing regorafenib for
more than one cycle prior to
disease progression and median
PFS. Post progression: based on
proportion of patients who
continued to receive regorafenib
after disease progression and
post-progression treatment rate
The ERG preferred to fit a
log-logistic model to the time
to treatment discontinuation
KM data
No subsequent therapies were
applied after discontinuation
AEs Grade 3 or 4 TEAEs occurring
in ≥ 10% of patients in the
sorafenib arm of SHARP69
Grade 3 or 4 TEAEs occurring
in ≥ 5% of patients in either
arm of REFLECT,12 or if
identified as being clinically or
economically significant by UK
clinical experts (diarrhoea,
asthenia and fatigue)
Grade 3 or 4 TEAEs occurring in
≥ 5% of patients in either arm of
RESORCE101
Results (ICER,
Δ£/ΔQALY)
Company base case (TA189):
£64,754
Updated company base case
(TA474): £39,162
DSU (TA474): between
£51,208 and £71,276
Company base case: lenvatinib
dominated sorafenib
ERG base case: lenvatinib
dominated sorafenib
Company base case: £33,437 per
QALY gained
ERG base case: £81,081 per
QALY gained
EQ-5D-3L, EuroQol-5 Dimensions, three-level version; ERG, Evidence Review Group; FACT-G, Functional Assessment
of Cancer Therapy – General; PSS, Personal Social Services; TEAE, treatment-emergent AE.
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Modelled HRQoL across all three appraisals was based on data collected in the respective pivotal trials.
In each appraisal, health state utilities were determined by the presence/absence of progressive
disease, with no treatment effect included. Progression-free utilities in TA474 and TA551 were similar
(0.69 and 0.693, respectively). However, progressive disease values differed, with 0.71 used in TA474
and 0.63 used in TA551. Utility values used in TA555 were generally higher than those in TA474 and
TA551. The progression-free utility value used was 0.81, with a utility decrement of –0.048 applied in
progression. The Evidence Review Group questioned the face validity of the utility values used, noting
the inconsistency with TA474 and TA551, which appraised first-line systemic therapy, whereas
regorafenib is positioned as a second-line therapy used after discontinuation of sorafenib. Costs were
broadly similar across each appraisal.
Time on treatment was sourced from the relevant pivotal trials through extrapolation of KM data.
In TA474, time on treatment was considered to be associated with significant uncertainty, as
observational data collected during the Cancer Drugs Fund period presented in the Cancer Drugs Fund
reconsideration showed that median time on treatment was much shorter than observed in the SHARP
trial.69 The committee also heard from NHS England that patients are treated for a shorter period of
time than was standard in 2007, trading a sizeable decrease in AEs for a small drop in effectiveness.
Despite this, the committee preferred to model time on treatment based on that observed in the
SHARP trial69 to retain consistency with other clinical inputs.
Health state resource use across all three appraisals was based on two surveys of clinical experts
conducted in the appraisals for sorafenib (TA189 and TA474), with unit costs updated in subsequent
appraisals. Health state costs included medical staff visits, laboratory and radiological tests, and
inpatient costs (including general ward, intensive care unit and accident and emergency admission).
The committee preferred to pool the original and revised estimates of resource use, as it was noted
that resource use data estimates varied widely.
Review of economic evidence submitted by companies
The Sirtex102 and BTG103 submissions included health economic evaluations assessing the cost-
effectiveness of SIR-Spheres and TheraSphere for the treatment of HCC, together with fully executable
health economic models. The Terumo submission104 included a budget impact analysis but did not
include any further economic evidence.
The Sirtex and BTG company submissions each present the methods and results of two separate
economic evaluations that split the population potentially eligible for SIRT into two main groups. The
two populations considered in each submission were (1) those eligible for CTT, referred to by Sirtex
as TACE, and BTG as TAE, assumed to consist primarily of BCLC B patients, and (2) those who are
ineligible for CTT, assumed to consist primarily of BCLC C patients.
Sirtex submission: conventional transarterial therapy-eligible analysis
A cost-minimisation analysis (CMA) was conducted by Sirtex to compare SIR-Spheres, TheraSphere,
TACE [referred to by Sirtex as conventional transarterial chemoembolisation (cTACE) in its company
submission] and DEB-TACE in the CTT-eligible population. A summary of the key features of the Sirtex
model is presented in Table 17. A CMA assumes that the treatments being compared are equivalent in
terms of their clinical effectiveness, and considers only the costs associated with each treatment. The
presented analysis, therefore, compares only the respective costs associated with each technology.
Sirtex’s justification for implementing a CMA rather than a cost–utility analysis was the lack of
comparative evidence available, and the uncertainty of the results of its NMA in this population.
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Evidence used to inform the company’s model
The presented CMA considered the following costs: (1) initial treatment, (2) hospitalisation and
(3) management of AEs.
Treatment costs of transarterial chemoembolisation and drug-eluting bead transarterial
chemoembolisation
Sirtex provided three alternative scenarios for the cost of TACE and DEB-TACE. In one scenario, these
costs were based on those estimated by Fateen et al.,105 a single-centre retrospective database study
from the UK. This study collected cost data for 101 procedures in 43 patients between 2006 and 2012
at a centre in Nottingham, UK. In this study, 25% of patients received DEB-TACE and the remaining
75% of patients received TACE. Costs reported in Fateen et al.105 were for the 2012 cost year: these
were inflated to 2018 costs.106
A second scenario used unit costs from National Schedule of Reference Costs 2017–2018107 for hospitalisation,
applied to resource use as estimated in the Fateen et al.105 study. The mean cost per day of hospitalisation
was estimated as £1757 (from Elective Inpatient, Percutaneous, Chemoembolisation or Radioembolisation,
of Lesion of Liver, YR57Z), and was assumed to include the cost of delivering TACE.
A third scenario incorporated the results of the resource use survey commissioned by Sirtex, which
were used to estimate the number of TACE and DEB-TACE procedures received by each patient, and
the proportion of patients receiving DEB-TACE and TACE. The resource use survey was completed by
five medical professionals from UK hospitals, comprising two oncologists, one hepatologist and two
specialist nurses. This scenario was presented to reflect that resource use might have changed since
the time that the Fateen et al.105 study was undertaken. The survey estimated that a greater proportion
of CTT patients receive DEB-TACE in the survey than in the earlier-conducted Fateen et al.105 study
(63% vs. 25%), and that, on average, there are fewer procedures undertaken for a given TACE patient
(2.5 vs. 3.03) but a greater number of DEB-TACE procedures (2.83 vs. 1.43).
TABLE 17 Sirtex model scope (CTT-eligible population)
Model component Description
Population The patient population that is the focus of the cost-effectiveness analysis includes patients
matching the following criteria:
l People with intermediate-stage (BCLC stage B) HCC, who are eligible for treatment
with CTT
Intervention SIRT:
l TheraSphere
l SIR-Spheres
Comparator Established clinical management without SIRT, consisting of CTT. These are:
l TACE
l DEB-TACE (TACE with drug-eluting beads)
Analysis type CMA
Economic outcome Total treatment-related cost
Perspective NHS and PSS
Time horizon N/A
Discount rate N/A
N/A, not applicable; PSS, Personal Social Services.
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The costs of providing CTT, estimated as a weighted average of DEB-TACE and TACE costs, ranged
from £8792.59 in the scenario based on the Fateen et al.105 study (scenario 1), to £13,702.37 in the
scenario incorporating the results of the resource use survey for the number of TACE and DEB-TACE
procedures (scenario 3). A full breakdown of costs is provided in Appendix 15, Table 48.
Treatment costs of selective internal radiation therapy
Procedure costs relating to the administration of SIR-Spheres were assumed to comprise the device
costs, the cost of work-up and the SIRT administration procedure (see Appendix 15, Table 49, for a
detailed breakdown).
The acquisition cost for a single administration of SIR-Spheres and TheraSphere was assumed to be £8000.
Sirtex provided a range of scenarios to explore work-up and procedure costs, using alternative sources
and assumptions to provide a range of plausible costs. Work-up costs were based on the number of
work-ups and the total length of hospital stay for a work-up. SIRT procedure costs were based on the
number of procedures and the total length of inpatient stay. If the hospital stay was < 1 day, the cost
of an outpatient visit was instead applied.
Unit costs Unit costs of outpatient visits and the inpatient cost for one night were obtained from
two different sources. These were from either National Schedule of Reference Costs 2017–2018107 or a
microcosting derived from a specialist nurse interview. The inpatient cost from the microcosting exercise
was lower than that from National Schedule of Reference Costs 2017–2018107 (£1178 compared with £1757).
Work-up resource use Two alternative sources of data were provided for the number of work-up
procedures and the length of stay for the work-up. In one source, these figures were informed by
a clinician survey, which did not differentiate between the resource use for TheraSphere and
SIR-Spheres, which estimated a mean of 1.05 work-ups required per patient. An alternative source
was from The Christie NHS Foundation Trust (The Christie NHS Foundation Trust, data on file, 2019,
personal communication), which estimated a greater number of work-ups at (confidential information
has been removed) per patient for SIR-Spheres and (confidential information has been removed) for
TheraSphere, and longer length of stay for each SIRT, equivalent to an inpatient admission.
Selective internal radiation therapy procedure resource use Data were taken from the clinician
survey and elicited from The Christie NHS Foundation Trust (personal communication) to define the
number of procedures and length of stay involved in an average SIRT procedure. Sangro et al.69 provided
an alternative source for the number of SIR-Spheres procedures, and two studies by Salem et al.25,108
were used for TheraSphere. The mean number of procedures ranged from 1.20 to (confidential
information has been removed) for TheraSphere, and from 1.08 to 1.20 for SIR-Spheres. Although the
SIRT procedure was provided on an inpatient basis in these scenarios, Sirtex also explored the provision
of SIRT on an outpatient basis.
Adverse event costs
The unit costs applied in the CTT-eligible model are reproduced in Appendix 15, Table 50. Sirtex
derived the unit costs for treating each event from previous NICE TAs, and AE rates were obtained
from Salem et al.,25 a Phase II RCT that compared TheraSphere with TACE in a population of early-
stage HCC patients with intent to transplant. Rates of AEs for SIR-Spheres were assumed to be
equivalent to those for TheraSphere. This study estimated a higher burden of AEs in CTT patients,
in particular neutropenia and elevated aspartate aminotransferase. Consequently, a higher cost was
applied in the model (£346 for CTT vs. £109 for TheraSphere).
Results of the economic analysis
Sirtex provided three alternative scenarios for the costs of CTT, which estimated a total cost of
providing CTT ranging between £9257 and £14,167 per patient (Table 18).
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A range of costing scenarios were presented for TheraSphere and SIR-Spheres based on the alternative
methods for delivering the SIRT. Total costs ranged from £12,026 to (confidential information has been
removed) for TheraSphere, and from £11,185 to (confidential information has been removed)
for SIR-Spheres. In the scenarios that differentiated costs between TheraSphere and SIR-Spheres,
TheraSphere costs were slightly higher than SIR-Spheres owing to an increased number of procedures
per patient.
Rather than selecting a preferred scenario, Sirtex noted that the range of costs associated with CTT,
TheraSphere and SIR-Spheres overlapped, demonstrating the comparability of treatment costs. Total
costs comprised mostly those directly related to the primary treatment, with treatment for AEs and
hospitalisation constituting a small proportion of total costs.
Assessment Group critique of the Sirtex conventional transarterial therapy-eligible model
Cost-minimisation analysis
The AG considered the presentation of a CMA for this population to be inappropriate and potentially
misleading. Such an analysis is appropriate only if there is compelling and unambiguous evidence for
equivalent efficacy between interventions. When a CMA is considered by NICE in other appraisals, it is
typically accompanied by an extensive and conclusive assessment of equivalence between treatment
TABLE 18 Total costs associated with providing CTT and SIRT in the CTT-eligible population
Scenario Total costs (£)
CTT costing
CTT cost from literature 9257
CTT resource use from literature with National Schedule of
Reference Costs 2017–2018107
11,919
CTT resource use from survey, literature with National
Schedule of Reference Costs 2017–2018107
14,167
With microcosting
With National Schedule of
Reference Costs 2017–2018107
SIR-Spheres costing
Survey results 12,279 13,419
Survey results with outpatient procedures 12,026 12,261
The Christie NHS Foundation Trust results
(personal communication)
Confidential information
has been removed
Confidential information has
been removed
Sangro et al.,69 Salem et al.25 for number of procedures,
rest survey
11,185 12,222
Sangro et al.,69 Salem et al.108 for number of procedures,
rest survey
11,185 12,222
TheraSphere costing
Survey results 12,279 13,419
Survey results with outpatient procedures 12,026 12,261
The Christie NHS Foundation Trust results
(personal communication)
Confidential information
has been removed
Confidential information has
been removed
Sangro et al.,69 Salem et al.25 for number of procedures,
rest survey
13,244 14,474
Sangro et al.,69 Salem et al.108 for number of procedures,
rest survey
15,800 17,269
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arms.109–111 Clinical equivalence is a dynamic concept and any demonstration of clinical equivalence
should be sustained over time. Therefore, it is important to assess whether or not the two therapies
are equivalent not just in response rate, but in terms of if PFS and OS are also similar.
Results of the AG systematic review found no high-quality evidence in this population. As discussed
in Chapter 3, Clinical effectiveness results, the RCTs directly comparing SIR-Spheres with TACE and
DEB-TACE were very small and of poor quality, and appeared to favour the chemoembolisation
procedure over SIRT in terms of survival outcomes. Although one RCT comparing TheraSphere with
TACE reported longer TTP, a higher proportion of patients undergoing transplant and a small but
non-significant OS benefit in the TheraSphere arm, this study enrolled a small number of patients and
was rated as having a high risk of bias.22
Therefore, although the AG acknowledges the cited limitation in the effectiveness evidence for this
population, and agrees that the development of a cost–utility model is inappropriate, the AG does not
consider the identified evidence sufficient to make the strong assumption of equivalence between CTT
and SIRT. Furthermore, a focus on treatment costs excludes possible important outcomes regarding
people who are downstaged after treatment and become eligible to receive curative therapy, or who
receive subsequent therapy after progression of disease.
Cost of treatment with conventional transarterial therapy
The cost analysis of CTT highlighted significant uncertainties in the number of CTT treatments that are
typically given, and the impact on the total costs. The applicability of the available sources was limited,
and included the only single UK centre collecting data between 2006 and 2012,105 and a survey of
five UK-based clinicians. These two sources were used to provide a range of the number of treatments
that CTT patients might receive in practice. For TACE, the estimated range was narrow and estimated
at between 2.5 and 3.03 treatments. A much wider range was, however, estimated for DEB-TACE
(1.43 to 2.83). To consider the plausibility of the presented estimates, the AG searched for alternative
estimates of the number of TACE and DEB-TACE procedures. The AG identified two alternative
sources of representative data: a UK-based multicentre trial of DEB-TACE enrolling patients between
2010 and 2015 found that a mean of 2.18 DEB-TACE treatments were given,22 and clinicians at a
centre in the UK with experience in delivering TACE reported that patients (up to 2010) received
a mean of 2.56 treatments with TACE (Dr Jai Patel, Leeds Teaching Hospitals NHS Trust, 2019,
personal communication). These estimates both fall within the ranges presented by Sirtex.
Number of selective internal radiation therapy procedures
Sirtex explored the cost impact from using a range of sources to estimate the number of procedures
with SIR-Spheres and with TheraSphere. Patients receiving treatment with SIRT typically receive
multiple procedures on the basis of their tumour burden (i.e. bilobar involvement requiring sequential
treatment visits), with patients not typically re-treated with SIRT on disease progression. Therefore,
the number of procedures required would not be expected to differ between treatment arms, and the
range of total treatment costs for SIR-Spheres and TheraSphere estimated by this analysis might be
expected to be more similar.
Sirtex submission: conventional transarterial therapy-ineligible analysis
The cost–utility model developed by Sirtex evaluates SIR-Spheres for the treatment of HCC in patients
currently ineligible to receive TACE, and assesses the incremental cost-effectiveness of SIR-Spheres
compared with sorafenib, as well as lenvatinib in a scenario analysis. Clinical inputs in the model
are largely based on a subgroup analysis of the SARAH trial.19 The scope of the company’s model
is summarised in Table 19. The model uses a lifetime (15-year) time horizon and takes an NHS
perspective. Costs and health outcomes are discounted at a rate of 3.5% per annum, with cost-
effectiveness expressed in terms of the incremental cost per QALY gained as per the NICE reference
case. Costs were valued at 2017/18 prices. The population considered in the company’s model is
limited to those patients who are currently ineligible to receive CTT, and focuses on a subgroup of
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patients with a low tumour burden and good liver function. Sirtex defines this as a maximum tumour
size of 25% of the liver volume, with ALBI 1. The AG noted that this population is far narrower than
the population that would be eligible for SIRT within the ‘CTT-ineligible’ population, and it does not
match the population defined in the NICE scope. It is also important to note that this subgroup
represents a post hoc subgroup analysis of the SARAH trial.19 The company submission also
presented a health economic analysis of the broader CTT-ineligible population as a scenario analysis.
Model structure
The structure of the economic model developed by Sirtex takes the form of a cohort-level partitioned
survival model. The main model includes three health states: (1) progression free, (2) post progression
and (3) dead. In addition to the main partitioned survival component, the model also permits patients
to receive curative therapy, assuming that a proportion of patients are downstaged and receive liver
transplant, resection or ablation. Patients who receive curative therapies do not enter the main model,
but instead effectively move into a separate two-state model, which comprises the health states
(1) alive/received curative therapy and (2) dead. The proportion of patients downstaged to receive
curative therapy is based on the numbers downstaged in the low tumour burden/ALBI 1 subgroup of
the SARAH trial.19 Figure 8 presents an overview of the model structure. Both submodels use a lifetime
time horizon of 15 years and monthly model cycle with a half-cycle correction applied.
In the partitioned survival submodel, the transitions between the three health states were determined
directly from the survival models of PFS and OS. Given the incomplete KM data available, parametric
functions were fitted to KM curves for OS and PFS from the low tumour burden subgroup of the
SARAH trial.19 Log-normal functions were selected to model both OS and PFS, assuming independent
(non-proportional) hazards between treatment groups.
TABLE 19 Sirtex model scope (CTT-ineligible population)
Model component Description
Population The patient population that is the focus of the cost-effectiveness analysis includes patients
matching the following criteria:
l Patients with unresectable intermediate (BCLC stage B) or advanced (BCLC stage C) HCC
¢ For whom any TAE therapies (TAE, TACE, DEB-TACE) are inappropriate
¢ With or without PVT/PVI
¢ Without extrahepatic disease
¢ With a tumour burden of ≤ 25%
¢ And with a preserved liver function (ALBI 1)
Intervention SIRT:
l SIR-Spheres yttrium-90 resin microspheres
Comparator Established clinical management without SIRT (including but not limited to target
chemotherapy). Established clinical management is limited to systemic therapy with
sorafenib or lenvatinib in UK clinical practice
Analysis type Cost-effectiveness (cost–utility) analysis
Economic outcome Incremental cost per QALY gained
Perspective NHS and PSS
Time horizon 20 years
Discount rate Annual rate of 3.5% applied to costs and QALYs
PSS, Personal Social Services.
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In the partitioned survival model, health state utilities are determined based on the presence or
absence of disease and the therapy received, with utility values drawn from the low tumour burden/
ALBI 1 subgroup of the SARAH trial.19 The model does not separately account for loss of QALYs as
a result of AEs, as these were assumed to be accounted for through the direct use of trial-based
utility values. Utility values used for patients receiving curative therapy were the same as those for
pre-progression in the SIR-Spheres arm of the main partitioned survival model.
The model includes the following costs: (1) procedural costs relating to the administration of
SIR-Spheres and liver transplant, (2) sorafenib/lenvatinib drug acquisition and administration costs,
(3) monitoring for participants receiving non-curative care and (4) costs associated with AEs.
The model employs the following structural assumptions:
l Health-related quality of life is determined according to the presence/absence of disease
progression and the therapy received.
l Progression-free survival and OS are modelled using Weibull functions assuming independent
(non-proportional) hazards.
l Survival models for PFS and OS were fitted to the low tumour burden/ALBI 1 subgroup of the
SARAH trial.19
l Adverse events are assumed to affect costs only, with HRQoL assumed to be captured by the use of
trial-based utility values.
l Utility values were assumed to differ according to therapy received in both the pre-progression and
post-progression health states.
l Patients downstaged to receive curative therapy were assumed not to have recurrence of disease,
with mortality outcomes determined from a US cohort study comparing outcomes for patients
receiving palliative and non-palliative care.112
Evidence used to inform the company’s model
Overall survival
Overall survival for patients downstaged and in receipt of palliative care was modelled separately, with
the proportion of patients downstaged based on observed values in the low tumour burden/ALBI 1
subgroup of the SARAH trial.19
Dead
Received curative therapy
Progression free
PFS
On assigned treatment/
on another treatment/
off treatment
OS
Curative
OS
Proportion downstaged
Post progression
Subsequent treatments/BSC
FIGURE 8 Model structure for the CTT-ineligible population. Reproduced with permission from Sirtex Medical Ltd.102
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Overall survival for patients who are not downstaged to curative therapies in the economic model
was based on observed survival in the SARAH trial,19 using data on the low tumour burden/ALBI 1
subgroup of patients, including 37 SIRT patients and 48 sorafenib patients.
Before fitting parametric functions to the available KM data, diagnostic plots were used to assess the
plausibility of assumption of proportional hazards. The plots revealed some evidence to suggest that
the proportional hazards assumption may not hold, as in some instances the lines were not parallel and
indeed crossed in some cases.102 The Schoenfeld residuals, however, suggest no significant deviation
from the proportion hazards assumption. Given this uncertainty, Sirtex opted to fit separate parametric
functions to the KM data.
The following parametric survival models were fitted to the observed KM data: Weibull, log-normal,
log-logistic, exponential and gamma functions. Assessment of the most appropriate parametric
extrapolation was made with reference to statistical goodness of fit, visual fit to the observed data and
assumptions made in previous TAs.11–13 Assessment of statistical fit (see Sirtex company submission,102
appendix F) revealed a similar statistical fit for the majority of curves, with the exponential curve
observed to have the highest statistical fit. In assessing visual fit, Sirtex noted that the generalised
gamma, Weibull and Gompertz curves crossed, which is not seen in the KM curves until the last few
patients, whereas the log-normal and log-logistic curves did not cross. Sirtex further noted that in
previous TAs of sorafenib (TA47419) and lenvatinib (TA55112), the log-logistic and log-normal curves
were considered the most appropriate, and in the analysis of the SARAH19 ITT population the
log-normal distribution fitted best, in terms of both goodness-of-fit statistical criteria and visual
inspection. On these grounds, Sirtex therefore selected the log-normal function for its base-case
analysis. Assessment of uncertainty in curve selection was also partially explored in two scenario
analyses considering the log-logistic and Weibull distributions.
Overall survival outcomes for patients downstaged to curative therapy were not drawn from the
SARAH trial,19 as OS data were censored on receipt of curative therapy. Survival outcomes for these
patients were, therefore, based on a US cohort study,112 which reported the outcomes for patients who
did and did not receive curative therapy. The survival HR for downstaged patients was 0.29 (95% CI
0.18 to 0.47). To model survival in the downstaged patients, this HR was applied to the treatment-
specific survival curves for SIR-Spheres and sorafenib patients. Importantly, because this HR was
applied to the individual survival curves for SIR-Spheres and sorafenib, the model implies differential
OS following receipt of curative therapies depending on the initial treatment received.
Progression-free survival
Progression-free survival was defined as the time from the closest date of radiological examination
before the first administration of the study treatment to disease progression (per investigator
assessment), or death from any cause. Because progression events were observed across patients who
were and were not downstaged to receive curative therapy, a common PFS curve was assumed for all
patients irrespective of whether or not they received subsequent curative therapy. Sirtex’s base-case
analysis drew PFS data from the low tumour burden/ALBI 1 subgroup of the SARAH trial.19
Assessment of the proportional hazards suggested a degree of uncertainty in whether or not this
assumption holds. Assessment of statistical fit based on Akaike information criterion (AIC) and
Bayesian information criterion (BIC) of the jointly fitted data found that the (assuming proportional
hazards) log-logistic and log-normal, as well as the independently fitted (no proportional hazards)
log-normal, distributions had the best statistical fit. Aligning with assumptions made for OS, Sirtex’s
base-case analysis used independently fitted log-normal distributions. Uncertainty in curve selection
was partially explored in a scenario analysis in which the log-logistic and Weibull distribution
were used.
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Health-related quality of life
The primary source of utility data used by Sirtex was the SARAH trial,19 which measured HRQoL using
the EORTC QLQ-C30 questionnaire. There were a significant number of missing responses over the
course of the study, ranging from 19% at baseline to 56.8% at 18 months, with an overall rate of
missing data of 38.5%. To calculate health state utilities from this data set, the mapping algorithm by
Longworth et al.113 was used to generate EQ-5D scores adjusted to reflect UK population weights.
Sirtex did not consider the SARAH trial19 to show evidence of an independent treatment effect on
utility, and there was no significant difference between the HRQoL of those treated with SIR-Spheres
and those treated with sorafenib. The company submission,102 however, also notes a statistically
significant difference in reported global health scores between treatment arms, and applies treatment-
specific utility values based on the subgroup of patients with a tumour burden of ≤ 25% and ALBI 1.
The values used in the base-case model are reported in Appendix 15, Table 51.
Selective internal radiation therapy procedure costs
Procedure costs relating to the administration of SIR-Spheres were assumed to comprise the device
costs and cost of the work-up and treatment procedures. All patients in the SIRT arm of the model
were assumed to undergo at least one work-up procedure, with 5% of patients also assumed to
undergo a second work-up based on clinical opinion. To account for the fact that not all patients will
go on to receive SIRT (e.g. owing to excess shunting), only a proportion of patients were assumed to
receive SIRT. Sirtex’s base case used the low tumour burden/ALBI 1 subgroup of the SARAH trial19 to
derive this figure. The model also permitted SIRT patients to be re-treated with SIRT. Sirtex did not
consider the average number of SIRT treatments in the SARAH trial19 to represent likely UK practice,
as the SARAH trial19 mandated separate administrations where bilobar disease was present. Sirtex
instead used data from the CIRT114 (Belgium, France, Germany, Italy, Spain and Switzerland) as well as
the ENRY study showing that patients with bilobar disease typically receive a single administration of
SIRT with both lobes treated simultaneously.69 The number of SIRT administrations was, therefore,
based broadly on the CIRT, with 1.20 treatments assumed per patient. Uncertainty in the number of
SIRT administrations was also explored in scenario analyses based on the SARAH trial,19 the SIRveNIB
trial,21 the ENRY study69 and The Christie NHS Foundation Trust data (personal communication).
Costs relating to the work-up and SIRT procedures were based on National Schedule of Reference Costs
2017–2018,107 with the cost of SIR-Spheres assumed to be £8000 per administration. Appendix 15,
Table 52, summarises the assumptions and costs of the SIRT procedure.
Drug acquisition costs: systemic therapies
Drug acquisition costs for sorafenib and lenvatinib were taken from the British National Formulary
(BNF).115 Dosing of sorafenib was based on the SARAH trial,19 assuming that 24% of patients received
an 800-mg dose and 76% received a 600-mg dose. In scenarios in which lenvatinib was included
as a comparator, dosing was based on TA551,12 with 65% assumed to receive an 8-mg dose and
35% assumed to receive a 12-mg dose.12 Duration of sorafenib therapy was based on the time-to-
discontinuation curve from the SARAH trial,19 which was extrapolated using a log-normal function.
Duration of lenvatinib therapy was estimated by applying a HR to the sorafenib time-to-discontinuation
curve taken from TA551.12
Subsequent treatments
Modelled subsequent treatments without curative intent were based on expert elicitation, as the
subsequent treatments received in the SARAH trial19 were not considered reflective of NHS practice.
Drug costs were taken from the electronic market information tool (eMIT)116 and the BNF.115
For patients downstaged to receive curative therapies, the modelled therapies were based on those
received in the ITT population of the SARAH trial,19 consisting of resection, liver transplantation and
tumour ablation. The proportion receiving each type of therapy is summarised in Appendix 15, Table 53.
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Costs of resection were based on NICE TA474,11 and costs of ablation and liver transplantation were
based on National Schedule of Reference Costs 2017–2018.107
Health state costs
Resource use estimates were based on a survey of clinical experts, and included medical staff contacts
[e.g. general practitioner (GP) appointments], diagnostic procedures, inpatient care and Personal Social
Services (PSS) contacts. Unit costs were derived from National Schedule of Reference Costs 2017–2018.107
Total costs by health state are reported in Appendix 15, Table 54.
Adverse event costs
The costs of grade 3 or 4 TRAEs experienced by ≥ 5% of the population were modelled, with rates drawn
from the SARAH19 and REFLECT81 trials. Costs for each AE were sourced from previous TAs and inflated
to the 2018 cost year as appropriate. See Appendix 15, Table 55, for a summary of included AE costs.
Model results
The headline results presented in the Sirtex company submission102 are based on the deterministic
version of the model. Uncertainty surrounding model parameters was explored using deterministic
sensitivity analysis (DSA) and PSA. The probabilistic results were estimated from 1000 Monte Carlo
samples. Uncertainty was represented using tornado diagrams, cost-effectiveness planes and
cost-effectiveness acceptability curves (CEACs).
Table 20 presents the base-case estimates of cost-effectiveness using the list price for sorafenib.
Based on the probabilistic version of the company’s model, SIR-Spheres are expected to generate an
additional 0.682 QALYs at an incremental cost of –£1979 compared with sorafenib; SIR-Spheres
were, therefore, estimated to be dominant, producing greater health benefits at lower overall cost.
The deterministic version of the model produces similar results, with SIR-Spheres estimated to
dominate sorafenib.
Figure 9 presents the results of the company’s DSA. The most influential parameters (of those assessed
by the company) relate to predicted OS (SIR-Spheres and sorafenib) and the proportion of patients
downstaged to receive curative therapy. Additional scenario analyses presented by the company
showed that the estimated ICER was generally robust to a range of alternative assumptions, including
alternative extrapolations of survival data. However, this analysis also showed that estimated ICERs
increased very significantly when the source of effectiveness estimates was changed from the low
tumour burden/ALBI 1 subgroup to the ITT or per-protocol population from the SARAH trial,19
which yielded ICERs of £58,763 and £680,276 per QALY gained, respectively.
TABLE 20 Sirtex base-case results (CTT-ineligible population)
Treatment
Absolute Incremental
ICER (£)QALYs Costs (£) QALYs Costs (£)
Probabilistic model
SIR-Spheres 2.009 24,456 0.682 –1979 Dominant
Sorafenib 1.408 26,435
Deterministic model
SIR-Spheres 1.982 29,143 0.601 –1784 Dominant
Sorafenib 1.381 30,927
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Critique of the Sirtex conventional transarterial therapy-ineligible model
Relevance of modelled population
The company’s health economic analysis is limited to a subpopulation of patients with a tumour burden
of ≤ 25% and with preserved liver function (ALBI 1). The company cited clinical opinion and published
literature in its justification for focusing on this group, stating that the ITT and per-protocol population
recruited to the SARAH trial19 was unreflective of that eligible in the UK, while also highlighting that
the trial included patients with high tumour volume, PVT and poor liver function. The company also
outlined that this subpopulation increased the probability of receiving SIRT and the probability of going
on to access curative therapy, citing figures from the SARAH trial.19
Consultation with the AG’s clinical experts confirmed that this subgroup could be identified
prospectively and treated with SIRT. However, they also noted that ALBIs are not routinely used to
assess liver function in UK practice, and that this definition did not represent a widely accepted
clinically distinct subgroup of patients.
The AG is further concerned that the selection of this subgroup is based on a post hoc analysis of a
relatively small subgroup of the SARAH trial,19 representing < 20% of the total trial population.
Comparison of the results for this subgroup on key outcomes, such as PFS and OS, revealed no
statistically significant differences between this group and the remaining population. Furthermore,
the randomisation procedure for the SARAH trial19 did not stratify by these baseline characteristics,
increasing the risk of baseline imbalances. This can be observed in the sample size of this group
between treatment arms, with 37 patients in the SIRT arm and 48 patients in the sorafenib arm. A
further consequence of using this subgroup is that potentially relevant data from the SIRveNIB trial21
cannot be used, as data on this subgroup were not available to the company. This is important for two
reasons: (1) it reduces the available sample size with consequences for precision and (2) it does not
allow for a confirmatory analysis of the PFS and OS benefits observed in this subgroup.
5000 22,50020,00017,50015,00012,500
Change in ICER (£)
10,0007500
Curative HRs – OS
Time to curative
TTD – sorafenib
Utilities – pre progression – SIR-Spheres
Utilities – post progression – SIR-Spheres
Utilities – post progression – sorafenib
Number of procedures – SIR-Spheres
Proportion curative – SIR-Spheres
OS – sorafenib
OS – SIR-Spheres
Value with lower range
Value with higher range
FIGURE 9 Sirtex DSA: tornado diagram. Reproduced with permission from Sirtex Medical Ltd.102
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The AG is, therefore, concerned that the purported treatment effects in this subgroup are potentially
an artefact of imbalances in characteristics between treatment arms. Available data do not allow
further analysis to establish the validity of the observed PFS and OS gains in this subgroup.
Model structure and clinical plausibility of downstaging
The company’s model allows a proportion of patients to move on to receive curative therapy. This is a
significant driver of the model results, as 66% of incremental QALYs are generated by patients who
received curative therapies.
The SARAH trial19 was used to support the downstaging paradigm used in the model, in which a small
number of patients went on to receive curative therapy. The plausibility of downstaging at such high
rates in UK practice is unclear. The AG was advised that downstaging of patients with advanced HCC
to transplant and other curative options is rare in UK clinical practice, with very few if any of these
patients receiving curative therapies. It is also notable that the SIRveNIB trial,21 which recruited a
similar population, makes no mention of any patients going on to receive curative therapy. Similarly,
none of the previous TAs that assessed systemic cancer treatments for advanced HCC modelled the
possibility of curative therapies. The AG is, therefore, concerned that the very sizable benefits resulting
from curative therapy would not be realised in practice, and that the rarity of downstaging means that
any resulting incremental benefits are subject to very considerable uncertainty.
Modelling of overall survival
The company fit independent parametric survival functions to the observed data from the SARAH
trial.19 This method makes fewer assumptions than a treatment–covariate-based approach, and is in
line with NICE DSU guidance on survival analysis.117 However, the AG does not accept the company’s
rationale for selecting the log-normal curve, which was based primarily on visual fit and its use in
previous HCC appraisals. The AG notes that the log-normal is the most optimistic of all the fitted
parametric curves, and has among the worst statistical fit. The log-normal also has a much longer tail,
and, in the AG’s view, fits poorly to the tail of the observed data for the SIR-Spheres arm of the
SARAH trial.19 Clinical advice to the AG indicated a preference for the Weibull function, which predicts
substantially shorter survival gains and also has better statistical fit.
In addition to the above, the AG is concerned that the parametric functions were fitted to the
observed data that had not been censored to exclude those patients downstaged to receive curative
therapy. In the economic model, the outcomes for these patients are modelling independently and,
therefore, using the uncensored data means that the OS benefits experienced by these patients
are double-counted. The impact of this double-counting is significant, and leads to a substantial
overestimation of survival gain. For example, based on a log-normal extrapolation (used in the Sirtex
base case) and using the uncensored data, estimated OS gain on SIR-Spheres is 8.27 months. Using the
log-normal function on the same data censored for downstaging results in a much reduced predicted
OS gain of 1.55 months.
Further to the above issues regarding the plausibility of downstaging, the AG has concerns around the
methods used to model the OS benefits associated with curative therapy. Postcurative OS is modelled
by using the HR from the Kanwal et al.112 cohort study to the OS curve for each treatment. This HR is
assumed to reflect the improvement in survival outcomes post curative therapy. The application of this
HR is treatment specific (i.e. is applied to the SIR-Spheres OS curve for SIR-Spheres patients and
to the sorafenib OS curve for sorafenib patients). This implies that OS postcurative therapy will differ
depending on the initial treatment received, and thus favours SIR-Spheres. Expert advice received by
the AG, however, considers this implausible and that outcomes will be the same post curative therapy
regardless of previous therapy received.
Furthermore, the application of a HR to the log-normal curve is inappropriate, as the log-normal
function is an accelerated failure time model and does not make assumptions about proportional
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hazard assumptions. Consequently, survival times are considerably over estimated. The AG also
questions the appropriateness of the HR of 0.29 used by the company, noting that this figure was
not based on the primary analysis presented in the cited study, but on a scenario analysis in which
classification of patients was based on both BCLC stage and ECOG performance status.
Modelling of progression-free survival
The company’s approach to modelling PFS was similar to that of modelling OS, with independent
parametric survival functions fitted to the observed data.
The AG is satisfied that the company’s approach of using independent curves was appropriate given
the presented evidence to support the non-proportionality of hazards. The AG, however, questions the
appropriateness of fitting parametric functions to PFS data at all, given that the available KM data are
all but complete; no patients remain at risk in the sorafenib arm and only one remained in the SIRT
arm. The company could, therefore, have used the observed data directly, avoiding any uncertainty in
the choice of parametric function.
The AG is also concerned that the modelled data were not censored for downstaging events and,
therefore, double-count patients who were downstaged to receive curative treatment. As with OS,
this results in PFS gains being overestimated, although to a lesser degree than OS. Mean PFS gain
assuming a log-normal function was 3.7 months using the uncensored data and 2.35 months using the
censored data.
Concerns regarding costs of selective internal radiation therapy
It is assumed in the Sirtex model that patients with bilobar tumours receive SIRT in both liver lobes
during the same treatment session. This is in contrast with how patients were treated in the SARAH
trial,19 which mandated that patients receive separate treatments with a delay between the first and
the second administration. Sequential treatment is implemented to mitigate the risk of REILD, which is
more likely to occur if both lobes are treated simultaneously. The company put forward evidence from
the European CIRT, and suggested that (confidential information has been removed).
The impact of this assumption is to reduce the costs of providing SIR-Spheres, as sequential treatment
involves additional administration and acquisition costs. However, clinical advisors to the AG disagree
with the assertion that simultaneous treatment would be implemented in the UK, and contend that in
UK practice it is likely that sequential treatment would be used as per the SARAH trial.19 Furthermore,
the AG notes that, although the company adjusts costs to account for the use of simultaneous treatment,
no corresponding adjustment is made to health outcomes to account for the increased risks associated
with simultaneous treatment.
Failed work-up procedures
In the Sirtex model, a proportion of patients are assumed to fail the work-up procedure and are thus
ineligible to receive SIR-Spheres. The proportion of patients receiving work-up who do not go on to
receive SIRT was drawn from the low tumour burden/ALBI 1 subgroup of the SARAH trial,19 which was
substantially lower than for the population as a whole (8.1% vs. 18.6%). The AG is concerned about the
appropriateness of this figure, given the post hoc nature of the analysis. The primary reason patients
become ineligible for SIRT following work-up is a high rate of shunting of radioactive material to the
lungs. Although this may be plausibly linked to tumour volume and liver status, any such association
has not been demonstrated, and it is not clear that the proportion of patients who experience
excessive lung shunt will vary substantially between patient groups.
Furthermore, the company’s model assumes that patients who fail work-up will move to the sorafenib
arm of the model. The AG considers this inappropriate as only 62% of patients in the SARAH trial19
who failed work-up subsequently received sorafenib. The outcomes of patients in the SARAH trial19
who received work-up but no SIRT were inferior to those who successfully received SIR-Spheres or
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were randomised to the sorafenib arm. Assuming that patients who fail work-up receive sorafenib
outcomes is therefore likely to overestimate the PFS and OS for those allocated to receive
SIR-Spheres.
Subsequent therapy costs
The company noted in its submission that the subsequent treatments received by patients in the
SARAH trial19 included a number of therapies (e.g. capecitabine and doxorubicin) not used in UK
practice. The treatments received following primary therapy in the model were, therefore, based on a
survey of 12 clinicians instead.
The AG considers the proportions of patients receiving subsequent therapies in the model to be
subject to substantial uncertainty, and notes that these differ substantially from those reported in
the SARAH trial.19 The proportion of patients assumed to receive sorafenib following SIR-Spheres is
higher than that observed in SARAH,19 as is the proportion of patients receiving further treatments
post sorafenib. The AG also notes that post-sorafenib treatment is based on the ITT population of
the SARAH trial19 and, therefore, does not reflect the modelled low tumour burden/ALBI 1 subgroup.
Given that the low tumour burden/ALBI 1 subgroup represents a particularly healthy population, it
may be anticipated that a much higher proportion of these patients would go on to receive subsequent
systemic therapies. As no figures on subsequent therapy in the low tumour burden/ALBI 1 subgroup
are reported, this cannot be verified.
Duration of subsequent sorafenib and lenvatinib therapy was drawn from the REFLECT trial,12 and
subsequent regorafenib was based on the RESORCE trial.101 The approach taken to define time on
treatment was inconsistent, as median values were used for sorafenib and lenvatinib, whereas a mean
value was used for regorafenib. The AG considers mean values more appropriate than the medians
used by the company, as the aim of the model is to calculate the mean costs of subsequent therapy.
The AG is also concerned that the REFLECT trial12 considers the use of sorafenib and lenvatinib in a
first-line setting, particularly as this implies that patients receiving sorafenib as a subsequent therapy
will receive treatment for much longer than those who received it as a first-line therapy. The AG,
therefore, considers that these values are likely to overestimate time on treatment, and that it may be
better to base duration of subsequent therapy on the RESORCE trial,101 which considers systemic
therapy use in a second-line setting.
Omission of palliative care costs
The Evidence Review Group notes that the company model does not include end-of-life costs to
account for palliation at the end of life. However, the impact of this omission is small, as fewer than 1%
of patients remain alive at the end of the modelled time horizon, meaning that nearly all modelled
patients incur this cost.
BTG submission: conventional transarterial therapy-eligible analysis
For the comparison with transarterial therapies, the company presented a cohort-based Markov model,
comparing TheraSphere, SIR-Spheres and QuiremSpheres with TACE (referred to by the company as
cTACE), DEB-TACE and TAE (referred to by the company as bland embolisation). Outcomes were
assessed over a time horizon of 20 years using 4-week cycles, and were discounted at a rate of 3.5%.
The scope of the company’s model is summarised in Table 21.
Model structure
The model presented by BTG for the CTT-eligible population was based on a Markov structure,
and contained the following health states: (1) watch and wait, (2) pre transplant, (3) post transplant
(a series of three tunnel states), (4) no HCC post transplant, (5) pharmacological management and
(6) dead. The model schematic is illustrated in Figure 10.
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Patients who are eligible for SIRT enter the model in the ‘watch and wait’ health state, following
initial treatment. Patients remain in this state until they (1) are downstaged and become eligible for
transplant, moving on to the pre-transplant state (equivalent to a transplant waiting list), (2) transition
to the pharmacological management state owing to not entering remission and being ineligible for liver
transplant, or (3) die.
Although the model includes the functionality for patients to receive resection after being downstaged
or achieving remission, these transitions are not included in the base-case analysis.
TABLE 21 BTG model scope (CTT-eligible population)
Model component Description
Population The patient population that is the focus of the cost-effectiveness analysis includes patients
matching the following criteria:
l People with intermediate-stage (BCLC stage B) HCC, who are eligible for treatment
with CTT
Intervention SIRT:
l TheraSphere
l SIR-Spheres
l QuiremSpheres
Comparator Established clinical management without SIRT (including but not limited to target
chemotherapy). The target chemotherapies are:
l TACE
l TAE
l DEB-TACE
Analysis type Cost-effectiveness (cost–utility) analysis
Economic outcome Incremental cost per QALY gained
Perspective NHS and PSS
Time horizon 20 years
Discount rate Annual rate of 3.5% applied to costs and QALYs
Watch and wait Resection
Pre transplant Post transplant
Pharmacological
management
No HCC (other)
No HCC 
post transplant
Dead
FIGURE 10 Model structure for the CTT-eligible population. Reproduced with permission from BTG Ltd.103
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The pre-transplant state captures the time when patients are on the donor organ waiting list.
Patients remain in this state until they (1) receive a transplant, and move to the post-transplant state,
(2) experience disease progression or become ineligible for a liver transplant, after which they move to
the pharmacological management state, or (3) die.
Following transplant, patients spend a single cycle in each of the post-transplant states before arriving
in the no-HCC post-transplant state, where they remain until death. The three tunnel states allow for
differing resource use over the time following the transplant. In addition, the model assumed that
patients would not experience a tumour recurrence after transplantation.
Patients entered the pharmacological management pathway from either the ‘watch and wait’ health state
or the pre-transplant health state. Patients remain in this health state until death, although the impact of
further disease progression is implicitly captured by assuming a 50 : 50 mix of patients who are in a
pre-progressed or a progressed HCC state. This split is used to estimate the mean utility value and
treatment-related costs. The patients in the pre-progression part of this health state received either
sorafenib (33%) or BSC (67%), and the patients in the progression portion of this health state received BSC.
Evidence used to inform the company’s model
Downstaging outcomes
In this model, it was assumed that the impact of treatment with SIRT compared with CTTwas limited to
differences in the likelihood of patients being downstaged and becoming eligible for curative therapy.
Non-mortality outcomes for the ‘watch and wait’ health state were estimated from a single-centre,
non-randomised comparison of TACE and TheraSphere patients.118 The study was undertaken in a
population of unresectable HCC patients who did not meet the Milan criteria9 at presentation, specifically
including patients who were of T3 United Network for Organ Sharing (UNOS) status. This is defined as
patients with either a single nodule of > 5.0 cm or two or three nodules, at least one of which is > 3.0 cm
in size,119 and downstaging was defined as a decrease in the maximal tumour dimension to 3.0 cm.
The probability of remaining in the watch and wait health state for all therapies was estimated by the
company using the median time to downstaging in the TheraSphere arm of the Lewandowski et al.118
study. The company assumed that the median time to downstaging represented the median time
to ‘prognosis’ (i.e. either to downstaging or to pharmaceutical management). The median time to
downstaging in the study for TheraSphere patients was 3.1 months; the median time to downstaging
in the TACE arm of the study had not been reached. The company converted the median time of
3.1 months to a per-cycle probability of leaving the watch and wait health state of 18.6%, resulting
in a per-cycle probability of remaining in this health state of 81.4%.
Of the proportion who leave the watch and wait health state in each cycle, the company used the
probability of downstaging from the Lewandowski et al.118 study to estimate the transition of patients
to the pre-transplant state. The remaining living patients entered the pharmacological management
health state. The study reported a probability of downstaging from TheraSphere treatment of 58%
(25/43), compared with 31% (11/35) downstaged from TACE.
The efficacy of SIR-Spheres and QuiremSpheres was assumed to be equal to that of TheraSphere,
and the efficacy of DEB-TACE and TAE was assumed to be equal to that of TACE.
Owing to a lack of data specific to this outcome, the probability of death in each model cycle for
the ‘watch and wait’ health state was assumed to be equivalent to that of patients on the wait list,
which was estimated from a cohort of NHS patients awaiting liver transplant (see Transplant wait list
outcomes). The mortality rate was assumed to be equal between all treatment arms. The greater
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predicted benefits of SIRT in this model are, therefore, entirely attributable to a greater proportion of
patients being successfully downstaged.
Appendix 15, Tables 56 and 57, summarise the transition probability values and mortality rates,
respectively, used in the model.
Transplant wait list outcomes
The probability of successfully receiving a transplant once on the wait list was calculated by the
company using the median wait time of 130 days for a liver transplant in the UK.120 This data set is
based on a cohort of 2706 NHS patients who were registered for a liver transplant between April
2013 and March 2016, and is not specific to an indication of HCC. This was converted to a per-cycle
probability of 13.9%. The probability of transplantation was not conditional on initial treatment.
Patients could transition from the pre-transplant state to pharmacological management, in the case
that a patient becomes ineligible for transplant while on the wait list. The probability of this happening
was informed by clinical advice to the company, with 16 cases of patients leaving the wait because of
disease progression for every 103 transplants (National Audit for Liver Transplant, incomplete source
provided by the company).
Mortality in the pre-transplant wait list health state was estimated from a figure quoted in an NHS
service specification for Liver Transplantation Service in Adults,121 in which ‘up to 18% of patients
die while on the liver transplant waiting list’ (reproduced with permission; contains public sector
information licensed under the Open Government Licence v3.0), and converted to a per-cycle mortality
rate using the median time to transplant of 130 days.
Pharmacological management outcomes
Patients entering the pharmacological management health state are assumed to remain there until
death. The mortality rate applied was based on the median OS of BSC patients reported in the NICE
sorafenib submission (34.4 weeks).11 Per-cycle mortality was estimated assuming that OS followed an
exponential distribution; the applied per-cycle mortality rate was 7.7%. This rate was applied to
patients in this health state regardless of their initial treatment.
Post-transplant outcomes
Mortality in the three cycles (12 weeks) following transplant was estimated using data from a study of
early-stage HCC patients, Bellavance et al.,122 which reported a 30-day mortality probability of 1.5%.
The post-transplant mortality rate beyond these three cycles was assumed to be lower, and was
estimated from NHS 5-year survival rates following transplantation120 of liver patients who had a
transplant between 2010 and 2012, which was estimated at 81%. These data reflect a general liver
transplant population and are not specific to those who have HCC. Furthermore, for the patients in the
population who did have HCC, they are also not specific to patients who had been downstaged after
having previously been ineligible for transplant before active treatment for HCC. The company justified
the assumption that the mortality rates for a downstaged population can be assumed to be equivalent
to a population who were not originally downstaged, on the basis of a systematic review by
Gordon-Weeks et al.123
Adverse events
For TheraSphere and SIR-Spheres, data on grade 3 and 4 TRAEs were sourced from a systematic
review of AEs.79 Event rates for QuiremSpheres were assumed to be the same as for SIR-Spheres.
Rates of TRAEs for TACE and DEB-TACE were sourced from a RCT of DEB-TACE versus TACE in
HCC.58 The company’s model included severe TRAEs that occurred in > 5% of patients in at least
one arm.
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Total TRAE utility decrements and treatment costs were applied in the first model cycle. The estimates
of utility decrements were based on the assumption that grade 3 and 4 AEs were associated with a
utility decrement of 0.012, which was multiplied by AE rates reported for each event. The total TRAE
disutility for TheraSphere, SIR-Spheres, QuiremSpheres and TACE was estimated as –0.002, with
–0.009 for TAE and 0.000 for DEB-TACE. Total TRAE costs ranged from £5.59 for DEB-TACE, to
£111.33 for SIR-Spheres, and £384.15 for sorafenib. Further details of TRAE rates and associated costs
are provided in Appendix 15, Tables 58 and 61, respectively.
Health-related quality of life
BTG drew on a variety of external sources for the utility values in its economic model (see Appendix 15,
Table 59). Utility values for all health states with the exception of the post-transplant tunnel states were
the same as the pre-progression values used in the TA551124 submission for lenvatinib (equal to 0.75),
which were estimated from EQ-5D data collected from patients in the REFLECT trial.81 The utility
applied to the ‘pharmacological management’ state is taken to be an average of the pre-progression
and post-progression health state values, as BTG states that this population comprises patients in both
progression states equally. Post-transplant utilities were derived from a study by Lim et al.,125 which
used an average of literature-derived utilities equal to 0.69. A scenario analysis was carried out using
significantly lower pre- and post-liver transplant utilities from Ratcliffe et al.;126 however, these values
were taken from a primarily non-HCC population.
Utilities were adjusted according to age and gender norms reported in Kind et al.;127 however, this
adjustment was applied incorrectly, which resulted in patients experiencing a much lower HRQoL
than reported in the cited sources. When this was highlighted to the company, it stated that this was
intentional, and considered the use of lower utility values appropriate and consistent with methods
reported in Kind et al.127
Costs of selective internal radiation therapy treatment
Procedure costs relating to the administration of SIRT were assumed to comprise microsphere (SIRT)
acquisition costs, the cost of the work-up and procedure costs relating to the administration of SIRT.
The mean number of SIRT treatments per patient was informed by an elicitation exercise undertaken
by BTG. Each patient was estimated as having an average of 1.2 SIRT treatments, with one work-up
per patient. Only patients who are eligible for SIRT enter the model, and so the costs of work-ups that
did not result in treatment with SIRT were not included.
The work-up procedure costs were based on a microcosting from The Christie NHS Foundation Trust,
Manchester, and were estimated as being £467.91. These costs included the time of the personnel
involved with the work-up (a technician, clinical scientist and radiologist) and a macroaggregated
albumin (MAA) body SPECT. The AG requested additional details of this microcosting; however, little
further granularity was provided. In addition, BTG identified further relevant cost items in the work-up
procedure, which increased the cost to £860.32 per work-up. The company assumed that the resources
required for the work-up associated with TheraSphere, SIR-Spheres and QuiremSpheres would be
the same.
Costs relating to the administration of the SIRT work-up and the SIRT procedure were based on National
Schedule of Reference Costs 2017–2018,107 and the cost of each SIRT was assumed to be £8000 per
procedure. Further details are provided in Appendix 15, where Table 60 summarises the assumptions
and costs of the SIRT work-up procedure and Table 62 summarises the associated unit costs.
Treatment costs of conventional transarterial therapy
Each patient in the TACE and TAE arms was assumed to have three initial treatments in their respective
arms, and patients in the DEB-TACE arm had an average of 1.5 initial treatments. The unit cost and the
frequency of their use was informed by clinician input.
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The cost of administration involved in each CTT was assumed to be captured in the Healthcare
Resource Group (HRG) code for the embolisation procedure (£2790, National Schedule of Reference
Costs 2017–2018,107 HRG code YR57Z).
Second-line treatment
After patients move into the pharmacological management health state, they were assumed to
receive sorafenib (33% of patients) or BSC (67% of patients). Patients remain in this state until death.
The unit cost of sorafenib was obtained from the BNF,115 with the total per-cycle cost estimated
assuming a posology of 400 mg twice daily. It was assumed that sorafenib would not be associated
with administration costs and that patients would orally self-administer this treatment. It was unclear
whether or not the costs of treating AEs associated with sorafenib treatment were captured within the
model. Costs associated with BSC were assumed to be captured within the health state resource use.
Health state resource use
Owing to an absence of evidence from published literature for resource use for the CTT-eligible health
states, expert opinion was sought from The Christie NHS Foundation Trust (see Appendix 15, Table 63,
for a summary of health state costs). These consisted of the following:
l physician visits (oncologist, hepatologist, Macmillan nurse, gastroenterologist, radiologist, clinical
nurse specialist and palliative care physician)
l laboratory tests [alpha-fetoprotein test, liver function test, international normalised ratio (INR),
complete blood count, biochemistry and endoscopy]
l radiological tests [computerised tomography (CT) scan, MRI scan and ultrasound scan]
l hospitalisation
l hospital follow-ups (specialist, GP and nurse)
l transplant aftercare (immunosuppressants).
Unit costs for each of these items, plus the cost of a transplant procedure, were obtained from national
sources.106,107
The AG requested additional details of how these resource use estimates were obtained. BTG clarified that
resource use estimates were provided by a single clinical expert whose role is consultant interventional
radiologist at a centre in the UK that uses SIRT. Opinion was elicited via an unstructured telephone
conversation, and the estimates were given verbally and were entered directly into the model; no
transcripts of this conversation were collected. Therefore, the AG cannot verify the estimation of the
resource use inputs.
Additional one-off costs were applied at the point of progression, relating to laboratory and radiological
tests (estimated as £95.32 in total) and were obtained from TA555.13
Palliative care costs
The company’s model also included a cost of £8191 to account for costs of palliation at the end of life,
which was applied on death. This was derived from a joint Nuffield Trust and Marie Curie report into
end-of-life cancer care and inflated to 2017/18 prices.128
Model results
Base-case results
Results of the base-case analysis are summarised in Table 22. In the company’s main analysis,
TheraSphere, SIR-Spheres and QuiremSpheres were associated with virtually identical numbers of
QALYs, owing to the assumption of equal efficacy between interventions. They were all estimated to
have similar total costs, with TheraSphere estimated to have marginally lower costs owing to lower
rates of AEs requiring treatment.
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Similarly, for TACE, DEB-TACE and TAE, marginal differences were observed owing to assumed
differences in AE rates and unit costs of treatment.
DEB-TACE was estimated as being the strategy with the lowest costs owing to the fewer procedures
required, and was used as the reference treatment in the incremental analysis. This resulted in an
ICER of £24,647 for each of the SIRT versus DEB-TACE, and TACE and TAE being dominated versus
DEB-TACE.
The probabilistic version of the model produced similar results, with the ICER relative to DEB-TACE
being £25,052 per QALY.
Probabilistic results
Uncertainty surrounding model parameters was explored using scenario analyses and PSA; the
executable model also included a number of DSAs that were not presented in the company submission
or appendices. The company’s probabilistic results were estimated from 1000 Monte Carlo samples and
were presented using CEACs and cost-effectiveness acceptability frontiers (CEAFs) only, with no ICERs
from the probabilistic model presented in the company submission.
Figure 11 presents the results of the company’s PSA. Up to a threshold of approximately £25,000 per
QALY, the company model estimated the treatment with the highest likelihood of being cost-effective
to be DEB-TACE. After this point, the probability of being cost-effective was highest for the three
SIRTs, which had similar probabilities of cost-effectiveness.
Scenario analyses
Table 23 presents the results of the company’s scenario analysis. The most influential parameters,
of those assessed by the company, relate to the proportion of patients who transition to resection,
and the proportion of patients who were downstaged after treatment with TheraSphere. Although
the amount by which the proportion of patients was varied was arbitrary, and the ICER does not
specifically represent a potential upper bound, this analysis showed that the model was most sensitive
to this parameter.
TABLE 22 Results of the CTT-eligible population analysis
Treatment Total costs (£) Total QALYs ΔCosts (£) ΔQALYs ICER (£)
Probabilistic analysis (estimated by the AG)
DEB-TACE 39,505 1.377 – – –
TAE 43,634 1.384 4129 0.007 621,795
TACE 43,525 1.373 4020 –0.004 Dominated
TheraSphere 57,334 2.089 17,829 0.712 25,051.73
QuiremSpheres 57,395 2.092 17,890 0.715 25,032.69
SIR-Spheres 57,415 2.093 17,910 0.716 25,008.53
Deterministic analysis
DEB-TACE 39,435 1.393 – – –
TAE 43,470 1.392 4035 –0.001 Dominated
TACE 43,488 1.393 4053 0.000 Dominated
TheraSphere 57,338 2.119 17,903 0.726 24,647
QuiremSpheres 57,361 2.119 17,925 0.726 24,647
SIR-Spheres 57,361 2.119 17,925 0.726 24,647
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Assessment Group critique of the BTG conventional transarterial therapy-eligible model
Downstaging and role of transplant in the UK
The company assumed that patients who are successfully downstaged become eligible for transplantation,
and that no patients receive any other kind of curative therapy including resection or ablation. This was
justified on the basis that few patients are expected to receive these other therapies. The company
provided two sources in support of this assumption. In these studies, of the patients who received radical
curative therapy after downstaging, the proportion who received resection ranged from approximately
5.9%129 to 10%.118
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FIGURE 11 Cost-effectiveness acceptability curve (CTT-eligible population). Reproduced with permission from BTG Ltd.103
TABLE 23 Results of scenario analyses in the BTG CTT-eligible model
Scenario ICER (£)
CTT-eligible scenarios: base case 24,647
50% discount on TheraSphere 18,039
TheraSphere treatment free when more than one treatment needed 21,676
50% of downstaged patients transition to resection rather than transplant 31,112
Removal of SIRT work-up costs 23,773
Alternative utility values 25,003
Alternative downstaging rates for SIRT (relative efficacy of SIRT decreased vs. TACE/TAE) 38,203
Alternative downstaging rates for SIRT (relative efficacy of SIRT increased vs. TACE/TAE) 20,561
Alternative post-transplant mortality rates (increased) 26,744
Adapted with permission from BTG Ltd.103
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Clinical advice received by the AG also suggested that at least a proportion of these patients would go
on to receive resection rather than a transplant. This AG therefore considers the assumption that all
patients will go on to receive a transplant to be unreasonable and likely to favour SIRT, as outcomes
following resection have been demonstrated to be associated with poorer outcomes (recurrence and
survival) than those following transplantation.122 The relevance of downstaging to transplantation in
UK practice is also unclear. Eligibility for transplantation in the UK has historically been defined by the
Milan criteria,130 and only recently has a service evaluation been introduced in which eligibility criteria
have been expanded to permit downstaged patients to receive a transplant.131,132 Furthermore, at the
time of writing, this study has recruited only a small number of patients, and does not represent
established national practice.
Modelling of pharmacological management
The progression status of patients in the pharmacological management health state was estimated as a
50 : 50 average of patients in the pre-progressed and post-progression states. This split is arbitrary and
unlikely to accurately reflect the actual proportion of patients in each health state. A visual comparison
of the PFS and OS extrapolation plots for sorafenib and BSC in the SHARP study69 appears to show
that a greater proportion of time is spent in the post-progressed health state. A more reasonable
estimate of the ratio of patients in each group is likely to be 33 : 67. Furthermore, given that the PFS
and OS plots for SHARP are available, time in state could have been explicitly modelled, avoiding the
need for such an assumption. The implications of this assumption are important and may lead to overly
pessimistic estimates for patients in this health state, as this split is used to estimate utility and cost
of active treatment. Based on the 50 : 50 split assumed, this will tend to overestimate total QALYs as
too many patients are assumed to be in the pre-progressed state, as well as overestimating costs
associated with time on sorafenib, where treatment duration is linked to progression.
Exclusion of patients who received selective internal radiation therapy work-up procedure
but not treatment with selective internal radiation therapy
An important omission from the economic analysis is the costs and outcomes associated with patients
who receive work-up associated with SIRT but who subsequently do not receive SIRT. These costs
should be included in the economic analysis because work-up costs will be incurred by the NHS if SIRT
was to be implemented in practice. Furthermore, patients who fail the work-up procedure are likely to
be different from those who go on to receive treatment, as demonstrated in the SARAH trial,19 in
which patients who failed work-up had significantly poorer outcomes than those who went on to
receive SIRT. Excluding these patients from the analysis therefore underestimates total costs in the
SIRT treatment arms and is likely to overestimate treatment benefits.
Modelling of comparator treatments
The company assumed equivalent efficacy between the SIRT treatments due to the paucity of comparative
data, which the AG considered reasonable given the lack of data, and similarities in the treatment modalities.
However, the BTG company submission103 states that it considers this assumption to be conservative,
and that it might be expected that TheraSphere would provide superior outcomes. The AG notes that no
plausible clinical argument or clinical evidence was provided in support of this statement.
Downstaging outcomes
The key benefit of SIRT in this analysis was through the increased proportion of patients who achieved
downstaging after treatment, which indirectly led to increased numbers of patients receiving curative
therapy. The probability of downstaging was estimated using data from a study of TheraSphere and
TACE patients.29 The AG had concerns relating to the robustness and generalisability of this study.
The study was retrospective and single centre, with non-randomised cohort arms, which could have
left it open to confounding bias. Furthermore, the study retrospectively identified patients who were
most likely to be downstaged to curative therapies and therefore the modelled population is not
representative of the broad CTT-eligible population in the scope of the analysis, and predicts higher
rates of downstaging than would otherwise be observed for this broader population.
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There are also issues regarding the generalisability of the downstaging criteria applied in the
Lewandowski et al.118 study, which were based on tumour dimensions only. However, UK criteria, used
in the UK service evaluation of downstaging, also take into account alpha-fetoprotein level.131 This may
mean that there are differences between these patients and those considered eligible for transplant in
the NHS.
To estimate the transition of patients to the pre-transplant wait list, the observed probability of
downstaging from the Lewandowski et al.118 study was applied to the proportion of patients who
remained in the ‘watch and wait’ health state, rather than being applied directly in the model.
As a result, this method underestimated the proportion of patients who were downstaged: for
TheraSphere, the model predicted that 48% patients were downstaged, compared with 58% reported
by Lewandowski et al.,118 and for TACE, the modelled versus observed proportion who were
downstaged was 26% vs. 35%.
The company assumed that the mortality rate of patients in the ‘watch and wait’ health state was
equivalent to that of the pre-transplant mortality rate, citing a lack of data to model this specific
outcome. However, the Lewandowski et al.118 study reported mortality rates that were censored to
curative therapies, and it was unclear why these were not leveraged in the model. The same mortality
rate was applied to both treatment arms, thereby assuming that the only impact of treatment on
mortality is through the bridging of patients to transplant. Furthermore, the data used to estimate
pre-transplant mortality was from a cohort of patients,121 of whom only a proportion had HCC. The
Lewandowski et al.118 study also reported progression outcomes, which again were not used in the
economic analysis.
The use of different sources for downstaging, progression and mortality outcomes also means that the
evidence was derived from very different study populations, which led to a lack of internal consistency,
and made it more difficult to validate the predictions of the model.
Transplant wait list outcomes
The data source used to estimate the time spent on the transplant wait list was estimated for a cohort
of patients not specific to HCC. Patients on the transplant wait list are prioritised by their Model for
End-Stage Liver Disease (MELD) score;133 however, the presence of HCC adds ‘exception points’ to
MELD, meaning that the wait list time is generally shorter for HCC patients. The AG obtained data
from a report on the 1-year outcomes following the introduction of the National Liver Offering Scheme,
which was implemented on 20 March 2018.134 The median waiting time under the old offering scheme
may not accurately reflect how long patients may wait under the new offering scheme. The median
waiting time to transplant for HCC patients who received a transplant between 20 March 2018 and
19 March 2019 was 49.5 days, which is substantially lower than the value for the overall cohort.
The company provided an incomplete reference on the source of the data used to estimate the
transition to pharmacological management, and so it was not possible to comment on the suitability
of this source. In an interim report on a service evaluation of transplantation following downstaging
of HCC patients in the UK,132 of 27 patients enrolled in the programme to date, only one was removed
from the wait list owing to the deterioration of their condition. This provides a much lower estimate
of dropout than that estimated by the company, although the AG acknowledges that it is based on a
smaller subset of patients.
The AG questions whether or not it is appropriate to apply the same transition probabilities and
mortality rate to patients regardless of their initial treatment; however, the AG is not aware of any
directly applicable evidence for a differential rate. There are many factors that determine the rate
at which patients receive transplant; some of these will not be treatment dependent, including the
availability of donor grafts, and some are dependent on treatment. Previous studies of SIRT and CTT
with intent to downstage have demonstrated differential outcomes of transplantation and progression
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between treatment arms; although these are based on very small patient numbers, there does appear
to be a small benefit in favour of SIRT.25,47 Although TheraSphere and TACE were given as downstaging
rather than bridging therapies in the Lewandowski et al.118 study and so are not directly applicable
to outcomes for patients on the transplant wait list, OS censored to curative therapies was also
significantly different between arms in favour of SIRT, particularly after 2 and 3 years. Similarly, the
rate at which patients receive curative therapy following downstaging is also likely to differ between
arms, as evidenced in the Lewandowski et al.118 study. As such, the AG considers it unlikely that
outcomes would be equivalent across different treatment modalities, although it is not possible to
estimate directly without estimates of survival conditional on downstaging.
Pharmacological management
Outcomes for patients in the pharmacological management health state were based on the BSC arm of
the SHARP trial;69 the company stated that this was to avoid applying any benefit associated with a
particular HCC treatment in the model, as patients modelled to receive pharmacological management
would be given different treatments. This is not representative of patients in this health state, as a
proportion of these patients would receive further active therapy, assumed by the company to be
sorafenib. Because patients receiving sorafenib experience better outcomes than patients on BSC
(as demonstrated by a HR of 0.69 for OS in SHARP69), this approach underestimates survival for patients
in this health state. A more accurate approach would be to calculate outcomes separately for sorafenib
and BSC and then weight according to the proportion of patients in the health state over time.
Furthermore, the SHARP trial69 is unrepresentative of the patients who would receive BSC in this
population for a number of reasons. Approximately 50% of patients in SHARP had extrahepatic spread,
and would thus be contraindicated for SIRT treatment. A subgroup analysis of SHARP patients
demonstrated that the sorafenib treatment effect was higher in patients with no extrahepatic spread
(HR of 0.55 compared with 0.69 in the ITT population). Data from REFLECT,12 which compared
lenvatinib with sorafenib, also demonstrated that the prognosis for patients with extrahepatic spread
is worse than for those without: in the ITT population, the median OS was 12.3 months, compared
with 18.0 months in a population with no extrahepatic spread. In addition, the SHARP trial enrolled
only patients who had not received previous treatment with systemic therapy, so BSC patients in
SHARP do not represent the patients in the pharmacological management health state who previously
received TACE or SIRT. The AG was advised that patients who present with HCC and are eligible for
sorafenib are typically associated with a more rapidly progressing form of the disease and will have a
higher mortality rate.
As a result, the cost-effectiveness analysis is biased in favour of SIRT through the selection of
unrepresentative comparator data. The use of these data from SHARP69 underestimates survival in the
pharmacological management health state, thereby further inflating the relative treatment effect of
SIRT, as fewer patients on SIRT than on other therapies enter this health state.
Post-transplant outcomes
The AG has concerns about the applicability of the sources used to estimate mortality following liver
transplantation, and considers it uncertain whether or not the assumed treatment pathway is reflective
of clinical practice.
The data set used to estimate long-term mortality after transplant is not specific to patients with
HCC. Patients with HCC are at risk of tumour recurrence, which is linked to increased mortality.122
This can be illustrated by a comparison of survival in the general liver transplant population and in a
HCC population. The AG obtained a HCC-specific data set of survival outcomes for liver transplant
recipients in the UK since 1994.134 In this data set, patients with HCC (restricted to those aged
> 60 years as a proxy for intermediate-HCC patients) had a 5-year survival of 71%. This was lower
than for those in the general liver transplant data set, whose 5-year survival was estimated as 81%.
Therefore, benefits estimated by the company model are likely to be overestimated.
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By excluding tumour recurrences, the treatment pathway is also misrepresented by the model.
Both the Bellavance et al.122 and Lewandowski et al.118 studies report on recurrences that occur after
transplantation: approximately 20% of patients in the Lewandowski et al.118 study and 14% of patients
in the Bellavance et al.122 study experienced recurrence after transplantation, with a 1-year relapse-free
survival rate of between 73% and 89%. In addition, the AG found that, in its analysis of the HCC-specific
transplant data set, > 10% of transplant recipients in the UK in this population experienced a recurrence
in the first 5 years post transplant. The patients who experience a recurrence are at an elevated risk of
death,122 and these patients often experience a reduced quality of life and additional treatment-related
costs.135 By excluding recurrence after transplant, the model overestimates the QALYs and underestimates
costs generated for transplant recipients, which biases the results in favour of the SIRT arm owing to a
higher proportion of patients being downstaged.
Health-related quality of life
The total number of QALYs generated by the model is likely to be underestimated, owing to the source
chosen and an error in how age-related disutility was applied.
Health state utility values were estimated from a range of sources, but were primarily based on
the NICE appraisal of lenvatinib (TA551),12 which enrolled patients with advanced HCC, of whom
approximately 60% had extrahepatic spread. This population therefore had more advanced disease
and does not reflect the model population of intermediate-HCC patients. Therefore, the utilities
drawn from TA55112 are likely to underestimate the quality of life for a CTT-eligible population, and
disadvantages any treatment arm associated with increased life-years.
The AG considers the company to have incorrectly implemented age-related disutilities in the model,
although the company contends that the application was appropriate. This ‘error’ has an impact on all
health states, and results in patients experiencing much lower utilities than those observed in the cited
sources. In the company’s model, the decrement associated with ageing is estimated by estimating an
absolute utility decrement for each health state relative to full health (i.e. 1 minus the reported health
state utility) and then subtracting this decrement from the age- and gender-adjusted population norm
from Kind et al.127 For example, as patients enter the model at the age of 65 years, the age-adjusted
utility started at 0.78, and the literature-derived absolute utility for ‘watch and wait’ patients was 0.75.12
This meant that the age-adjusted utility for patients in the ‘watch and wait’ health state was 0.53
(0.78 – 0.25). The application of age-adjusted utilities in this way is inappropriate and ignores the fact
that each health state utility is derived from an age-appropriate source, and thus already accounts for
any age-related decline in HRQoL. Furthermore, this method is inconsistent with previous TAs136–138
in which age-related disutilities have been applied, where age-related decrements are applied as a
multiplier to health state utilities rather than as an absolute decrement.
Resource use estimates
Resource use was estimated in the model based on feedback from a single clinician at a centre in the
UK that uses SIRT. As the company could not provide details of the questionnaire or transcript of
the interview, it has not been possible to verify how these data were estimated. Therefore, there
are a number of uncertainties regarding which treatment costs are included, such as AEs relating to
subsequent therapy (sorafenib) or to transplant, or whether or not any bridging therapy was provided
for patients on the transplant wait list.
The company’s clinical expert advised that TACE and TAE patients had around three initial treatments in
their respective arms, whereas patients in the DEB-TACE arm had an average of 1.5 initial treatments.
As described in Chapter 5, Sirtex submission: conventional transarterial therapy-eligible analysis, there is
apparent variation in the number of treatments that patients receive in practice, with values identified
between 1.43 and 2.83 per patient for DEB-TACE and between 2.5 and 3.03 for TACE patients. The
uncertainty in these numbers was not explored by the company. By implementing a single embolisation
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cost for each CTT procedure, the company also did not explore any differences in the length of hospital
stay between the different CTT treatments.
A proportion of patients in the pharmacological management health state receive sorafenib. This was
estimated using data obtained from a survey of clinicians; as there were limited details provided on
how the proportion was estimated, the underlying assumptions could not be validated. It appears that
the cost of sorafenib was applied for the time that patients were in the pre-progression health state;
however, this would overestimate the cost of treatment, because mean time on treatment with
sorafenib is less than mean TTP.11 The analysis also excludes patients who receive lenvatinib instead of
sorafenib, and the proportion of patients who progress on sorafenib and receive subsequent treatment
with regorafenib; clinical advisors to the AG suggest that this would be approximately 20% of patients.
The company assumed that the work-up procedure for each SIRT would be associated with the same
resource use. This underestimates the costs for QuiremSpheres, as the use of QuiremScout is required
and is associated with an additional procurement cost.
BTG submission: conventional transarterial therapy-ineligible analysis
The second model submitted by the company assessed the incremental cost-effectiveness of SIRT
compared with systemic therapy for the treatment of HCC in patients ineligible for TACE. The SIRTs
assessed in this analysis were TheraSphere, SIR-Spheres and QuiremSpheres. The systemic therapies
assessed were sorafenib, lenvatinib and regorafenib. Clinical inputs in the model were drawn primarily
from a NMA of comparative studies and a single-arm Phase 2 trial of TheraSphere.139 The scope of the
company’s model is summarised in Table 24. The time horizon considered in the model is 20 years and
adopts an NHS and PSS perspective in line with the NICE reference case. Costs and health benefits in
the model were discounted at a rate of 3.5%. The price year used in the model was 2017/18. The BTG
company submission103 states that the model aimed to consider patients who are considered to have
later-stage HCC, which the company defines as patients who either are ineligible for or have previously
failed TACE.
TABLE 24 BTG model scope (CTT-ineligible population)
Model component Description
Population The patient population that is the focus of the cost-effectiveness analysis includes patients
matching the following criteria:
l People with later-stage disease who are ineligible to receive CTT
Intervention SIRT:
l TheraSphere
l SIR-Spheres
l QuiremSpheres
Comparators Established clinical management without SIRT (including but not limited to target
chemotherapy). The target chemotherapies are:
l Sorafenib
l Lenvatinib
l Regorafenib
Analysis type Cost-effectiveness (cost–utility) analysis
Economic outcome Incremental cost per QALY gained
Perspective NHS and PSS
Time horizon 20 years
Discount rate Annual rate of 3.5% applied to costs and QALYs
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Model structure
The model is a cohort-level partitioned survival model, which includes three health states: (1) progression
free, (2) post progression and (3) dead. The model does not allow for downstaging to curative therapies.
Figure 12 presents an overview of the adopted model structure. The proportion of patients in each health
state is determined as a function of the TTP and OS. The proportion of patients in the progression-free
health state was based on the TTP curve, and the post-progression state was estimated as the difference
between the OS and TTP curves. The proportion of patients in the dead state was determined by the
OS curve.
For OS, the estimated treatment effect was drawn from a NMA of studies identified in the presented
systematic review. This was then applied to parametric survival models fitted to KM data from a
single-arm Phase II trial of TheraSphere.139 A Weibull function was selected as the most appropriate
survival model. TTP was modelled based on a naive comparison of relevant TTP data, and was assumed
to follow an exponential survival function.
Health state utilities in the model are primarily determined by the presence or absence of disease
progression, with values based on those used in TA551.12 The model also separately accounts for loss
of QALYs as a result of AEs. The model attempts to account for the impact of ageing by implementing
an age adjustment factor; however, this was implemented incorrectly (see Application of age-adjusted
utilities for further discussion).
The model includes the following resource costs: (1) procedural costs relating to the administration of
SIRT, (2) drug acquisition and administration costs associated with systemic therapy, (3) monitoring and
disease management costs, (4) costs associated with AEs and (5) palliative care costs.
The model employs the following structural assumptions:
l Health-related quality of life is determined according to the presence or absence of disease
progression and the therapy received.
l Patients were not permitted to be downstaged to receive curative therapy; all patients were,
therefore, assumed to receive palliative care.
l Time to progression for TheraSphere was modelled using an exponential function fitted to a
single-arm study; comparator TTP was modelled based on median PFS extracted from trial and
observational evidence identified as relevant by the company.
l Overall survival was modelled using a Weibull function fitted to a single-arm study of TheraSphere
with a HR derived from a NMA to determine OS for other therapies.
l Adverse events are assumed to affect both costs and HRQoL.
l Palliative care costs are assumed to be incurred only during the final month of life.
Evidence used to inform the company’s model
Overall survival
Overall survival for patients receiving TheraSphere was based on a single-arm Phase II trial of
52 patients with intermediate and advanced HCC.139
Progression free Post progression Dead
FIGURE 12 BTG CTT-ineligible model structure. Reproduced with permission from BTG Ltd.103
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The following standard parametric survival models were fitted to the observed data: Weibull,
log-normal, log-logistic, exponential and gamma functions. Assessment of the most appropriate
parametric extrapolation was made with reference to statistical goodness of fit and clinical plausibility
of survival estimates. The log-logistic and log-normal curves were eliminated on this basis, as they
predicted that a small proportion of patients would not die within the time horizon of the model.
The Weibull function was selected for the base-case analysis; no other extrapolations were explored
in scenario analysis.
Estimation of OS for comparator therapies was based on a NMA of studies identified in the presented
clinical effectiveness review. The NMA drew evidence from RCTs as well as non-comparative studies.
The primary NMA reported better survival for TheraSphere than for sorafenib [HR (confidential
information has been removed), 95% CrI (confidential information has been removed)], although this
was not statistically significant.
Progression-free survival
Modelling of TTP for TheraSphere was implemented by fitting standard parametric functions to
reported KM data from the same Phase II study used to model OS.139 TTP was defined from first SIRT
to first progression at any site. TTP, therefore, excluded mortality events, as the model only permits
death following progression. As with OS, standard parametric curves were fitted to available KM data
and the exponential function was selected as the most appropriate survival model based on the clinical
plausibility of predicted outcomes. No other parametric functions were explored in the presented
scenario analyses.
Owing to inconsistent reporting of TTP in the studies identified in the systematic review, a NMA for
TTP was not feasible. Time-to-progression outcomes for comparator therapies were, therefore, based
on a naive comparison, generated via median TTP and PFS data from relevant sources, which were
converted to survival curves by assuming that TTP followed an exponential function. Median TTP
for SIR-Spheres was based on a retrospective cohort study of patients who received SIR-Spheres,45
with TTP assumed to be the same for QuiremSpheres owing to a lack of appropriate data. Median
TTP for sorafenib was based on a weighted average of values reported in TA474,11 TA55112 and
a retrospective cohort study.45 Lenvatinib TTP was sourced from TA551,12 and median TTP for
regorafenib was sourced from TA555.13 Note that all values sourced from TAs were based on PFS
rather than TTP.
Health-related quality of life
The primary source of utility data used by BTG was TA551,12 which drew evidence from the REFLECT
trial81 comparing lenvatinib with sorafenib, which collected EuroQol-5 Dimensions, three-level version
(EQ-5D-3L), values from participants. The values used assume no differences in HRQoL between treatment
arms, but do not attempt to account for differences in HRQoL as a result of AEs. This was carried out by
applying a one-off utility decrement in the first cycle of the model, which was estimated by applying a
0.012 decrement per grade 3 or 4 event. Note that the BTG company submission103 erroneously reports
that a 0.014 decrement was applied in the model and miscalculates the decrement to be applied in the
executable model.
In addition to the above, adjustments were also made to the health state utilities to account for the
impact of ageing. This was undertaken by applying a decrement to every model cycle. The decrement
applied was estimated by subtracting 1 from the age- and gender-adjusted population norm. Note that
the BTG company submission103 erroneously reports the decrements applied as 0.26 for the progression
health state and 0.32 for the progressive disease health state, when the model applies a common
decrement to both health states, which changes over time to reflect the increased age of the cohort.
General population utility norms were sourced from Kind et al.127 Utility values applied in the base-case
analysis along with utility decrements are reported in Appendix 15, Table 64.
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Selective internal radiation therapy procedure costs
See the review of the CTT-eligible population model (Chapter 5, Evidence used to inform the company’s
model) for details of SIRT procedure costs.
Drug acquisition costs: systemic therapies
Drug acquisition costs for sorafenib, lenvatinib and regorafenib were taken from the BNF.115 Respective
dosing was 800 mg, 12 mg and 160 mg per day. Dosing was based on recommended doses for HCC
patients, described in their respective European Medicines Agency summary of product characteristics
(SmPC). Duration of systemic therapy was based on progression, with patients assumed to continue
systemic therapy until either progressive disease or death. Appendix 15, Table 65, summarises the drug
acquisition costs applied in the model.
Subsequent treatments
A proportion of the patients receiving SIRT were assumed to receive sorafenib therapy following SIRT,
with patients assumed to receive sorafenib after cycle 1 until disease progression or death. In the base-
case analysis, the proportion of patients assumed to receive sorafenib was 33%, based on ‘data on file’.
Patients not receiving concomitant sorafenib were assumed to receive BSC. No subsequent therapies
were modelled following disease progression in either model arm (SIRT or systemic therapy).
Health state costs
Resource use estimates were based on a survey of clinical experts conducted to inform resource use in
TA189,140 TA47411 and TA551.12 These included physician visits, laboratory and radiological tests, and
hospital stays. Unit costs were derived from TA189,140 and updated using National Schedule of Reference
Costs 2017–2018.107
In addition to the above, a one-off cost was applied on treatment progression based on the costs applied
in TA551.124 This comprised additional laboratory and radiological tests (see Appendix 15, Table 67).
Total costs by health state are reported in Appendix 15, Table 66, along with a summary of one-off
progression costs.
Adverse event costs
Unit costs associated with AEs were drawn from National Schedule of Reference Costs 2017–2018107 and
are summarised in Appendix 15, Table 68. No information or justification was presented with regard to
how the specific costs used were selected.
Palliative care costs
The company’s model includes a cost of £8191 to account for costs of palliation at the end of life.
This was derived from a joint Nuffield Trust and Marie Curie report128 into end-of-life cancer care and
inflated to 2017/18 prices. This cost was applied on a patient’s death and was applied for all modelled
interventions.
Model results
The headline results presented in the BTG company submission103 are based on the deterministic
version of the model. Uncertainty surrounding model parameters was explored using scenario analysis
and a PSA. The executable model also included a number of DSAs that were not presented in the
company submission or appendices. The company’s probabilistic results were estimated from 1000
Monte Carlo samples and were presented using CEACs and CEAFs only, with no ICERs from the
probabilistic model in the company submission.
Table 25 presents the company’s base-case estimates of cost-effectiveness using the corrected version
of the model at the list price for sorafenib, lenvatinib and regorafenib. Based on the probabilistic
version of the company’s model, regorafenib was estimated to be the most cost-effective therapy.
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The results of the fully incremental analysis suggested that SIR-Spheres, QuiremSpheres and lenvatinib
were dominated by one or more therapies, whereas sorafenib was extendedly dominated by TheraSphere.
The estimated ICER for TheraSphere compared with regorafenib was £69,070 per QALY and estimated
that TheraSphere generates an additional 0.185 QALYs at an additional cost of £12,778. The deterministic
version of the model produces similar results, with an ICER relative to regorafenib of £66,624 per QALY.
Figure 13 presents the results of the DSA generated by the AG. The most influential parameters
(of those assessed by the company) relate to the OS HR for regorafenib and the proportion of patients
TABLE 25 Summary of base-case results: BTG CTT-ineligible population
Treatment
Absolute Incremental (relative to regorafenib)
ICER (£)QALYs Costs (£) QALYs Costs (£)
Probabilistic model (calculated by the Evidence Review Group)
TheraSphere 0.681 49,574 0.185 12,778 69,070
QuiremSpheres 0.466 37,446 –0.030 650 Dominated
SIR-Spheres 0.465 37,406 –0.031 610 Dominated
Sorafenib 0.496 38,977 0.000 2181 Extendedly dominated
Lenvatinib 0.526 61,282 0.030 24,486 Dominated
Regorafenib 0.496 36,796
Deterministic model
TheraSphere 0.695 49,984 0.200 13,331 66,624
QuiremSpheres 0.470 37,496 –0.025 843 Dominated
SIR-Spheres 0.470 37,496 –0.025 843 Dominated
Sorafenib 0.500 39,059 0.005 2406 Extendedly dominated
Lenvatinib 0.530 62,647 0.035 25,995 Dominated
Regorafenib 0.495 36,653
–100,000 0 100,000 200,000
OS HR for regorafenib (0.75; 2.38)
Weighted-average cost of treatment post SIRT
(£716; £2147)
TTP HR for regorafenib (1.72; 5.16)
Cost sorafenib (£1788; £5365)
Proportion on sorafenib post SIRT
(16.50%; 49.50%)
Utility pre progressed (0.68; 1.00)
Cost TheraSphere (£4000; £12,000)
Utility progressed (0.30; 0.75)
TRAE cycle cost regorafenib (£280; £840)
TRAE cycle cost TheraSphere (£44; £133)
Change in ICER (£)
Low value
High value
FIGURE 13 BTG DSA: tornado diagram. Reproduced with permission from BTG Ltd.103
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assumed to go on to receive post-SIRT sorafenib. Additional scenario analysis presented by the
company showed that the estimated ICER was influenced significantly by assumptions made about
post-SIRT treatment. In the presented scenario analysis, in which no concomitant sorafenib was
assumed, TheraSphere was estimated to be the most cost-effective intervention, with a deterministic
ICER of £5870 per QALY.
The AG questioned the face validity of the utility values applied, and were concerned that the
company had made a calculation error with respect to the calculation of the utility decrements.
After clarification from the company, BTG confirmed that the utility decrements applied in the model
were as intended by the company. See below for further critique of the utility values applied.
Critique of the BTG conventional transarterial therapy-ineligible model
Inappropriate inclusion of regorafenib as a comparator
The base-case analysis presented in the BTG economic analysis includes three systemic therapies:
sorafenib, lenvatinib and regorafenib. The AG is of the view that regorafenib should not have been
included as a comparator, as it is used only as a second-line therapy following sorafenib. This is stated
in the SmPC for regorafenib and NICE’s recommendation13 for regorafenib, which restricts use to
patients who have been previously treated with sorafenib.141 The AG considers it entirely reasonable to
model subsequent regorafenib use following sorafenib, but it should not have been directly compared
with SIRT and the other systemic therapies.
Work-up without selective internal radiation therapy procedure
An important omission from the BTG economic analysis is the costs associated with patients who
received work-up but did not continue on to the SIRT procedure. In the SARAH19 and SIRveNIB21 trials,
18.6% and 28.6% of patients, respectively, received work-up but did not continue on to receive SIRT.
The AG considers the cost of patients who do not proceed to SIRT treatment important, as they
constitute part of the incremental costs of implementing SIRT in the NHS. The AG further notes
that many of these patients will receive other active therapies instead of SIRT, and it is therefore
appropriate to model the associated costs and outcomes. For example, in the SARAH trial,19 62% of
patients for whom work-up failed went on to receive sorafenib. The AG, therefore, considers that the
costs associated with the administration of these alternatives should also be included in the economic
analysis. The AG also notes that the clinical effectiveness data used to populate the model were based
on the ITT population and, therefore, the clinical outcomes of these patients for whom work-up failed
are implicitly included. This is inconsistent with BTG’s stated position that only patients receiving
therapy were considered.
Network meta-analysis and estimation of relative overall survival benefits
BTG conducted a NMA to compare TheraSphere with sorafenib for the treatment of unresectable
HCC patients. Seven studies formed the primary network: two RCTs, one prospective study and four
retrospective studies. There are differences in the studies included in the NMAs conducted by BTG and
the AG. The BTG network included only studies conducted outside Asia, owing to known differences
in both aetiology and treatment patterns in Asian populations. The AG identified additional studies
that the company did not include or identify in its systematic literature review.40 Unlike the AG, the
company did not split the NMA into different populations of patients with differing stages of HCC
disease. Therefore, the baseline BCLC stage, Child–Pugh status and the proportion of patients
with PVT differed across studies. However, the population in the primary network was mostly
advanced-stage HCC patients.
The validity of results from the NMA relies on the quality of the studies that make up the evidence base.
However, there are considerable concerns regarding the quality of the prospective and retrospective
studies. The prospective observational study by Woodall et al.,37 comparing TheraSphere with BSC, which
was excluded from the AG’s NMA, presented significant baseline imbalances and evidence of selection
DOI: 10.3310/hta24480 Health Technology Assessment 2020 Vol. 24 No. 48
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
89
bias, as patients who failed to meet the pre-treatment TheraSphere requirements formed the ‘no-treatment’
arm. In addition, the retrospective studies39,44,45 were all associated with a high risk of bias as there are
significant baseline imbalances, unclear reporting of blinding and missing outcome data, and were
excluded from the AG’s primary NMA for these reasons.
Although the NMA reports better survival for TheraSphere than for sorafenib, this appears to be on
the basis of the inclusion of a particular retrospective study, Biederman et al.,39 which reports a very
strong treatment effect on OS with TheraSphere compared with SIR-Spheres (HR 0.40, 95% CrI 0.20
to 0.78). As discussed in Chapter 3, Risk of bias, the four retrospective studies (including Biederman et al.39)
and the prospective observational study are poor quality and were rated as being at a high risk of bias,
which reduces the reliability of the NMA results.
Limited exploration of uncertainty surrounding survival functions
The BTG company submission103 does not include any consideration of the uncertainty surrounding the
range of potentially plausible survival functions for OS. Although a number of parametric functions
were fitted to the available data for OS, the impact of alternative functions was not explored in the
company’s presented scenario analyses. Furthermore, there is no functionality in the presented
executable model to implement alternative survival functions.
Omission of downstaging
The AG notes that the BTG economic model did not consider the possibility that patients may be
downstaged to receive curative therapy. As stated in relation to the Sirtex CTT-ineligible model, the
relevance of downstaging in an advanced-HCC population is unclear, with the AG’s clinical experts
suggesting that this would be a very rare occurrence in UK practice. However, downstaging was
observed in a small number of patients in the SARAH trial19 and, therefore, the potential benefits of
downstaging represent an important uncertainty. Therefore, although the AG recognises that the
inclusion of downstaging in the company’s base case may be inappropriate, this uncertainty should
have been explored in scenario analysis.
Modelling of progression-free survival
The BTG company submission states that it was not possible to obtain estimates of relative PFS from
the NMA and, therefore, PFS was based on a naive comparison of reported estimates from studies
identified as relevant by the company. The AG considers there to be a number of significant
weaknesses in the company’s approach, and that the selected median PFS for TheraSphere lacks face
validity. Although the AG acknowledges that a NMA could not be run for PFS outcomes, based on
the studies included in the company’s network, the AG does not agree that a relevant network could
not have been constructed (see Chapter 4). Importantly, as reported in Chapters 3 and 4, there are
randomised comparisons of SIRT (SIR-Spheres) and systemic therapies (sorafenib) on which estimates
of median PFS could have been based. The AG would consider such an approach preferable to the
company’s naive comparison, which used populations poorly matched with the modelled population.
The AG further notes that this randomised evidence was ignored in favour of studies used in
the relevant NICE appraisals, which focused on populations including a significant proportion of
patients with extrahepatic spread, and, with respect to regorafenib, had already failed previous
sorafenib therapy.
Further to the above, the AG also questions the plausibility of the modelled median PFS for TheraSphere.
The modelled value of 11 months is 3.5 times longer than the value used for SIR-Spheres (3 months) and
longer than the median OS reported in the SARAH trial19 for both SIR-Spheres and sorafenib. Given the
broad clinical similarity between TheraSphere and SIR-Spheres, and the lack of high-quality comparative
evidence, the AG considers that it is unreasonable to assume such a large disparity in PFS.
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Dosing and time on systemic therapy
Dosing of systemic therapies in the BTG economic analysis was based on the relevant SmPC, with a
dose of 800 mg, 12 mg and 160 mg assumed for sorafenib, lenvatinib and regorafenib, respectively.
These figures are likely to overestimate the dose received for all three drugs, as dose reductions and
interruptions are common in patients receiving systemic therapy, and were observed in all relevant
trial data. For example, the mean dose of sorafenib received in the SARAH trial19 was 648 mg, not
800 mg. The company’s model also does not account for the fact that the dosing of lenvatinib is weight
dependent, with patients < 60 kg receiving 8 mg daily; 13% of patients in the Western subgroup of the
REFLECT trial81 weighed < 60 kg.
Time on systemic treatment in the BTG economic analysis is assumed to align with PFS. This is consistent
with the SmPC for both sorafenib and lenvatinib, both of which indicate that therapy should continue
for as long as clinical benefit is observed, or until toxicity becomes unacceptable. However, sorafenib,
lenvatinib and regorafenib are all associated with significant tolerability issues, which means that many
patients discontinue therapy prior to disease progression. This is seen in the pivotal trials, in which time on
systemic therapy is always less than PFS. For example, median time on sorafenib in the SARAH trial19 was
2.8 months, whereas median PFS was 3.7 months. Using PFS as an indicator of treatment discontinuation,
therefore, may produce overestimates of time on treatment and consequently total drug acquisition costs
for sorafenib, lenvatinib and regorafenib.
Subsequent therapy costs
The BTG economic analysis assumes that a proportion of patients receiving SIRT treatment
(TheraSphere, SIR-Spheres or QuiremSpheres) move on to receive subsequent systemic therapy
immediately following initial SIRT. These patients are assumed to continue therapy until disease
progression. The AG considers the modelling of subsequent therapy in this way to be inconsistent with
likely NHS practice and the supporting trial evidence, and that initiation of systemic therapy following
SIRT would typically happen following disease progression. The AG acknowledges that, in the SARAH
trial,19 a proportion (11/52, 21%) of patients did receive subsequent systemic therapy prior to
progression. However, there is no evidence to suggest that this was initiated immediately following
SIRT; indeed, the SARAH19 and SIRveNIB21 trial protocols stipulated that further therapy should not
commence until disease progression.
A further issue relating to the company’s modelling of subsequent therapy is the assumption that
patients receiving first-line sorafenib therapy will not receive further active therapy following
progression. This is inconsistent with clinical practice, in which a proportion of patients will receive
second-line regorafenib as per NICE’s recommendations.13 It is also not consistent with the modelled
trial evidence, as a proportion of patients in the SARAH and SIRveNIB trials went on to receive
subsequent therapy following discontinuation of sorafenib.
Application of age-adjusted utilities
Similar to the BTG economic analysis in the CTT-eligible population, the estimation of age-related
disutility was implemented incorrectly, resulting in health state utilities being applied that are
inconsistent with values used in previous TAs, as well as values reported in the SARAH trial.19
For further details of this error, see Chapter 5, Evidence used to inform the company’s model.
Further to the above, the AG considers age adjustment unnecessary in an advanced population
in which the majority of patients die within 5 years; the application of age-adjusted utilities is
unnecessary and not in keeping with norms for this type of model.
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Calculation errors
A small number of calculation errors were identified and corrected as part of the AG’s assessment of
the BTG economic analysis. These errors related to:
l the estimation of the comparator TTP, which used an incorrectly estimated HR
l the calculation of per-cycle mortality and progression, which were estimated using a monthly cycle,
whereas the rest of the model used a 4-week cycle.
These errors have only a marginal effect on the reported ICER, increasing the deterministic ICER from
£64,693 to £66,624 per QALY.
Conclusions from the Assessment Group’s assessment of the company’s economic evidence
Conclusions from the company submissions provided by Sirtex and BTG are provided in the following
sections. Please note that Terumo did not submit any economic evidence, and so a critique is
not provided.
Sirtex submission: conventional transarterial therapy-eligible population
The Sirtex submission included a CMA of SIR-Spheres, TheraSphere, TACE and DEB-TACE in the
CTT-eligible population. A cost–utility analysis was not undertaken for the CTT-eligible population
owing to a lack of comparative evidence available for this group of patients. The CMA considered the
costs of initial treatment, hospitalisation and management of AEs. The company presented a range of
scenarios for the costs of each treatment option, using alternative sources and assumptions to provide
a range of plausible costs. Rather than selecting a preferred scenario, the company noted that the
range of costs associated with CTT, TheraSphere and SIR-Spheres overlapped, demonstrating the
comparability of treatment costs.
The AG considered the presentation of a CMA for this population to be inappropriate and potentially
misleading. Such an analysis is appropriate only if there is compelling and unambiguous evidence for
equivalent efficacy between interventions. Results of the AG systematic review found very little
high-quality evidence in this population, and the data identified were not sufficient to demonstrate
clinical equivalence or a clinical difference between treatments. A focus on treatment costs only
excludes possible important outcomes regarding people who are downstaged after treatment and
become eligible to receive curative therapy, or receive subsequent therapy after progression of disease.
Sirtex submission: conventional transarterial therapy-ineligible population
The Sirtex submission also included a de novo model-based health economic evaluation of SIR-Spheres
versus sorafenib in the restricted low tumour burden/ALBI 1 subgroup for CTT-ineligible patients.
An economic analysis for the broader population of patients with intermediate or advanced HCC
was also presented in scenario analysis. The company’s model suggested that SIR-Spheres dominates
sorafenib, producing more QALYs at a lower cost. The AG notes several concerns relating to the
company’s submitted model, in particular (1) the questionable relevance and validity of an analysis
based on the low tumour burden/ALBI 1 subgroup, (2) the relevance and methods used to model the
downstaging of patients to curative therapies, (3) the modelling of OS and in particular the use of data
that was not censored for downstaging to curative therapy, (4) the questionable assumptions regarding
the modelling of patients who underwent work-up but did not receive SIR-Spheres, (5) the number of
SIRT treatments received, particularly the assumption that patients with bilobar tumours will have both
lobes treated in one session, and (6) the duration of treatment on subsequent treatment.
Given the consistent direction of bias in the issues described in the sections above, the AG considers
it probable that the incremental cost-effectiveness of SIR-Spheres compared with sorafenib is
considerably higher than the estimates presented in the Sirtex company submission.102
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BTG submission: conventional transarterial therapy-eligible population
For the CTT-eligible population, the BTG submission included a de novo model-based health economic
evaluation of TheraSphere compared with two other SIRTs (SIR-Spheres and QuiremSpheres) and with
TAE, TACE and DEB-TACE. The key benefit of SIRT assumed by this analysis was through the increased
proportion of patients who achieved downstaging after treatment, which indirectly led to an increased
number of patients receiving curative therapy. These outcomes were based on Lewandowski et al.,29 a
retrospective analysis of TheraSphere and TACE in patients identified as being candidates for downstaging.
SIR-Spheres and QuiremSpheres were assumed to have equivalent efficacy to TheraSphere, and TAE and
DEB-TACE were assumed to be equivalent to TACE.
The model estimated that the cheapest strategy was DEB-TACE, which dominated TAE and TACE.
TheraSphere, QuiremSpheres and SIR-Spheres had a probabilistic ICER of £25,052 per QALY gained,
compared with DEB-TACE.
The AG notes several concerns relating to the company’s analysis, in particular (1) the relevance of
downstaging to transplant in this population to UK clinical practice and the use of a non-HCC-specific
data set to model outcomes in these patients, (2) the failure to properly account for patients who fail the
work-up procedure and do not go on to receive SIRT, (3) the significant limitations in the clinical evidence
used to model the relative effectiveness of TheraSphere with other therapies, (4) the inappropriate and
incorrect implementation of age-adjusted utility values and (5) the inaccurate representation of patients
in the pharmacological management health state. The net effect of these issues on the estimated ICER is
unclear, as many issues work in opposing directions.
BTG submission: conventional transarterial therapy-ineligible population
For the CTT-ineligible population, the BTG submission included a de novo model-based health economic
evaluation of TheraSphere compared with two other SIRTs (SIR-Spheres and QuiremSpheres) and three
systemic therapies (sorafenib, lenvatinib and regorafenib). The corrected version of the company’s
submitted model suggests that the probabilistic ICER for TheraSphere versus regorafenib is
approximately £64,513 per QALY gained.
The AG has several concerns relating to the company’s submitted model, which serve to critically
undermine the validity of the presented model. Many of these concerns were also present in the
CTT-eligible model presented by BTG. These concerns include (1) the inclusion of regorafenib as a
direct comparator at first-line when it is licensed only for use following sorafenib therapy, (2) the
failure to properly account for patients who fail the work-up procedure and do not go on to receive
SIRT, (3) the significant limitations in the clinical evidence used to model the relative effectiveness of
TheraSphere with other therapies, (4) the inappropriate and incorrect implementation of age-adjusted
utility values, (5) the questionable assumptions regarding the modelling of time on systemic therapies
and (6) the assumptions made regarding subsequent therapies received following SIRT. As with the
CTT-eligible model, the net effect of these issues on the estimated ICER is unclear, as many issues
work in opposing directions.
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Chapter 6 Independent economic assessment:
scope of analysis
As described in Chapter 2, the scope of the systematic review conducted by the AG into the relativeeffectiveness of SIRT covered a broad population, which the AG split into three distinct
populations based on the intent of treatment and the eligibility to receive CTTs. These three
populations largely corresponded to early, intermediate and advanced HCC.
Assessment of the available clinical evidence to support an economic analysis in each of these three
populations, however, revealed that much of the available evidence is from poor-quality observational
studies, with only a very small number of high-quality randomised trials. These limitations in the
availability of evidence have a number of important implications for the scope of the economic
evaluation undertaken by the AG.
As described in Chapter 3, Clinical effectiveness results, only three studies were identified for the
population with early HCC (patients who are eligible for transplant and CTT). The intent of treatment
in this population is primarily to act as a bridge to transplantion and, therefore, to control disease
so as to allow patients to remain within transplant criteria until a donor organ becomes available.
The primary benefit of SIRT or CTT in this population would, therefore, be through its capacity to
sustain a greater proportion of patients through to receiving a transplant. In this context, waiting time
to transplant is of crucial importance, and is a determining factor in the proportion of patients who are
ultimately likely to receive transplant. However, studies identified by the AG on bridging treatment
efficacy were from a US setting, where waiting list residence times are significantly longer than in the
UK: roughly 6–12 months in the USA,25–28 compared with an average waiting time of approximately
50 days for HCC patients in the UK.134 The relevance of the available data on bridging to transplant
was therefore limited, and basing estimates of the relative proportion of patients successfully bridged
to transplant in this context would provide potentially misleading estimates of the relative effectiveness
of SIRT and CTT. Furthermore, in the UK, where wait times for transplant are relatively short, there is
relatively limited scope for SIRT to offer significant health benefits and, therefore, it is unclear whether
or not any additional costs associated with a SIRT procedure would be justified in this setting.
In the intermediate, CTT-eligible population, the evidence base was also considered too limited to
inform a NMA (see Chapter 3, Clinical effectiveness results), with only one available randomised study
providing comparative evidence on the effectiveness of SIRT with CTT. This RCT recruited 24 patients
and compared SIR-Spheres with DEB-TACE.23 In the intermediate-HCC population, the primary aim of
therapy is to maintain locoregional control of the tumour to prevent progression to advanced disease,
for which treatment options are more limited and survival outcomes are poor. There may also be a role
for the use of locoregional therapy to downstage certain patients to make them eligible for potentially
curative therapies such as liver transplant or resection. Key outcomes in this population are, therefore,
TTP, as patient survival is largely dictated by progression to advanced disease, and the proportion of
patients who are downstaged to curative therapy. However, the identified RCT23 provided very limited
data on TTP and PFS and did not report any downstaging events. Moreover, evidence on the relative
effectiveness of alternative CTT was largely limited to survival outcomes. As a consequence, any
economic analysis implemented in the CTT-eligible population would have had to rely on the Pitton
et al.23 RCT alone. A model based on this single small study would, however, have generated significant
challenges in populating key clinical inputs, and it would not have permitted the model to address the
potential role of downstaging in this population. Furthermore, any estimates of relative benefit would
have been subject to very considerable uncertainty, meaning that the results of any model would have
limited value for decision-making. The AG, therefore, considered it inappropriate to develop a full
economic analysis in the CTT-eligible population. The AG notes that Sirtex reached a similar conclusion
regarding the availability of evidence to inform a full economic analysis, and opted instead to present a
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CMA. As outlined in Chapter 5, Sirtex submission: conventional transarterial therapy-eligible analysis, the
AG considers the value of such an approach limited, as a CMA relies on the assumption of equal
efficacy, for which there was not sufficient evidence.
In contrast with early and intermediate populations, the systematic review identified two large RCTs
comparing SIR-Spheres with sorafenib in the advanced-HCC population.19,21 The focus of the AG
economic analysis is, therefore, on the CTT-ineligible population. Details of the AG’s economic analysis
are outlined in Chapter 7.
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Chapter 7 Independent economic assessment:
conventional transarterial therapy-ineligible
population
A summary of the key features of the AG economic analysis for the CTT-ineligible population ispresented in Table 26. The population covered by the AG base-case analysis is Child–Pugh class A
patients, who are ineligible or who have failed CTT. Scenario analysis considers two further subgroups:
(1) patients who have a low tumour burden and are ALBI 1 and (2) patients with MVI.
It should be noted that these analyses are limited in that they do not include all patients who are
ineligible to receive or have failed CTT, as they do not cover Child–Pugh class B patients ineligible for
CTT. In practice, these patients would be ineligible to receive systemic therapy as they are not covered
by the relevant NICE recommendations and, therefore, in practice would receive BSC. The clinical
evidence available comparing SIRT with BSC in an advanced-HCC population is, however, very limited,
and as such it is not possible to extend the economic analysis to cover this population.
The interventions considered in the AG analysis were the three SIRTs (QuiremSpheres, SIR-Spheres
and TheraSphere) and the comparators were the systemic therapies sorafenib and lenvatinib.
Regorafenib was not included as a comparator in the AG’s analysis as the NICE recommendation
and SmPC for regorafenib in HCC permits use only in patients who have previously failed sorafenib
therapy. Patients in the AG model are, however, permitted to move on to regorafenib following
discontinuation of sorafenib.
TABLE 26 Summary of key features of the AG base-case model
Model component Description
Population The patient population that is the focus of the cost-effectiveness analysis includes patients
matching the following criteria:
l Patients with unresectable intermediate (BCLC stage B) or advanced (BCLC stage C) HCC
¢ For whom any conventional TAE therapies (TAE, TACE, DEB-TACE) are inappropriate
¢ With or without MVI
¢ Without extrahepatic disease
Intervention SIRT:
l SIR-Spheres yttrium-90 resin microspheres
l TheraSphere yttrium-90 glass microspheres
l QuiremSpheres holmium-166 PLLA microspheres
Comparator Established clinical management without SIRT using the following targeted systemic
therapies:
l Sorafenib
l Lenvatinib
Analysis type Cost-effectiveness (cost–utility) analysis
Economic outcome Incremental cost per QALY gained, incremental net monetary benefit
Perspective NHS and PSS
Time horizon Lifetime (10 years)
Discount rate Annual rate of 3.5% applied to costs and QALYs
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In all analyses, cost-effectiveness is evaluated in terms of the incremental cost per QALY gained over a
lifetime time horizon from an NHS and PSS perspective. In line with the NICE reference,142 case costs
and health benefits were discounted at a rate of 3.5% per annum. Costs in the model were based on
the 2017/18 price year.
Model structure
The structure of the AG model is presented in Figure 14. The AG model consists of a three-state
partitioned survival model and decision tree for those intended to receive SIRT. Also presented is
the structure of the downstaging scenario (see dashed lines), for which the outcomes of patients
successfully downstaged to receive curative therapy are modelled separately. In the AG model, those
allocated to receive SIRT enter a decision tree representing the work-up procedure. A proportion of
these patients go on to receive SIRT following work-up, whereas others are not considered suitable for
SIRT or otherwise withdraw consent, so can go on to receive either BSC or a systemic therapy. In the
AG base case, patients then move into the main partitioned survival model.
The proportion of patients who receive work-up in the AG base case is based on the SARAH trial,19 from
which efficacy outcomes for these patients are drawn. Of the 226 patients who underwent work-up,
42 (18.6%) did not receive SIRT. Two further scenarios are presented in Scenario analyses, which explore the
effect of using the lower and upper bounds of work-up ‘failure’ identified in the literature (5%143 to 28.6%21).
The model uses a lifetime (10-year) time horizon (< 0.1% of patients alive at 10 years in the most
optimistic scenario), and takes an NHS and PSS perspective. Costs and health outcomes are discounted
at a rate of 3.5% per annum, with cost-effectiveness expressed in terms of the incremental cost per
QALY gained and incremental net monetary benefit (NMB). Costs were valued at 2017/18 prices.
SIRT
Curative therapy
(a)
Non-curative
Curative therapy
Non-curativeNo SIRT
Work-up
Post-curative therapy
PFS Post progression
DeadDead
(b)
FIGURE 14 Overview of the CTT-ineligible population AG model structure (with dashed curative therapy scenario).
(a) Work-up outcome decision tree; and (b) post-SIRT Markov model.
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As shown in Figure 14, the structure of the partitioned survival model is broadly similar to that adopted
within both the BTG and Sirtex models (see Chapter 5, Review of economic evidence submitted by
companies), consisting of three health states: (1) progression free, (2) post progression and (3) dead.
For any time, t, the probability that a patient is alive and progression free is given by the cumulative
survival probability for PFS, whereas the probability that a patient is alive is given by the cumulative
survival probability for OS. The probability that a patient is in the post-progression state at any time,
t, is given by the difference between the cumulative survival probabilities for PFS and OS. Health and
cost outcomes from the partitioned survival models for each intervention were multiplied by the
proportion of patients who received each within the particular treatment arm as per the decision tree.
As with the Sirtex model, HRQoL is defined according to the presence or absence of disease
progression as well as treatment received. The model includes costs associated with SIRT procedures
(work-up costs, acquisition costs and procedure costs), drug acquisition, health-state costs (consultant-
led outpatient visits, nurse-led outpatient visits, electrocardiography, blood tests and CT scans), costs
associated with managing grade 3 or 4 AEs, BSC-related costs (consultant-led outpatient visits, CT
scans, MRI scans, specialist palliative care visits and palliative radiotherapy) and end-of-life care costs.
Model input parameters
A summary of the data sources used to populate the AG’s base-case model is presented in Table 27.
These are discussed in greater depth over the following sections.
Treatment effectiveness
The base-case analysis used data from the SARAH,19 SIRveNIB21 and REFLECT trials.81 Scenario
analyses also drew on a number of observational comparisons of SIR-Spheres and TheraSphere
(see Chapter 4, Network 3: adults with unresectable hepatocellular carcinoma who are ineligible for
conventional transarterial therapies, for details).
The comparison of SIR-Spheres with sorafenib was based on pooled data from the SARAH and
SIRveNIB trials. Modelled data from SARAH were supplied by Sirtex for both PFS and OS, and data
were extracted from published literature sources from SIRveNIB.
The source of modelled survival data from the SARAH and SIRveNIB trials differed according to
therapy received. For patients receiving sorafenib, OS and PFS outcomes were based on the ITT
populations (sorafenib, n = 400), whereas OS and PFS outcomes for patients receiving SIR-Spheres
are modelled based on the per-protocol population of each trial (SIR-Spheres, n = 304). This is done
to account for the proportion of patients who fail the SIRT work-up procedure, and subsequently do
not undergo the main SIRT procedure. The outcomes of patients who fail the work-up procedure are
modelled independently, and are based on near-complete KM data from the SARAH trial (work-up
failures, n = 42). The proportion of patients failing the work-up procedure is based on the SARAH trial.
The DSA included a range of estimates for work-up failure, based on the number of work-up failures
reported in SARAH and SIRveNIB and other estimates provided by Sirtex. To avoid the double-
counting of patients who are downstaged to receive curative therapies, the data included from SARAH,
for both SIR-Spheres and sorafenib, are censored for downstaging. There was no downstaging reported
in the SIRveNIB trial publication21 and no patients received subsequent therapies that could be
considered ‘curative’, so it was assumed that no patients were downstaged to receive curative
therapies in these data.
The comparative effectiveness of lenvatinib was drawn from the NMA presented in Chapter 4, Results.
The HR for lenvatinib versus sorafenib was applied to the Weibull curve fitted to the sorafenib data
drawn from the SARAH and SIRveNIB trials. Proportional hazards is, therefore, assumed between
sorafenib and lenvatinib.
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In the AG’s base-case analysis, equivalence is assumed between the SIRTs owing to a lack of randomised
evidence on the relative effectiveness of each SIRT. An exploratory scenario analysis is also presented
in which the effectiveness of TheraSphere was based on two non-randomised comparative studies39,40
(SIR-Spheres, n = 34; TheraSphere, n = 78), with a HR versus SIR-Spheres drawn from the NMA. In this
scenario, the HR is applied to the modelled parametric functions fitted to the pooled SIR-Spheres data
and, therefore, proportional hazards is assumed for this comparison (see Extrapolation of progression-free
survival and overall survival evidence for consideration of the plausibility of this assumption).
In addition to the base-case analysis in which the modelled population was based on pooled analysis
of the SARAH and SIRveNIB trials, additional scenario analysis was implemented in a number of
alternative populations. To account for uncertainties in the relevance of the Asia-Pacific population to
TABLE 27 Summary of sources of input parameters in the AG base-case economic model
Model parameter Evidence source
OS Parametric survival models fitted to pooled OS data from the SARAH19 and SIRveNIB21 trials
for both SIR-spheres (per protocol) and sorafenib (ITT). A HR from the AG’s NMA was
applied to the sorafenib OS curve to estimate OS for lenvatinib. The OS for patients who
received work-up but were ineligible to receive SIRT was modelled using the observed
KM data from SARAH19
PFS Parametric survival models fitted to pooled PFS data from the SARAH19 and SIRveNIB21
trials for both SIR-spheres and sorafenib. A HR from the AG’s NMA was applied to the
sorafenib PFS curve to estimate OS for lenvatinib
Health state utilities Utilities were generated by Sirtex from SARAH trial19 data, and were applied by treatment
class (SIRT/systemic therapy)
Pre progression: EORTC QLQ-C30 scores taken from the post hoc analyses of the SARAH
trial19 for the per-protocol population were mapped to EQ-5D using a mapping algorithm
developed by Longworth et al.113
Post progression: EORTC QLQ-C30 scores taken from the post hoc analyses of the SARAH
trial19 for the per-protocol population were mapped to EQ-5D using the algorithm developed
by Longworth et al.113
Proportion receiving
SIRT
The proportion receiving SIRT after work-up was based on the full SARAH trial19 population.
Number of administrations of SIRT was based on the SARAH trial19
SIRT costs Acquisition cost: Sirtex company submission,102 BTG company submission103 and Terumo
company submission104
Work-up costs: BTG-elicited values from The Christie NHS Foundation Trust (personal
communication)
Procedure costs: National Schedule of Reference Costs 2017–2018107
Systemic therapies
costs
Sorafenib and lenvatinib: BNF115
Dosing of sorafenib: SARAH trial19
Dosing of lenvatinib: REFLECT81 Western subgroup
Duration of sorafenib: SARAH trial19
Duration of lenvatinib: PFS HR from REFLECT.81 Applied to SARAH,19 sorafenib time on treatment
Subsequent treatment
costs
BNF,115 eMIT116 and TA555 (regorafenib)13
AE costs AEs experienced by ≥ 5% of the population were modelled, with rates drawn from the
SARAH19 and REFLECT81 trials. Costs were drawn from National Schedule of Reference Costs
2017–2018,107 with cost categories based on NICE TA47411 and 55112
Health state costs Sirtex survey of clinical experts and National Schedule of Reference Costs 2017–2018107
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UK practice, a scenario was implemented using data only from the SARAH trial. Two further subgroup
analyses based on the SARAH trial were also considered: the restricted low-tumour burden and ALBI 1
subgroup (SIR-Spheres, n = 28; sorafenib, n = 44), and patients with MVI (SIR-Spheres, n = 64;
sorafenib, n = 81). In both subgroup analyses, the comparison between SIR-Spheres and sorafenib is
made using data drawn from the relevant subgroup of the SARAH trial only. Appropriate IPD were
requested by the AG for these subgroups of the SIRveNIB trial but Sirtex had only limited access to
the IPD from the SIRveNIB trial and did not have subgroup data from all enrolling centres. Subgroup
data were not available to support the comparative effectiveness of lenvatinib and TheraSphere.
This scenario, therefore, uses only data for SIR-Spheres and sorafenib, assuming equivalent efficacy
across SIRTs and between lenvatinib and sorafenib.
Extrapolation of overall survival and progression-free survival evidence
For each data set, model selection was conducted in line with the process described in the NICE DSU
Technical Support Document 14.117 To assess the appropriateness of alternative parametric models,
log-cumulative hazard plots were produced to illustrate and assess the hazards observed in the trial.
Curve fitting was conducted using the ‘survival’ and ‘flexsurv’ packages in R (The R Foundation for
Statistical Computing, Vienna, Austria). Exponential, Weibull, Gompertz, log-normal, log-logistic, gamma
and generalised gamma models were considered.
The AIC and BIC fit statistics were examined to assess the comparative internal validity of competing
models. The final choice of models for the economic analysis was made on the basis of fit to the
observed data as well as consideration of the clinical plausibility of candidate models.
Overall survival
The analysis of OS for the base-case analysis was based on time-to-event data from the SARAH trial
supplied by Sirtex, and KM curves from the SIRveNIB trial.21 Pooled KM curves for the base-case
population are presented in Appendix 16, Figures 26 and 27. Survival estimates can be found in
Appendix 16, Table 71.
Standard parametric survival functions were fitted to the survival data available for each of the
considered populations, and log-cumulative hazard plots were generated to assess any changes in
hazards over time (see Appendix 16, Figure 28). Plots of each of the fitted parametric models with the
observed KM OS curves are presented in Figures 15 (SIR-Spheres) and 16 (sorafenib). Model fit
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FIGURE 15 Extrapolation of OS: SIR-Spheres.
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statistics are summarised in Appendix 16, Table 72, which showed that the generalised gamma model
had the best fit, with the log-normal and log-logistic curves also having similar statistical fit, thereby
providing little justification to discriminate between these models on this basis of fit statistics. The
generalised gamma, log-normal and log-logistic models are, however, all accelerated failure time models
and, as such, a HR cannot be applied to estimate outcomes for lenvatinib patients, and would likewise
not permit scenarios in which differential outcomes are assumed for TheraSphere, which would
similarly require the application of a HR. To accommodate the use of HRs, the AG base-case analysis,
therefore, selected the Weibull function, which has the best statistical fit from the remaining curves,
and was considered the most clinically plausible. The AG considered this reasonable given the limited
data to accommodate accelerated failure time functions and the small variation in predicted
incremental survival across all six functions, but acknowledges this as a limitation of the presented
base-case analysis. Scenario analysis is, therefore, presented, in which the generalised gamma, log-
normal and log-logistic functions are used to model OS. In these scenarios, equivalence is assumed
between sorafenib and lenvatinib.
For scenarios run on the SARAH trial19 subpopulations described previously, the Weibull function was
retained to model OS outcomes. Fit statistics for the SARAH trial whole population, low tumour
burden/ALBI 1 subgroup and no-MVI subgroup are reported in Appendix 16, Table 74. Plots of each of
the fitted parametric models with the observed KM OS curves are presented in Appendix 16, Figures 30
and 31 (SIR-Spheres) and Figures 32 and 33 (sorafenib). In all three scenarios, the Weibull function had
a good statistical and visual fit to the observed data.
Progression-free survival
The analysis of PFS for the base-case analysis was based on supplied time-to-event data from the
SARAH trial19 and KM curves from the SIRveNIB trial.21
Similar to the approach previously described for OS, standard parametric survival functions were fitted to
the survival data available for each of the considered populations (Figures 17 and 18), and log-cumulative
hazard plots generated to consider the change in hazards over time (see Appendix 16, Figure 29). Plots of
each of the fitted parametric models with the observed KM OS curves are presented in Appendix 16,
Figures 34 and 35 (SIR-Spheres) and Figures 36 and 37 (sorafenib). Similar to OS, model fit statistics for the
generalised gamma, log-normal and log-logistic functions were superior to other functions (see Appendix 16,
Table 73). These functions were, however, rejected to accommodate the application of a HR for lenvatinib
0
0 24 48 72 96 120 144 168 192 216 240
10
20
30
40
50
60
70
80
90
100
Weeks
O
S
 (
%
)
Exponential
Kaplan–Meier
Weibull
Gompertz
Log-logistic
Log-normal
Generalised gamma
FIGURE 16 Extrapolation of OS: sorafenib.
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and the implementation of scenarios assuming differential effectiveness for TheraSphere. The Weibull
function was, therefore, selected in the AG base-case analysis as this had the best statistical and visual fit to
the observed data and was considered clinically plausible.
Overall survival for patients downstaged to curative therapy
The base-case analysis does not allow for downstaging to curative therapies, owing to uncertainties
over whether or not this is realistic in a population of patients with advanced disease. A number of
scenarios are presented in which downstaging is allowed for. The proportion of patients downstaged
is based on the values reported in the SARAH trial19 and varied depending on the efficacy subgroup
used (see Appendix 16, Table 69). Outcomes for patients downstaged to curative therapy were based
on a US prospective cohort study,112 which recruited 267 patients with HCC, including 191 with
intermediate and advanced disease. This study compared outcomes for patients who had received
palliative care with those who received potentially curative therapies (liver transplantation, surgical
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FIGURE 17 Extrapolation of PFS: SIR-Spheres.
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FIGURE 18 Extrapolation of PFS: sorafenib.
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resection or tumour ablation). Using Cox multivariate proportional hazards, the HR for OS with
potentially curative treatments versus non-curative treatment was 0.29 (95% CI 0.18 to 0.47). This
HR was applied to the pooled sorafenib ITT arms of the SARAH and SIRveNIB trials in all scenarios.
This was carried out to prevent the outcomes of downstaged patients varying depending on the patient
population selected or by treatment arm; advice from clinical advisors to the AG suggested that
outcomes post-curative therapy would be similar regardless of patient characteristics or treatment
received to achieve downstaging. The sorafenib ITT arm was used as this was considered to best match
care received in the analysed patient cohort, and is most representative of the current standard of
care in UK practice.
Adverse event rates
The probability of experiencing grade 3 or 4 AEs for SIR-Spheres and sorafenib was taken directly
from the per-protocol population of the SARAH trial.19 Based on clinical advice received by the AG,
AE rates for TheraSphere and QuiremSpheres were assumed to be the same as for SIR-Spheres. AE
rates for lenvatinib were drawn from the REFLECT trial.81 See Appendix 16, Table 70, for rates applied.
Health-related quality of life
Literature review and mapping of health-related quality-of-life estimates
A targeted review of published studies reporting utility estimates for patients with HCC or cirrhosis
was undertaken to supplement data extracted from studies on SIRT and its comparators. Details of
the search strategy used are described in Appendix 3. The objective of these searches was to identify
health state utilities of patient populations that may not have been captured in studies included in the
main systematic reviews. The required utilities included:
l decompensated cirrhosis (any cause)
l post-CTT disutility
l post-resection disutility
l pre- and post-transplant utilities.
The identified studies recorded HRQoL using a number of tools, namely Short Form questionnaire-36
items (SF-36) and EORTC QLQ-C30. NICE prefers the use of generic preference-based measures
(i.e. EQ-5D) for the calculation of health state utilities. Therefore, mapping algorithms typically based
on multinomial regression model coefficients can be used to transform disease-specific measures of
health status into a EQ-5D-based utility score. Domain scores for relevant populations were mapped
onto EQ-5D using the two-part beta model as developed by Woodcock and Doble144 for EORTC
QLQ-C30 scores, and a model developed by Rowen et al.145 was used to transform SF-36 outcomes.
Modelled health state utilities
The AG’s base-case model for CTT-ineligible patients applies different health state utilities based on
the type of therapy received to reflect any differences in their respective AE burdens. Because utilities
were drawn from patients in the SARAH trial, disutilities associated with type and length of any AEs
were assumed to have been captured, and thus were not considered separately. In the absence of
any evidence suggestive of a difference in HRQoL between the three SIRTs, the AG has assumed
that patients experience the same quality of life regardless of whether they received SIR-Spheres,
TheraSphere or QuiremSpheres. Likewise, the HRQoL estimates associated with the systemic therapies,
namely sorafenib and lenvatinib, are assumed to be the same as one another, but marginally lower
than those applied to SIRT, as observed in the SARAH trial19 (see Table 28). An additional scenario
in which health state utilities from the lenvatinib technology appraisal are applied is presented in
Scenario analyses.
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Age-related disutilities
Age-adjusted UK population norms from Szende et al.146 were applied to the utility values included in
the model. Age-related decrements were estimated in the form of a multiplier, with decrements applied
relative to the populations on entering the model. This allows for the trial-derived utilities applied in
the model to account for age-related decline in HRQoL as the population ages over time.
Selective internal radiation therapy health state utilities
The health state utilities associated with SIRT in the CTT-ineligible model were based on the per-protocol
subgroup of the SARAH trial as calculated by Sirtex in its evidence submission (see Chapter 5, Evidence
used to inform the company’s model, for details). EORTC QLQ-C30 summary scores were mapped to EQ-5D
using the algorithm developed by Longworth et al.,113 and utilities were calculated based on UK general
population weights.
The per-protocol utilities were considered to better reflect the HRQoL associated with SIRT than those
derived from the ITT population, as 22.4% of patients randomised to SIRT did not receive SIRT in the
SARAH trial. These patients may have received other systemic therapies or BSC, or were otherwise too
unwell to receive SIRT; thus, the ITT utility values may not have represented those of a SIRT-treated
population. There were no further utility decrements applied to these utilities as these are likely to
have been captured in the SARAH trial results. The health state utilities applied in the model are
presented in Table 28.
Systemic therapy health state utilities
Health state utilities applied to modelled patients receiving the systemic therapies sorafenib and
lenvatinib were taken from the per-protocol subgroup of sorafenib patients in the SARAH trial.19 The
difference in utility between SIRT and sorafenib in this subgroup was 0.011, which the AG considered
to account sufficiently for the ostensibly greater burden of AEs associated with these drugs. Utilities
applied to patients who received work-up but ultimately did not receive SIRT were weighted by the
proportion on systemic therapy versus BSC (61.9% and 38.1%, respectively). This assumes that patients
not on systemic therapy had a utility equivalent to those on SIRT, which may overestimate the HRQoL
of BSC patients, as a proportion were likely to have been too unwell to receive systemic therapy.
Post-transplant health state utilities
The AG scenarios 6 and 10 include the possibility for downstaging; therefore, post-transplant utilities
were considered for use in the model. Pre-transplant health state utilities are assumed to be equal to
those experienced in pre-progression for SIRT, systemic therapies and BSC. Post-transplant health
state utilities are assumed to be equal to those experienced on SIRT, regardless of which treatment a
patient received before downstaging to transplant. However, it is likely that patients who received a
transplant may have a better HRQoL than the per-protocol population of the SARAH trial.
Despite multiple studies showing that recipients of liver transplant enjoy increased HRQoL post
transplant in comparison with pre transplant,113,147–149 a lack of generalisability between these studies
TABLE 28 Health state utilities included in the AG CTT-ineligible model
Health state
Utility
SIRT Systemic therapy Work-up: no SIRT
PFS 0.710 0.699 0.703
Progressive disease 0.668 0.657 0.661
Post transplanta 0.710 0.710 0.710
a AG scenarios 6 and 10 only.
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and the population included in the model renders the absolute utility values reported in the literature
too uncertain for inclusion. Studies also show that HRQoL remains lower for liver transplant recipients
than for healthy patient controls.150–152 However, as with the pre- and post-transplant utilities, there is
insufficient evidence to suggest that these studies are generalisable to the modelled population. Given
the lack of evidence to definitively suggest that utility values in the post-transplant HCC population
are lower than in the general population, the AG believes that the utility values observed in the
general population represent the upper bound of the utility expected in the post-transplant population.
Sources of resource utilisation and cost data
A targeted review of published studies reporting resource use and cost data for patients with HCC or
cirrhosis was undertaken. Details of the search strategy used are described in Appendix 4. This review,
however, identified little in the way of published literature. Resource use and cost inputs used in the
AG’s economic model were, therefore, derived primarily from targeted literature searches, previous
NICE technology appraisals and the estimates presented in the companies’ evidence submissions
for the present appraisal. Overall costs are determined by treatment costs (acquisition, procedures
and monitoring), changes in health service utilisation driven by disease status (i.e. progression free,
progressed disease and death) and AE management. The assumptions applied to each category are
discussed in the following sections. Note that confidential Patient Access Scheme (PAS) discounts are
available but not included here for QuiremScout, sorafenib, lenvatinib and regorafenib. Please refer
to Appendix 17 for results including all PAS discounts. A summary of the AG model cost inputs is
presented in Summary of Assessment Group base-case analysis inputs and assumptions.
Treatment costs and resource use
Work-up costs and number of procedures
Patients allocated to receive SIRT must first undergo a work-up procedure to assess their suitability
for treatment with SIRT, and to plan the procedure through angiographic evaluation and occlusion
of any vessels that could carry microspheres away from the liver to the gut. Although work-up is a
one-off procedure, those patients who required a second SIRT procedure owing to an unsuccessful or
incomplete first procedure are likely to need a second work-up.
In the SARAH trial,19 17 of the 184 patients who received SIRT required re-treatment owing to an
unsuccessful or incomplete first procedure (nine received a second work-up but were not re-treated).
Therefore, patients who received any of the SIRTs incurred the cost of 1.09 work-up procedures to
account for re-treatment. As the model independently considered the costs and outcomes for patients
who underwent work-up but ultimately did not receive SIRT, these individuals were assumed to
receive 1.0 work-up procedures. The AG’s base case assumed that 18.6% of patients who underwent
work-up did not go on to receive SIRT in line with the SARAH trial19 data. However, in recognition of
the uncertainty around this value, a number of alternative scenarios are presented in Sensitivity
analyses results.
Work-up costs used in the AG base case were based on the values BTG elicited from The Christie
NHS Foundation Trust (see Appendix 15, Table 60). The largest expenditures were staff costs and
SPECT/CT. The total cost of a single work-up procedure for SIR-Spheres and TheraSphere used in the
AG model was £860.32, and the work-up cost of £5178.32 for QuiremSpheres comprised the list price
of QuiremScout and the BTG-elicited value excluding the £74 cost of the technetium-99m MAA agent.
This does not include the PAS discount available for QuiremScout.
Selective internal radiation therapy treatment costs and number of procedures
Patients in the AG model received an average of 1.21 SIRT procedures. This is based on the
assumption that patients requiring bilobar treatment will require two separate SIRT procedures,
separated by a few weeks (as per the SARAH protocol153), and that patients will be re-treated owing to
an incomplete or unsuccessful first treatment. The clinical advisors to the AG stated that it would be
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very unlikely that both lobes would be treated in the same treatment session in UK practice owing to
an increased risk of REILD. SIRT patients in the SARAH study19 had 1.28 separate SIRT treatments on
average [222 treatments, 173 patients (one or two treatments only)]. This broadly reflects the results
of the Sirtex resource use survey (1.2 treatments per patient). This value excludes the 11 patients
who had three separate SIRT treatments, and includes only one procedure for the nine patients who
received a second treatment owing to disease progression, as it was unclear whether or not this would
be permitted in UK practice.
The acquisition cost of a single SIRT treatment was taken from each company submission: SIR-Spheres,
£8000; TheraSphere, £8000; and QuiremSpheres, £9896.
The cost of the SIRT procedure applied in the AG model was taken from National Schedule of Reference
Costs 2017–2018107 (YR57Z). The average cost of ‘Percutaneous, Chemoembolisation, or Radioembolisation,
of Lesion of Liver’ was £2790. This cost was incurred for each separate SIRT administration for patients
receiving TheraSphere and QuiremSpheres in the AG model. The Sirtex company submission102 stated
that SIR-Spheres administration procedures use intermittent contrast-medium injection to assess the
distribution of the microspheres under radiography over the course of approximately 1 hour. The AG,
therefore, included an additional cost of £209 for the SIR-Spheres administration procedure (RD32Z –
Contrast Fluoroscopy Procedures with duration of more than 40 minutes), for a total of £2999.
Costs of systemic therapies
The pack costs for sorafenib (£3576.56), lenvatinib (£1437.00) and regorafenib (£3744.00) were taken
from the BNF.115 The confidential PAS discounts available for sorafenib, lenvatinib and regorafenib are
not included in this report. For results of the AG’s economic analysis that include these discounts,
please refer to Appendix 17.
The daily dose of sorafenib used in the AG base case was based on the SARAH trial19 (648.5 mg), and
the mean time on treatment was calculated by applying an exponential function to the median time on
treatment reported in the SARAH trial19 (exponential mean 122.95 days).
The base-case daily dose of lenvatinib was 10.2 mg per day, based on the Western subgroup of the
REFLECT trial81 for lenvatinib. This value was considered by the technology appraisal committee in
TA55112 to better represent the average weight-based dose used in UK practice. The AG considered
the time on treatment reported in the REFLECT trial81 for lenvatinib to be excessively long compared
with SARAH,19 and reflective of differences in the baseline characteristics of the populations recruited
to these trials. To avoid inflating the relative cost of lenvatinib, the AG applied the reported HR of PFS
between lenvatinib and sorafenib in REFLECT to the SARAH time on treatment to produce an estimate
of 124.07 days on treatment.
Wastage was accounted for in the AG model using the simple assumption that if a new pack was
started then in the case of treatment discontinuation, the remainder could not be used to treat other
patients. However, this may be a conservative assumption, as it was reported in TA55513 that many
centres have measures in place to reduce wastage of expensive cancer treatments, such as issuing only
a 1-month supply of tablets at a time (approximately one pack of sorafenib). However, as it generally
cannot be predetermined when therapy will be discontinued owing to AEs, death or non-compliance,
it can be reasonably assumed that some wastage will occur.
Cost of subsequent treatment
The interventions used following first-line treatment in the SARAH trial19 were not representative of
current UK practice; however, as the efficacy data used in the model are derived from these patients,
the trial values are most appropriate. Therefore, the proportion of patients who received subsequent
systemic therapy (98% sorafenib) following SIRT in the SARAH trial19 (28.8%) was used to estimate
the size of this population in the AG model. The AG was advised that current NICE recommendations
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mean that lenvatinib is rarely used in practice, as this would preclude second-line use of regorafenib.
Therefore, 95% of patients continuing to subsequent systemic therapies following SIRT treatment are
assumed to receive sorafenib, and 5% are assumed to receive lenvatinib.
As a number of chemotherapeutic/systemic agents administered to patients following sorafenib in the
SARAH trial19 have now been displaced in practice by regorafenib, or are otherwise no longer in use,
the AG model assumes that the proportion of those who received systemic therapies after sorafenib in
the trial (12.04%) would receive regorafenib in UK practice. A small proportion (3.47%; i.e. 12.04% of
28.8%) of SIRT patients also receive regorafenib following second-line sorafenib treatment. Duration of
therapy and dose intensity of each of the three systemic agents modelled is assumed to be the same as
first-line treatment, whereas regorafenib is assumed to have the same time on treatment as sorafenib
(122.95 days), with a mean daily dose of 160 mg (RESORCE trial).101
Disease management costs
There are a number of issues with the health state unit costs used in previous technology appraisals in
this indication, which precluded their use in the AG base case. The primary concern with these costs is
that the original resource use surveys given to clinicians were based on the ongoing costs associated
with sorafenib treatment. The resource use implications for systemic therapies may be very different
with regard to monitoring and diagnostic testing to those for SIRT as a one-off procedure; therefore,
these values may overestimate the disease management costs associated with the PFS health state for
SIRT patients. Furthermore, the committee-preferred resource use data used in TA551124 were collated
from two resource use surveys conducted 10 years apart, generating very different estimates that may
reflect differences in practice, costs and experience. As targeted therapies such as sorafenib were not
yet in use at the time of this first survey, it is unlikely that these values are sufficiently representative
of current practice.
In the light of these limitations, the AG used the results of a resource use survey conducted by Sirtex,
which elicited information from 11 clinicians on the frequency and type of medical staff contact,
monitoring and follow-up, hospitalisation frequency and length, and any use of PSS. Resource use pre
progression, post progression and on progression were reported separately. Unit costs for each resource
use item were derived from National Schedule of Reference Costs 2017–2018107 and Personal Social
Services Research Unit (PSSRU).106 Differential costs were applied for systemic therapy patients during
pre-progression, reflecting higher levels of ongoing diagnostic testing and additional follow-up contact.
The per-cycle post-progression costs applied in the AG model are significantly lower than those used
in TA551124 (£229.69 vs. £1268.16). This was driven primarily by greatly reduced use of hospital- and
social care-based palliative care on progression since the original resource use survey. The health state
costs used in the AG model are presented in Table 29.
TABLE 29 Assessment Group model health state costs
Cost item
Cost (£)
Pre-progression post
SIRT (per cycle)
Pre-progression
on systemic
therapy (per cycle)
On progression
(one off)
Progressive
disease
(per cycle)
Medical staff contact 47.30 58.18 54.51 102.55
Diagnostic procedures 59.92 61.90 41.07 2.83
Inpatient care 3.13 9.33 0.00 36.11
PSS 2.68 2.68 0.00 88.20
Total 113.03 132.10 95.57 229.69
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A scenario that instead uses the committee-preferred costs from the lenvatinib appraisal is presented
in Sensitivity analyses results.
Adverse event costs
Costs associated with the management of AEs were derived from previous NICE TAs of HCC,11–13 using
the latest National Schedule of Reference Costs 2017–2018107 values or costs inflated to the 2018 cost
year, where applicable. The AG base case used AE incidence rates from the SIR-Spheres arm of the
SARAH trial19 for the three SIRTs, and from the sorafenib arm of this trial for sorafenib. AE rates for
lenvatinib were taken from the REFLECT trial.81 For patients who received work-up but did not
progress onto SIRT, the proportion of patients who received sorafenib incurred sorafenib AE
management costs.
A full list of AE costs used in the AG model is presented in Appendix 16, Table 75.
Summary of Assessment Group base-case analysis inputs and assumptions
A summary of the resource use assumptions and costs applied in the AG base-case analysis is
presented in Table 30.
TABLE 30 Summary of resource use and cost inputs in the AG model
Parameter Treatment Model input Reference
Proportion of work-ups
leading to SIRT
SIR-Spheres 81.4% SARAH19
TheraSphere 81.4% SARAH19
QuiremSpheres 81.4% SARAH19
Treatment of SIRT work-up
failure patients
Sorafenib 61.9% SARAH19
BSC 38.1% AG assumption
Mean number of work-ups
(treated patients)
SIR-Spheres 1.09 SARAH19
TheraSphere 1.09 SARAH19
QuiremSpheres 1.09 SARAH19
Mean number of SIRT
procedures
SIR-Spheres 1.28 SARAH19
TheraSphere 1.28 SARAH19
QuiremSpheres 1.28 SARAH19
Subsequent systemic therapies
Post SIRT Sorafenib 27.4% SARAH19/AG assumption
Lenvatinib 1.4% AG assumption
Regorafenib (third line) 3.3% AG assumption
BSC 71.2% AG assumption
Post sorafenib Regorafenib 12.0% AG assumption
BSC 88.0% AG assumption
Post lenvatinib BSC 100% AG assumption
Subsequent curative therapies
Liver transplant £16,556.07 National Schedule of Reference Costs 2017–2018107
Resection £9676.59 National Schedule of Reference Costs 2017–2018107
Ablation £2344.55 National Schedule of Reference Costs 2017–2018107
(YG01A/YG01B)
continued
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TABLE 30 Summary of resource use and cost inputs in the AG model (continued )
Parameter Treatment Model input Reference
Treatment cost inputs
Work-up SIR-Spheres £860.32 BTG elicitation (The Christie NHS Foundation
Trust, personal communication)
TheraSphere £860.32 BTG elicitation (The Christie NHS Foundation
Trust, personal communication)
QuiremSpheres £5178.32 BTG elicitation (The Christie NHS Foundation
Trust, personal communication); Terumo
submission104
Procedure SIR-Spheres £2999.00 National Schedule of Reference Costs 2017–2018107
(YR57Z and RD32Z)
TheraSphere £2790.00 National Schedule of Reference Costs 2017–2018107
(YR57Z)
QuiremSpheres £2790.00 National Schedule of Reference Costs 2017–2018107
(YR57Z)
Acquisition (list price) SIR-Spheres £8000.00 Sirtex submission102
TheraSphere £8000.00 BTG submission103
QuiremSpheres £9896.00 Terumo submission104
Sorafenib £3576.56 BNF115
Lenvatinib £1437.00 BNF115
Regorafenib £3744.00 BNF115
Management costs
AE costs (total) SIR-Spheres £477.69 NICE TA474,11 TA514,13 TA535,154 TA551;124
National Schedule of Reference Costs 2017–2018107
TheraSphere £477.69 NICE TA474,11 TA514,13 TA535,154 TA551;124
National Schedule of Reference Costs 2017–2018107
QuiremSpheres £477.69 NICE TA474,11 TA514,13 TA535,154 TA551;124
National Schedule of Reference Costs 2017–2018107
Sorafenib £932.79 NICE TA474,11 TA514,13 TA535,154 TA551;124
National Schedule of Reference Costs 2017–2018107
Lenvatinib £542.08 NICE TA474,11 TA514,13 TA535,154 TA551;124
National Schedule of Reference Costs 2017–2018107
Sorafenib/BSC
(work-up/no SIRT)
£577.40 NICE TA474,11 TA514,13 TA535,154 TA551;124
National Schedule of Reference Costs 2017–2018107
Health state costs (per cycle) PFS (SIRT) £113.03 Sirtex expert elicitation; National Schedule of
Reference Costs 2017–2018,107 PSSRU 2018106
PFS (systemic
therapies)
£132.10 Sirtex expert elicitation; National Schedule of
Reference Costs 2017–2018,107 PSSRU 2019106
On progression £95.57 Sirtex expert elicitation; National Schedule of
Reference Costs 2017–2018,107 PSSRU 2020106
Post progression £229.69 Sirtex expert elicitation; National Schedule of
Reference Costs 2017–2018,107 PSSRU 2021106
End of life £8191.00 Georghiou and Bardsley128
Postcurative therapy
(scenario)
£113.03 Sirtex expert elicitation; National Schedule of
Reference Costs 2017–2018107
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Analytic methods
Base-case analysis
The AG produced fully incremental ICERs for each strategy included in the model; however, this
approach generated a number of ICERs expressed in terms of dominance owing to the close similarity
of health outcomes predicted for the SIRTs.
The AG, therefore, considered a net benefit framework to be the most appropriate approach to present
the relative cost-effectiveness of the three SIRTs with existing practice. This method is often preferred
when there are a number of technologies under comparison, particularly when incremental costs and
benefits are very similar. Technologies with identical health outcomes and marginal differences in
costs are often labelled as ‘dominant/dominated’ using incremental cost-effectiveness analysis with
conventional decision rules. Considering net health benefit instead permits a more informative
comparison of the effect of alternative strategies.
Net monetary benefit is calculated using a rearrangement of the ICER formula, but inherently compares
the incremental health gain with the comparator with a willingness-to-pay (WTP) threshold. The NMB
formula thereby assigns a value to the additional QALYs generated by an intervention, and considers the
opportunity cost associated with generating these health benefits. The formula used to define NMB is
λ ×ΔE –ΔC, where the difference in health effects (ΔE) is multiplied by the selected WTP threshold (λ)
minus the difference in costs (ΔC) (i.e. £30,000 in the results presented below). Using this approach, if an
intervention has an incremental NMB of > 0, then it would be considered more cost-effective than the
baseline option, in this case the least costly option. NMB results (including PAS discounts) at a £20,000
and £30,000 threshold are also presented in Appendix 17.
The AG model accounted for uncertainty using probabilistic and deterministic sensitivity analyses.
PSA was undertaken using simple Monte Carlo sampling methods, using 20,000 samples for the AG
base case and 5000 samples in the primary scenario analyses. The choice of distribution to reflect
uncertainty around each parameter was selected for each according to its statistical suitability. To
account for uncertainty around the parametric survival models fitted to OS and PFS, outcomes were
sampled via Cholesky decomposition using the variance–covariance matrices produced during survival
modelling. When a HR was used to estimate PFS and OS outcomes, alternate values were drawn in
each model iteration from the NMA output from WinBUGS (CODA) to model uncertainty in the
predicted treatment effects.
Model validation
The AG adopted a number of approaches to ensure the credibility and validity of the model. These
included scrutiny of the implemented model coding and formulae by two modellers, black-box testing
in which the predictive validity of parameter inputs (e.g. that increasing effectiveness of the treatment
lowers cost-effectiveness) was assessed, checking the accuracy of all model inputs against the original
sources and consultation with clinical experts on key assumptions (see Acknowledgements).
Results of the independent economic assessment
Base-case results
The deterministic and probabilistic fully incremental results of the AG’s base-case analysis (excluding
confidential PAS discounts for QuiremScout, sorafenib, lenvatinib and regorafenib) are presented in
Table 31. The probabilistic results were based on 20,000 model iterations.
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The AG’s base case was based on the following assumptions and data sources:
l SIR-Spheres efficacy based on a pooled survival analysis of SARAH19 and SIRveNIB21 data
(per-protocol population)
l QuiremSpheres and TheraSphere efficacy equal to SIR-Spheres
l for patients who received work-up but no SIRT, OS and PFS based on SARAH19 KM
l sorafenib efficacy based on a pooled survival analysis of SARAH19 and SIRveNIB21 data (ITT population)
l lenvatinib HR derived from the AG’s NMA (ITT population)
l OS and PFS extrapolated using a Weibull model
l decision tree transition probabilities estimated using data from the SARAH19 trial
l no downstaging to curative therapy permitted
l bilobar treatments performed in two separate procedures
l work-up costs from The Christie NHS Foundation Trust elicitation (as per the BTG economic analysis)
l health state utilities from the SARAH19 per-protocol subgroup, based on therapeutic class (SIRT and
systemic therapy).
Based on the probabilistic version of the AG model, the three SIRTs are each expected to generate
fewer QALYs than sorafenib or lenvatinib, but were associated with higher costs. SIRT generated 0.765
QALYs; this was 0.076 QALYs fewer than generated by sorafenib and 0.060 fewer than by lenvatinib.
TheraSphere and SIR-Spheres had very similar total costs, and QuiremSpheres was the most costly
owing to the additional costs associated with procurement of QuiremScout.
Figure 19 presents CEACs for the fully incremental results of the AG model. Lenvatinib has the highest
likelihood of being cost-effective across any WTP threshold of < £100,000. Assuming a WTP threshold
of £30,000 per QALY gained, TheraSphere had an incremental NMB of –£2154, and this was –£2323
for SIR-Spheres. The NMB for QuiremSpheres versus lenvatinib was –£8741. All three SIRTs were
dominated by lenvatinib. Disaggregated deterministic results show that just under half of the QALY
gain in both groups is accrued in the post-progression health state.
For results including the confidential PAS discounts for sorafenib, lenvatinib, regorafenib and
QuiremSpheres, see Appendix 17.
TABLE 31 Fully incremental results of the AG’s base-case analysis
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
AG deterministic base case
TheraSphere 29,888 1.110 0.764
Lenvatinib 30,005 1.183 0.805 117 0.04 2911 1090 2911
SIR-Spheres 30,107 1.110 0.764 218 0.000 More costly –218 Extendedly
dominated
Sorafenib 32,082 1.243 0.841 2194 0.076 28,728 97 57,488
QuiremSpheres 36,503 1.110 0.764 6614 0.000 More costly –6614 Extendedly
dominated
AG probabilistic base case
Lenvatinib 29,658 1.202 0.825
TheraSphere 30,014 1.111 0.765 356 –0.060 Dominated –2154 Dominated
SIR-Spheres 30,196 1.111 0.765 538 –0.060 Dominated –2323 Dominated
Sorafenib 32,444 1.244 0.841 2786 0.016 174,320 –2306 174,320
QuiremSpheres 36,613 1.111 0.765 6955 –0.060 Dominated –8741 Dominated
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Sensitivity analyses results
Scenario analyses
Scenario 1: efficacy data from SARAH only
The first scenario analysis explores the effect of using only data from the European SARAH trial19 to
inform efficacy estimates for SIRT and sorafenib, on the basis that these might better represent the
patient population and clinical practice in the UK. Deterministic and probabilistic results are presented
in Table 32. The probabilistic results are based on 5000 model iterations. As with the AG base case,
each SIRT is associated with almost the same number of life-years and QALYs; however, this scenario
predicts lower OS (and thus life-years/QALYs) than in the base case, which makes SIR-Spheres
marginally cheaper than lenvatinib.
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FIGURE 19 Cost-effectiveness acceptability curve for the AG probabilistic base-case analysis.
TABLE 32 Assessment Group scenario 1 results: efficacy data from SARAH only
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
Deterministic scenario 1: efficacy data from SARAH only
TheraSphere 29,395 0.976 0.671
SIR-Spheres 29,614 0.976 0.671 218 0.000 More costly –218 Extendedly
dominated
Lenvatinib 29,893 1.150 0.782 498 0.111 4475 2840 4475
Sorafenib 31,951 1.209 0.817 2556 0.147 17,424 1845 58,080
QuiremSpheres 36,010 0.976 0.671 6614 0.000 More costly –6614 Extendedly
dominated
Probabilistic scenario 1: efficacy data from SARAH only
Lenvatinib 29,413 1.171 0.805
TheraSphere 29,476 0.978 0.672 62 –0.133 Dominated –4044 Dominated
SIR-Spheres 29,660 0.977 0.671 246 –0.134 Dominated –4267 Dominated
Sorafenib 32,300 1.213 0.818 2887 0.014 212,505 –2479 212,505
QuiremSpheres 36,064 0.977 0.670 6650 –0.134 Dominated –10,684 Dominated
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Scenario 2: low tumour burden/albumin–bilirubin 1 subgroup (SARAH)
This scenario explores the use of the company’s preferred post hoc grouping of patients from the
SARAH trial19 as the source of efficacy data for SIRT and sorafenib. Further changes from the AG base
case are the use of the higher low tumour burden/ALBI 1 subgroup utilities from the SARAH trial,19
and the significantly lower proportion of patients who receive work-up but not SIRT (8.1% vs. 18.6%).
Note that although Sirtex used a proportion of 2.9% for work-up failures in this population, it was
unclear how this figure was reached. Increasing the number of work-up failures, however, increases the
cost-effectiveness of SIRT.
This scenario predicts the cost-effectiveness of an optimised decision in which only patients who have
a tumour burden of ≤ 25% and a preserved liver function would be eligible to receive SIRT. As there is
no equivalent evidence available for lenvatinib, this scenario assumes that the HR between sorafenib
and lenvatinib remains the same as in the base-case population.
Table 33 shows that although the systemic therapies were less costly than SIRT in this scenario,
SIR-Spheres generated an additional 0.139 QALYs compared with lenvatinib and 0.117 compared with
sorafenib in the probabilistic model. This resulted in fully incremental ICERs of £20,926 per QALY
gained for TheraSphere compared with lenvatinib, and £119,562 for SIR-Spheres compared with
TheraSphere. However, the two technologies were distinguished only by the additional fluoroscopy
cost associated with the SIR-Spheres procedure, resulting in very similar NMB at a £30,000 threshold.
This is notably the only scenario in which TheraSphere and SIR-Spheres have a positive incremental
NMB versus lenvatinib at a WTP threshold of £30,000 (excluding scenario 4). This is illustrated by the
CEAC in Figure 20, which shows lenvatinib to have the highest likelihood of being cost-effective up
to a WTP threshold of approximately £27,000, at which point it is surpassed by TheraSphere and by
SIR-Spheres at a WTP threshold of ≥ £32,000.
Results including the confidential PAS discounts for sorafenib, lenvatinib, regorafenib and
QuiremSpheres can be found in Appendix 17.
TABLE 33 Assessment Group scenario 2 results: low tumour burden/ALBI 1 subgroup
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
Deterministic scenario 2: low tumour burden/ALBI 1 subgroup
Lenvatinib 31,388 1.366 1.000
Sorafenib 33,388 1.420 1.037 2000 0.038 53,320 –875 Extendedly
dominated
TheraSphere 34,021 1.542 1.153 2633 0.153 17,175 1966 17,175
SIR-Spheres 34,267 1.542 1.153 2879 0.153 18,783 1720 Dominated
QuiremSpheres 40,931 1.542 1.153 9543 0.153 62,257 –4945 Dominated
Probabilistic scenario 2: low tumour burden/ALBI 1 subgroup
Lenvatinib 31,233 1.397 1.024
Sorafenib 33,834 1.436 1.048 2601 0.024 109,709 –1890 Extendedly
dominated
TheraSphere 34,086 1.552 1.161 2854 0.136 20,926 1237 20,926
SIR-Spheres 34,389 1.553 1.163 3156 0.139 22,725 1010 119,562
QuiremSpheres 41,088 1.552 1.162 9855 0.138 71,372 –5712 Extendedly
dominated
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Scenario 3: no macroscopic vascular invasion (SARAH)
This scenario limits the patient population to only those who had no MVI, referred to elsewhere as PVI,
at baseline. These patients may be expected to benefit more from SIRT owing to a more favourable
positioning and spread of their tumour, and were thus defined as a subgroup of interest in NICE’s scope.
As there is no equivalent evidence for lenvatinib, this scenario assumes that the HR between sorafenib
and lenvatinib remains the same as in the base-case population.
The probabilistic analysis in Table 34 found all three SIRTs to be dominated by lenvatinib, with a
significantly lower NMB than either systemic therapy. Notably, the gap in QALYs produced by SIRT
versus sorafenib widened in this analysis versus the base case, implying a reduced benefit of SIRT in
this population.
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FIGURE 20 Cost-effectiveness acceptability curve for AG scenario 2: low tumour burden/ALBI 1 subgroup.
TABLE 34 Assessment Group scenario 3 results: no MVI
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
Deterministic scenario 3: no MVI (SARAH)
TheraSphere 29,949 1.078 0.740
SIR-Spheres 30,167 1.078 0.740 218 0.000 More costly –218 Extendedly
dominated
Lenvatinib 30,399 1.272 0.865 451 0.125 3594 3310 3594
Sorafenib 32,452 1.326 0.897 2503 0.157 15,923 2213 64,437
QuiremSpheres 36,563 1.078 0.740 6614 0.000 More costly –6614 Extendedly
dominated
Probabilistic scenario 3: no MVI (SARAH)
Lenvatinib 29,985 1.295 0.888
TheraSphere 30,094 1.086 0.746 109 –0.142 Dominated –4382 Dominated
SIR-Spheres 30,314 1.086 0.746 329 –0.143 Dominated –4616 Dominated
Sorafenib 32,876 1.335 0.905 2890 0.017 170,117 –2381 170,117
QuiremSpheres 36,662 1.086 0.745 6676 –0.143 Dominated –10,965 Dominated
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Scenario 4: TheraSphere hazard ratio from the Biederman et al. and Van Der Gucht et al.
network meta-analysis scenario
The results presented in Table 35 use the HR derived from the AG’s NMA scenario, which included
the low-quality retrospective studies by Biederman et al.39 and Van Der Gucht et al.40 The patient
population in Biederman et al.39 was particularly mismatched with the others included in this analysis,
as it included only patients with MVI, which appeared to have a substantial impact on the treatment
effect associated with TheraSphere.
A HR of 0.46 versus SIR-Spheres was applied for both OS and PFS outcomes for TheraSphere. Based
on the probabilistic analysis (5000 iterations), TheraSphere is expected to generate an additional 0.507
QALYs compared with lenvatinib, at an additional cost of £4068, producing an ICER of £8017 per
QALY gained, and a NMB of £11,413. TheraSphere was associated with higher costs than SIR-Spheres
owing to the increased disease management costs associated with lower mortality, but it also produced
an additional 0.566 QALYs, yielding an ICER of £6060 per QALY gained.
Further scenario analyses
Table 36 presents a number of other scenarios on the AG base case that explore the impact of
alternative assumptions, including sources of utilities, downstaging to curative therapy, resource use
and survival models.
Scenarios 6 and 10 include the possibility for downstaging; in these scenarios, the distribution of the
three liver-targeted treatments was derived from the SARAH trial.19 Patients who received TACE or
radiation therapy were excluded as these would not be permitted options in this population in UK
practice. Liver transplant was undergone by 1.09% of SIRT patients and 0.46% of sorafenib patients;
1.63% of SIRT patients and 0% of sorafenib patients underwent liver resection, and 3.26% of SIRT
patients and 0.92% of sorafenib patients received ablation therapy.
Only the deterministic results are produced for these analyses.
TABLE 35 Assessment Group scenario 4 results: TheraSphere HR from Biederman et al.39 and Van Der Gucht et al.40
NMA scenario
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
Deterministic scenario 4: TheraSphere HR from Biederman et al. and Van Der Gucht et al. NMA scenario
Lenvatinib 30,005 1.183 0.805
SIR-Spheres 30,107 1.110 0.764 101 –0.040 Dominated –1308 Dominated
Sorafenib 32,082 1.243 0.841 2077 0.036 57,488 –993 Extendedly
dominated
TheraSphere 33,373 1.883 1.297 3368 0.493 6835 11,413 6835
QuiremSpheres 36,503 1.110 0.764 6497 –0.040 Dominated –7705 Dominated
Probabilistic scenario 4: TheraSphere HR from Biederman et al. and Van Der Gucht et al. NMA scenario
Lenvatinib 29,601 1.197 0.822
SIR-Spheres 30,242 1.110 0.764 641 –0.058 Dominated –2387 Dominated
Sorafenib 32,477 1.244 0.843 2876 0.021 140,205 –2260 Extendedly
dominated
TheraSphere 33,670 1.931 1.330 4068 0.507 8017 11,156 8017
QuiremSpheres 36,616 1.111 0.765 7014 –0.058 Dominated –8746 Dominated
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TABLE 36 Further scenario analyses (AG scenarios 5–17)
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
Scenario 5: utilities from lenvatinib TA551124
TheraSphere 29,888 1.110 0.791
Lenvatinib 30,005 1.183 0.846 117 0.055 2113 1546 2113
SIR-Spheres 30,107 1.110 0.791 218 0.000 More costly –218 Extendedly
dominated
Sorafenib 32,082 1.243 0.881 2194 0.091 24,145 532 58,615
QuiremSpheres 36,503 1.110 0.791 6614 0.000 More costly –6614 Extendedly
dominated
Scenario 6: downstaging to curative therapy possible (SARAH19 ITT proportions)
TheraSphere 28,990 1.217 0.842
SIR-Spheres 29,208 1.217 0.842 218 0.000 More costly –218 Extendedly
dominated
Lenvatinib 29,817 1.212 0.826 827 –0.016 Dominated –1292 Dominated
Sorafenib 31,850 1.271 0.862 2860 0.020 142,238 –2256 142,238
QuiremSpheres 35,605 1.217 0.842 6614 0.000 More costly –6614 Extendedly
dominated
Scenario 7: bilobar disease treated in same procedure
TheraSphere 29,159 1.110 0.764
SIR-Spheres 29,364 1.110 0.764 204 0.000 More costly –204 Extendedly
dominated
Lenvatinib 30,005 1.183 0.805 846 0.040 21,026 361 21,026
Sorafenib 32,082 1.243 0.841 2923 0.076 38,274 –632 57,488
QuiremSpheres 35,646 1.110 0.764 6486 0.000 More costly –6486 Extendedly
dominated
Scenario 8: work-up costs from National Schedule of Reference Costs 2017–2018107 (Sirtex assumption)
Lenvatinib 30,005 1.183 0.805
TheraSphere 30,170 1.110 0.764 165 –0.040 Dominated –1372 Dominated
SIR-Spheres 30,389 1.110 0.764 383 –0.040 Dominated –1590 Dominated
Sorafenib 32,082 1.243 0.841 2077 0.036 57,488 –993 57,488
QuiremSpheres 36,864 1.110 0.764 6859 –0.040 Dominated –8066 Dominated
Scenario 9: disease management costs taken from TA551124
Lenvatinib 48,033 1.183 0.805
TheraSphere 48,186 1.110 0.764 152 –0.040 Dominated –1360 Dominated
SIR-Spheres 48,404 1.110 0.764 371 –0.040 Dominated –1578 Dominated
Sorafenib 53,682 1.243 0.841 5649 0.036 156,367 –4565 156,367
QuiremSpheres 54,800 1.110 0.764 6767 –0.040 Dominated –7974 Dominated
continued
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TABLE 36 Further scenario analyses (AG scenarios 5–17) (continued )
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
Scenario 10: low tumour burden/ALBI 1 subgroup including possibility of downstaging
Lenvatinib 31,072 1.404 1.029
TheraSphere 31,467 1.736 1.303 395 0.274 1440 7826 1440
SIR-Spheres 31,713 1.736 1.303 641 0.274 2339 7579 Dominated
Sorafenib 33,007 1.457 1.066 1935 0.037 52,685 –833 Extendedly
dominated
QuiremSpheres 38,377 1.736 1.303 7305 0.274 26,660 915 Dominated
Scenario 11: Gompertz OS
TheraSphere 30,015 1.127 0.776
Lenvatinib 30,066 1.188 0.808 51 0.033 1555 926 1555
SIR-Spheres 30,234 1.127 0.776 218 0.000 More costly –218 Extendedly
dominated
Sorafenib 32,190 1.255 0.849 2174 0.073 29,634 27 52,020
QuiremSpheres 36,630 1.127 0.776 6614 0.000 More costly –6614 Extendedly
dominated
Scenario 12: exponential OS
Lenvatinib 30,239 1.215 0.826
TheraSphere 30,245 1.160 0.798 5 –0.028 Dominated –860 Dominated
SIR-Spheres 30,463 1.160 0.798 224 –0.028 Dominated –1078 Dominated
Sorafenib 32,379 1.285 0.868 2139 0.042 50,493 –868 50,493
QuiremSpheres 36,859 1.160 0.798 6620 –0.028 Dominated –7474 Dominated
Scenario 13: generalised gamma OS (lenvatinib OS equal to sorafenib)
TheraSphere 30,992 1.277 0.875
Lenvatinib 31,148 1.357 0.919 155 0.044 3561 1154 3561
SIR-Spheres 31,211 1.277 0.875 218 0.000 More costly –218 Extendedly
dominated
Sorafenib 32,854 1.357 0.916 1862 0.040 46,103 –650 Extendedly
dominated
QuiremSpheres 37,607 1.277 0.875 6614 0.000 More costly –6614 Extendedly
dominated
Scenario 14: log-normal OS (lenvatinib OS equal to sorafenib)
TheraSphere 30,208 1.156 0.795
SIR-Spheres 30,426 1.156 0.795 218 0.000 More costly –218 Extendedly
dominated
Lenvatinib 31,480 1.408 0.952 1273 0.158 8078 3454 8078
Sorafenib 33,187 1.408 0.949 2979 0.154 19,311 1649 Extendedly
dominated
QuiremSpheres 36,822 1.156 0.795 6614 0.000 More costly –6614 Extendedly
dominated
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Table 37 presents the results of the base-case and selected scenario analyses in terms of their effect
on the NMB ranking of the five technologies at list price. This shows lenvatinib to be consistently
ranked first in terms of incremental NMB, except in those scenarios that use more favourable
assumptions in favour of SIRT. As SIRT produces QALYs above the WTP threshold, increasing the
proportion of patients who fail work-up (scenario 17) and do not go on to receive SIRT increases its
cost-effectiveness, as overall costs are reduced and the more cost-effective QALYs produced on BSC
and sorafenib are up-weighted.
Deterministic sensitivity analysis
Results of the DSAs are presented in Figures 21–25 for the AG base-case scenario and the four
scenarios presented in Scenario analyses. The tornado diagrams present the 10 most influential
parameters in each analysis. SIR-Spheres was compared with sorafenib because sorafenib was
considered the most relevant comparator and had direct evidence compared with SIR-Spheres.
TABLE 36 Further scenario analyses (AG scenarios 5–17) (continued )
Intervention
Total Incremental (vs. baseline)
ICER (£) (fully
incremental)Costs (£) Life-years QALYs Costs (£) QALYs ICER (£) NMB (£)
Scenario 15: log-logistic OS (lenvatinib OS equal to sorafenib)
TheraSphere 30,301 1.169 0.804
SIR-Spheres 30,519 1.169 0.804 218 0.000 More costly –218 Extendedly
dominated
Lenvatinib 31,543 1.420 0.960 1242 0.156 7962 3439 7962
Sorafenib 33,249 1.420 0.956 2949 0.153 19,303 1634 Extendedly
dominated
QuiremSpheres 36,915 1.169 0.804 6614 0.000 More costly –6614 Extendedly
dominated
Scenario 16: 5% work-up/no SIRT
Lenvatinib 30,005 1.183 0.805
Sorafenib 32,082 1.243 0.841 2077 0.036 57,488 –993 57,488
TheraSphere 32,603 1.183 0.816 2597 0.011 239,222 –2272 Extendedly
dominated
SIR-Spheres 32,858 1.183 0.816 2852 0.011 262,683 –2526 Extendedly
dominated
QuiremSpheres 39,601 1.183 0.816 9596 0.011 883,746 –9270 Extendedly
dominated
Scenario 17: SIRveNIB21 work-up/no SIRT (28.57%)
TheraSphere 27,898 1.056 0.727
SIR-Spheres 28,090 1.056 0.727 192 0.000 More costly –192 Extendedly
dominated
Lenvatinib 30,005 1.183 0.805 2107 0.078 27,118 224 27,118
Sorafenib 32,082 1.243 0.841 4184 0.114 36,757 –769 57,488
QuiremSpheres 34,232 1.056 0.727 6333 0.000 More costly –6333 Dominated
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TABLE 37 Incremental NMB rankings
Intervention
Incremental NMB rank (vs. baseline)
Base
case S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17
SIR-Spheres 4 4 2 4 4 4 2 3 4 3 2 4 4 3 4 4 4 3
TheraSphere 2 3 1 3 1 3 1 2 3 2 1 3 3 2 3 3 3 2
QuiremSpheres 5 5 5 5 5 5 5 5 5 5 3 5 5 5 5 5 5 5
Lenvatinib 1 1 3 1 2 1 3 1 1 1 4 1 1 1 1 1 1 1
Sorafenib 3 2 4 2 3 2 4 4 2 4 5 2 2 4 2 2 2 4
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FIGURE 21 Tornado diagram: SIR-Spheres vs. sorafenib; base-case analysis (SARAH19 and SIRveNIB21).
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FIGURE 22 Tornado diagram: SIR-Spheres vs. sorafenib; using SARAH19 efficacy data (scenario 1).
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FIGURE 23 Tornado diagram: SIR-Spheres vs. sorafenib; low tumour burden/ALBI 1 subgroup (scenario 2).
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FIGURE 24 Tornado diagram: SIR-Spheres vs. sorafenib; no MVI subgroup (scenario 3).
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FIGURE 25 Tornado diagram: TheraSphere vs. sorafenib; TheraSphere HR from Van Der Gucht et al.40 and Biederman
et al.39 NMA (scenario 4).
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The AG base-case analysis (see Figure 21) was robust to a range of parameters, with the most
influential parameters providing a range of NMBs between approximately –£1600 and £1000, with
the base-case NMB as –£315. The most influential parameters were the health state utilities, the
number of SIRT procedures and the proportion of patients receiving SIRT after work-up. In these
scenarios, SIR-Spheres became cost-effective compared with sorafenib for some of the range of values
of the parameter (i.e. SIR-Spheres had a positive incremental NMB). However, when the confidential
PAS for sorafenib was applied, this was no longer the case.
In scenario 1, with efficacy data based only on SARAH19, varying the parameters in the DSA had a larger
impact on NMB than in the base-case analysis, although the variation remains small (see Figure 22). Similarly
to the base-case analysis, the results were most sensitive to health state utilities and SIRT procedures;
however, in this analysis, OS for sorafenib and SIR-Spheres was also an influential parameter. There were
no scenarios in which SIR-Spheres was estimated to be cost-effective compared with sorafenib.
The most influential parameter in the low tumour burden/ALBI 1 subgroup was OS for both
SIR-Spheres and sorafenib (see Figure 23). SIR-Spheres remained cost-effective compared with
sorafenib over the range of parameters; however, when the confidential PAS for sorafenib was
applied, this was no longer the case.
In the ‘no-MVI’ subgroup, the most influential parameters were the health state utilities and OS for
sorafenib and SIR-Spheres (see Figure 24). There were are no scenarios in which SIR-Spheres was
estimated to be cost-effective compared with sorafenib.
In Figure 25, TheraSphere was compared with sorafenib. In this scenario, the results of the analysis were
robust to the range of parameters, and found TheraSphere to be cost-effective across all scenarios.
Discussion of the independent economic assessment
In the light of the AG’s concerns regarding the relevance of the economic analyses identified in the
review of cost-effectiveness studies and highlighted limitations in the economic evaluations developed
by BTG and Sirtex, the AG developed a de novo health economic model. The AG model evaluated the
three SIRTs and current UK practice for the treatment of advanced HCC in Child–Pugh class A patients
ineligible to receive (or who had previously failed) CTT. Results were generated as fully incremental
ICERs and in terms of incremental NMB, which allows for easier comparison of ‘dominated’ results
with small differences in cost and efficacy. The AG model used a three-state partitioned survival model
approach with a decision tree, which determined the proportion of patients who did not continue on to
receive SIRT following the work-up procedure. The model utilises all currently available RCT evidence to
generate estimates of clinical effectiveness, using data directly drawn from the SARAH19 and SIRveNIB21
trials, and HRs generated in the AG’s NMA.
Based on the AG’s probabilistic base-case analysis at list price, none of the three SIRTs is expected to
be cost-effective at any WTP threshold, being more costly and less effective than lenvatinib. When the
modelled population was limited to only those with a low tumour burden and preserved liver function,
the ICERs for TheraSphere and SIR-Spheres were £17,165 and £18,783 per QALY gained versus the
most cost-effective systemic therapy. The most optimistic ICERs were generated in the scenario
presented for the low tumour burden and preserved liver function in which downstaging to curative
therapy was permitted. In this scenario, the ICERs for TheraSphere and SIR-Spheres decreased to
£1440 and £2339, respectively. However, there was no scenario in which SIRT was predicted to
be cost-effective at a WTP threshold of £30,000 when confidential PAS discounts were included
(see Appendix 17). In all scenarios, QuiremSpheres was not cost-effective compared with other SIRTs
owing to higher work-up and acquisition costs (see below for further discussion of QuiremSpheres in
relation to the limitations of the model).
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The AG scenario 4 (including the Biederman et al.39 and Van Der Gucht et al.40 studies) found
TheraSphere to be cost-effective versus lenvatinib when the confidential PAS prices were used.
However, the AG considers the data used to model comparative effectiveness to be of low quality
and inconsistent with the wider body of evidence on the comparative effectiveness of SIR-Spheres
and TheraSphere. The AG, therefore, does not consider this scenario to represent a realistic estimate
of the relative benefits of TheraSphere.
The results of the AG’s base-case analysis are robust to a wide range of assumptions, reflecting the
completeness and quality of the included studies, and the substantial differences seen in costs and
QALYs between the SIRTs and current UK practice (including confidential PAS). The AG’s analyses
predicted lenvatinib to rank first in terms of NMB in all scenarios (excluding scenario 4), whereas
sorafenib was a cost-effective alternative, producing more QALYs at a higher cost. There are a
number of differences between the AG model and those presented by the companies, which primarily
concern the issues highlighted in the critique of these models in Chapter 5, Review of economic evidence
submitted by companies. Strengths of the AG model include (1) all available high-quality RCT data
were used to model the outcomes of the most relevant patient population to UK practice, (2) analyses
included all appropriate comparators, (3) independent modelling of the costs and outcomes of patients
who receive work-up but were ineligible to receive SIRT and (4) preserved randomisation and greater
internal consistency with regard to the use of subsequent and curative therapies.
Insurmountable limitations in the evidence base meant that the AG was unable to address the
question of the cost-effectiveness of SIRT in patients with early or intermediate HCC. The evidence for
TheraSphere and QuiremSpheres in advanced HCC was extremely limited, and a lack of head-to-head
evidence prevented a meaningful comparison of SIR-Spheres, TheraSphere and QuiremSpheres with
one another in terms of clinical effectiveness. This essentially limits this particular comparison to that
of a cost-minimisation, with a full comparison of the cost-effectiveness of SIRT versus sorafenib and
lenvatinib. Although it is therefore not possible to discern which of the SIRTs offers the best value for
money, the increased cost of the QuiremSpheres work-up procedure meant that it was consistently
positioned last by some way in terms of NMB. The structure of the AG model and a lack of supporting
evidence on the comparative effectiveness of QuiremSpheres, however, meant that there were no
means by which the concept of ‘suboptimal SIRT’, as proposed by Terumo,104 could realistically be
explored. This includes the ostensibly greater selectivity of QuiremScout, and any quantifiable
improvement in treatment effect resulting from optimisation of patient selection.
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Chapter 8 Assessment of factors relevant
to the NHS and other parties
End-of-life considerations
In the early- and intermediate-HCC populations, life expectancy reported in the most recent European
Society For Medical Oncology guidelines155 is > 24 months, with reported expected survival of > 5 years
in the early population and > 2.5 years in the intermediate population. There is insufficient reliable
evidence to indicate whether or not SIRT provides an extension to life of > 3 months.
The NICE end-of-life supplementary advice142 outlines that end-of-life criteria should be applied when
both of the criteria below are satisfied:
l The treatment is indicated for patients with a short life expectancy, normally < 24 months.
l There is sufficient evidence to indicate that the treatment offers an extension to life, normally of at
least an additional 3 months, compared with current NHS treatment.
Undiscounted LYG predicted in the AG’s base-case analysis are presented in Table 38. These indicate
that normal life expectancy for patients ineligible for CTT is < 24 months, with expected mean survival
of 14.72 months on lenvatinib and 15.49 months on sorafenib. This conclusion remains consistent
irrespective of the subgroup considered or the choice of parametric model used to represent OS.
Regarding the criterion relating to > 3 months’ life extension, the AG’s base-case analysis suggests that
SIRT is marginally inferior to both systemic therapies (sorafenib and lenvatinib), indicating that this criterion
is not met. The results for the subgroup with no MVI similarly suggest that sorafenib produces marginally
greater LYG than SIRT. In the low tumour burden/ALBI 1 subgroup, SIRTs are predicted to provide an
extension to life of 2.11 months compared with sorafenib and 2.80 months compared with lenvatinib.
These predicted survival gains, however, exclude potential gains from downstaging. In scenarios conducted
in the low tumour burden/ALBI 1 subgroup that allow for downstaging, predicted survival gains increase to
4.61 months compared with sorafenib and 5.30 months compared with lenvatinib. These predicted gains
are, however, subject to significant uncertainty owing to the small sample sizes and the fact that this is a
post hoc subgroup analysis. There are also very significant uncertainties regarding the plausibility of
downstaging patients in this population.
TABLE 38 Undiscounted survival estimates used in the AG model
Treatment
Survival estimates (months)
AG base case
Low tumour/ALBI 1
subgroup MVI subgroup
No
downstaging
With
downstaging
No
downstaging
With
downstaging
No
downstaging
With
downstaging
Undiscounted LYG: lenvatinib 14.72 15.12 16.98 17.49 15.80 16.14
Undiscounted LYG: sorafenib 15.49 15.89 17.68 18.17 16.49 16.82
Incremental undiscounted
LYG: SIRT vs. lenvatiniba
–0.95 0.11 2.80 5.30 –2.49 –1.51
Incremental undiscounted
LYG: SIRT vs. sorafeniba
–1.73 –0.65 2.11 4.61 –3.18 –2.19
a Each SIRT is associated with the same number of life-years owing to assumed equal efficacy.
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Chapter 9 Discussion
Statement of principal findings
Treatment options vary for patients with unresectable HCC according to the stage of the cancer and
the underlying liver disease. The AG, therefore, considered three distinct unresectable HCC patient
populations, defined with respect to the aim of therapy and eligibility for comparator treatments.
These three populations were as follows: (1) patients eligible for transplant, (2) patients ineligible for
transplant but eligible for CTT and (3) patients ineligible for CTT. These three populations largely
correspond to early-, intermediate- and advanced-stage HCC.
There is a large body of evidence on the clinical effectiveness and safety of SIRT compared with
sorafenib or TACE; seven RCTs, seven prospective comparative studies, five retrospective comparative
studies and one non-comparative case series were included in the review of clinical effectiveness.
However, only two studies were considered to have a low risk of bias, the SARAH19 and SIRveNIB21
RCTs, which both compared SIR-Spheres with sorafenib. These studies enrolled patients with locally
advanced HCC not amenable to curative treatment modalities and ineligible for CTT; the evidence
for the early- and intermediate-HCC populations was significantly more limited. Both RCTs found
no significant difference in OS or PFS between SIR-Spheres and sorafenib, despite a statistically
significantly greater tumour response rate in the SIR-Spheres arm of both trials. The SARAH trial19
reported a significant difference between groups in HRQoL, favouring SIR-Spheres; however, the
proportion of patients who completed the questionnaires was low. AEs, particularly grade ≥ 3 events,
were more frequent in the sorafenib group in both trials. There are some concerns regarding the
generalisability of the results of these two RCTs to the UK HCC population, particularly the SIRveNIB
trial,21 which was conducted in the Asia-Pacific region, where the aetiology and treatment of HCC
differ from those in Europe.
The Sirtex company submission102 selected a subgroup of patients from the SARAH trial19 with ≤ 25%
tumour burden and preserved liver function, defined as having ALBI 1, for the base-case analysis in
its economic analysis. Although results appeared more promising in this subgroup of patients with a
better prognosis, the results of this post hoc subgroup analysis should be prospectively validated
before being considered relevant for clinical practice.
In studies that directly compared the different SIRTs, patients with PVT appeared to have better
survival outcomes with TheraSphere than with SIR-Spheres; however, this result was from a small
retrospective comparative study rated as being at a high risk of bias and, therefore, may not be
reliable. Other studies comparing TheraSphere with SIR-Spheres that were not restricted to patients
with PVT had conflicting results. The only study that compared QuiremSpheres with SIR-Spheres and
TheraSphere was provided by Terumo as an addendum to its submission.104 Clinical outcomes appeared
to be similar between treatment groups; however, this was a very small pilot study with several
methodological limitations.
Three NMA models were produced to represent the three different populations of unresectable HCC
patients described above. Both the NMA in patients eligible for transplant and the NMA in patients
eligible for CTT were not conducted owing to the uncertainty of using SIRT for bridging to transplant
and downstaging in the UK, and a lack of good-quality evidence in patients eligible for CTT.
The base-case NMA was conducted in adults with unresectable HCC who have Child–Pugh class A
liver function and are ineligible for CTT. There were no meaningful differences in OS between
SIR-Spheres, sorafenib and lenvatinib in the per-protocol or ITT populations. All treatments appeared
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to have similar efficacy. There was only one low-quality retrospective study that directly compared
TheraSphere with SIR-Spheres in the base-case population.39 Adding this study as a sensitivity analysis
had a substantial effect on the NMA results: TheraSphere showed a significant improvement in OS
when compared with SIR-Spheres, sorafenib and lenvatinib. However, these results may be biased and
unreliable as they rely on only one low-quality retrospective study.
The limitations in the effectiveness evidence had an important role in shaping the economic analysis
and restricted the focus of the AG’s economic analysis to the population ineligible for CTT; this was
the only population for which there were reliable estimates of the comparative effectiveness of SIRT
with comparator technologies. The structure of the AG’s model was broadly similar to the structures
of the models developed by BTG and Sirtex for this population and was designed around a decision
tree and partitioned survival model. The decision tree was used to model the fact that some patients
eligible to receive SIRT will fail the work-up procedure and will not receive SIRT treatment; in a
scenario analysis, the decision tree was also used to allow a proportion of patients to go on to receive
curative therapies. The partitioned survival model developed was based on three health states: PFS,
progressive disease and death.
The results of the AG’s base-case analysis (probabilistic analysis), which assumed equal efficacy
across all three SIRTs, suggested that TheraSphere is cost saving relative to both SIR-Spheres and
QuiremSpheres. However, the incremental costs between TheraSphere and SIR-Spheres are < £300
and result from the additional cost of angiography required as part of the SIR-Spheres administration
procedure. Pairwise NMB, assuming a £30,000 WTP threshold, for SIR-Spheres compared with
TheraSphere was, therefore, close to zero (–£182). QuiremSpheres is associated with an incremental
cost of £6955 relative to TheraSphere (exclusive of PAS). Pairwise NMB between QuiremSpheres
and TheraSphere in the AG’s base case was –£6599, exclusive of PAS. In the analysis including the
confidential PAS for QuiremScout, QuiremSpheres remained more costly than both TheraSphere
and SIR-Spheres and, as such, the pairwise NMB remained negative (see Appendix 17 for full results).
In a fully incremental analysis, exclusive of the PAS discounts available for QuiremScout, sorafenib,
lenvatinib and regorafenib, lenvatinib was the most cost-effective therapy and dominated TheraSphere
(the lowest-costing SIRT treatment). Predicted NMB for lenvatinib compared with TheraSphere was
–£2154. In a pairwise comparison of sorafenib with TheraSphere, the ICER for sorafenib was £31,974
per QALY, with an estimated NMB of –£150 (implying that TheraSphere is cost-effective compared
with sorafenib at a WTP threshold of £30,000). In a fully incremental analysis inclusive of all
confidential PAS discounts, lenvatinib remained the most cost-effective therapy across all scenarios,
and dominated all three SIRTs, generating greater health benefits at lower costs. In pairwise
comparisons of sorafenib with each SIRT, sorafenib also dominated all three SIRTs. Lenvatinib remained
the most cost-effective option across 15 of the 17 AG scenarios when PAS discounts were included.
The results of the scenario analyses presented at list price showed that SIRTs were more likely to be
cost-effective in the low tumour burden and ALBI 1 subgroup of patients, and when downstaging was
permitted. The results of analyses conducted including PAS discounts for QuiremScout, sorafenib,
lenvatinib and regorafenib, however, showed that the results of the AG’s economic analysis were
robust to a range of alternative parameter values and assumptions, with a negative incremental NMB
predicted for all SIRTs at a £30,000 WTP threshold (see Appendix 17 for details).
The AG’s economic analysis suggests that, although current life expectancy in patients ineligible
for CTT is likely to be < 24 months, the predicted life extension generated by SIRT is likely to be
< 3 months.
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Strengths and limitations of the assessment
The key strengths of this assessment are as follows:
l The reviews of clinical effectiveness and cost-effectiveness were based on comprehensive searches
of the literature, which were supplemented by data identified in recent systematic reviews of
CTT treatments.
l The review of clinical effectiveness evidence included a detailed mapping and quality assessment
of all comparative evidence on SIRT treatments across a range of alternative positions in the
treatment pathway.
l The AG’s economic evaluation includes a fully incremental analysis of the three SIRTs (SIR-Spheres,
TheraSphere and QuiremSpheres) and relevant systemic therapies (sorafenib and lenvatinib) in
patients with CTT-ineligible HCC.
l The AG appropriately accounts for the fact that some patients eligible for SIRT treatment will fail
the work-up procedure and will not go on to receive SIRT. Importantly, it recognises that patients
who fail work-up are different from patients who successfully receive SIRT and tend to have inferior
progression and survival outcomes.
l The AG’s economic analysis includes an exploratory analysis of two potentially plausible prospective
subgroups: (1) low tumour burden/ALBI 1 and (2) no MVI.
l The AG’s economic analysis includes an exploration of the impact of downstaging in CTT-ineligible
patients. The AG economic analysis also avoids double-counting the outcomes of patients who are
downstaged to curative therapies.
The main weaknesses of the assessment are largely a consequence of weaknesses and gaps in the
clinical evidence base:
l There is very limited evidence on the comparative effectiveness of SIRT with CTT in patients with either
early- or intermediate-stage HCC. The AG did not consider the identified clinical evidence sufficient to
produce an economic analysis and, therefore, the presented independent economic assessment covers
only part of the NICE scope. The BTG company submission included an economic analysis of
downstaging in CTT-eligible patients, whereas Sirtex presented a cost-minimisation model.
The limits of the clinical evidence supporting these analyses and uncertainties regarding the
equivalence of SIRT and CTT in this population mean that these analyses may be of limited
relevance for decision-making.
l The AG did not have access to IPD from the SIRveNIB trial;21 instead, PFS and OS outcomes were
replicated using a published algorithm. Although the precision of this replication is likely to be good,
this process may have introduced a small loss of accuracy relative to the use of IPD directly.
Furthermore, the lack of IPD meant that the SIRveNIB trial could not be included in scenario
analyses exploring the low tumour burden/ALBI 1 and no-MVI subgroups.
l Lack of IPD for the REFLECT trial,81 comparing lenvatinib with sorafenib, meant that there were
limited options for including lenvatinib in the economic analysis and the modelled HRs were based
on a subgroup that did not fully align with the population eligible for SIRT. Furthermore, the AG’s
base case makes the assumption of proportional hazards between lenvatinib and sorafenib despite
some evidence presented in previous technology appraisals that this assumption may not hold.
l There was limited evidence on the relative effectiveness of TheraSphere compared with other SIRTs
or systemic therapy, with the limited studies identified all rated as being at a high risk of bias.
l There is no evidence on the comparative effectiveness of QuiremSpheres, with the exception of one
small, methodologically weak pilot study provided as a late addendum by Terumo.
l There is limited evidence on the long-term outcomes of patients who receive therapy with curative
intent. The AG’s analysis and the Sirtex model present data from a historical US cohort study; these
data are now several years old and potentially reflect a broader population of patients with HCC.
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Uncertainties
The main uncertainties associated with the appraisal are as follows:
l The comparative effectiveness of SIRT in patients eligible for transplant or eligible for CTTs, such as
DEB-TACE, TACE and TAE, is highly uncertain, with identified evidence limited to a small number of
mainly observational studies.
l The comparative effectiveness of alternative SIRT (SIR-Spheres, TheraSphere and QuiremSpheres) in
all HCC populations is largely unknown. The limited evidence available suggests that TheraSphere
may be superior to SIR-Spheres for advanced HCC with PVI. The identified evidence is, however,
of very low quality and, therefore, it is unknown whether or not the observed effects are the result
of confounding bias. There is also no evidence on the comparative effectiveness of QuiremSpheres
with any therapy, other than a very small pilot study with several methodological limitations that
was provided as an addendum. This is significant, as QuiremSpheres uses a different work-up
procedure and different radioactive isotope and therefore it is plausible that QuiremSpheres may
have differential effectiveness when compared with SIR-Spheres and TheraSphere.
l The Sirtex submission102 puts forward a subgroup of patients with a low tumour burden and
preserved liver function as a potential subgroup of patients who may benefit from treatment with
SIR-Spheres. This subgroup was, however, not prespecified and the randomisation procedure did
not stratify for these characteristics. The subgroup analysis is also based on very few patients.
The extent of any benefits in this subgroup are, therefore, subject to considerable uncertainty and a
confirmatory study would be required to be confident that the observed benefits are not spurious.
l The role of downstaging in a CTT-ineligible population is currently unclear. In the SARAH trial,19 a
small proportion of patients were successfully downstaged to curative therapies. Advice received by
the AG from clinical experts, however, suggests that downstaging in this population is likely to be
very rare, and it is unclear whether or not the SARAH trial is representative of UK practice in
this regard.
l In the SARAH trial,19 patients with bilobar HCC had each lobe treated in separate SIRT
administrations to avoid the risk of REILD. The Sirtex submission, however, suggests that, in UK
practice, patients with bilobar HCC would have both lobes treated simultaneously. The impact of
sequential versus simultaneous treatment is largely unknown and it is not fully clear what practice
would be adopted in the UK; advice received from the AG’s clinical advisors, however, suggests that
sequential treatment would be more likely to be used in the UK.
l There is currently only limited evidence on the comparative effectiveness of combination therapy
(SIRT combined with a systemic therapy). The searches of trial registration databases completed as
part of the clinical effectiveness review, however, identified that a large RCT, STOP-HCC,74 is set to
report shortly. This RCT compares TheraSphere plus sorafenib with sorafenib alone and will provide
new evidence on this comparison.
l In the NHS, systemic therapies are recommended only for those with Child–Pugh class A liver
function; thus, the current standard of care for those with Child–Pugh class B liver function is BSC.
There is a potential place for SIRT in a Child–Pugh class B7 population, who were represented
in in the SARAH19 and SIRveNIB21 trials. However, there is currently no direct evidence on the
comparative effectiveness of SIRT with BSC in this population, and currently no means of comparing
them indirectly.
DISCUSSION
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Chapter 10 Conclusions
The existing evidence cannot provide decision-makers with clear guidance on the comparativeeffectiveness of treatments in early- and intermediate-stage HCC. All of the identified studies
were rated as being at a high risk of bias and included highly heterogeneous populations, limiting the
conclusions that can be drawn from these results. The results of individual studies varied considerably,
with some showing that CTT was superior to SIRT and vice versa. However, the available evidence
suggests that SIRT may be beneficial in this population, with moderate improvements in PFS and
transplantation rates.
The very limited evidence on the effectiveness of SIRT in early- and intermediate-HCC patients means
that the AG was not able to generate a meaningful analysis of the value of SIRT in these populations.
The focus of the AG’s economic assessment was therefore on the advanced-HCC population who are
ineligible to receive CTT. In this population, two large randomised trials (SARAH19 and SIRveNIB21)
have assessed the comparative effectiveness of SIR-Spheres with sorafenib. The results of these trials
show that SIRT has similar effectiveness to sorafenib; notably, these studies were not designed as
non-inferiority or equivalence trials. The systematic review also identified further evidence from a large
RCT of the comparative effectiveness of the alternative systemic therapy lenvatinib with sorafenib,
as well as observational evidence on the comparative effectiveness of TheraSphere with SIR-Spheres.
The results of these studies were combined in a NMA, which showed no meaningful differences in
OS between SIR-Spheres, sorafenib and lenvatinib. TheraSphere showed a significant improvement
in OS when compared with SIR-Spheres, sorafenib and lenvatinib. However, there were only two
retrospective studies that directly compared TheraSphere and SIR-Spheres and both were rated as
being at a high risk of bias. Therefore, there is considerable uncertainty regarding the efficacy of
TheraSphere, and the AG elected to assume equal efficacy across each SIRT technology in its
base-case analysis.
The AG’s economic analysis showed that SIRTs are very unlikely to be cost-effective up to a threshold
of £30,000 per QALY. The fully incremental analysis, including confidential PAS discounts, showed
that lenvatinib was the most cost-effective therapy, dominating all three SIRTs (i.e. producing more
QALYs at a lower cost). Pairwise comparisons of sorafenib with each SIRTs also showed that sorafenib
dominated all three SIRTs. The results of DSA and scenarios analysis, considering a variety of alternative
assumptions, including the modelling of two alternative subgroups (low tumour burden/ALBI 1 and no
MVI), showed that the results of the AG’s economic analysis were generally robust to alternative
parameter values and assumptions.
The AG’s economic analysis suggests that NICE’s criteria142 for life-extending therapies given at the
end of life are not met for SIRT in the broad advanced population as they do not meet the required
3-month extension to life. In the low tumour burden/ALBI 1 subgroup, there is a possibility that SIRT
treatments may meet this threshold. However, the ICER for the most cost-effective SIRT technology in
this scenario remains > £50,000 when PAS discounts are considered.
Implications for service provision
In the event that SIRT was recommended for use in the NHS, the AG does not anticipate that any
substantial changes to service provision would be required, as SIRT (SIR-Spheres and TheraSphere) is
already routinely administered across a number of specialist liver units.
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Suggested research priorities
As discussed above, no strong conclusions should be drawn in the early- and intermediate-HCC
populations owing to considerable uncertainty in estimates of effectiveness and a high risk of bias.
A priority for further research is, therefore, the conduct of studies in these populations. In designing
any evaluations, careful consideration should be given to the recruited population, and, where possible,
studies should avoid combining these heterogeneous populations as the aims of therapy and range of
treatments available vary considerably. Careful consideration should also be given to the outcomes
measured. Many studies reported on TTP, but this was rarely defined within the study report and there
were concerns regarding whether or not these data had been properly analysed. Few studies also
reported on downstaging outcomes; these potentially play an important role in determining patient
outcomes and downstaging is increasingly becoming a realistic option for some patients with
intermediate-stage HCC.
The low tumour burden and preserved liver function subgroup potentially represents a group of
prospectively identifiable patients for whom SIRT may be beneficial when compared with sorafenib.
However, the evidence in support of these observed benefits is weak, because the observed results are
based on a post hoc analysis of the SARAH trial,19 which included only a small proportion of the total
number of recruited patients. Future work considering this subgroup may, therefore, be useful. Of
priority would be a similar analysis of the results of the SIRveNIB trial;21 this could not be undertaken
as part of the current appraisal as IPD were unavailable. A confirmatory trial in this subgroup may also
be desirable depending on the results of any analysis of the SIRveNIB trial.21
There is currently only very limited evidence on the comparative effectiveness of the three SIRTs with
one another. Future randomised prospective studies evaluating the alternative SIRTs would, therefore,
be useful.
CONCLUSIONS
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Appendix 1 Search strategies for clinical
effectiveness and cost-effectiveness
The search strategies below were used to identify studies for the systematic reviews of the clinicaleffectiveness and cost-effectiveness of SIRT.
Database search strategies
MEDLINE all
Includes Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and
Ovid MEDLINE.
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1946 to 25 January 2019.
Date searched: 28 January 2019.
Records retrieved: 1790.
Search strategy
1. Carcinoma, Hepatocellular/ (77,414)
2. Liver Neoplasms/ (137,452)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (131,703)
4. hepatocarcinoma$.ti,ab. (3749)
5. hepatoma$.ti,ab. (27,351)
6. or/1-5 (207,214)
7. (Therasphere$ or Thera-sphere$).ti,ab. (66)
8. (SIR-Sphere$ or SIRSphere$).ti,ab. (100)
9. (QuiremSphere$ or Quirem-Sphere$).ti,ab. (0)
10. or/7-9 (142)
11. 6 and 10 (127)
12. Microspheres/ (27,127)
13. (microsphere$ or sphere$).ti,ab. (67,569)
14. (microbead$ or bead$).ti,ab. (49,738)
15. or/12-14 (123,972)
16. Yttrium Radioisotopes/ (2861)
17. Yttrium/ (2899)
18. Yttrium Isotopes/ (708)
19. (Yttrium$ or 90Yttrium$ or Y90 or Y-90 or 90Y or 90-Y).ti,ab. (8538)
20. Holmium/ (806)
21. (Holmium$ or 166Holmium$ or Ho-166 or Ho166 or 166Ho or 166-Ho).ti,ab. (2939)
22. Radiopharmaceuticals/ (47,137)
23. or/16-22 (60,317)
24. 15 and 23 (1616)
25. ((radioactiv$ or radio-activ$ or radionuclide$ or radio-nuclide$ or radioisotope$ or radio-isotope$
or radiolabel$ or radio-label$ or radiopharmaceutic$ or radio-pharmaceutic$) adj2 (sphere$ or
microsphere$ or bead$ or microbead$)).ti,ab. (4140)
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26. (radiomicrosphere$ or radio-microsphere$).ti,ab. (31)
27. or/24-26 (5660)
28. 6 and 27 (1020)
29. Brachytherapy/ (18,640)
30. (brachytherap$ or brachy-therap$ or microbrachytherap$).ti,ab. (16,214)
31. Embolization, Therapeutic/ (29,974)
32. or/29-31 (53,284)
33. 32 and (23 or 25 or 26) (1603)
34. 6 and 33 (815)
35. (radioemboli$ or radio-emboli$ or radioembolotherap$ or radio-embolotherap$).ti,ab. (1365)
36. TARE.ti,ab. (158)
37. (internal$ adj3 (radiation$ or radiotherap$ or radio therap$ or radionuclide$ or radio-nuclide$ or
radioisotope$ or radio-isotope$)).ti,ab. (2182)
38. ((intra-arterial$ or intraarterial$) adj3 (radiation$ or radiotherap$ or radio therap$ or radionuclide$
or radio-nuclide$ or radioisotope$ or radio-isotope$)).ti,ab. (276)
39. ((intra-arterial$ or intraarterial$) adj2 (brachytherap$ or brachy-therap$)).ti,ab. (19)
40. SIRT.ti,ab. (1120)
41. (SIR adj2 (therap$ or treatment$)).ti,ab. (80)
42. (radiation adj2 (segmentectom$ or lobectom$)).ti,ab. (32)
43. or/35-42 (4675)
44. 6 and 43 (1675)
45. 11 or 28 or 34 or 44 (1978)
46. exp animals/not humans/ (4,541,052)
47. 45 not 46 (1915)
48. limit 47 to yr = “2000 -Current” (1790).
Key:
l / = indexing term [Medical Subject Heading (MeSH)]
l exp = exploded indexing term (MeSH)
l $ = truncation
l ti,ab = terms in either title or abstract fields
l adj3 = terms within three words of each other (any order).
EMBASE
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1974 to 25 January 2019.
Date searched: 28 January 2019.
Records retrieved: 3440.
Search strategy
1. liver cell carcinoma/ (137,127)
2. liver cancer/ (28,908)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (185,054)
4. hepatocarcinoma$.ti,ab. (4972)
5. hepatoma$.ti,ab. (30,720)
6. or/1-5 (242,887)
7. (Therasphere$ or thera-sphere$).ti,ab,dv. (320)
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8. (SIR-Sphere$ or SIRSphere$).ti,ab,dv. (479)
9. (QuiremSphere$ or Quirem-Sphere$).ti,ab,dv. (2)
10. brachytherapy device/ (555)
11. or/7-10 (1167)
12. 6 and 11 (487)
13. microsphere/ (28,744)
14. (microsphere$ or sphere$).ti,ab. (73,618)
15. (microbead$ or bead$).ti,ab. (71,652)
16. or/13-15 (148,521)
17. yttrium/ (4631)
18. yttrium 90/ (7567)
19. (Yttrium$ or 90Yttrium$ or Y90 or Y-90 or 90Y or 90-Y).ti,ab. (11,105)
20. holmium/ (1495)
21. (Holmium$ or 166Holmium$ or Ho-166 or Ho166 or 166Ho or 166-Ho).ti,ab. (4761)
22. radiopharmaceutical agent/ (26,611)
23. or/17-22 (46,979)
24. 16 and 23 (2924)
25. radioactive microsphere/ (937)
26. ((radioactiv$ or radio-activ$ or radionuclide$ or radio-nuclide$ or radioisotope$ or radio-isotope$
or radiolabel$ or radio-label$ or radiopharmaceutic$ or radio-pharmaceutic$) adj2 (sphere$ or
microsphere$ or bead$ or microbead$)).ti,ab. (4430)
27. (radiomicrosphere$ or radio-microsphere$).ti,ab. (39)
28. or/24-27 (7517)
29. 6 and 28 (1922)
30. brachytherapy/ (34,809)
31. (brachytherap$ or brachy-therap$ or microbrachytherap$).ti,ab. (27,633)
32. artificial embolization/ (6954)
33. or/30-32 (44,694)
34. 33 and (23 or 25 or 26 or 27) (869)
35. 6 and 34 (221)
36. radioembolization/ (1554)
37. selective internal radiation.dq. (258)
38. intra arterial brachytherapy.dq. (1)
39. transarterial radioembolization.dq. (72)
40. (radioemboli$ or radio-emboli$ or radioembolotherap$ or radio-embolotherap$).ti,ab. (2887)
41. TARE.ti,ab. (416)
42. (internal$ adj3 (radiation$ or radiotherap$ or radio-therap$ or radionuclide$ or radio-nuclide$ or
radioisotope$ or radio-isotope$)).ti,ab. (3166)
43. ((intra-arterial$ or intraarterial$) adj3 (radiation$ or radiotherap$ or radio-therap$ or radionuclide$
or radio-nuclide$ or radioisotope$ or radio-isotope$)).ti,ab. (363)
44. ((intra-arterial$ or intraarterial$) adj2 (brachytherap$ or brachy-therap$)).ti,ab. (18)
45. SIRT.ti,ab. (2238)
46. (SIR adj2 (therap$ or treatment$)).ti,ab. (185)
47. (radiation adj2 (segmentectom$ or lobectom$)).ti,ab. (77)
48. or/36-47 (8358)
49. 6 and 48 (3229)
50. 12 or 29 or 35 or 49 (3651)
51. (animal/or animal experiment/or animal model/or animal tissue/or nonhuman/) not exp
human/ (5,653,185)
52. 50 not 51 (3560)
53. limit 52 to yr = “2000 -Current” (3440).
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Key:
l / = indexing term (Emtree heading)
l exp = exploded indexing term (Emtree heading)
l $ = truncation
l ti,ab = terms in either title or abstract fields
l dv = terms in the device trade name field
l dq = terms in the candidate term word field
l adj3 = terms within three words of each other (any order).
Cumulative Index to Nursing and Allied Health Literature Plus
Via EBSCOhost (www.ebscohost.com/).
Date range searched: inception to 28 January 2019.
Date searched: 28 January 2019.
Records retrieved: 724.
Search strategy
S1 (MH “Carcinoma, Hepatocellular”) (7801)
S2 (MH “Liver Neoplasms”) (12,189)
S3 TI ((liver or hepato* or hepatic*) N3 (carcinoma* or cancer* or neoplas* or tumour* or tumor* or
malign*)) OR AB ((liver or hepato* or hepatic*) N3 (carcinoma* or cancer* or neoplas* or tumour* or
tumor* or malign*)) (14,708)
S4 TI hepatocarcinoma* OR AB hepatocarcinoma* (173)
S5 TI hepatoma* OR AB hepatoma* (649)
S6 S1 OR S2 OR S3 OR S4 OR S5 (20,300)
S7 TI (Therasphere* or Thera-sphere*) OR AB (Therasphere* or Thera-sphere*) (19)
S8 TI (SIR-Sphere* or SIRSphere*) OR AB (SIR-Sphere* or SIRSphere*) (33)
S9 TI (QuiremSphere* or Quirem-Sphere*) OR AB (QuiremSphere* or Quirem-Sphere*) (0)
S10 S7 OR S8 OR S9 (46)
S11 S6 AND S10 (42)
S12 TI (microsphere* or sphere*) OR AB (microsphere* or sphere*) (3575)
S13 TI (microbead* or bead*) OR AB (microbead* or bead*) (2272)
S14 S12 OR S13 (5795)
S15 (MH “Radioisotopes”) (3321)
S16 TI (Yttrium* or 90Yttrium* or Y90 or Y-90 or 90Y or 90-Y) OR AB (Yttrium* or 90Yttrium* or
Y90 or Y-90 or 90Y or 90-Y) (1061)
S17 TI (Holmium* or 166Holmium* or Ho-166 or Ho166 or 166Ho or 166-Ho) OR AB (Holmium*
or 166Holmium* or Ho-166 or Ho166 or 166Ho or 166-Ho) (281)
S18 (MH “Radiopharmaceuticals”) (6050)
S19 S15 OR S16 OR S17 OR S18 (9807)
S20 S14 AND S19 (356)
S21 TI ((radioactiv* or radio-activ* or radionuclide* or radio-nuclide* or radioisotope* or radio-
isotope* or radiolabel* or radio-label* or radiopharmaceutic* or radio-pharmaceutic*) N2 (sphere*
or microsphere* or bead* or microbead*)) OR AB ((radioactiv* or radio-activ* or radionuclide* or
radio-nuclide* or radioisotope* or radio-isotope* or radiolabel* or radio-label* or radiopharmaceutic*
or radio-pharmaceutic*) N2 (sphere* or microsphere* or bead* or microbead*)) (104)
S22 TI (radiomicrosphere* or radio-microsphere*) OR AB (radiomicrosphere* or
radio-microsphere*) (1)
S23 S20 OR S21 OR S22 (440)
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S24 S6 AND S23 (261)
S25 (MH “Brachytherapy”) (3045)
S26 TI (brachytherap* or brachy-therap* or microbrachytherap*) OR AB (brachytherap* or
brachy-therap* or microbrachytherap*) (2956)
S27 (MH “Embolization, Therapeutic”) (5975)
S28 S25 OR S26 OR S27 (10,145)
S29 S19 OR S21 OR S22 (9890)
S30 S28 AND S29 (603)
S31 S6 AND S30 (309)
S32 (MH “Radioembolization”) (29)
S33 TI ((radioemboli* or radio-emboli* or radioembolotherap* or radio-embolotherap*) OR AB
((radioemboli* or radio-emboli* or radioembolotherap* or radio-embolotherap*) (654)
S34 TI TARE OR AB TARE (49)
S35 TI (internal* N3 (radiation* or radiotherap* or radio-therap* or radionuclide* or radio-nuclide*
or radioisotope* or radio-isotope*)) OR AB (internal* N3 (radiation* or radiotherap* or radio-therap*
or radionuclide* or radio-nuclide* or radioisotope* or radio-isotope*)) (327)
S36 TI ((intra-arterial* or intraarterial*) N3 (radiation* or radiotherap* or radio-therap* or
radionuclide* or radio-nuclide* or radioisotope* or radio-isotope*)) OR AB ((intra-arterial* or
intraarterial*) N3 (radiation* or radiotherap* or radio-therap* or radionuclide* or radio-nuclide* or
radioisotope* or radio-isotope*)) (45)
S37 TI ((intra-arterial* or intraarterial*) N2 (brachytherap* or brachy-therap*)) OR AB ((intra-arterial*
or intraarterial*) N2 (brachytherap* or brachy-therap*)) (5)
S38 TI SIRT OR AB SIRT (187)
S39 TI (SIR N2 (therap* or treatment*)) OR AB (SIR N2 (therap* or treatment*)) (37)
S40 TI (radiation N2 (segmentectom* or lobectom*)) OR AB (radiation N2 (segmentectom*
or lobectom*)) (15)
S41 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 (1140)
S42 S6 AND S41 (639)
S43 S11 OR S24 OR S31 OR S42 (727)
S44 TI (animal or animals or rat or rats or mouse or mice or rodent or rodents or porcine or
murine or sheep or lamb or lambs or ewe or ewes or pig or pigs or piglet or piglets or sow or sows
or minipig or minipigs or rabbit or rabbits or kitten or kittens or dog or dogs or puppy or puppies or
monkey or monkeys or horse or horses or foal or foals or equine or calf or calves or cattle or heifer
or heifers or hamster or hamsters or chicken or chickens or livestock or alpaca* or llama*) (87,260)
S45 S43 NOT S44 (724)
S46 S43 NOT S44
Limiters - Published Date: 20000101-20191231 (724).
Key:
l MH = indexing term (CINAHL heading)
l * = truncation
l TI = terms in the title
l AB = terms in the abstract
l N3 = terms within three words of each other (any order).
Science Citation Index
Via Web of Science, Clarivate Analytics (https://clarivate.com/).
Date range searched: 1900 to 25 January 2019.
Date searched: 28 January 2019.
Records retrieved: 2242.
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Search strategy
# 38 2242 #35 NOT #36
Indexes=SCI-EXPANDED Timespan=2000-2019
# 37 2347 #35 NOT #36
# 36 2,811,336 TI=(animal or animals or rat or rats or mouse or mice or rodent or rodents or
porcine or murine or sheep or lamb or lambs or ewe or ewes or pig or pigs or piglet or piglets or
sow or sows or minipig or minipigs or rabbit or rabbits or kitten or kittens or dog or dogs or puppy
or puppies or monkey or monkeys or horse or horses or foal or foals or equine or calf or calves or
cattle or heifer or heifers or hamster or hamsters or chicken or chickens or livestock or alpaca*
or llama*)
# 35 2419 #34 OR #24 OR #20 OR #9
# 34 2106 #33 AND #4
# 33 7874 #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25
# 32 48 TS=(radiation NEAR/2 (segmentectom* or lobectom*))
# 31 205 TS=(SIR NEAR/2 (therap* or treatment*))
# 30 1676 TS=SIRT
# 29 20 TS=((intra-arterial* or intraarterial*) NEAR/2 (brachytherap* or brachy-therap*))
# 28 289 TS=((intra-arterial* or intraarterial*) NEAR/3 (radiation* or radiotherap* or radio-therap*
or radionuclide* or radio-nuclide* or radioisotope* or radio-isotope*))
# 27 3822 TS=(internal* NEAR/3 (radiation* or radiotherap* or radio-therap* or radionuclide* or
radio-nuclide* or radioisotope* or radio-isotope*))
# 26 883 TS=TARE
# 25 2096 TS=(radioemboli* or radio-emboli* or radioembolotherap* or radio-embolotherap*)
# 24 263 #23 AND #4
# 23 533 #22 AND #21
# 22 47,345 #18 OR #17 OR #15
# 21 24,888 TS=(brachytherap* or brachy-therap*or microbrachytherap*)
# 20 1517 #19 AND #4
# 19 4871 #18 OR #17 OR #16
# 18 19 TS=(radiomicrosphere* or radio-microsphere*)
# 17 2262 TS=((radioactiv* or radio-activ* or radionuclide* or radio-nuclide* or radioisotope* or
radio-isotope* or radiolabel* or radio-label* or radiopharmaceutic* or radio-pharmaceutic*) NEAR/2
(sphere* or microsphere* or bead* or microbead*))
# 16 2721 #15 AND #12
# 15 45,198 #14 OR #13
# 14 7124 TS=(Holmium* or 166Holmium* or Ho-166 or Ho166 or 166Ho or 166-Ho)
# 13 38,768 TS=(Yttrium* or 90Yttrium* or Y90 or Y-90 or 90Y or 90-Y)
# 12 310,417 #11 OR #10
# 11 81,252 TS=(microbead* or bead*)
# 10 235,358 TS=(microsphere* or sphere*)
# 9 216 #8 AND #4
# 8 283 #7 OR #6 OR #5
# 7 0 TS=(QuiremSphere* or Quirem-Sphere*)
# 6 172 TS=(SIR-Sphere* or SIRSphere*)
# 5 145 TS=(Therasphere* or Thera-sphere*)
# 4 199,180 #3 OR #2 OR #1
# 3 31,512 TS=(hepatoma*)
# 2 3551 TS=(hepatocarcinoma*)
# 1 173,805 TS=((liver or hepato* or hepatic*) NEAR/3 (carcinoma* or cancer* or neoplas* or
tumour* or tumor* or malign*)).
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Key:
l TS = topic tag; searches in title, abstract, author keywords and keywords plus fields
l TI = search in title field
l * = truncation
l NEAR/2 = terms within two words of each other (any order).
Cochrane Central Register of Controlled Trials
Via Wiley (http://onlinelibrary.wiley.com/).
Date range searched: issue 1 of 12, January 2019.
Date searched: 28 January 2019.
Records retrieved: 144.
The strategy below was used to search both the Cochrane Central Register of Controlled Trials and
the Cochrane Database of Systematic Reviews.
Search strategy
#1 MeSH descriptor: [Carcinoma, Hepatocellular] this term only (1483)
#2 MeSH descriptor: [Liver Neoplasms] this term only (2218)
#3 ((liver or hepato* or hepatic*) near/3 (carcinoma* or cancer* or neoplas* or tumour* or tumor*
or malign*)):ti,ab,kw (6211)
#4 hepatocarcinoma*:ti,ab,kw (57)
#5 hepatoma*:ti,ab,kw (119)
#6 [OR #1-#5] (6287)
#7 (Therasphere* or Thera next sphere*):ti,ab,kw (9)
#8 (SIRSphere* or SIR next Sphere*):ti,ab,kw (43)
#9 (QuiremSphere* or Quirem next Sphere*):ti,ab,kw (0)
#10 [OR #7-#9] (52)
#11 #6 AND #10 (42)
#12 MeSH descriptor: [Microspheres] this term only (216)
#13 (microsphere* or sphere*):ti,ab,kw (1202)
#14 (microbead* or bead*):ti,ab,kw (948)
#15 [OR #12-#14] (2109)
#16 MeSH descriptor: [Yttrium Radioisotopes] this term only (78)
#17 MeSH descriptor: [Yttrium] this term only (123)
#18 MeSH descriptor: [Yttrium Isotopes] this term only (8)
#19 (Yttrium* or 90Yttrium* or “Y90” or “Y-90” or “90Y” or “90-Y”):ti,ab,kw (1147)
#20 MeSH descriptor: [Holmium] this term only (27)
#21 (Holmium* or 166Holmium* or “Ho-166” or “Ho166” or “166Ho” or “166-Ho”):ti,ab,kw (334)
#22 MeSH descriptor: [Radiopharmaceuticals] this term only (1425)
#23 [OR #16-#22] (2844)
#24 #15 AND #23 (117)
#25 ((radioactiv* or (radio next activ*) or radionuclide* or (radio next nuclide*) or radioisotope* or
(radio next isotope*) or radiolabel* or (radio next label*) or radiopharmaceutic* or (radio next
pharmaceutic*)) near/2 (sphere* or microsphere* or bead* or microbead*)):ti,ab,kw (15)
#26 (radiomicrosphere* or (radio next microsphere*)):ti,ab,kw (0)
#27 #24 OR #25 OR #26 (123)
#28 #6 AND #27 (94)
#29 MeSH descriptor: [Brachytherapy] this term only (653)
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#30 (brachytherap* or brachy next therap* or microbrachytherap*):ti,ab,kw (1583)
#31 MeSH descriptor: [Embolization, Therapeutic] this term only (340)
#32 [OR #29-#31] (1919)
#33 #32 AND (#23 OR #25 OR #26) (46)
#34 #6 AND #33 (21)
#35 (radioemboli* or (radio next emboli*) or radioembolotherap* or (radio next embolotherap*)):ti,
ab,kw (95)
#36 TARE:ti,ab,kw (105)
#37 (internal* near/3 (radiation* or radiotherap* or (radio next therap*) or radionuclide* or (radio
next nuclide*) or radioisotope* or (radio next isotope*))):ti,ab,kw (116)
#38 ((intraarterial* or (intra next arterial)) near/3 (radiation* or radiotherap* or (radio next therap*)
or radionuclide* or (radio next nuclide*) or radioisotope* or (radio next isotope*))):ti,ab,kw (17)
#39 ((intraarterial* or (intra next arterial*)) near/2 (brachytherap* or (brachy next therap*))):ti,ab,kw (2)
#40 SIRT:ti,ab,kw (99)
#41 (SIR near/2 (therap* or treatment*)):ti,ab,kw (10)
#42 (radiation near/2 (segmentectom* or lobectom*)):ti,ab,kw (1)
#43 [OR #35-#42] (336)
#44 #6 AND #43 (133)
#45 #11 OR #28 OR #34 OR #44 (150)
#46 #11 OR #28 OR #34 OR #44 with Cochrane Library publication date Between Jan 2000 and
Jan 2019, in Cochrane Reviews, Cochrane Protocols (3)
#47 #11 OR #28 OR #34 OR #44 with Publication Year from 2000 to 2019, in Trials (144).
Key:
l MeSH descriptor = indexing term (MeSH)
l * = truncation
l ti,ab,kw = terms in either title or abstract or keyword fields
l near/3 = terms within three words of each other (any order)
l next = terms are next to each other.
Cochrane Database of Systematic Reviews
Via Wiley (http://onlinelibrary.wiley.com/).
Date range searched: issue 1 of 12, January 2019.
Date searched: 28 January 2019.
Records retrieved: 3.
See above under Cochrane Central Register of Controlled Trials for search strategy used.
Database of Abstracts of Reviews of Effects
URL: www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2015.
Date searched: 28 January 2019.
Records retrieved: 13.
The strategy below was used to search all three of the CRD databases: Database of Abstracts of
Reviews of Effects, the HTA database and NHS EED.
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Search strategy
1. MeSH DESCRIPTOR Carcinoma, Hepatocellular (385)
2. MeSH DESCRIPTOR Liver Neoplasms (567)
3. ((liver or hepato* or hepatic*) NEAR3 (carcinoma* or cancer* or neoplas* or tumour* or tumor*
or malign*)) (850)
4. ((carcinoma* or cancer* or neoplas* or tumour* or tumor* or malign*) NEAR3 (liver or hepato*
or hepatic*)) (587)
5. (hepatocarcinoma*) (8)
6. (hepatoma*) (7)
7. #1 OR #2 OR #3 OR #4 OR #5 OR #6 (891)
8. (Therasphere* or Thera-sphere*) (2)
9. (SIR-Sphere* or SIRSphere*) (5)
10. (QuiremSphere* or Quirem-Sphere*) (0)
11. #8 OR #9 OR #10 (5)
12. #7 AND #11 (4)
13. MeSH DESCRIPTOR Microspheres (16)
14. (microsphere* or sphere*) (44)
15. (micro-sphere* or sphere*) (16)
16. (microbead* or bead*) (34)
17. #13 OR #14 OR #15 OR #16 (74)
18. MeSH DESCRIPTOR Yttrium Radioisotopes (16)
19. MeSH DESCRIPTOR Yttrium (1)
20. MeSH DESCRIPTOR Yttrium Isotopes (0)
21. (Yttrium* or 90Yttrium* or Y90 or Y-90 or 90Y or 90-Y) (43)
22. MeSH DESCRIPTOR Holmium (9)
23. (Holmium* or 166Holmium* or Ho-166 or Ho166 or 166Ho or 166-Ho) (43)
24. MeSH DESCRIPTOR Radiopharmaceuticals (276)
25. #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 (350)
26. #17 AND #25 (10)
27. ((radioactiv* or radio-activ* or radionuclide* or radio-nuclide* or radioisotope* or radio-isotope* or
radiolabel* or radio-label* or radiopharmaceutic* or radio-pharmaceutic*) NEAR2 (sphere* or
microsphere* or bead* or microbead*)) (5)
28. ((sphere* or microsphere* or bead* or microbead*) NEAR2 (radioactiv* or radio-activ* or
radionuclide* or radio-nuclide* or radioisotope* or radio-isotope* or radiolabel* or radio-label* or
radiopharmaceutic* or radio-pharmaceutic*)) (3)
29. (radiomicrosphere* or radio-microsphere*) (0)
30. #26 OR #27 OR #28 OR #29 (11)
31. #7 AND #30 (11)
32. MeSH DESCRIPTOR Brachytherapy (133)
33. (brachytherap* or brachy-therap* or microbrachytherap*) (205)
34. MeSH DESCRIPTOR Embolization, Therapeutic (145)
35. #32 OR #33 OR #34 (348)
36. #25 OR #27 OR #28 (351)
37. #35 AND #36 (13)
38. #7 AND #37 (9)
39. (radioemboli* or radio-emboli* or radioembolotherap* or radio-embolotherap*) (17)
40. (TARE) (2)
41. (internal* NEAR3 (radiation* or radiotherap* or radio-therap* or radionuclide* or radio-nuclide* or
radioisotope* or radio-isotope*)) (15)
42. ((radiation* or radiotherap* or radio-therap* or radionuclide* or radio-nuclide* or radioisotope* or
radio-isotope*) NEAR3 internal*) (2)
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43. ((intra-arterial* or intraarterial*) NEAR3 (radiation* or radiotherap* or radio-therap* or
radionuclide* or radio-nuclide* or radioisotope* or radio-isotope*)) (0)
44. ((radiation* or radiotherap* or radio-therap* or radionuclide* or radio-nuclide* or radioisotope* or
radio-isotope*) NEAR3 (intra-arterial* or intraarterial*)) (2)
45. ((intra-arterial* or intraarterial*) NEAR2 (brachytherap* or brachy-therap*)) (0)
46. ((brachytherap* or brachy-therap*) NEAR2 (intra-arterial* or intraarterial*)) (0)
47. (SIRT) (9)
48. (SIR NEAR2 (therap* or treatment*)) (0)
49. ((therap* or treatment*) NEAR2 SIR) (1)
50. (radiation NEAR2 (segmentectom* or lobectom*)) (0)
51. ((segmentectom* or lobectom*) NEAR2 radiation) (0)
52. #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50
OR #51 (34)
53. #7 AND #52 (25)
54. #12 OR #31 OR #38 OR #53 (29)
Key:
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation
l NEAR3 = terms within three words of each other (order specified).
Health Technology Assessment database
URL: www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2018.
Date searched: 28 January 2019.
Records retrieved: 14.
See above under Database of Abstracts of Reviews of Effects for search strategy used.
NHS Economic Evaluations Database
URL: www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2015.
Date searched: 28 January 2019.
Records retrieved: 2.
See above under Database of Abstracts of Reviews of Effects for search strategy used.
EconLit
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1886 to 17 January 2019.
Date searched: 28 January 2019.
Records retrieved: 0.
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Search strategy
1. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (17)
2. hepatocarcinoma$.ti,ab. (0)
3. hepatoma$.ti,ab. (0)
4. or/1-3 (17)
5. (Therasphere$ or Thera-sphere$).ti,ab. (0)
6. (SIR-Sphere$ or SIRSphere$).ti,ab. (0)
7. (QuiremSphere$ or Quirem-Sphere$).ti,ab. (0)
8. 5 or 6 or 7 (0)
9. 4 and 8 (0)
10. (microsphere$ or sphere$).ti,ab. (2659)
11. (microbead$ or bead$).ti,ab. (12)
12. 10 or 11 (2671)
13. (Yttrium$ or 90Yttrium$ or Y90 or Y-90 or 90Y or 90-Y).ti,ab. (3)
14. (Holmium$ or 166Holmium$ or Ho-166 or Ho166 or 166Ho or 166-Ho).ti,ab. (1)
15. 13 or 14 (4)
16. 12 and 15 (0)
17. ((radioactiv$ or radio-activ$ or radionuclide$ or radio-nuclide$ or radioisotope$ or radio-isotope$
or radiolabel$ or radio-label$ or radiopharmaceutic$ or radio-pharmaceutic$) adj2 (sphere$ or
microsphere$ or bead$ or microbead$)).ti,ab. (0)
18. (radiomicrosphere$ or radio-microsphere$).ti,ab. (0)
19. 16 or 17 or 18 (0)
20. 4 and 19 (0)
21. (brachytherap$ or brachy-therap$ or microbrachytherap$).ti,ab. (6)
22. 21 and (15 or 17 or 18) (0)
23. 4 and 22 (0)
24. (radioemboli$ or radio-emboli$ or radioembolotherap$ or radio-embolotherap$).ti,ab. (0)
25. TARE.ti,ab. (2)
26. (internal$ adj3 (radiation$ or radiotherap$ or radio therap$ or radionuclide$ or radio-nuclide$ or
radioisotope$ or radio-isotope$)).ti,ab. (1)
27. ((intra-arterial$ or intraarterial$) adj3 (radiation$ or radiotherap$ or radio therap$ or radionuclide$
or radio-nuclide$ or radioisotope$ or radio-isotope$)).ti,ab. (0)
28. ((intra-arterial$ or intraarterial$) adj2 (brachytherap$ or brachy-therap$)).ti,ab. (0)
29. SIRT.ti,ab. (1)
30. (SIR adj2 (therap$ or treatment$)).ti,ab. (0)
31. (radiation adj2 (segmentectom$ or lobectom$)).ti,ab. (0)
32. or/24-31 (4)
33. 4 and 32 (0)
34. 9 or 20 or 23 or 33 (0).
Key:
l $ = truncation
l ti,ab = terms in either title or abstract fields
l adj3 = terms within three words of each other (any order).
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Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov
URL: https://clinicaltrials.gov/.
Date searched: 1 February 2019.
Records retrieved: 157.
Advanced search screen used. Ten separate searches were used, retrieving 681 records in total, which
were imported into EndNote X9 and deduplicated.
Search strategy
1. 93 studies found for: (Therasphere OR Thera-sphere OR SIR-Sphere OR SIRSphere OR
QuiremSphere OR Quirem-Sphere) | (hepatocellular OR liver OR hepatic) AND (carcinoma OR
cancer OR neoplasm OR tumour OR tumor OR malignancy)
2. 73 studies found for: (Therasphere OR Thera-sphere OR SIR-Sphere OR SIRSphere OR
QuiremSphere OR Quirem-Sphere) | (hepatocarcinoma OR hepatoma)
3. 103 studies found for: (Microsphere OR sphere OR microbead OR bead) AND (Yttrium OR
90Yttrium OR Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR Ho-166 OR
Ho166 OR 166Ho OR 166-Ho) | (hepatocellular OR liver OR hepatic) AND (carcinoma OR cancer
OR neoplasm OR tumour OR tumor OR malignancy)
4. 77 studies found for: (Microsphere OR sphere OR microbead OR bead) AND (Yttrium OR
90Yttrium OR Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR Ho-166 OR
Ho166 OR 166Ho OR 166-Ho) | (hepatocarcinoma OR hepatoma)
5. 38 studies found for: (brachytherapy OR brachy-therapy OR microbrachytherapy) AND (Yttrium
OR 90Yttrium OR Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR Ho-166 OR
Ho166 OR 166Ho OR 166-Ho) | (hepatocellular OR liver OR hepatic) AND (carcinoma OR cancer
OR neoplasm OR tumour OR tumor OR malignancy)
6. 26 studies found for: (brachytherapy OR brachy-therapy OR microbrachytherapy) AND (Yttrium
OR 90Yttrium OR Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR Ho-166 OR
Ho166 OR 166Ho OR 166-Ho) | (hepatocarcinoma OR hepatoma)
7. 123 studies found for: (radioembolisation OR radioembolization OR radio-embolisation OR
radio-embolization OR TARE OR SIRT OR SIR) | (hepatocellular OR liver OR hepatic) AND
(carcinoma OR cancer OR neoplasm OR tumour OR tumor OR malignancy)
8. 94 studies found for: (radioembolisation OR radioembolization OR radio-embolisation OR
radio-embolization OR TARE OR SIRT OR SIR) | (hepatocarcinoma OR hepatoma)
9. 32 studies found for: selective AND internal AND (radiation OR radiotherapy OR radio-therapy) |
(hepatocellular OR liver OR hepatic) AND (carcinoma OR cancer OR neoplasm OR tumour OR
tumor OR malignancy)
10. 22 studies found for: selective AND internal AND (radiation OR radiotherapy OR radio-therapy) |
(hepatocarcinoma OR hepatoma)
World Health Organization International Clinical Trials Registry Platform
URL: www.who.int/ictrp/search/en/.
Date searched: 1 February 2019.
Records retrieved: 68.
Advanced search screen used. Ten separate searches were used, retrieving 103 records in total, which
were imported into EndNote X9 and deduplicated.
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Search strategy
1. Condition: hepatocellular carcinoma OR liver cancer AND Intervention: Therasphere OR
Thera-sphere OR SIR-Sphere OR SIRSphere OR QuiremSphere OR Quirem-Sphere (11 hits)
2. Condition: hepatocarcinoma OR hepatoma AND Intervention: Therasphere OR Thera-sphere OR
SIR-Sphere OR SIRSphere OR QuiremSphere OR Quirem-Sphere (4 hits)
3. Condition: hepatocellular carcinoma OR liver cancer AND Intervention: Microsphere OR sphere
OR Yttrium OR 90Yttrium OR Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR
Ho-166 OR Ho166 OR 166Ho OR 166-Ho 45 records (37 trials)
4. Condition: hepatocarcinoma OR hepatoma AND Intervention: Microsphere OR sphere OR Yttrium
OR 90Yttrium OR Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR Ho-166 OR
Ho166 OR 166Ho OR 166-Ho (6 hits)
5. Condition: hepatocellular carcinoma OR liver cancer AND Intervention: brachytherapy OR
brachy-therapy OR microbrachytherapy (21 hits)
6. Condition: hepatocarcinoma OR hepatoma AND Intervention: brachytherapy OR brachy-therapy
OR microbrachytherapy (6 hits)
7. Condition: hepatocellular carcinoma OR liver cancer AND Intervention: radioembolisation OR
radioembolization OR radio-embolisation OR radio-embolization OR TARE OR SIRT OR SIR
(23 records for 15 trials)
8. Condition: hepatocarcinoma OR hepatoma AND Intervention: radioembolisation OR
radioembolization OR radio-embolisation OR radio-embolization OR TARE OR SIRT OR SIR (2 hits)
9. Condition: hepatocellular carcinoma OR liver cancer AND Intervention: selective internal radiation
OR selective internal radiotherapy OR selective internal radio-therapy (1 hit)
10. Condition: hepatocarcinoma OR hepatoma AND Intervention: selective internal radiation OR
selective internal radiotherapy OR selective internal radio-therapy (0 hits).
European Union Clinical Trials Register
URL: www.clinicaltrialsregister.eu/ctr-search/search.
Date searched: 1 February 2019.
Records retrieved: 62.
Search strategy
1. 3 result(s) found for: hepatocellular carcinoma AND (Therasphere OR Thera-sphere OR SIR-Sphere
OR SIRSphere OR QuiremSphere OR Quirem-Sphere)
2. 3 result(s) found for: liver cancer AND (Therasphere OR Thera-sphere OR SIR-Sphere OR
SIRSphere OR QuiremSphere OR Quirem-Sphere
3. 5 result(s) found for: hepatocellular carcinoma AND (Microsphere OR sphere OR Yttrium OR
90Yttrium OR Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR Ho-166 OR
Ho166 OR 166Ho OR 166-Ho)
4. 12 result(s) found for: liver cancer AND (Microsphere OR sphere OR Yttrium OR 90Yttrium OR
Y90 OR Y-90 OR 90Y OR 90-Y OR Holmium OR 166Holmium OR Ho-166 OR Ho166 OR 166Ho
OR 166-Ho)
5. 1 result(s) found for: hepatocellular carcinoma AND (brachytherapy OR brachy-therapy
OR microbrachytherapy)
6. 7 result(s) found for: liver cancer AND (brachytherapy OR brachy-therapy OR microbrachytherapy)
7. 10 result(s) found for: hepatocellular carcinoma AND (radioembolisation OR radioembolization OR
radio-embolisation OR radio-embolization OR TARE OR SIRT OR SIR)
8. 19 result(s) found for: liver cancer AND (radioembolisation OR radioembolization OR radio-
embolisation OR radio-embolization OR TARE OR SIRT OR SIR)
9. 1 result(s) found for: hepatocellular carcinoma AND selective internal radiation
10. 1 result(s) found for: liver cancer AND selective internal radiation.
DOI: 10.3310/hta24480 Health Technology Assessment 2020 Vol. 24 No. 48
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
161
PROSPERO
URL: www.crd.york.ac.uk/PROSPERO/.
Date searched: 1 February 2019.
Records retrieved: 23.
Search strategy
#1 MeSH DESCRIPTOR Carcinoma, Hepatocellular (107)
#2 MeSH DESCRIPTOR Liver Neoplasms (158)
#3 (liver or hepato* or hepatic*) adj3 (carcinoma* or cancer* or neoplas* or tumour* or tumor*
or malign*) (342)
#4 (carcinoma* or cancer* or neoplas* or tumour* or tumor* or malign*) ADJ3 (liver or hepato*
or hepatic*) (206)
#5 hepatocarcinoma* (8)
#6 hepatoma* (11)
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 (411)
#8 Therasphere* or Thera-sphere* (1)
#9 SIR-Sphere* or SIRSphere* (1)
#10 QuiremSphere* or Quirem-Sphere* (0)
#11 #8 OR #9 OR #10 (1)
#12 #11 AND #7 (1)
#13 MeSH DESCRIPTOR Microspheres (4)
#14 microsphere* or sphere* (87)
#15 microbead* or bead* (33)
#16 #13 OR #14 OR #15 (118)
#17 MeSH DESCRIPTOR Yttrium Radioisotopes (4)
#18 MeSH DESCRIPTOR Yttrium (3)
#19 MeSH DESCRIPTOR Yttrium Isotopes (0)
#20 Yttrium* or 90Yttrium* or Y90 or Y-90 or 90Y or 90-Y (13)
#21 MeSH DESCRIPTOR Holmium (1)
#22 Holmium* or 166Holmium* or Ho-166 or Ho166 or 166Ho or 166-Ho (11)
#23 MeSH DESCRIPTOR Radiopharmaceuticals (10)
#24 #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 (32)
#25 #24 AND #16 (6)
#26 (radioactiv* or radio-activ* or radionuclide* or radio-nuclide* or radioisotope* or radio-isotope*
or radiolabel* or radio-label* or radiopharmaceutic* or radio-pharmaceutic*) adj2 (sphere* or
microsphere* or bead* or microbead*) (0)
#27 (sphere* or microsphere* or bead* or microbead*) adj2 (radioactiv* or radio-activ* or
radionuclide* or radio-nuclide* or radioisotope* or radio-isotope* or radiolabel* or radio-label* or
radiopharmaceutic* or radio-pharmaceutic*) (0)
#28 radiomicrosphere* or radio-microsphere* (0)
#29 #26 OR #27 OR #28 (0)
#30 #25 OR #29 (6)
#31 #30 AND #7 (6)
#32 MeSH DESCRIPTOR Brachytherapy (14)
#33 brachytherap* or brachy-therap* or microbrachytherap* (76)
#34 MeSH DESCRIPTOR Embolization, Therapeutic (27)
#35 #32 OR #33 OR #34 (104)
#36 #24 OR #26 OR #27 OR #28 (32)
#37 #35 AND #36 (0)
#38 #37 AND #7 (0)
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#39 radioemboli* or radio-emboli* or radioembolotherap* or radio-embolotherap* (14)
#40 TARE (10)
#41 internal* adj3 (radiation* or radiotherap* or radio therap* or radionuclide* or radio-nuclide* or
radioisotope* or radio-isotope*) (10)
#42 (radiation* or radiotherap* or radio therap* or radionuclide* or radio-nuclide* or radioisotope*
or radio-isotope*) adj3 internal* (3)
#43 (intra-arterial* or intraarterial*) adj3 (radiation* or radiotherap* or radio therap* or
radionuclide* or radio-nuclide* or radioisotope* or radio-isotope*) (1)
#44 (radiation* or radiotherap* or radio therap* or radionuclide* or radio-nuclide* or radioisotope*
or radio-isotope*) adj3 (intra-arterial* or intraarterial*) (3)
#45 (intra-arterial* or intraarterial*) adj2 (brachytherap* or brachy-therap*) (0)
#46 (brachytherap* or brachy-therap*) adj2 (intra-arterial* or intraarterial*) (0)
#47 SIRT (5)
#48 SIR adj2 (therap* or treatment*) (0)
#49 (therap* or treatment*) adj2 SIR (0)
#50 radiation adj2 (segmentectom* or lobectom*) (0)
#51 (segmentectom* or lobectom*) adj2 radiation (0)
#52 #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR
#50 OR #51 (35)
#53 #52 AND #7 (23)
#54 #53 OR #38 OR #31 OR #12 (23).
Key:
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation
l adj3 = terms within three words of each other (order specified).
National Institute for Health and Care Excellence website
URL: www.nice.org.uk/.
Date searched: 8 May 2019.
Records retrieved: 6.
Search terms entered into main search box of the website:
1. 5 results for Therasphere OR Thera-sphere OR SIR-Sphere OR SIRSphere OR QuiremSphere OR
Quirem-Sphere
2. 10 results for SIRT OR “SIR therapy” OR “SIR treatment” – browsed for any relevant to HCC –
3 results found
3. 5 results for radioembolisation OR radioembolization OR radioembolotherapy OR TARE - browsed
for any relevant to HCC – 2 results found
4. 60 results found for hepatocellular carcinoma – browsed for any relevant to SIRT – 4 results found
Browsed the NICE guidance for liver cancers section of the website (www.nice.org.uk/guidance/
conditions-and-diseases/cancer/liver-cancers): 3 results found relevant to SIRT.
The above search results were deduplicated, leaving six results in total retrieved from searches of
this website.
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NHS Evidence
URL: www.evidence.nhs.uk/.
Date searched: 8 May 2019.
Records retrieved: 18.
The following search strings were entered into the search box with the inbuilt guidance filters box
checked to limit results to guidelines:
1. Therasphere OR “Thera sphere” OR “Thera-sphere” OR “SIR Sphere” OR “SIR-Sphere” OR
SIRSphere OR QuiremSphere OR “Quirem Sphere” OR “Quirem-Sphere”.
Two results.
2. “hepatocellular carcinoma” AND (SIRT OR “SIR therapy” OR “SIR treatment”).
Nine results.
3. “hepatocellular carcinoma” AND (radioembolisation OR radioembolization OR radioembolotherapy
OR TARE).
13 results.
4. “hepatocellular carcinoma” AND (microsphere OR yttrium or holmium).
12 results.
5. “hepatocellular carcinoma” AND (brachytherapy OR microbrachytherapy).
Four results.
The above search results were imported into EndNote X9 and deduplicated, leaving 18 results in total.
Conference Proceedings Citation Index – Science
Via Web of Science, Clarivate Analytics (https://clarivate.com/).
Date range searched: 1990 to 25 January 2019.
Date searched: 28 January 2019.
Records retrieved: 377.
Search strategy
# 38 (377) #35 not #36 Timespan=2000-2019
# 37 (391) #35 NOT #36
# 36 (257,731) TI=(animal or animals or rat or rats or mouse or mice or rodent or rodents or
porcine or murine or sheep or lamb or lambs or ewe or ewes or pig or pigs or piglet or piglets or
sow or sows or minipig or minipigs or rabbit or rabbits or kitten or kittens or dog or dogs or puppy
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or puppies or monkey or monkeys or horse or horses or foal or foals or equine or calf or calves or
cattle or heifer or heifers or hamster or hamsters or chicken or chickens or livestock or alpaca*
or llama*)
# 35 (398) #34 OR #24 OR #20 OR #9
# 34 (316) #33 AND #4
# 33 (1585) #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25
# 32 (4) TS=(radiation NEAR/2 (segmentectom* or lobectom*))
# 31 (24) TS=(SIR NEAR/2 (therap* or treatment*))
# 30 (333) TS=SIRT
# 29 (4) TS=((intra-arterial* or intraarterial*) NEAR/2 (brachytherap* or brachy-therap*))
# 28 (52) TS=((intra-arterial* or intraarterial*) NEAR/3 (radiation* or radiotherap* or radio-therap*
or radionuclide* or radio-nuclide* or radioisotope* or radio-isotope*))
# 27 (755) TS=(internal* NEAR/3 (radiation* or radiotherap* or radio-therap* or radionuclide* or
radio-nuclide* or radioisotope* or radio-isotope*))
# 26 (180) TS=TARE
# 25 (357) TS=(radioemboli* or radio-emboli* or radioembolotherap* or radio-embolotherap*)
# 24 (11) #23 AND #4
# 23 (48) #22 AND #21
# 22 (8066) #18 OR #17 OR #15
# 21 (6589) TS=(brachytherap* or brachy-therap*or microbrachytherap*)
# 20 (193) #19 AND #4
# 19 (606) #18 OR #17 OR #16
# 18 (2) TS=(radiomicrosphere* or radio-microsphere*)
# 17 (153) TS=((radioactiv* or radio-activ* or radionuclide* or radio-nuclide* or radioisotope* or
radio-isotope* or radiolabel* or radio-label* or radiopharmaceutic* or radio-pharmaceutic*) NEAR/2
(sphere* or microsphere* or bead* or microbead*))
# 16 (468) #15 AND #12
# 15 (7929) #14 OR #13
# 14 (1346) TS=(Holmium* or 166Holmium* or Ho-166 or Ho166 or 166Ho or 166-Ho)
# 13 (6670) TS=(Yttrium* or 90Yttrium* or Y90 or Y-90 or 90Y or 90-Y)
# 12 (44,967) #11 OR #10
# 11 (10,567) TS=(microbead* or bead*)
# 10 (34,955) TS=(microsphere* or sphere*)
# 9 (34) #8 AND #4
# 8 (56) #7 OR #6 OR #5
# 7 (0) TS=(QuiremSphere* or Quirem-Sphere*)
# 6 (29) TS=(SIR-Sphere* or SIRSphere*)
# 5 (30) TS=(Therasphere* or Thera-sphere*)
# 4 (22,436) #3 OR #2 OR #1
# 3 (1675) TS=(hepatoma*)
# 2 (305) TS=(hepatocarcinoma*)
# 1 (20,826) TS=((liver or hepato* or hepatic*) NEAR/3 (carcinoma* or cancer* or neoplas* or
tumour* or tumor* or malign*)).
Key:
l TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields
l TI = search in title field
l * = truncation
l NEAR/3 = terms within three words of each other (any order).
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ProQuest Dissertations & Theses A&I
Via ProQuest (www.proquest.com/).
Date searched: 28 January 2019.
Records retrieved: 25.
Six separate searches were run in this database, giving 38 hits in total, which were then imported into
EndNote X9 for deduplication.
1. (TI,AB,IF(Therasphere* OR Thera-sphere*) OR TI,AB,IF(SIR-Sphere* OR SIRSphere*) OR TI,AB,IF
(QuiremSphere* OR Quirem-Sphere*)) AND (TI,AB,IF((liver OR hepato* OR hepatic*) NEAR/3
(carcinoma* OR cancer* OR neoplas* OR tumour* OR tumor* OR malign*)) OR TI,AB,IF
(hepatocarcinoma*) OR TI,AB,IF(hepatoma*)).
0 hits
2. (TI,AB,IF((liver OR hepato* OR hepatic*) NEAR/3 (carcinoma* OR cancer* OR neoplas* OR
tumour* OR tumor* OR malign*)) OR TI,AB,IF(hepatocarcinoma*) OR TI,AB,IF(hepatoma*)) AND
(((TI,AB,IF(microsphere* OR sphere*) OR TI,AB,IF(microbead* OR bead*)) AND (TI,AB,IF(Yttrium*
OR 90Yttrium* OR Y90 OR Y-90 OR 90Y OR 90-Y) OR TI,AB,IF(Holmium* OR 166Holmium*
OR Ho-166 OR Ho166 OR 166Ho OR 166-Ho))) OR TI,AB,IF((radioactiv* OR radio-activ* OR
radionuclide* OR radio-nuclide* OR radioisotope* OR radio-isotope* OR radiolabel* OR radio-label*
OR radiopharmaceutic* OR radio-pharmaceutic*) NEAR/2 (sphere* OR microsphere* OR bead* OR
microbead*)) OR TI,AB,IF(radiomicrosphere* OR radio-microsphere*)) date limit 2000-2019.
15 hits
3. (TI,AB,IF(brachytherap* OR brachy-therap*or microbrachytherap*) AND ((TI,AB,IF(Yttrium* OR
90Yttrium* OR Y90 OR Y-90 OR 90Y OR 90-Y) OR TI,AB,IF(Holmium* OR 166Holmium* OR
Ho-166 OR Ho166 OR 166Ho OR 166-Ho)) OR TI,AB,IF((radioactiv* OR radio-activ* OR
radionuclide* OR radio-nuclide* OR radioisotope* OR radio-isotope* OR radiolabel* OR radio-label*
OR radiopharmaceutic* OR radio-pharmaceutic*) NEAR/2 (sphere* OR microsphere* OR bead*
OR microbead*)) OR TI,AB,IF(radiomicrosphere* OR radio-microsphere*))) AND (TI,AB,IF((liver
OR hepato* OR hepatic*) NEAR/3 (carcinoma* OR cancer* OR neoplas* OR tumour* OR tumor* OR
malign*)) OR TI,AB,IF(hepatocarcinoma*) OR TI,AB,IF(hepatoma*)) date limit 2000-2019.
One hit
4. (TI,AB,IF(radioemboli* OR radio-emboli* OR radioembolotherap* OR radio-embolotherap*) OR
TI,AB,IF(TARE)) AND (TI,AB,IF((liver OR hepato* OR hepatic*) NEAR/3 (carcinoma* OR cancer*
OR neoplas* OR tumour* OR tumor* OR malign*)) OR TI,AB,IF(hepatocarcinoma*) OR TI,AB,IF
(hepatoma*)) date limit 2000-2019.
0 hits
5. (TI,AB,IF(internal* NEAR/3 (radiation* OR radiotherap* OR radio-therap* OR radionuclide* OR
radio-nuclide* OR radioisotope* OR radio-isotope*)) OR TI,AB,IF((intra-arterial* OR intraarterial*)
NEAR/3 (radiation* OR radiotherap* OR radio-therap* OR radionuclide* OR radio-nuclide* OR
radioisotope* OR radio-isotope*))) AND (TI,AB,IF((liver OR hepato* OR hepatic*) NEAR/3 (carcinoma*
OR cancer* OR neoplas* OR tumour* OR tumor* OR malign*)) OR TI,AB,IF(hepatocarcinoma*) OR
TI,AB,IF(hepatoma*)) date limit 2000-2019.
12 hits
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6. (TI,AB,IF((intra-arterial* OR intraarterial*) NEAR/2 (brachytherap* OR brachy-therap*)) OR
TI,AB,IF(SIRT) OR TI,AB,IF(SIR NEAR/2 (therap* OR treatment*)) OR TI,AB,IF(radiation NEAR/2
(segmentectom* OR lobectom*))) AND (TI,AB,IF((liver OR hepato* OR hepatic*) NEAR/3 (carcinoma*
OR cancer* OR neoplas* OR tumour* OR tumor* OR malign*)) OR TI,AB,IF(hepatocarcinoma*) OR
TI,AB,IF(hepatoma*)) date limit 2000-2019.
10 hits
Key:
l TI,AB,IF = terms in title or abstract or keywords field.
l * = truncation
l NEAR/3 = terms within three words of each other (any order).
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Appendix 2 Search strategies for
comparator therapies
MEDLINE all
Includes Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and
Ovid MEDLINE.
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1946 to 3 May 2019.
Date searched: 7 May 2019.
Records retrieved: 449.
Lines 25–104 below are to limit the search to systematic reviews or meta-analyses, taken from a
previous search strategy for finding reviews in MEDLINE developed by the CRD.17 The strategy has
been updated to include new MeSH terms and terminology relating to systematic reviews and NMA.
Search strategy
1. Carcinoma, Hepatocellular/ (78,688)
2. Liver Neoplasms/ (139,353)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (133,795)
4. hepatocarcinoma$.ti,ab. (3798)
5. hepatoma$.ti,ab. (27,491)
6. or/1-5 (209,848)
7. Chemoembolization, Therapeutic/ (5314)
8. (chemo-emboli$ or chemoemboli$).ti,ab. (7127)
9. (chemoembolotherap$ or chemo-embolotherap$).ti,ab. (4)
10. TACE.ti,ab. (4674)
11. cTACE.ti,ab. (87)
12. (DEBTACE or DEB-TACE).ti,ab. (157)
13. (eluting adj2 bead$).ti,ab. (500)
14. DC bead$.ti,ab. (95)
15. or/7-14 (9758)
16. 6 and 15 (7632)
17. Embolization, Therapeutic/ (30,350)
18. (embolization$ or embolisation$ or embolize$ or embolise$ or embolizing$ or embolising$ or
embolotherap$).ti,ab. (46,678)
19. TAE.ti,ab. (2173)
20. or/17-19 (56,670)
21. 6 and 20 (6182)
22. ((locoregional or loco-regional) adj2 (therap$ or intervention$ or treatment$)).ti,ab. (2545)
23. 6 and 22 (914)
24. 16 or 21 or 23 (12,277)
25. “systematic review”/ (105,413)
26. systematic$ review$.ti,ab. (145,034)
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27. meta-analysis as topic/ (16,900)
28. network meta-analysis/ (771)
29. meta-analytic$.ti,ab. (6484)
30. meta-analysis.ti,ab,pt. (150,374)
31. metanalysis.ti,ab. (186)
32. metaanalysis.ti,ab. (1505)
33. meta analysis.ti,ab. (125,205)
34. meta-synthesis.ti,ab. (731)
35. metasynthesis.ti,ab. (277)
36. meta synthesis.ti,ab. (731)
37. meta-regression.ti,ab. (6437)
38. metaregression.ti,ab. (577)
39. meta regression.ti,ab. (6437)
40. (synthes$ adj3 literature).ti,ab. (2958)
41. (synthes$ adj3 evidence).ti,ab. (8954)
42. integrative review.ti,ab. (2486)
43. data synthesis.ti,ab. (10,362)
44. (research synthesis or narrative synthesis).ti,ab. (2491)
45. (systematic study or systematic studies).ti,ab. (11,184)
46. (systematic comparison$ or systematic overview$).ti,ab. (3075)
47. evidence based review.ti,ab. (1870)
48. comprehensive review.ti,ab. (13,081)
49. critical review.ti,ab. (14,731)
50. quantitative review.ti,ab. (638)
51. structured review.ti,ab. (759)
52. realist review.ti,ab. (252)
53. realist synthesis.ti,ab. (173)
54. ((mixed or multiple or indirect) adj treatment$ comparison$).ti,ab. (672)
55. or/25-54 (310,742)
56. review.pt. (2,507,320)
57. medline.ab. (102,777)
58. pubmed.ab. (94,743)
59. cochrane.ab. (69,813)
60. embase.ab. (75,244)
61. cinahl.ab. (23,088)
62. psyc?lit.ab. (913)
63. psyc?info.ab. (28,630)
64. (literature adj3 search$).ab. (52,835)
65. (database$ adj3 search$).ab. (52,049)
66. (bibliographic adj3 search$).ab. (2270)
67. (electronic adj3 search$).ab. (19,250)
68. (electronic adj3 database$).ab. (25,028)
69. (computeri?ed adj3 search$).ab. (3402)
70. (internet adj3 search$).ab. (2953)
71. included studies.ab. (19,694)
72. (inclusion adj3 studies).ab. (14,219)
73. inclusion criteria.ab. (74,336)
74. selection criteria.ab. (28,289)
75. predefined criteria.ab. (1803)
76. predetermined criteria.ab. (1001)
77. (assess$ adj3 (quality or validity)).ab. (71,198)
78. (select$ adj3 (study or studies)).ab. (60,541)
79. (data adj3 extract$).ab. (55,029)
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80. extracted data.ab. (12,670)
81. (data adj2 abstracted).ab. (4907)
82. (data adj3 abstraction).ab. (1520)
83. published intervention$.ab. (160)
84. ((study or studies) adj2 evaluat$).ab. (169,641)
85. (intervention$ adj2 evaluat$).ab. (10,195)
86. confidence interval$.ab. (373,846)
87. heterogeneity.ab. (149,380)
88. pooled.ab. (79,714)
89. pooling.ab. (11,224)
90. odds ratio$.ab. (244,194)
91. (Jadad or coding).ab. (169,547)
92. or/57-91 (1,312,289)
93. 56 and 92 (226,468)
94. review.ti. (419,930)
95. 94 and 92 (121,453)
96. (review$ adj4 (papers or trials or studies or evidence or intervention$ or evaluation$)).ti,ab. (169,610)
97. 55 or 93 or 95 or 96 (514,084)
98. letter.pt. (1,024,828)
99. editorial.pt. (488,807)
100. comment.pt. (769,090)
101. 98 or 99 or 100 (1,719,142)
102. 97 not 101 (502,003)
103. exp animals/not humans/ (4,576,104)
104. 102 not 103 (489,196)
105. 24 and 104 (587)
106. limit 105 to yr = “2010 -Current” (449).
Key:
l / = indexing term (MeSH)
l exp = exploded indexing term (MeSH)
l $ = truncation
l ? = optional wildcard – stands for zero or one character
l ti,ab = terms in either title or abstract fields
l adj3 = terms within three words of each other (any order)
l pt. = publication type.
EMBASE
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1974 to 3 May 2019.
Date searched: 7 May 2019.
Records retrieved: 826.
Lines 26–122 below are to limit the search to systematic reviews or meta-analyses, taken from a
previous search strategy for finding reviews in EMBASE developed by the CRD.17 The strategy has
been updated to include terminology relating to NMA.
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Search strategy
1. liver cell carcinoma/ (139,370)
2. liver cancer/ (29,412)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (188,432)
4. hepatocarcinoma$.ti,ab. (5049)
5. hepatoma$.ti,ab. (30,865)
6. or/1-5 (246,579)
7. chemoembolization/ (14,765)
8. (chemo-emboli$ or chemoemboli$).ti,ab. (12,156)
9. (chemoembolotherap$ or chemo-embolotherap$).ti,ab. (6)
10. TACE.ti,ab. (9522)
11. cTACE.ti,ab. (242)
12. (DEBTACE or DEB-TACE).ti,ab. (563)
13. (eluting adj2 bead$).ti,ab,dq. (1254)
14. DC bead$.ti,ab. (291)
15. or/7-14 (20,050)
16. 6 and 15 (14,882)
17. artificial embolization/ (7551)
18. (embolization$ or embolisation$ or embolize$ or embolise$ or embolizing$ or embolising$ or
embolotherap$).ti,ab. (68,834)
19. arterial embolization/ (2817)
20. TAE.ti,ab. (3247)
21. or/17-20 (72,488)
22. 6 and 21 (6603)
23. ((locoregional or loco-regional) adj2 (therap$ or intervention$ or treatment$)).ti,ab,dq. (4421)
24. 6 and 23 (1805)
25. 16 or 22 or 24 (19,749)
26. systematic$ review$.ti,ab. (179,774)
27. systematic$ literature review$.ti,ab. (13,292)
28. “systematic review”/ (201,979)
29. “systematic review (topic)”/ (23,396)
30. meta analysis/ (161,490)
31. “meta analysis (topic)”/ (39,538)
32. network meta-analysis/ (1756)
33. meta-analytic$.ti,ab. (7595)
34. meta-analysis.ti,ab. (162,787)
35. metanalysis.ti,ab. (506)
36. metaanalysis.ti,ab. (7350)
37. meta analysis.ti,ab. (162,787)
38. meta-synthesis.ti,ab. (789)
39. metasynthesis.ti,ab. (328)
40. meta synthesis.ti,ab. (789)
41. meta-regression.ti,ab. (7989)
42. metaregression.ti,ab. (948)
43. meta regression.ti,ab. (7989)
44. ((mixed or multiple or indirect) adj treatment$ comparison$).ti,ab. (1407)
45. (synthes$ adj3 literature).ti,ab. (3468)
46. (synthes$ adj3 evidence).ti,ab. (9985)
47. (synthes$ adj2 qualitative).ti,ab. (2510)
48. integrative review.ti,ab. (2400)
49. data synthesis.ti,ab. (12,440)
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50. (research synthesis or narrative synthesis).ti,ab. (2765)
51. (systematic study or systematic studies).ti,ab. (11,923)
52. (systematic comparison$ or systematic overview$).ti,ab. (3381)
53. (systematic adj2 search$).ti,ab. (27,836)
54. systematic$ literature research$.ti,ab. (306)
55. (review adj3 scientific literature).ti,ab. (1709)
56. (literature review adj2 side effect$).ti,ab. (17)
57. (literature review adj2 adverse effect$).ti,ab. (3)
58. (literature review adj2 adverse event$).ti,ab. (15)
59. (evidence-based adj2 review).ti,ab. (3512)
60. comprehensive review.ti,ab. (15,039)
61. critical review.ti,ab. (15,755)
62. critical analysis.ti,ab. (7854)
63. quantitative review.ti,ab. (732)
64. structured review.ti,ab. (1026)
65. realist review.ti,ab. (267)
66. realist synthesis.ti,ab. (168)
67. (pooled adj2 analysis).ti,ab. (18,168)
68. (pooled data adj6 (studies or trials)).ti,ab. (2772)
69. (medline and (inclusion adj3 criteria)).ti,ab. (23,061)
70. (search adj (strateg$ or term$)).ti,ab. (34,448)
71. or/26-70 (501,726)
72. medline.ab. (127,052)
73. pubmed.ab. (120,450)
74. cochrane.ab. (90,230)
75. embase.ab. (95,039)
76. cinahl.ab. (26,915)
77. psyc?lit.ab. (992)
78. psyc?info.ab. (26,334)
79. lilacs.ab. (7057)
80. (literature adj3 search$).ab. (67,451)
81. (database$ adj3 search$).ab. (65,231)
82. (bibliographic adj3 search$).ab. (2672)
83. (electronic adj3 search$).ab. (23,469)
84. (electronic adj3 database$).ab. (33,807)
85. (computeri?ed adj3 search$).ab. (4093)
86. (internet adj3 search$).ab. (3981)
87. included studies.ab. (24,875)
88. (inclusion adj3 studies).ab. (17,595)
89. inclusion criteria.ab. (128,601)
90. selection criteria.ab. (33,810)
91. predefined criteria.ab. (2418)
92. predetermined criteria.ab. (1252)
93. (assess$ adj3 (quality or validity)).ab. (94,916)
94. (select$ adj3 (study or studies)).ab. (79,681)
95. (data adj3 extract$).ab. (75,259)
96. extracted data.ab. (16,453)
97. (data adj2 abstracted).ab. (8082)
98. (data adj3 abstraction).ab. (2225)
99. published intervention$.ab. (204)
100. ((study or studies) adj2 evaluat$).ab. (242,677)
101. (intervention$ adj2 evaluat$).ab. (14,361)
102. confidence interval$.ab. (448,335)
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103. heterogeneity.ab. (190,795)
104. pooled.ab. (111,807)
105. pooling.ab. (14,826)
106. odds ratio$.ab. (306,423)
107. (Jadad or coding).ab. (200,705)
108. evidence-based.ti,ab. (130,860)
109. or/72-108 (1,828,351)
110. review.pt. (2,433,403)
111. 109 and 110 (227,600)
112. review.ti. (477,956)
113. 109 and 112 (151,152)
114. (review$ adj10 (papers or trials or trial data or studies or evidence or intervention$ or evaluation$
or outcome$ or findings)).ti,ab. (501,852)
115. (retriev$ adj10 (papers or trials or studies or evidence or intervention$ or evaluation$ or
outcome$ or findings)).ti,ab. (26,856)
116. 71 or 111 or 113 or 114 or 115 (945,210)
117. letter.pt. (1,060,080)
118. editorial.pt. (598,624)
119. 117 or 118 (1,658,704)
120. 116 not 119 (927,165)
121. (animal/or nonhuman/) not exp human/ (5,382,670)
122. 120 not 121 (894,026)
123. 25 and 122 (1410)
124. limit 123 to yr = “2010 -Current” (1141)
125. limit 124 to conference abstracts (315)
126. 124 not 125 (826).
Key:
l / = indexing term (Emtree heading)
l exp = exploded indexing term (Emtree heading)
l $ = truncation
l ? = optional wildcard – stands for zero or one character
l ti,ab = terms in either title or abstract fields
l dq = terms in the candidate term word field
l adj3 = terms within three words of each other (any order)
l pt. = publication type.
Cochrane Database of Systematic Reviews
Via Wiley (http://onlinelibrary.wiley.com/).
Date range searched: issue 5 of 12, May 2019.
Date searched: 7 May 2019.
Records retrieved: 19.
Search strategy
#1 MeSH descriptor: [Carcinoma, Hepatocellular] this term only (1552)
#2 MeSH descriptor: [Liver Neoplasms] this term only (2259)
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#3 ((liver or hepato* or hepatic*) near/3 (carcinoma* or cancer* or neoplas* or tumour* or tumor*
or malign*)):ti,ab,kw (8211)
#4 hepatocarcinoma*:ti,ab,kw (74)
#5 hepatoma*:ti,ab,kw (141)
#6 [OR #1-#5] (8301)
#7 MeSH descriptor: [Chemoembolization, Therapeutic] this term only (289)
#8 (chemo next emboli* or chemoemboli*):ti,ab,kw (1252)
#9 (chemoembolotherap* or chemo next embolotherap*):ti,ab,kw (0)
#10 TACE:ti,ab,kw (991)
#11 cTACE:ti,ab,kw (35)
#12 (DEBTACE or DEB next TACE):ti,ab,kw (46)
#13 (eluting near/2 bead*):ti,ab,kw (100)
#14 DC next bead*:ti,ab,kw (32)
#15 [OR #7-#14] (1478)
#16 #6 and #15 (1332)
#17 MeSH descriptor: [Embolization, Therapeutic] this term only (345)
#18 (embolization* or embolisation* or embolize* or embolise* or embolizing* or embolising* or
embolotherap*):ti,ab,kw (2276)
#19 TAE:ti,ab,kw (3688)
#20 [OR #17-#19] (5858)
#21 #6 and #20 (521)
#22 ((locoregional or loco next regional) near/2 (therap* or intervention* or treatment*)):ti,
ab,kw (426)
#23 #6 and #22 (122)
#24 #16 or #21 or #23 (1641)
#25 #16 or #21 or #23 with Cochrane Library publication date Between Jan 2010 and May 2019,
in Cochrane Reviews, Cochrane Protocols (19).
Key:
l MeSH descriptor = indexing term (MeSH)
l * = truncation
l ti,ab,kw = terms in either title or abstract or keyword fields
l near/3 = terms within three words of each other (any order)
l next = terms are next to each other.
Database of Abstracts of Reviews of Effects
Via www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2015.
Date searched: 7 May 2019.
Records retrieved: 78.
Search strategy
1. MeSH DESCRIPTOR Carcinoma, Hepatocellular IN DARE,HTA (316)
2. MeSH DESCRIPTOR Liver neoplasms IN DARE,HTA (459)
3. (((liver or hepato* or hepatic*) NEAR3 (carcinoma* or cancer* or neoplas* or tumour* or tumor* or
malign*))) IN DARE, HTA (627)
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4. ((carcinoma* or cancer* or neoplas* or tumour* or tumor* or malign*) NEAR3 (liver or hepato* or
hepatic*)) IN DARE, HTA (457)
5. (hepatocarcinoma*) IN DARE, HTA (3)
6. (hepatoma*) IN DARE, HTA (3)
7. #1 OR #2 OR #3 OR #4 OR #5 OR #6 (652)
8. MeSH DESCRIPTOR Chemoembolization, Therapeutic IN DARE,HTA (74)
9. ((chemo-emboli* or chemoemboli*)) IN DARE, HTA (98)
10. (chemoembolotherap* or chemo-embolotherap*) IN DARE, HTA (0)
11. (TACE) IN DARE, HTA (23)
12. (cTACE) IN DARE, HTA (0)
13. (DEBTACE or DEB-TACE) IN DARE, HTA (2)
14. (eluting NEAR2 bead*) IN DARE, HTA (10)
15. (bead* NEAR2 eluting) IN DARE, HTA (0)
16. (DC bead*) IN DARE, HTA (3)
17. #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 (101)
18. #7 AND #17 (98)
19. MeSH DESCRIPTOR Embolization, Therapeutic IN DARE,HTA (106)
20. ((emboli* or embolotherap*)) IN DARE, HTA (759)
21. (TAE) IN DARE, HTA (12)
22. #19 OR #20 OR #21 (767)
23. #7 AND #22 (39)
24. ((locoregional or loco-regional) NEAR2 (therap* or intervention* or treatment*)) IN
DARE, HTA (17)
25. ((therap* or intervention* or treatment*) NEAR2 (locoregional or loco-regional)) IN
DARE, HTA (6)
26. #24 OR #25 (19)
27. #7 AND #26 (7)
28. #18 OR #23 OR #27 (119)
29. (#28) IN DARE, HTA FROM 2010 TO 2019 (96)
30. (#29) IN DARE (78)
31. (#29) IN HTA (18)
Key:
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation
l NEAR3 = terms within three words of each other (order specified).
Health Technology Assessment database
Via www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2018.
Date searched: 7 May 2019.
Records retrieved: 18.
See above under Database of Abstracts of Reviews of Effects for search strategy used.
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PROSPERO
URL: www.crd.york.ac.uk/PROSPERO/.
Date searched: 7 May 2019.
Records retrieved: 63.
Search strategy
#1 MeSH DESCRIPTOR Carcinoma, Hepatocellular (119)
#2 MeSH DESCRIPTOR Liver Neoplasms (172)
#3 (liver or hepato* or hepatic*) adj3 (carcinoma* or cancer* or neoplas* or tumour* or tumor*
or malign*) (378)
#4 (carcinoma* or cancer* or neoplas* or tumour* or tumor* or malign*) adj3 (liver or hepato*
or hepatic*) (224)
#5 hepatocarcinoma* (9)
#6 hepatoma* (12)
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 (452)
#8 MeSH DESCRIPTOR Liver Neoplasms EXPLODE ALL TREES (183)
#9 MeSH DESCRIPTOR Chemoembolization, Therapeutic (14)
#10 chemo-emboli* or chemoemboli* (47)
#11 chemoembolotherap* or chemo-embolotherap* (0)
#12 TACE (41)
#13 cTACE (1)
#14 DEBTACE or DEB-TACE (6)
#15 eluting adj2 bead* (7)
#16 bead* adj2 eluting (0)
#17 DC bead* (0)
#18 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 (59)
#19 #18 AND #7 (54)
#20 #18 NOT #19 (5)
#21 MeSH DESCRIPTOR Chemoembolization, Therapeutic EXPLODE ALL TREES (14)
#22 MeSH DESCRIPTOR Embolization, Therapeutic (29)
#23 embolization* or embolisation* or embolize* or embolise* or embolizing* or embolising*
or embolotherap* (173)
#24 TAE (64)
#25 #22 OR #23 OR #24 (238)
#26 #25 AND #7 (34)
#27 (locoregional or loco-regional) adj2 (therap* or intervention* or treatment*) (20)
#28 #27 AND #7 (6)
#29 #28 OR #26 OR #19 (63).
Key:
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation
l adj3 = terms within three words of each other (order specified).
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Appendix 3 Search strategies for
quality-of-life studies
The aim of the search was to identify published studies reporting utility estimates for patients withHCC or cirrhosis. A search strategy was developed in MEDLINE (Ovid), consisting of terms for
HCC or cirrhosis combined with a study design search filter to restrict retrieval to health state utility
studies.156 Specific named instruments used to measure HRQoL in HCC patients were also included in
the strategy. No language or date restrictions were applied to the searches. The MEDLINE strategy
was translated to run appropriately on the other databases searched.
The following databases were searched in February 2019: MEDLINE all (Ovid), Cost-Effectiveness
Analysis Registry, EMBASE (Ovid), HTA database (CRD databases), NHS EED (CRD databases) and
ScHARRHUD database.
Search results were imported into EndNote X9 and deduplicated.
MEDLINE all
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1946 to 25 February 2019.
Date searched: 26 February 2019.
Records retrieved: 1837.
A study design search filter developed by Arber et al.156 designed to restrict retrieval to health state
utility studies was included in the strategy. The sensitivity-maximising version of the filter was used;
see lines 13–35 below.
Search strategy
1. Carcinoma, Hepatocellular/ (77,760)
2. Liver Neoplasms/ (137,948)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (132,386)
4. hepatocarcinoma$.ti,ab. (3764)
5. hepatoma$.ti,ab. (27,397)
6. or/1-5 (208,036)
7. exp Liver Cirrhosis/ (84,653)
8. (cirrhos$ or cirrhot$).ti,ab. (93,295)
9. ((liver or hepatic$) adj3 fibros$).ti,ab. (22,118)
10. (biliary adj3 (cirrhos$ or cirrhot$ or cholangitis)).ti,ab. (9992)
11. or/7-10 (132,914)
12. 6 or 11 (311,502)
13. quality-adjusted life years/ (10,727)
14. (quality adjusted or adjusted life year$).ti,ab,kf. (14,531)
15. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kf. (9350)
16. (illness state$1 or health state$1).ti,ab,kf. (5828)
17. (hui or hui1 or hui2 or hui3).ti,ab,kf. (1350)
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18. (multiattribute$ or multi attribute$).ti,ab,kf. (814)
19. (utility adj3 (score$1 or valu$ or health$ or cost$ or measur$ or disease$ or mean or gain or gains
or index$)).ti,ab,kf. (13,429)
20. utilities.ti,ab,kf. (6374)
21. (eq-5d or eq5d or eq-5 or eq5 or euro qual or euroqual or euro qual5d or euroqual5d or euro qol
or euroqol or euro qol5d or euroqol5d or euro quol or euroquol or euro quol5d or euroquol5d or
eur qol or eurqol or eur qol5d or eur qol5d or eur?qul or eur?qul5d or euro$ quality of life or
european qol).ti,ab,kf. (9564)
22. (euro$ adj3 (5 d or 5d or 5 dimension$ or 5dimension$ or 5 domain$ or 5domain$)).ti,ab,kf. (3329)
23. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kf. (20,320)
24. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kf. (1743)
25. quality of life/and ((quality of life or qol) adj (score$1 or measure$1)).ti,ab,kf. (10,526)
26. quality of life/and ec.fs. (9271)
27. quality of life/and (health adj3 status).ti,ab,kf. (8092)
28. (quality of life or qol).ti,ab,kf. and Cost-Benefit Analysis/ (11,091)
29. ((qol or hrqol or quality of life).ti,kf. or *quality of life/) and ((qol or hrqol$ or quality of life) adj2
(increas$ or decrease$ or improv$ or declin$ or reduc$ or high$ or low$ or effect or effects or
worse or score or scores or change$1 or impact$1 or impacted or deteriorat$)).ab. (32,288)
30. Cost-Benefit Analysis/and (cost-effectiveness ratio$ and (perspective$ or life expectanc$)).ti,ab,
kf. (2980)
31. *quality of life/and (quality of life or qol).ti. (48,595)
32. quality of life/and ((quality of life or qol) adj3 (improv$ or chang$)).ti,ab,kf. (23,881)
33. quality of life/and health-related quality of life.ti,ab,kf. (27,802)
34. models,economic/ (9191)
35. or/13-34 (146,623)
36. 12 and 35 (1437)
37. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or
weight or weights or weighting or information or data or unit or units or health$ or life or estimat$
or elicit$ or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or
analysis or index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or
states or status)).ti,ab,kf. (29,854)
38. disutili$.ti,ab,kf. (405)
39. (short form$ or shortform$).ti,ab,kf. (29,550)
40. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kf. (4154)
41. or/37-40 (61,362)
42. 12 and 41 (709)
43. 36 or 42 (1801)
44. “European Organization for Research and Treatment of Cancer Quality of Life”.ti,ab. (830)
45. “European Organisation for Research and Treatment of Cancer Quality of Life”.ti,ab. (336)
46. EORTC quality of life.ti,ab. (412)
47. (EORTC QLQ$ or EORTCQLQ$).ti,ab. (3173)
48. (QLQ-C30$ or QLQC30$ or QLQ-C-30$ or QLQC-30$).ti,ab. (3609)
49. (FACT-Hep or FACTHep).ti,ab. (35)
50. FACT-hepatobiliary.ti,ab. (10)
51. Functional Assessment of Cancer Therapy Hepatobiliary.ti,ab. (45)
52. (FHSI-8 or FHSI8).ti,ab. (6)
53. (FACT-G or FACTG).ti,ab. (554)
54. FACT-General.ti,ab. (69)
55. Functional Assessment of Cancer Therapy General.ti,ab. (452)
56. (QLQ-LC$ or QLQLC$).ti,ab. (114)
57. (QLQ-HCC18$ or QLQHCC18$ or QLQ-HCC-18$ or QLQHCC-18$).ti,ab. (11)
58. (QLQ-PAN$ or QLQPAN$).ti,ab. (40)
59. (Gastrointestinal Quality of Life adj (index$ or indices)).ti,ab. (387)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
60. GIQLI$.ti,ab. (329)
61. or/44-60 (5833)
62. 12 and 61 (132)
63. 43 or 62 (1837).
Key:
l / = indexing term (MeSH)
l exp = exploded indexing term (MeSH)
l $ = truncation
l $1 = limited truncation – restricts to one character only after word
l ti,ab = terms in either title or abstract fields
l ec.fs. = floating economics subheading search
l kf = author keywords field
l adj3 = terms within three words of each other (any order).
Cost Effectivieness Analysis Registry
URL: http://healtheconomics.tuftsmedicalcenter.org/cear2n/search/search.aspx.
Date searched: 26 February 2019.
Records retrieved: 124.
The Cost-Effectiveness Analysis Registry was searched using the basic search interface using a set of
simple searches for the population. Duplicates were removed before exporting records.
Search strategy
1. hepatocellular carcinoma (86)
2. hepatocellular cancer (1)
3. hepatocellular neoplasm (0)
4. hepatocellular tumor (0)
5. hepatocellular tumour (0)
6. hepatocellular malignancy (0)
7. hepatocarcinoma (0)
8. hepatoma (1)
9. liver cancer (12)
10. liver carcinoma (0)
11. liver neoplasm (6)
12. liver tumor (2)
13. liver tumour (1)
14. liver malignancy (0)
15. liver cirrhosis (21)
16. liver fibrosis (15).
EMBASE
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1974 to 25 February 2019.
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Date searched: 26 February 2019.
Records retrieved: 2415.
Retrieval was restricted to health state utility studies using terms based on a study design search filter
developed by Arber et al.156 for use in Ovid MEDLINE. This was translated for use in Ovid EMBASE;
see lines 13–42 below.
1. liver cell carcinoma/ (136,695)
2. liver cancer/ (28,869)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (184,856)
4. hepatocarcinoma$.ti,ab. (4990)
5. hepatoma$.ti,ab. (30,679)
6. or/1-5 (242,352)
7. exp liver cirrhosis/ (141,130)
8. (cirrhos$ or cirrhot$).ti,ab. (135,400)
9. ((liver or hepatic$) adj3 fibros$).ti,ab. (36,133)
10. (biliary adj3 (cirrhos$ or cirrhot$ or cholangitis)).ti,ab. (13,554)
11. or/7-10 (194,904)
12. 6 or 11 (388,577)
13. quality adjusted life year/ (23,009)
14. (quality adjusted or adjusted life year$).ti,ab,kw. (21,303)
15. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kw. (17,652)
16. (illness state$1 or health state$1).ti,ab,kw. (10,032)
17. (hui or hui1 or hui2 or hui3).ti,ab,kw. (2027)
18. (multiattribute$ or multi attribute$).ti,ab,kw. (1040)
19. (utility adj3 (score$1 or valu$ or health$ or cost$ or measur$ or disease$ or mean or gain or gains
or index$)).ti,ab,kw. (21,358)
20. utilities.ti,ab,kw. (10,356)
21. (eq-5d or eq5d or eq-5 or eq5 or euro qual or euroqual or euro qual5d or euroqual5d or euro qol
or euroqol or euro qol5d or euroqol5d or euro quol or euroquol or euro quol5d or euroquol5d or
eur qol or eurqol or eur qol5d or eur qol5d or eur?qul or eur?qul5d or euro$ quality of life or
european qol).ti,ab,kw. (17,622)
22. (euro$ adj3 (5 d or 5d or 5 dimension$ or 5dimension$ or 5 domain$ or 5domain$)).ti,ab,
kw. (5144)
23. short form 36/ (24,680)
24. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kw. (34,476)
25. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kw. (2512)
26. quality of life/and ((quality of life or qol) adj (score$1 or measure$1)).ti,ab,kw. (22,209)
27. “quality of life”/and pe.fs. (8003)
28. “quality of life”/and de.fs. (300)
29. “quality of life”/and (health adj3 status).ti,ab,kw. (14,248)
30. (quality of life or qol).ti,ab,kw. and “cost benefit analysis”/ (5014)
31. ((qol or hrqol or quality of life).ti,kw. or *”quality of life”/) and ((qol or hrqol$ or quality of life) adj2
(increas$ or decrease$ or improv$ or declin$ or reduc$ or high$ or low$ or effect or effects or
worse or score or scores or change$1 or impact$1 or impacted or deteriorat$)).ab. (49,462)
32. “cost benefit analysis”/and (cost-effectiveness ratio$ and (perspective$ or life expectanc$)).ti,ab,
kw. (726)
33. *”quality of life”/and (quality of life or qol).ti. (74,391)
34. “quality of life”/and ((quality of life or qol) adj3 (improv$ or chang$)).ti,ab,kw. (65,833)
35. “quality of life”/and health-related quality of life.ti,ab,kw. (50,090)
36. economic model/ (1547)
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37. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or
weight or weights or weighting or information or data or unit or units or health$ or life or estimat$
or elicit$ or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or
analysis or index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or
states or status)).ti,ab,kw. (45,473)
38. disutili$.ti,ab,kw. (802)
39. (short form$ or shortform$).ti,ab,kw. (39,683)
40. short form 12/ (5132)
41. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kw. (7154)
42. or/13-41 (294,270)
43. 12 and 42 (3994)
44. “European Organization for Research and Treatment of Cancer Quality of Life”.ti,ab. (1083)
45. “European Organisation for Research and Treatment of Cancer Quality of Life”.ti,ab. (445)
46. EORTC quality of life.ti,ab. (678)
47. (EORTC QLQ$ or EORTCQLQ$).ti,ab. (6855)
48. (QLQ-C30$ or QLQC30$ or QLQ-C-30$ or QLQC-30$).ti,ab. (7303)
49. (FACT-Hep or FACTHep).ti,ab. (88)
50. FACT-hepatobiliary.ti,ab. (21)
51. Functional Assessment of Cancer Therapy Hepatobiliary.ti,ab. (58)
52. (FHSI-8 or FHSI8).ti,ab. (14)
53. (FACT-G or FACTG).ti,ab. (1231)
54. FACT-General.ti,ab. (112)
55. Functional Assessment of Cancer Therapy General.ti,ab. (678)
56. (QLQ-LC$ or QLQLC$).ti,ab. (254)
57. (QLQ-HCC18$ or QLQHCC18$ or QLQ-HCC-18$ or QLQHCC-18$).ti,ab. (21)
58. (QLQ-PAN$ or QLQPAN$).ti,ab. (77)
59. (Gastrointestinal Quality of Life adj (index$ or indices)).ti,ab. (526)
60. GIQLI$.ti,ab. (550)
61. or/44-60 (11,272)
62. 12 and 61 (236)
63. 43 or 62 (4054)
64. (animal/or animal experiment/or animal model/or animal tissue/or nonhuman/) not exp
human/ (5,661,185)
65. 63 not 64 (3979)
66. limit 65 to conference abstracts (1564)
67. 65 not 66 (2415).
Key:
l / = indexing term (Emtree heading)
l exp = exploded indexing term (Emtree heading)
l $ = truncation
l $1 = limited truncation – restricts to one character only after word
l ti,ab = terms in either title or abstract fields
l pe.fs = floating pharmacoeconomics subheading search
l de.fs = floating device economics subheading search
l kw = terms in the author keywords field
l adj3 = terms within three words of each other (any order).
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Health Technology Assessment database
Via www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2018.
Date searched: 26 February 2019.
Records retrieved: 188.
Search strategy
1. MeSH DESCRIPTOR Carcinoma, Hepatocellular IN NHSEED,HTA (97)
2. MeSH DESCRIPTOR Liver Neoplasms IN NHSEED,HTA (174)
3. ((liver or hepato* or hepatic*) NEAR3 (carcinoma* or cancer* or neoplas* or tumour* or tumor* or
malign*)) IN NHSEED, HTA (343)
4. ((carcinoma* or cancer* or neoplas* or tumour* or tumor* or malign*) NEAR3 (liver or hepato* or
hepatic*)) IN NHSEED, HTA (202)
5. (hepatocarcinoma*) IN NHSEED, HTA (8)
6. (hepatoma*) IN NHSEED, HTA (5)
7. #1 OR #2 OR #3 OR #4 OR #5 OR #6 (365)
8. MeSH DESCRIPTOR Liver Cirrhosis EXPLODE ALL TREES IN NHSEED,HTA (129)
9. (cirrhos* or cirrhot*) IN NHSEED, HTA (340)
10. ((liver or hepatic*) NEAR3 fibros*) IN NHSEED, HTA (43)
11. (fibros* NEAR3 (liver or hepatic*)) IN NHSEED, HTA (11)
12. (biliary NEAR3 (cirrhos* or cirrhot* or cholangitis)) IN NHSEED, HTA (14)
13. ((cirrhos* or cirrhot* or cholangitis) NEAR3 biliary) IN NHSEED, HTA (8)
14. #8 OR #9 OR #10 OR #11 OR #12 OR #13 (350)
15. #7 OR #14 (540)
16. (#15) IN NHSEED (352)
17. (#15) IN HTA (188).
Key:
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation
l NEAR3 = terms within three words of each other (order specified).
NHS Economic Evaluations Database
Via www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2015.
Date searched: 26 February 2019.
Records retrieved: 352.
See above under Health Technology Assessment database for search strategy used.
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ScHARRHUD
URL: www.scharrhud.org/.
Date searched: 26 February 2019.
Records retrieved: 11.
Search strategy
1. liver OR hepato* OR hepatic*
2. cirrhos* OR cirrhot*
3. biliary AND cholangitis
4. (#1 OR #2 OR #3).
Key:
l * = truncation.
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Appendix 4 Search strategies for resource
use and cost evidence
The aim of the search was to identify published studies relating to costs or resource use in patientswith HCC. A search strategy was developed in MEDLINE (Ovid), comprising a set of terms for HCC
combined with terms relating to costs or resource use. The terms included for costs were based on a
search strategy developed by the Canadian Agency for Drugs and Technologies in Health (CADTH).157
Retrieval was restricted to studies published from 2010 onwards in any language. The MEDLINE
strategy was translated to run appropriately on the other databases searched.
The following databases were searched on 7 March 2019: MEDLINE all (Ovid) and EMBASE (Ovid).
The previous results obtained for the health utilities search from the HTA database and NHS EED
were added to the results from MEDLINE and EMBASE.
Search results were imported into EndNote X9 and deduplicated.
MEDLINE all
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1946 to 6 March 2019.
Date searched: 7 March 2019.
Records retrieved: 2153.
Lines 7–19 below are based on a search strategy developed by CADTH to identify studies about
costs/economics.157
Search strategy
1. Carcinoma, Hepatocellular/ (77,885)
2. Liver Neoplasms/ (138,136)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (132,179)
4. hepatocarcinoma$.ti,ab. (3767)
5. hepatoma$.ti,ab. (27,406)
6. or/1-5 (207,882)
7. economics/ (27,006)
8. exp “costs and cost analysis”/ (222,429)
9. economics, dental/ (1901)
10. exp “economics, hospital”/ (23,378)
11. economics, medical/ (9002)
12. economics, nursing/ (3986)
13. economics, pharmaceutical/ (2843)
14. exp “Fees and Charges”/ (29,616)
15. exp Budgets/ (13,465)
16. budget*.ti,ab,kf. (27,124)
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17. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ti,kf. (209,622)
18. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ab./freq = 2 (258,034)
19. or/7-18 (523,885)
20. 6 and 19 (1325)
21. Health Resources/ (12,010)
22. Healthcare Financing/ (695)
23. (resource$ adj2 (“use” or utilis$ or utiliz$ or consum$ or usage)).ti,ab. (25,314)
24. ((healthcare or health-care) adj2 (“use” or utilis$ or utiliz$ or consum$ or usage)).ti,ab. (25,383)
25. 21 or 22 or 23 or 24 (56,988)
26. 6 and 25 (134)
27. Length of Stay/ (80,203)
28. (cost$ adj2 (illness$ or disease$ or sickness$)).ti,ab. (4600)
29. (burden$ adj2 (disease$ or illness$ or sickness$)).ti,ab. (22,257)
30. ((length or hospital$ or duration) adj2 stay$).ti,ab. (120,889)
31. ((extended or prolonged) adj stay$).ti,ab. (1013)
32. ((hospitali?ation$ or hospitali?ed) adj3 (economic$ or cost or costs or costly or costing or price or
prices or pricing)).ti,ab. (6753)
33. economic consequenc$.ti,ab. (3229)
34. or/27-33 (190,256)
35. 6 and 34 (2349)
36. 20 or 26 or 35 (3467)
37. exp animals/not humans/ (4,553,712)
38. 36 not 37 (3454)
39. limit 38 to yr = “2010 -Current” (2153).
Key:
l / = indexing term (MeSH)
l exp = exploded indexing term (MeSH)
l $ = truncation
l ? = optional wild card – stands for zero or one character within a word
l ti,ab = terms in either title or abstract fields
l ab./freq = 2 = frequency operator – term must appear at least twice in the abstract for the record
to be retrieved
l kf = author keywords field
l adj3 = terms within three words of each other (any order).
EMBASE
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1974 to 6 March 2019.
Date searched: 7 March 2019.
Records retrieved: 3913.
Lines 7–14 below are based on a search strategy developed by CADTH to identify studies about
costs/economics.158
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Search strategy
1. liver cell carcinoma/ (136,950)
2. liver cancer/ (28,936)
3. ((liver or hepato$ or hepatic$) adj3 (carcinoma$ or cancer$ or neoplas$ or tumour$ or tumor$ or
malign$)).ti,ab. (185,215)
4. hepatocarcinoma$.ti,ab. (5000)
5. hepatoma$.ti,ab. (30,696)
6. or/1-5 (242,760)
7. Economics/ (231,508)
8. Cost/ (56,142)
9. exp Health Economics/ (783,424)
10. Budget/ (26,815)
11. budget*.ti,ab,kw. (35,333)
12. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ti,kw. (253,689)
13. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ab./freq = 2 (357,407)
14. or/7-13 (1,153,032)
15. 6 and 14 (4962)
16. health care utilization/ (63,300)
17. health care financing/ (12,931)
18. (resource$ adj2 (“use” or utilis$ or utiliz$ or consum$ or usage)).ti,ab. (39,541)
19. ((healthcare or health-care) adj2 (“use” or utilis$ or utiliz$ or consum$ or usage)).ti,ab. (36,926)
20. 16 or 17 or 18 or 19 (122,638)
21. 6 and 20 (501)
22. disease burden/ (8049)
23. Length of Stay/ (159,340)
24. (cost$ adj2 (illness$ or disease$ or sickness$)).ti,ab. (6874)
25. (burden$ adj2 (disease$ or illness$ or sickness$)).ti,ab. (33,648)
26. ((length or hospital$ or duration) adj2 stay$).ti,ab. (204,289)
27. ((extended or prolonged) adj stay$).ti,ab. (1581)
28. ((hospitali?ation$ or hospitali?ed) adj3 (economic$ or cost or costs or costly or costing or price or
prices or pricing)).ti,ab. (11,727)
29. economic consequenc$.ti,ab. (4245)
30. or/22-29 (313,622)
31. 6 and 30 (3966)
32. 15 or 21 or 31 (8470)
33. (animal/or animal experiment/or animal model/or animal tissue/or nonhuman/) not exp
human/ (5,667,672)
34. 32 not 33 (8389)
35. limit 34 to yr = “2010 -Current” (6403)
36. limit 35 to conference abstracts (2490)
37. 35 not 36 (3913)
Key:
l / = indexing term (Emtree heading)
l exp = exploded indexing term (Emtree heading)
l $ = truncation
l ? = optional wild card – stands for zero or one character within a word
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l ti,ab = terms in either title or abstract fields
l ab./freq = 2 = frequency operator – term must appear at least twice in the abstract for a record to
be retrieved
l kw = terms in the author keywords field
l adj3 = terms within three words of each other (any order).
Health Technology Assessment database
Via www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2018.
Date searched: 26 February 2019.
Records retrieved: 188.
To view the search strategy, see under HRQoL search strategies in Appendix 3.
NHS Economic Evaluations Database
Via www.crd.york.ac.uk/CRDWeb/.
Date range searched: inception to 31 March 2015.
Date searched: 26 February 2019.
Records retrieved: 352.
To view the search strategy, see under HRQoL search strategies in Appendix 3.
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Appendix 5 Risk-of-bias assessment results
Risk-of-bias assessment results for randomised controlled trials
Trial (first author
and year)
Risk of bias
arising from the
randomisation
process
Risk of bias
owing to
deviations from
the intended
interventions
Missing
outcome
data
(primary
outcome)
Risk of bias in
measurement
of the outcome
Risk of bias in
selection of
the reported
result
Overall
judgement of
risk of bias
Vilgrain 201719,84 Low Low Low Low Low Low
SARAH
Chow 201821 Low Low Low Low Low Low
SIRveNIB
Kolligs 201522 High Low High High Low High
SIRTACE
Pitton 201523 Some concerns Low Low Low Low Some concerns
Ricke 201524 Some concerns High Low Low Low High
SORAMIC
Salem 201625–27 High Some concerns Low Low Low High
PREMIERE
Kulik 201428–30 Some concerns Some concerns Low Some concerns Low Some concerns
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Risk-of-bias assessment results for prospective comparative studies
Risk-of-bias assessment results for retrospective comparative studies
Trial (first author
and year)
Inclusion criteria
clearly defined
Allocation to treatment
groups adequately
described/appropriate
Groups similar
at baseline
Clearly described
and consistently
delivered
intervention
Clearly described
and consistently
delivered
comparator
Outcome
assessors
blinded
Missing
outcome data
balanced across
groups
Free from
suggestion
of selective
reporting
Overall
judgement of
risk of bias
Kirchner 201931 No No No Yes No No Yes Yes High
El Fouly 201532 Yes No No Yes Yes No Yes Yes High
Salem 201333 Yes No No Yes Yes No Yes Yes High
Memon 201334 Yes No Yes Yes Yes No Yes Unclear High
Hickey 201635 Yes No No Yes Yes No Yes Yes High
Maccauro 201436 No No Unclear No No Unclear Unclear Unclear High
Woodall 200937 Yes No No Yes Yes No Yes Yes High
Trial (first author
and year)
Inclusion criteria
clearly defined
Representative
sample from relevant
population
Groups similar
at baseline
Clearly described
and consistently
delivered
intervention
Clearly described
and consistently
delivered
comparator
Outcome
assessors
blinded
Missing
outcome data
balanced across
groups
Free from
suggestion
of selective
reporting
Overall
judgement of
risk of bias
Biederman
201538
No Unclear Unclear No No Unclear Unclear Unclear High
Biederman
201639
Yes Yes No Yes Yes Unclear Unclear Unclear High
Van Der Gucht
201740
Yes Yes No Yes Yes Unclear Yes Yes High
Bhangoo 201541 Yes Yes Unclear Yes Yes Unclear Unclear Yes Unclear
d’Abadie 201842 No Unclear No No No Unclear Unclear Yes High
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Appendix 6 Study details and results for
all studies included in the systematic
review of clinical effectiveness (n = 20)
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Vilgrain 201719,84
SARAH
France
Multicentre
open-label RCT
Funding: Sirtex
Locally advanced HCC (BCLC
C), or new HCC not eligible
for surgery/ablation after
previously cured HCC, or HCC
with two unsuccessful rounds
of TACE. Life expectancy
of > 3 months, ECOG
performance status of 0 or 1,
Child–Pugh class A or B
score of ≤ 7
SIR-Spheres
(n = 237)
Sorafenib (400 mg twice daily
orally, administered until the
occurrence of radiological
progression, unacceptable AEs
or death) (n = 222)
OS:
SIR-Spheres: median 8.0 months (95% CI
6.7 to 9.9 months); 196/237 (83%) patients
died; 1-year OS: 39.5% (95% CI 33.3% to
45.9%)
Sorafenib: median 9.9 months (95% CI 8.7
to 11.4 months); 177/222 (80%) patients
died; 1-year OS: 42.1% (95% CI 35.6%
to 48.7%)
Comparison between groups:
ITT population HR 1.15 (95% CI 0.94 to
1.41; p = 0.18)
Per-protocol population HR 0.99 (95% CI
0.79 to 1.24)
PFS:
SIR-Spheres: median 4.1 months (95% CI
3.8 to 4.6 months); 218/237 (92%) had
progression events
Sorafenib: median 3.7 months (95% CI
3.3 to 5.4 months).; 205/222 (92%) had
progression events
Comparison between groups:
ITT population HR 1.03 (95% CI 0.85 to
1.25; p = 0.76)
Complete or partial response rate:
SIR-Spheres: 36/190 (19%) evaluable
patients
Sorafenib: 23/198 (12%) evaluable patients
Low
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
HRQoL:
The global health status subscore was
significantly better in the SIRT group than
in the sorafenib group (group effect
p = 0.0048; time effect p < 0.0001) and
the between- group difference tended to
increase with time (group*time interaction
p = 0.0447) for both the ITT and
per-protocol populations
AEs:
SIR-Spheres: 173/226 (77%) patients
reported at least one AE; 19 treatment-
related deaths (six did not receive SIRT and
subsequently received sorafenib)
Sorafenib: 203/216 (94%) patients reported
at least one AE; 12 treatment-related
deaths; 139/216 (64%) patients discontinued
sorafenib owing to drug-related toxicity,
108 of whom permanently discontinued
Time on treatment/number of treatments:
SIR-Spheres: 53/237 (22%) did not receive
SIRT. Of 184 patients who received SIRT,
115 (63%) received a single administration,
58 patients received two treatments,
11 patients received three treatments
Sorafenib: median dose intensity:
800mg/day (IQR 585–800mg/day).
Median cumulative time of sorafenib intake
2.8 months (IQR 1.0–5.8 months); 82/216
(38%) required a dose reduction. Permanent
discontinuation occurred in 132 (61%)
patients; 49 (37%) patients discontinued
sorafenib before tumour progression
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funding source Population Intervention Comparator Main results Risk of bias
Chow 201821
SIRveNIB
Asia-Pacific region
Multicentre
open-label RCT
Funding: Sirtex
Locally advanced HCC (BCLC
B or C without extrahepatic
disease) with or without PVT,
not amenable to curative
treatment modalities
SIR-Spheres
(n = 182)
Sorafenib (400 mg twice daily
orally, administered until the
occurrence of treatment
failure, complete response,
initiation of other HCC
therapies, unacceptable AEs,
patient request to stop
treatment or death) (n = 178)
OS:
SIR-Spheres: median 8.8 months (95% CI
7.5 to 10.8 months)
Sorafenib: median 10.0 months (95% CI
8.6 to 13.8 months)
Comparison between groups:
ITT population HR 1.12 (95% CI 0.9 to 1.4;
p = 0.36)
Per-protocol population HR 0.86 (95% CI
0.7 to 1.1; p = 0.27)
PFS:
SIR-Spheres: median 5.8 months (95% CI
3.7 to 6.3 months)
Sorafenib: median 5.1 months (95% CI
3.9 to 5.6 months)
Comparison between groups:
ITT population HR 0.89 (95% CI 0.7 to 1.1;
p = 0.31)
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Complete or partial response rate:
SIR-Spheres: 16.5%
Sorafenib: 1.7%
HRQoL:
There were no statistically significant
differences in the EQ-5D index between
the SIR-Spheres and sorafenib groups
throughout the study in either the ITT
or the treated populations
AEs:
SIR-Spheres: 78/130 (60.0%) patients
reported at least one AE; 36/130 (27.7%)
reported at least one grade ≥ 3 AE; 27/130
(20.8%) reported at least one serious AE
Sorafenib: 137/162 (84.6%) patients
reported at least one AE; 82/130 (50.6%)
reported at least one grade ≥ 3 AE; 57/162
(35.2%) reported at least one serious AE
Time on treatment/number of treatments:
SIR-Spheres: 52/182 (28.6%) did not
receive SIRT. All 130 patients who received
SIRT received a single administration
Sorafenib: 16/178 (9%) did not receive
sorafenib. Median treatment duration was
13.8 weeks and mean daily dose was
644.5 mg
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Kolligs 201522
SIRTACE
Germany and Spain
Multicentre
open-label RCT
Funding: Sirtex
Unresectable HCC with
preserved liver function
(Child–Pugh class ≤ B7; total
bilirubin ≤ 2 mg/dl), an ECOG
performance status of ≤ 2, and
absence of any form of
vascular invasion or
extrahepatic spread
SIR-Spheres
(n = 13)
TACE (n = 15) Overall survival:
Not reported
PFS:
SIR-Spheres: median 3.6 months (95% CI
2.3 to 6.2 months)
TACE: median 3.7 months (95% CI 1.6 to
11.0 months)
Complete or partial response rate:
SIR-Spheres: 4/13 (30.8%)
TACE: 2/15 (13.3%)
HRQoL:
HRQoL data were analysed for 18 patients
(8 SIRT and 10 TACE). Higher scores reflect
higher functioning and fewer symptoms.
At baseline, median scores were lower for
patients receiving SIRT than for patients
receiving TACE, particularly for subscales
of physical functioning (82.0 vs. 96.0;
p = 0.04) by Kruskal–Wallis test
This manifested in the lower scores with
SIRT throughout the first 12 weeks after
treatment, although the differences
between the treatment groups by week
12 were not statistically significant for
either FACT-Hep total or its subscales
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
AEs:
SIR-Spheres: 12/13 (92.3%) patients
reported at least one AE; 3/13 reported at
least one grade ≥ 3 AE; 7/13 reported at
least one serious AE requiring
hospitalisation
TACE: 10/15 (66.7%) patients reported at
least one AE; 2/15 reported at least one
grade ≥ 3 AE; 5/15 reported at least one
serious AE requiring hospitalisation
Time on treatment/number of treatments:
SIR-Spheres: 7/13 (53.8%) received whole-
liver SIRT, 5 (38.5%) received lobar and
1 (7.7%) received segmental treatment. All
patients received one course of treatment
TACE: on average, patients received
3.4 (SD 2.9, median 2.0) separate sessions
during the study. three patients received
one course of TACE, five patients received
two courses, three patients received four
courses, three patients received five courses
and one patient received 11 courses
Pitton 201523
Germany
Single-centre
open-label RCT
Funding: Johannes
Gutenberg
University of
Mainz (Mainz,
Germany)
Unresectable N0, M0 HCC
(BCLC stage B)
SIR-Spheres
(n = 12)
DEB-TACE (n= 12) OS:
SIR-Spheres: median 592 days (Q1: 192
days, Q3: –)
Mean 437 days (SE 72 days). Cause of
death was predominantly liver failure
(n = 4), with only one death because of
tumour progression
DEB-TACE: median 788 days
(Q1: 178 days, Q3: 950 days)
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concerns
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
4
8
0
H
e
a
lth
T
e
ch
n
o
lo
g
y
A
sse
ssm
e
n
t
2
0
2
0
V
o
l.
2
4
N
o
.
4
8
©
Q
u
e
e
n
’s
P
rin
te
r
an
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
2
0
.T
h
is
w
o
rk
w
as
p
ro
d
u
ce
d
b
y
W
alto
n
et
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
e
d
b
y
th
e
S
e
cre
tary
o
f
S
tate
fo
r
H
e
alth
an
d
S
o
cial
C
are
.T
h
is
issu
e
m
ay
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riv
ate
re
se
arch
an
d
stu
d
y
an
d
extracts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
ay
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
al
jo
u
rn
als
p
ro
v
id
e
d
th
at
su
itab
le
ack
n
o
w
le
d
g
e
m
e
n
t
is
m
ad
e
an
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
asso
ciate
d
w
ith
an
y
fo
rm
o
f
ad
v
e
rtisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
e
rcial
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
als
L
ib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
e
alth
R
e
se
arch
,
E
v
alu
atio
n
,
T
rials
an
d
S
tu
d
ie
s
C
o
o
rd
in
atin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
iv
e
rsity
o
f
S
o
u
th
am
p
to
n
S
cie
n
ce
P
ark
,S
o
u
th
am
p
to
n
S
O
1
6
7
N
S
,
U
K
.
2
0
1
Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Mean 583 days (SE 119 days). Cause
of death was predominantly tumour
progression (n = 4), with only one death
because of liver failure
PFS:
SIR-Spheres: median 180 days (Q1: 120
days, Q3: 414 days)
Mean 266 days (SE 55 days)
DEB-TACE: median 216 days (Q1: 88 days,
Q3: 355 days)
Mean 237 days (SE 49 days)
Complete or partial response rate:
Not reported
HRQoL:
Not reported
AEs:
Not reported
Time on treatment/number of treatments:
SIR-Spheres: patients received either one
(n = 4) or two (n= 8) treatment sessions.
Eight patients had a bilobar approach
DEB-TACE: the mean number of treatment
sessions was 3.8± 2.6 (range 1–10).
Embolisation was unilobar in five and
bilobar in seven patients
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Ricke 201524
SORAMIC
Germany
Multicentre
open-label RCT
Funding: Sirtex
and Bayer
HealthCare
(Leverkusen,
Germany)
Unresectable intermediate or
advanced HCC (BCLC stage B
or C) with preserved liver
function (Child–Pugh class
≤ B7) and ECOG performance
status of < 2, who were poor
candidates for TACE (including
those failing TACE)
SIR-Spheres
plus sorafenib
(n = 20)
Sorafenib alone (n= 20) OS:
Not reported
PFS:
Not reported
Complete or partial response rate:
Not reported
HRQoL:
Not reported
AEs:
SIR-Spheres plus sorafenib: there were 196
AEs reported; 43/196 (21.9%) were grade 3
or worse
Sorafenib alone: there were 222 AEs
reported; 47/222 (21.2%) were grade 3
or worse
Time on treatment/number of treatments:
SIR-Spheres plus sorafenib: SIRT was
administered as a sequential lobar
treatment in 10/20 patients, and 10
patients received unilobar treatment.
Patients received a median daily sorafenib
dose of 614 mg (range 45–793mg) over a
median of 8.5 months
Sorafenib alone: patients received a median
daily sorafenib dose of 557 mg (range
284–792mg) over a median of 9.6 months
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Salem 201625–27
PREMIERE
USA
Single-centre
open-label RCT
Funding: National
Institutes of
Health grant
(in part)
BCLC stage A/B unablatable/
unresectable HCC with no
vascular invasion. Child–Pugh
class A/B
TheraSphere
(n = 24)
TACE (n = 21) Overall survival:
TheraSphere: median 18.6 months (95% CI
7.4 to 32.5 months)
TACE: median 17.7 months (95% CI 8.3 to
not calcuable months)
TTP:
TheraSphere: not reached (> 26 months)
TACE: 6.8 months
Complete or partial response rate:
TheraSphere: 20/23 (87%) achieved EASL
response, 12/23 (52%) achieved WHO
response
TACE: 14/19 (74%) achieved EASL
response, 12/19 (63%) achieved WHO
response
HRQoL:
Not reported
AEs:
Not reported
Time on treatment/number of treatments:
TheraSphere: SIRT treatment was
performed in 17/24 patients; seven were
lobar treatments
TACE: selective chemoembolisation was
performed in 16/19 patients; three were
lobar treatments
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Kulik 201428–30
USA
Single-centre
open-label RCT
pilot study
Funding: Bayer/
Onyx (Novato, CA,
USA) and a
Northwestern
University
(Evanston, IL, USA)
departmental pilot
grant programme
HCC, Child–Pugh class ≤ B8
and potential candidates
for orthotopic liver
transplantation
TheraSphere
(n = 10)
TheraSphere plus sorafenib
(n = 10)
OS:
TheraSphere: three patients died
TheraSphere plus sorafenib: two patients died
PFS:
Not reported
Complete or partial response rate:
Not reported
HRQoL:
Not reported
AEs:
The most commonly reported AEs were
fatigue (9/10 TheraSphere patients and
4/10 TheraSphere plus sorafenib patients),
pain (5/10 TheraSphere patients and 0
TheraSphere plus sorafenib patients) and
nausea (7/10 TheraSphere patients and
2 TheraSphere plus sorafenib patients)
Time on treatment/number of treatments:
TheraSphere: 2/10 patients had more than
one SIRT treatment; one patient had two
SIRT treatments and one patient had three
SIRT treatments plus one TACE
TheraSphere plus sorafenib: 3/10 patients
had more than one SIRT treatment; one
patient had three SIRT treatments, one
patient had a second SIRT treatment plus
TACE and one patient had a second SIRT
treatment plus radiofrequency ablation
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Kirchner 201931
Germany
Prospective single-
centre comparative
study
Funding: none
All patients undergoing initial
TACE or TARE due to HCC
between November 2014
and March 2016 agreed to
participate (n= 94). Twenty-
seven patients failed to
answer the questionnaire;
therefore, quality of life after
67 interventions was analysed
TheraSphere
(n = 21)
cTACE (n = 33)
DEB-TACE (n= 13)
OS:
Not reported
PFS:
Not reported
Complete or partial response rate
(RECIST):
TheraSphere: 0/19 (0%) evaluable patients
TACE: 1/44 (2.3%) evaluable patients
Complete or partial response rate (WHO):
TheraSphere: 1/19 (5.3%) evaluable
patients
TACE: 3/44 (6.8%) evaluable patients
HRQoL:
Before the intervention, the mean global
health status/QoL in the SIRT group
(50.8%) was significantly lower than in the
TACE group (62.5%, p = 0.029)
After treatment, the mean absolute
decrease in global health status/QoL was
higher in the TACE group (–10.5%) than in
the SIRT group (–4.8%), which was not
statistically significant (p = 0.396). The
absolute increase in fatigue after initial
treatment was significantly higher with
TACE (+19.1%) than with SIRT (+7.9%)
(p = 0.021)
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
The SIRT group showed the highest
changes in financial difficulties (14.3%
increase), role functioning (12.7% decrease)
and dyspnoea (11.1% increase), C30 role
functioning (12.7% decrease), social
functioning (10.3% decrease) and
QLQ-HCC18 nutrition (10.2% increase).
The TACE group showed the highest
changes in QOL-C30 physical functioning
(14.1% decrease), role functioning
(21.7% decrease), emotional functioning
(10.2% decrease), social functioning (17.4%
decrease) and fatigue (19.1% increase).
It also showed an 11.6% increase in pain,
QLQ-HCC18 fatigue (11.6% increase),
body image (11.2% increase) and sex life
(11.6% increase)
Relative pre/post change in global health
status was –16.8% in the TACE group and
–9.4% in the SIRT group
AEs:
Not reported
Time on treatment/number of treatments:
Not reported
El Fouly 201532
Germany and
Egypt
Prospective
multicentre
comparative study
Funding: not
reported
Intermediate-stage (BCLC B)
HCC and good liver function
(Child–Pugh class B < 7)
TheraSphere
(n = 44)
TACE (n = 42) OS:
TheraSphere: median 16.4 months (95% CI
7.9 to 25.3 months); 1-year OS: 59%,
2-year OS: 40%, 3-year OS: 31%
TACE: median 18 months (95% CI 12.1 to
25.5 months); 1-year OS: 64%, 2-year OS:
36%, 3-year OS: 11%
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
TTP:
TheraSphere: median 13.3 months (95% CI
3.4 to 23.1 months)
TACE: median 6.8 months (95% CI 3.9 to
8.8 months)
Complete or partial response rate:
TheraSphere: 7% complete response,
68% partial response
TACE: 5% complete response, 45% partial
response
HRQoL:
Not reported
AEs:
The most commonly reported AE was
unspecific abdominal pain, which was found
in 83% of TACE patients (vs. 5% of SIRT
patients)
Time on treatment/number of treatments:
TheraSphere: total number of sessions = 63,
with a mean of 1.4 sessions per patient
(median 1)
TACE: total number of sessions = 93,
with a mean of 2.2 sessions per patient
(median 2 sessions)
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Salem 201333
USA
Prospective
comparative study
Funding:
Dimitrovich Family
Foundation and
National Institutes
of Health (in part)
Treatment-naive HCC patients
with ECOG performance
status 0–2
TheraSphere
(n = 29)
TACE (n = 27) OS:
Not reported
PFS:
Not reported
Complete or partial response rate:
Not reported
HRQoL:
Overall, most of the FACT-Hep scales showed
a reduction in score in the TACE group, with
stability or increase in the SIRT group
between baseline and 4-week assessments
Despite more advanced disease at baseline
(regression analysis incorporating BCLC
stage), SIRT patients showed significantly
better quality of life relative to TACE in
social well-being (p = 0.019), functional
well-being (p = 0.031) and embolotherapy-
specific score (p = 0.018). Strong trends
favouring SIRT were noted in overall quality
of life (p = 0.055), the Trial Outcome Index
(p = 0.05) and FACT-Hep (p = 0.071)
Differences in physical well-being,
hepatobiliary cancer subscale and
FACT-Hep were less pronounced. The only
subscale that appeared to favour TACE was
emotional well-being (p = 0.656)
In terms of specific variables, 2 weeks after
treatment, SIRT patients reported greater
closeness to friends (p= 0.035), and TACE
patients reported a greater feeling of sadness
(p= 0.034). At 4 weeks, TACE patients
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
complained of being bothered by treatment
side effects (p= 0.029) and nervousness
(p= 0.047). SIRT patients experienced greater
satisfaction with coping with illness
(p= 0.019) and good appetite (p= 0.045)
AEs:
Not reported
Time on treatment/number of treatments:
Not reported
Memon 201334
USA
Prospective
follow-up to a
retrospective
comparative study
Funding: National
Institutes of
Health (in part)
HCC that progressed after
intra-arterial locoregional
therapies: TACE and SIRT
TheraSphere
(n = 42)
TACE (n = 54) OS:
Not reported
TTP:
TheraSphere: median 13.3 months
(range 9.3–25.0 months)
TACE: median 8.4 months
(range 7.3–10.6 months)
Complete or partial response rate:
Not reported
HRQoL:
Not reported
AEs:
Not reported
Time on treatment/number of treatments:
Not reported
High
A
P
P
E
N
D
IX
6
N
IH
R
Jo
u
rn
als
L
ib
rary
w
w
w
.jo
u
rn
a
lslib
ra
ry
.n
ih
r.a
c.u
k
2
1
0
Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Hickey 201635
USA
Prospective
single-centre
comparative study
Funding: not
reported
Unresectable HCC and
bilirubin ≤ 3.0 mg/dl
TheraSphere
(n = 428)
TACE (n = 337) OS:
Survival outcomes (months) were stratified
by Child–Pugh class and BCLC stage:
TheraSphere,
median
(95% CI)
TACE,
median
(95% CI)
BCLC A and
Child–Pugh A
21.4
(9.8 to 33.1)
Not evaluable
(most
patients still
alive at study
termination)
BCLC A and
Child–Pugh B
27.6
(11.6 to 43.6)
BCLC B and
Child–Pugh A
18.3
(12.3 to 24.3)
19.2
(16.0 to 22.4)
BCLC B and
Child–Pugh B
12.2
(8.1 to 16.3)
17.4
(8.8 to 26.0)
BCLC C and
Child–Pugh A
9.5
(7.0 to 11.9)
8.6
(5.1 to 12.0)
BCLC C and
Child–Pugh B
5.6
(4.1 to 7.1)
3.5
(2.6 to 4.4)
PFS:
Not reported
Complete or partial response rate:
Not reported
HRQoL:
Not reported
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
AEs:
Not reported
Time on treatment/number of treatments:
Not reported
Maccauro 201436
Location not
reported
Prospective
matched
case–control study
Funding: not
reported
Unresectable HCC,
Child–Pugh class A. 80%
patients in both groups were
BCLC stage C because of PVT
TheraSphere
plus sorafenib
(n = 15)
TheraSphere alone (n= 30) OS:
TheraSphere plus sorafenib: median
10 months
TheraSphere alone: median 10 months
PFS:
TheraSphere plus sorafenib: median
6 months
TheraSphere alone: median 7 months
Complete or partial response rate:
TheraSphere plus sorafenib: 45.5%
mRECIST, 10% EASL
TheraSphere alone: 42.8% mRECIST,
40% EASL
HRQoL:
Not reported
AEs:
Not reported
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Time on treatment/number of treatments:
TheraSphere plus sorafenib: patients
started sorafenib at a median time of
2 months prior to SIRT; median time on
sorafenib = 9 months and median
dose = 600mg/day
Woodall 200937
USA
Prospective
comparative study
Funding: MDS
Nordion (Ottawa,
ON, Canada)
(maker of
TheraSphere)
Unresectable HCC, including
patients with and those
without PVT
TheraSphere
in patients
without PVT
(n = 20)
TheraSphere in
patients with
PVT (n= 15)
BSC/no treatment (n= 17) OS:
TheraSphere: HCC patients without PVT:
median 13.9 months; HCC patients with
PVT: median 3.2 months
BSC/no treatment: median 5.2 months
PFS:
Not reported
Complete or partial response rate:
Not reported
HRQoL:
Not reported
AEs:
TheraSphere: AEs were reported by 25% of
patients without PVT and 33% of patients
with PVT
Time on treatment/number of treatments:
TheraSphere: median 2 treatments per
patient (range 1–3)
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Biederman 201538
Location not
reported
Retrospective
comparative study
Funding: not
reported
BCLC stage C HCC with PVT TheraSphere
(n = 72)
SIR-Spheres (n = 25) OS:
TheraSphere: median 15 months (95% CI
8.6 to 19.5 months)
SIR-Spheres: median 4.1 months (95% CI
2.7 to 6.6 months)
TTP:
Median 9.1 months (95% CI 5.4 to
11.7 months) – not reported for separate
treatment groups
Complete or partial response rate:
4/40 (10%) evaluable patients had complete
response, 16/40 (40%) evaluable patients
had partial response – not reported for
separate treatment groups
HRQoL:
Not reported
AEs:
Clinical toxicities included grade 1/2:
fatigue = 30%, abdominal pain = 28%,
nausea = 17%, ascites= 7% – not reported
for separate treatment groups
Laboratory toxicities included grade 1/2:
bilirubin = 37%, AST = 64%, ALT = 46% and
grade 3/4: bilirubin = 17%, AST = 15%,
ALT = 2% – not reported for separate
treatment groups
Time on treatment/number of treatments:
A total of 101 treatments (across both
treatment arms) were administered
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Biederman 201639
USA
Retrospective
comparative study
Funding: not
reported
Unresectable HCC with
associated main or lobar PVT
SIR-Spheres
(n = 21)
TheraSphere (n= 69) OS:
SIR-Spheres: median 3.7 months (95% CI
2.3 to 6.0 months)
TheraSphere: median 9.5 months (95% CI
7.6 to 15.0 months)
Comparison between groups:
HR 0.39 (95% CI 0.23 to 0.67, p < 0.001)
TTP:
SIR-Spheres: median 2.8 months (95% CI
1.9 to 4.3 months)
TheraSphere: median 5.9 months (95% CI
4.2 to 9.1 months)
Complete or partial response rate:
SIR-Spheres: 0/15 (0%) evaluable patients
had complete response, 2/15 (13.3%) had
partial response, 4/15 (26.7%) had stable
disease, 9/15 (60%) had progressive disease
TheraSphere: 5/57 (8.8%) evaluable
patients had complete response, 18/57
(31.6%) had partial response, 8/57 (14%)
had stable disease, 26/57 (45.6%) had
progressive disease
HRQoL:
Not reported
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
AEs:
Grade 3/4 bilirubin: 39% SIR-Spheres vs.
14% TheraSphere group
Grade 3/4 AST: 44% SIR-Spheres vs. 9%
TheraSphere group
Grade 3/4 ALT: 0% SIR-Spheres vs. 4%
TheraSphere group
Grade 3/4 alkaline phosphatase: 0%
SIR-Spheres vs. 7% TheraSphere group
Grade 3/4 albumin: 0% SIR-Spheres vs. 2%
TheraSphere group
Abdominal pain (32.9%) and fatigue (18.3%)
were the most common clinical toxicities
experienced; clinical toxicities were not
significantly different between treatment
groups
Reported in supplementary data file
(online):
Pain: 41.2% SIR-Spheres vs. 30.8%
TheraSphere group
Fatigue: 17.6% SIR-Spheres vs. 18.5%
TheraSphere group
Nausea: 17.6% SIR-Spheres vs. 3.1%
TheraSphere group
Anorexia: 0% SIR-Spheres vs. 9.2%
TheraSphere group
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Time on treatment/number of treatments:
A total of 100 treatments (across both
treatment arms) were administered, with
10 (11.1%) patients undergoing staged
treatment
Van Der Gucht
201740
Switzerland
Retrospective
comparative study
Funding: not
reported
Unresectable HCC, ECOG
performance status of < 2 and
life expectancy of > 3 months
SIR-Spheres
(n = 41)
TheraSphere (n= 36) OS:
SIR-Spheres: median 7.7 months (95% CI
7.2 to 8.2 months)
OS at 6 months= 63%, 1 year = 22%,
2 years = 11%
TheraSphere: median 7.0 months (95% CI
1.6 to 12.4 months)
OS at 6 months= 57%, 1 year = 29%,
2 years = 14%
PFS:
SIR-Spheres: median 6.1 months (95% CI
4.7 to 7.4 months)
PFS at 6 months= 52%, 1 year = 7%,
2 years = 0%
TheraSphere: median 5.0 months (95% CI
0.9 to 9.2 months)
PFS at 6 months= 47%, 1 year = 18%,
2 years = 6%
Complete or partial response rate:
Not reported
High
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
HRQoL:
Not reported
AEs:
Not reported
Time on treatment/number of treatments:
Not reported
Bhangoo 201541
USA
Retrospective
comparative study
Funding: not
reported
Unresectable HCC patients
who either had failed or had
disease not amenable to
alternative locoregional
therapies. ECOG performance
status of < 2, serum total
bilirubin < 2mg/dl
TheraSphere
(n = 11)
SIR-Spheres (n = 6) OS:
TheraSphere: median 8.4 months (95% CI
1.3 to 21.1 months)
SIR-Spheres: median 7.8 months (95% CI
2.3 to 12.5 months)
OS results presented for 15 out of the full
17-patient cohort, as two patients still alive
PFS:
Not reported
Complete or partial response rate:
0/17 patients had complete response, 4/17
(24%) had partial response, 4/17 (24%) had
stable disease, 6/17 (35%) had progressive
disease and 3/17 (18%) had no data – not
reported for separate treatment groups
HRQoL:
Not reported
Unclear
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
AEs:
Grade 3/4 bilirubin: 18% TheraSphere vs.
0% SIR-Spheres group
Grade 3/4 albumin: 11% TheraSphere vs.
0% SIR-Spheres group
Grade 3/4 alkaline phosphatase: 0%
TheraSphere vs. 17% SIR-Spheres group
Fatigue: 45% TheraSphere vs.
67% SIR-Spheres group
Abdominal pain: 27% TheraSphere vs.
33% SIR-Spheres group
Nausea/vomiting: 55% TheraSphere vs.
67% SIR-Spheres group
Anorexia/weight loss: 9% TheraSphere vs.
33% SIR-Spheres group
Diarrhoea: 0% TheraSphere vs.
17% SIR-Spheres group
Gastric ulcer: 0% TheraSphere vs.
17% SIR-Spheres group
Time on treatment/number of treatments:
65% of patients received one treatment
and 35% received two treatments (across
both treatment arms)
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
d’Abadie 201842
USA
Retrospective
comparative study
Funding: not
reported
HCC imaged by yttrium-90
TOF-PET
TheraSphere
(n = 33
procedures)
SIR-Spheres (n = 25
procedures)
OS:
Not reported (KM curves for different
equivalent uniform doses presented in
publication)
PFS:
Not reported
Complete or partial response rate:
Not reported
HRQoL:
Not reported
AEs:
Not reported
Time on treatment/number of treatments:
Not reported
High
Radosa 201951
Germany
Single-centre
retrospective case
series
Funding: none
HCC QuiremSpheres
(n = 9)
Not applicable OS:
Not reported
PFS:
Not reported
High
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Study (first author,
year, name and
location)
Study design and
funding source Population Intervention Comparator Main results Risk of bias
Complete or partial response rate:
60 days: 0 complete response, 5/9 (56%)
partial response, 3/9 (33%) stable disease,
1/9 (11%) progressive disease
6 months: 1/9 (11%) complete response,
4/9 (45%) partial response, 3/9 (33%) stable
disease, 1/9 (11%) progressive disease
HRQoL:
Not reported
AEs:
Presence of REILD at 60 days: 0
Median MELD score (range) 1 day before
SIRT: 8 (7–13)
Median MELD score (range) 1 day after
SIRT: 8 (6–11)
Median MELD score (range) 60 days after
SIRT: 8 (6–14)
There were 16 reportable AEs in the nine
patients, but no grade 3/4 AEs. Most
common AEs were nausea (n = 3), fatigue
(n = 3), vomiting (n = 3), abdominal pain
(n = 2) and ascites (n = 2)
Time on treatment/number of treatments:
Not reported
ALT, alanine aminotransferase; AST, aspartate aminotransferase; IQR, interquartile range; QoL, quality of life; SE, standard error; TOF-PET, Time-of-Flight Positron emission tomography.
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Appendix 7 Lower-priority studies not
included in the systematic review of
clinical effectiveness or considered for
the network meta-analyses (n = 28)
Study (first author
and year) Intervention Comparator Reason for not including in the systematic review
Moroz 200153 SIR-Spheres plus
hepatic arterial
chemotherapy
Hepatic arterial
chemotherapy
Clinical advice that hepatic arterial chemotherapy
is not applicable to current UK practice
Pellerito 201355 SIR-Spheres 131-iodine Lipiodol Clinical advice that 131-iodine Lipiodol is not
applicable to current UK practice
Steel 200452 TheraSphere Hepatic arterial
infusion of cisplatin
Clinical advice that hepatic arterial infusion of
cisplatin is not applicable to current UK practice
Maccauro 201654 Standard-dose
TheraSphere
Personalised
treatment planning
TheraSphere
Clinical advice that standard-dose TheraSphere is
not applicable to current UK practice
She 2014159 SIR-Spheres TACE Group imbalances make comparison meaningless
(patients were allocated to SIRT if they were not
eligible for TACE, e.g. had previously failed on
TACE)
Kooby 2010160 SIR-Spheres TACE Study included a more advanced population than in
other studies in the NMA of patients eligible for
CTTs and there was a baseline imbalance between
groups in relation to PVI
Kwok 2014161 SIR-Spheres No SIR-Spheres All patients included in the study opted for SIRT,
but 16 were ineligible (primarily owing to lung
shunt); the study compares those who received it
with those who did not
Song 2017162 SIR-Spheres Concurrent
chemoradiation
therapy
Clinical advice that concurrent chemoradiation
therapy is not applicable to current UK practice
Oladeru 2016163 SIR-Spheres External beam
radiotherapy
Clinical advice that external beam radiotherapy is
not applicable to current UK practice
Rühl 2009164 SIR-Spheres High-dose-rate
brachytherapy
Clinical advice that high-dose-rate brachytherapy is
not applicable to current UK practice
D’Avola 2009165 SIR-Spheres No SIRT (combination
of conventional or
experimental
therapies or no
therapy)
Comparator was a combination of conventional or
experimental therapies or no therapy; conventional
therapy patients were not reported separately;
therefore, the trial was not informative for
the NMA
Carr 2010166 TheraSphere TACE All patients had ECOG performance status of > 2
and therefore were a more advanced population
than in other studies in the NMA of patients
eligible for CTTs
Kallini 2018167 TheraSphere TACE No OS or PFS outcomes reported and therefore
not informative for the NMA
Gabr 2017168 TheraSphere TACE Population of patients who had received a
transplant; therefore, not comparable population
with other studies in the NMA of patients eligible
for CTTs
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Study (first author
and year) Intervention Comparator Reason for not including in the systematic review
Riaz 2009169 TheraSphere TACE Group imbalances make comparison meaningless
Biederman 2018170 TheraSphere TACE Patients within Milan criteria, therefore not
comparable population to other studies in the NMA
of patients eligible for CTTs
Lewandowski
2009118
TheraSphere TACE No HRs or KM curves presented, therefore not
informative for the NMA. In addition, patients
received SIRT or TACE for downstaging; therefore,
not comparable population to other studies in the
NMA of patients eligible for CTTs
Ahmad 2005171 TheraSphere TACE No OS or PFS outcomes reported; therefore, not
informative for the NMA
Padia 2017172,173 TheraSphere TACE or DEB-TACE Mixed population of BCLC A, B and C (70% within
Milan criteria); therefore, not informative for the
NMA of patients eligible for CTTs
Newell 2015174 TheraSphere TACE or DEB-TACE Mixed population of BCLC B and C patients;
therefore, not informative for the NMA of patients
eligible for CTTs
Taussig 2017175 TheraSphere TACE or DEB-TACE No OS or PFS outcomes reported; therefore, not
informative for the NMA
McDevitt 2017176 TheraSphere DEB-TACE Mixed population of BCLC B and C patients,
therefore not informative for the NMA of patients
eligible for CTTs. Patients without main PVI could
receive DEB-TACE; those with PVI received SIRT
and therefore group imbalances
Akinwande
2015177,178
TheraSphere DEB-TACE Unclear population, but all patients had PVT;
therefore, not informative for the NMA of patients
eligible for CTTs
Biederman
2017179,180
TheraSphere TACE combined with
microwave ablation
Clinical advice that TACE combined with
microwave ablation is not widely practised in
the UK
Padia 2015181 TheraSphere Ablation,
chemoembolisation
or BSC
Comparator was a combination of ablation,
chemoembolisation and BSC. Chemoembolisation
patients were not reported separately; therefore,
the trial was not informative for the NMA of
patients eligible for CTTs
Radunz 2017182 TheraSphere TACE, radiofrequency
ablation or no
bridging therapy
Patients were eligible for transplant and received
SIRT or TACE for bridging; therefore, not
comparable population to other studies in the NMA
of patients eligible for CTTs
Salem 2018108 TheraSphere N/A Non-comparative study
Ali 2018183 TheraSphere N/A Non-comparative study
N/A, not applicable.
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Appendix 8 Risk-of-bias assessment results
for retrospective comparative studies used in
the network meta-analysis
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Study (first author
and year)
Inclusion
criteria clearly
defined
Representative
sample from
relevant
population
Groups similar
at baseline
Clearly described
and consistently
delivered
intervention
Clearly described
and consistently
delivered
comparator
Outcome
assessors
blinded
Missing outcome
data balanced
across groups
Free from
suggestion
of selective
reporting
Overall
judgement
of risk of
bias
Biederman 201538 No Unclear Unclear No No Unclear Unclear Unclear High
Biederman 201639 Yes Yes No Yes Yes Unclear Unclear Unclear High
Van Der Gucht
201740
Yes Yes No Yes Yes Unclear Yes Yes High
Bhangoo 201541 Yes Yes Unclear Yes Yes Unclear Unclear Yes Unclear
d’Abadie 201842 No Unclear No No No Unclear Unclear Yes High
Gramenzi 201545 Yes Yes No Yes Yes Unclear Unclear Yes High
de la Torre 201644 Yes Yes No Yes Yes Unclear Unclear Yes High
Cho 201643 Yes Yes No Yes Yes Unclear Yes Yes High
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Appendix 9 Risk-of-bias assessment
results for randomised controlled trials
of comparative therapies used in the
network meta-analysis
Trial (first author
and year)
Risk of bias
arising from the
randomisation
process
Risk of bias
owing to
deviation from
the intended
interventions
Missing
outcome data
(primary
outcomes)
Risk of bias in
measurement
of the
outcomes
Risk of bias
in selection
of the
reported
result
Overall
judgement of
risk of bias
Yu 201465 Some concerns Low Low Low Low Some concerns
Chang 199463 Some concerns Some concerns Low Low Low Some concerns
Meyer 201364 Some concerns Low Low Low Low Some concerns
Malagari 201066 Some concerns Some concerns Low Low Low Some concerns
Sacco 201159 High Low Low Low Low High
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Appendix 10 Study details and results for
studies of comparators included in the
network meta-analysis
Study (first author,
year and location)
Study design and
funding source Population Intervention Comparator Main results
Yu 201465
China
Parallel-group
RCT
Funding: not
reported
Patients with
unresectable HCC
with Child–Pugh
class A or B
and ECOG
performance
status of < 2
TAE (n= 45) TACE (n = 45) OS:
TAE: median 24.3 months
(95% CI 12.8 to 32.7 months)
TACE: median 20.1 months
(95% CI 9.3 to 31.2 months)
PFS:
TAE: median 6.5 months
(95% CI 7.8 to 9.2 months)
TACE: median 4.4 months
(95% CI 1.6 to 7.2 months)
TTP:
TAE: median 8.4 months
(95% CI 5.3 to 11.4
months)
TACE: median 4.4 months
(95% CI 1.7 to 7.1 months)
Malagari 201066
Greece
RCT
Funding: not
reported
Patients with HCC
unsuitable for
curative therapy
and at high risk
for surgery
DEB-TACE
(n= 48)
TAE (n = 47) OS:
DEB-TACE: 100% were
alive at 6 months and
85.3% at 12 months
TAE: 100% were alive at
6 months and 86% at
12 months
PFS:
Not reported
TTP:
DEB-TACE: 42.4±
9.5 weeks
TAE: 36.2 ± 9.0 weeks
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Study (first author,
year and location)
Study design and
funding source Population Intervention Comparator Main results
Sacco 201159
Italy
Single-centre RCT
Funding: not
reported
Patients with
unresectable HCC
with Child–Pugh
class A or B, ECOG
performance
status of 0–1
and unsuitable
for ablative
treatments
TACE
(n= 34)
DEB-TACE
(n = 33)
OS:
TACE: 83.6% were alive at
24 months
DEB-TACE: 86.8% were
alive at 24 months
PFS:
TACE: 80.1% were disease
progression free
DEB-TACE: 82.5% were
disease progression free
TTP:
TACE: mean 24.2 months
DEB-TACE: mean
15.6 months
Meyer 201364
UK
Phase II/III RCT
Funding: National
Institute for
Health Research,
Experimental
Cancer Medicine
Centre Network
Patients with
unresectable HCC
with Child–Pugh
class A or B
and ECOG
performance
status of 0–2
TAE (n= 42) TACE (n= 44) OS:
HR 0.91, 95% CI 0.51 to
1.62
TAE: median 17.3 months
TACE: median 16.3 months
PFS:
HR 0.87, 95% CI 0.52 to
1.45
TAE: median 7.2 months
TACE: median 7.5 months
TTP:
Not reported
Chang 199463
China
Single-centre RCT
Funding: not
reported
Patients with
inoperable HCC
and Child–Pugh
class A or B
TACE
(n= 22)
TAE (n = 24) OS:
TACE: 52.5% were alive at
1 year and 26.2% were
alive at 2 years
TAE: 72.5% were alive at
1 year and 39.5% were
alive at 2 years
PFS:
Not reported
TTP:
Not reported
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Appendix 11 Schoenfield residual plots
for the studies included in the network
meta-analysis for adults with unresectable
hepatocellular carcinoma who are ineligible
for conventional transarterial therapy
Studies: (a) and (b) SARAH;19 (c) and (d) SIRveNIB;21 (e) Biederman et al.;39 (f) and (g) Van Der Gucht et al.40
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Appendix 12 Results of the network
meta-analysis for all patients in the
intention-to-treat population
There were three studies included in the NMA of all adults with unresectable HCC who areineligible for CTT: SARAH,19 SIRveNIB21 and Kudo.184 There were no significant differences in OS
between the treatments when all patients, not just Child–Pugh A patients, were included (see Table 39).
SIR-Spheres showed a non-significant improvement in PFS when compared with sorafenib (HR 0.97,
95% CrI 0.84 to 1.12) but showed a significant reduction in PFS compared with lenvatinib (HR 1.34,
95% Crl 1.01 to 1.73). The HR estimates for each treatment comparison are presented in Tables 41 and 42.
Scenario 2: inclusion of Biederman et al. and Van Der Gucht et al. into
network meta-analysis for all adults in the intention-to-treat population
The two retrospective comparative studies, Biederman et al.39 and Van Der Gucht et al.,40 were added
to the NMA of all patients with unresectable HCC, who are ineligible for CTT, which allowed a
comparison to be made with TheraSphere. A subgroup of 42 patients with advanced-stage HCC was
used from the Van Der Gucht et al.40 study. The fixed-effects model was chosen as the DIC and the
number of parameters were lower. There was a significant improvement in OS with TheraSphere when
compared with sorafenib (HR 0.53, 95% CrI 0.31 to 0.84), SIR-Spheres (HR 0.46, 95% CrI 0.28 to 0.72)
and lenvatinib (HR 0.51, 95% CrI 0.28 to 0.86). As discussed earlier, Biederman et al.39 and Van Der
Gucht et al.40 both have large treatment effects and, therefore, result in TheraSphere being significantly
better for OS in the NMA. There were no notable differences between any of the other treatments for
OS (see Table 40).
TABLE 39 Overall survival and PFS results for all adults with unresectable HCC who are ineligible for CTT in the
ITT population
Intervention Comparator
HR (95% CrI)
OS PFS
SIR-Spheres Sorafenib 1.14 (0.98 to 1.32) 0.97 (0.84 to 1.12)
SIR-Spheres Lenvatinib 1.10 (0.78 to 1.49) 1.34 (1.01 to 1.73)
Lenvatinib Sorafenib 1.06 (0.79 to 1.40) 0.73 (0.58 to 0.91)
DIC –3.22 –4.86
pD 2.00 2.00
pD, number of parameters.
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TABLE 40 Network meta-analysis results of all adults with unresectable HCC who are
ineligible for CTT including the studies by Biederman et al.39 and Van Der Gucht et al.40
Intervention Comparator OS HR (95% CrI), fixed effects
SIR-Spheres Sorafenib 1.14 (1.01 to 1.28)
SIR-Spheres Lenvatinib 1.10 (0.80 to 1.48)
TheraSphere SIR-Spheres 0.46 (0.28 to 0.72)
TheraSphere Sorafenib 0.53 (0.31 to 0.84)
TheraSphere Lenvatinib 0.51 (0.28 to 0.86)
Lenvatinib Sorafenib 1.06 (0.79 to 1.40)
TABLE 42 Hazard ratio estimates (95% CrI) for PFS for each treatment comparison
for all patients in the NMA ITT population
Sorafenib 1.04 (0.89 to 1.20) 1.61 (0.45 to 4.15)
0.97 (0.84 to 1.12) SIR-Spheres 1.56 (0.43 to 4.07)
0.86 (0.24 to 2.22) 0.89 (0.25 to 2.31) Lenvatinib
TABLE 41 Hazard ratio estimates (95% CrI) for OS for each treatment comparison
for all patients in the NMA ITT population
Sorafenib 0.88 (0.78 to 0.99) 0.96 (0.71 to 1.27)
1.14 (1.01 to 1.28) SIR-Spheres 1.1 (0.80 to 1.48)
1.06 (0.79 to 1.40) 0.93 (0.67 to 1.25) Lenvatinib
Significant differences in the relative effects between a pair of agents are given
in bold.
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Appendix 13 Random-effects network
meta-analysis results
TABLE 43 Random-effects NMA OS results of base-case NMA, including Biederman et al.39 in the ITT and per-protocol
populations: adults with unresectable HCC who are ineligible for CTT
Intervention Comparator
HR (95% CrI)
ITT Per protocol
SIR-Spheres Sorafenib 0.94 (0.68 to 1.26) 1.13 (0.86 to 1.46)
SIR-Spheres Lenvatinib 0.92 (0.52 to 1.51) 1.11 (0.66 to 1.74)
TheraSphere SIR-Spheres 0.46 (0.19 to 0.94) 0.42 (0.19 to 0.82)
TheraSphere Sorafenib 0.42 (0.18 to 0.83) 0.48 (0.20 to 0.97)
TheraSphere Lenvatinib 0.41 (0.15 to 0.89) 0.46 (0.17 to 1.02)
Lenvatinib Sorafenib 1.07 (0.67 to 1.63) 1.07 (0.70 to 1.58)
SD 0.11 (0.004 to 0.352) 0.13 (0.005 to 0.378)
DIC 0.9 2.1
pD 3.4 3.4
pD, number of parameters.
TABLE 44 Random-effects OS and PFS outcomes for all patients in the NMA ITT population: adults with unresectable
HCC who are ineligible for CTT
Intervention Comparator
HR (95% CrI), random effects
OS PFS
SIR-Spheres Sorafenib 0.97 (0.73 to 1.26) 1.15 (0.89 to 1.45)
SIR-Spheres Lenvatinib 1.58 (0.40 to 4.21) 1.12 (0.68 to 1.73)
Lenvatinib Sorafenib 0.87 (0.23 to 2.33) 1.07 (0.70 to 1.57)
SD 0.11 (0.004 to 0.352) 0.12 (0.005 to 0.367)
DIC –1.69 2.18
pD 2.4 2.5
pD, number of parameters.
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TABLE 45 Random-effects NMA of all adults with unresectable HCC who are
ineligible for CTT, including studies Biederman et al.39 and Van Der Gucht et al.40
Intervention Comparator OS HR (95% CrI)
SIR-Spheres Sorafenib 1.15 (0.89 to 1.45)
SIR-Spheres Lenvatinib 1.11 (0.68 to 1.73)
TheraSphere SIR-Spheres 0.50 (0.26 to 0.89)
TheraSphere Sorafenib 0.58 (0.29 to 1.06)
TheraSphere Lenvatinib 0.56 (0.24 to 1.13)
Lenvatinib Sorafenib 1.07 (0.70 to 1.57)
TABLE 46 Results of random-effects base-case NMA, excluding the SIRveNIB study
Intervention Comparator
OS HR (95% CrI)
ITT population Per-protocol population
SIR-Spheres Sorafenib 1.16 (0.71 to 1.78) 1.03 (0.63 to 1.61)
SIR-Spheres Lenvatinib 1.13 (0.55 to 2.09) 1.02 (0.49 to 1.88)
Lenvatinib Sorafenib 1.08 (0.65 to 1.71) 1.08 (0.65 to 1.71)
SD 0.15 (0.006 to 0.426) 0.15 (0.006 to 0.426)
DIC 0.92 1.1
pD 2.0 2.0
pD, number of parameters.
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Appendix 14 Quality assessment of
identified economic evidence
TABLE 47 Quality assessment of economic studies: modified Philips checklist88
Assessment criteria
Study
Rostambeigi
et al.91,92
Rognoni
et al.89,90
Structure
1. Is there a clear statement of the decision problem? Yes Yes
2. Is the perspective and scope of the model stated clearly? No Yes
3. Are the model inputs consistent with the stated perspective? N/A Yes
4. Are the outcomes of the model consistent with the perspective, scope and overall
objective of the model?
N/A Yes
5. Are the structural assumptions reasonable given the overall objective, perspective and
scope of the model?
No Yes
6. Is there a clear definition and justification for the alternative options under evaluation? Yes Yes
7. Is the chosen model type appropriate given the decision problem and specified causal
relationships within the model?
No Yes
8. Are the time horizon of the model, the duration of treatment and the duration of
treatment effect described and appropriately justified?
No Yes
9. Do the disease states (state transition model) or the pathways (decision tree model)
reflect the underlying biological process of the disease in question and the impact of
interventions?
No Yes
10. Is the cycle length defined and justified in terms of the natural history of disease? No Yes
Data
11. Are the data identification methods transparent and appropriate given the objectives
of the model?
Yes Yes
12. Has the quality of the data been assessed appropriately? No N/A
13. Is the data modelling methodology based on justifiable statistical and epidemiological
techniques?
Partial Yes
14. Is the choice of baseline data described and justified? N/A Yes
15. Are transition probabilities calculated appropriately? N/A Yes
16. Has a half-cycle correction been applied to both costs and outcomes? N/A No
17. If relative treatment effects have been derived from trial data, have they been
synthesised using appropriate techniques?
No N/A
18. Have the methods and assumptions used to extrapolate short-term results to final
outcomes been documented and justified?
Partial Partial
19. Have alternative assumptions been explored through sensitivity analysis? Partial Yes
20. Have assumptions regarding the continuing effect of treatment once treatment is
complete been documented and justified?
No N/A
continued
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TABLE 47 Quality assessment of economic studies: modified Philips checklist88 (continued )
Assessment criteria
Study
Rostambeigi
et al.91,92
Rognoni
et al.89,90
Costs and discounting
21. Are the costs incorporated into the model described and justified? Yes Yes
22. Has the source for all costs been described? Yes Yes
23. Have discount rates been described and justified given the target decision-maker? N/A Yes
24. Were currency, price date and price adjustments/currency conversion
information stated?
No Yes
HRQoL
25. Are the utilities incorporated into the model appropriate? N/A Yes
26. Is the source for the utility weights referenced? N/A Yes
Validation
27. Has heterogeneity been dealt with by running the model separately for
different subgroups?
Yes N/A
28. Have the results of the model been compared with those of previous models and any
differences in results explained?
No Partial
N/A, not applicable.
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Appendix 15 Model parameters from
submitted economic models
Sirtex model parameters: conventional transarterial therapy-eligible model
TABLE 48 Summary of TACE treatment costs: Sirtex CTT-eligible model
Input Inflated value Source
Scenario 1: CTT cost from literature
Proportion of CTT with DEB-TACE 25% Fateen et al.105
TACE cost £9801.00 Fateen et al.105
DEB-TACE cost £5727.03 Fateen et al.105
CTT cost (literature) £8792.59 Calculated
Scenario 2: CTT resource use from literature, with National Schedule of Reference Costs 2017–2018107
Drug-eluding beads £594.30 Fateen et al.105
TACE length of stay (days) 2.37 Fateen et al.105
DEB-TACE length of stay (days) 2.81 Fateen et al.105
Mean number of TACE procedures 3.03 Fateen et al.105
Mean number of DEB-TACE procedures 1.43 Fateen et al.105
Proportion of CTT with DEB-TACE 25% Fateen et al.105
TACE cost £12,620.41 Calculated
DEB-TACE cost £7911.80 Calculated
CTT cost (reference costs) £11,454.91 Calculated
Scenario 3: CTT resource use from survey, literature with National Schedule of Reference Costs 2017–2018107
Drug-eluding beads £594.30 Fateen et al.105
TACE length of stay (days) 2.37 Fateen et al.105
DEB-TACE length of stay (days) 2.81 Fateen et al.105
Mean number of TACE procedures 2.5 Sirtex resource use survey
(personal communication)
Mean number of DEB-TACE procedures 2.83 Sirtex resource use survey
(personal communication)
Proportion of CTT with DEB-TACE 63% Sirtex resource use survey
(personal communication)
TACE cost £10,412.88 Calculated
DEB-TACE cost £15,676.06 Calculated
CTT cost £13,702.37 Calculated
Adapted with permission from Sirtex Medical Ltd.102
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TABLE 49 Summary of cost of SIRT: Sirtex CTT-eligible model
Parameter
SIR-Spheres TheraSphere
Value Source Value Source
Outpatient costs for code YR57Z £1123.15 National Schedule
of Reference Costs
2017–2018107
£1123.15 National Schedule
of Reference Costs
2017–2018107Inpatient cost/day for YR57Z £1757.45 £1757.45
SIRT £8000.00 Sirtex102 £8000.00 Sirtex102
Survey results
Number of work-ups 1.05 Survey 1.05 Assumed same as
SIR-Spheres
Length of stay for work-up (days) 0.69 0.69
Number of procedures 1.20 1.20
Length of stay for procedure (days) 1.19 1.19
Cost of work-up £1175.56 – £1175.56 –
Cost of procedure £2500.13 – £2500.13 –
Total cost £13,239.33 – £13,239.33 –
Survey results with outpatient procedures
Number of work-ups 1.05 Survey 1.05 Assumed same as
SIR-Spheres
Length of stay for work-up (days) Outpatient Outpatient
Number of procedures 1.20 1.20
Length of stay for procedure (days) Outpatient Outpatient
Cost of work-up £1175.56 – £1175.56 –
Cost of procedure £1342.67 – £1342.67 –
Total cost £12,081.87 – £12,081.87 –
The Christie NHS Foundation Trust results
Number of work-ups Confidential
information has
been removed
The Christie NHS
Foundation Trust
data (personal
communication)
Confidential
information has
been removed
The Christie NHS
Foundation Trust
data (personal
communication)
Length of stay for work-up (days) Confidential
information has
been removed
Confidential
information has
been removed
Number of procedures Confidential
information has
been removed
Confidential
information has
been removed
Length of stay for procedure (days) Confidential
information has
been removed
Confidential
information has
been removed
Cost of work-up Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Cost of procedure Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Total cost Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
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Sirtex model parameters: conventional transarterial therapy-ineligible model
TABLE 49 Summary of cost of SIRT: Sirtex CTT-eligible model (continued )
Parameter
SIR-Spheres TheraSphere
Value Source Value Source
Sangro et al.69 and Salem et al.108 for number of procedures, rest survey
Number of work-ups 1.05 Survey 1.05 Survey
Length of stay for work-up (days) 0.69 Survey 0.69 Survey
Number of procedures 1.08 ENRY reigster69 1.58 PREMIERE108
Length of stay for procedure (days) 1.19 Survey 1.19 Survey
Cost of work-up £1175.56 – £1175.56 –
Cost of procedure £2252.24 – £3298.08 –
Total cost £12,043.19 – £17,089.64 –
Adapted with permission from Sirtex Medical Ltd.102
TABLE 50 Adverse event rates: Sirtex CTT-eligible model
AE
TACE
(n= 19)
TheraSphere
(n= 24) Unit costs Source for unit cost
Abdominal pain 0% 4% £42.19 NICE TA47411 sorafenib technology appraisal
Elevated aspartate
aminotransferase level
11% 0% £634.50 NICE TA55112 lenvatinib technology appraisal
Hypoalbuminemia 0% 4% £634.50 Assumed average of elevated aspartate
aminotransferase and blood bilirubin
Increased blood bilirubin 5% 8% £916.47 NICE TA55112 lenvatinib technology appraisal
Leukopenia 0% 4% £215.00 NICE TA509 pertuzumab185
Neutropenia 11% 0% £2097.50 National Schedule of Reference Costs
2017–2018107 (WJ11Z)
Total costs £346.34 £108.99
Reproduced with permission from Sirtex Medical Ltd.102
TABLE 51 Summary of the base-case utility values: Sirtex CTT-ineligible model
Comparator
Utility value: mean
(standard error) Reference
Pre progression: SIR-Spheres 0.762 (0.078) Post hoc analyses of the SARAH trial19 for the
low tumour burden/ALBI 1 subgroup
Pre progression: sorafenib 0.746 (0.076)
Post progression: SIR-Spheres 0.738 (0.075)
Post progression: sorafenib 0.722 (0.074)
After subsequent treatment with
curative intent
0.762 (0.078) Assumed same as the pre-progression utilities
with SIR-Spheres
Reproduced with permission from Sirtex Medical Ltd.102
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TABLE 52 Assumptions and costs of the SIRT procedure: Sirtex CTT-ineligible model
Cost item Value Source
Outpatient costs for code YR57Z £1123.15 National Schedule of Reference Costs 2017–2018107
Inpatient cost/day for YR57Z £1757.45
SIR-Spheres £8000.00 Sirtex102
Number of work-ups per patient 1.05 Resource use survey
Length of stay for work-up (days) 0.69
Number of treatments per patient 1.20
Length of stay for treatment (days) 1.19
Cost of a single work-up £1175.56 Subtotal
Cost of a single treatment £2500.13 Subtotal
Total cost £13,239.33 –
Reproduced with permission from Sirtex Medical Ltd.102
TABLE 53 Proportions of treatments with curative intent observed in the SARAH trial: Sirtex CTT-ineligible model
Proportions After SIRT After sorafenib
% of liver resection among treatments with curative intent 33.3 0.0
% of liver transplantation among treatments with curative intent 16.7 33.3
% of ablation among treatments with curative intent 58.3 66.7
Reproduced with permission from Sirtex Medical Ltd.102
TABLE 54 Health state costs: Sirtex CTT-ineligible model
Cost item
Pre-progression
post SIRT
(per month)
Pre-progression on
sorafenib/lenvatinib
(per month)
At progression
(one off)
Progressive disease
(per month)
Medical staff contact £102.84 £126.49 £118.50 £222.96
Diagnostic procedures £130.26 £134.58 £89.28 £6.15
Inpatient care £6.80 £20.29 – £78.50
PSS £5.83 £5.83 – £191.76
Total £245.74 £287.19 £207.79 £499.37
Reproduced with permission from Sirtex Medical Ltd.102
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TABLE 55 Adverse event costs: Sirtex CTT-ineligible model
AE Inflated cost Reported costs Costing year Source
Abdominal pain £42.19 £40.15 2014/15 NICE TA47411 sorafenib TA
Alopecia £18.59 £17.69 2014/15 NICE TA47411 sorafenib TA
Anaemia £1319.84 £1283.67 2015/16 NICE TA51413 regorafenib TA
Anorexia £657.86 £639.83 2016/17 NICE TA535154 lenvatinib and
sorafenib
Ascites £1713.98 £1667.00 2015/16 NICE TA51413 regorafenib TA
Aspartate aminotransferase
level increased
£634.50 £617.11 2016/17 NICE TA551124 lenvatinib TA
Asthenia £677.68 £659.11 2016/17 NICE TA551124 lenvatinib TA
Blood bilirubin level increased £916.47 £891.35 2016/17 NICE TA551124 lenvatinib TA
Cardiac failure, congestive £1979.71 £1979.71 2017/18 National Schedule of Reference
Costs 2017–2018:107 weighted-
average HRG codes EB03A
and EB03E
Diarrhoea £605.13 £588.54 2016/17 NICE TA551124 lenvatinib TA
Fatigue £677.68 £659.11 2016/17 NICE TA551124 lenvatinib TA
Gamma-glutamyl transferase
level increased
£634.50 £617.11 2016/17 NICE TA551124 lenvatinib TA
Haematological biological
abnormalities
£1319.84 £1283.67 2015/16 NICE TA51413 regorafenib TA
Haemorrhage £0.00 £0.00 2014/15 NICE TA47411 sorafenib TA
Hand–foot skin reaction £897.98 £873.37 2015/16 NICE TA51413 regorafenib TA
Hypertension £888.12 £863.78 2016/17 NICE TA551124 lenvatinib TA
Hypophosphataemia £1297.52 £1261.96 2015/16 NICE TA51413 regorafenib TA
Liver dysfunction £1713.98 £1667.00 2015/16 NICE TA51413 regorafenib TA
Nausea/vomiting £82.18 £78.20 2014/15 NICE TA47411 sorafenib TA
Other increase in liver
function
£634.50 N/A N/A NICE TA551124 lenvatinib TA
Palmar–plantar
erythrodysesthesia syndrome
£443.80 £431.64 2016/17 NICE TA551124 lenvatinib TA
Platelet count decreased £634.50 £617.11 2016/17 NICE TA551124 lenvatinib TA
Proteinuria £812.04 £789.78 2016/17 NICE TA551124 lenvatinib TA
Rash/desquamation £71.09 £67.65 2014/15 NICE TA47411 sorafenib TA
Weight decreased £665.35 £647.11 2016/17 NICE TA551124 lenvatinib TA
N/A, not applicable; TA, technology appraisal.
Reproduced with permission from Sirtex Medical Ltd.102
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BTG model parameters: conventional transarterial therapy-eligible model
TABLE 56 Summary of per-cycle transition probabilities: BTG CTT-eligible model
Parameter
Per-cycle transition
probability Source
‘Watch and wait’ to pre transplant SIRT = 10.8%
CTT = 5.8%
Lewandowski et al.118
‘Watch and wait’ to pharmacological management SIRT= 7.8%
CTT = 12.8%
Calculation
‘Watch and wait’ to ‘watch and wait’ 81.4% Lewandowski et al.118
Pre transplant to pharmacological management 2.2% National Audit for Liver Transplant
(personal communication)
Pre transplant to post transplant 13.9% NHS Annual Report on Liver
Transplantation 2017/18120
Pre transplant to pre transplant 84.0% Calculation
TABLE 57 Summary of per-cycle mortality parameters: BTG CTT-eligible model
Health state
Mortality rate
(per cycle) Source
Watch and wait 3.88% Assumed the same as pre
transplant
Pre transplant 3.88% NHS England. Schedule 2 – The
Services. A. Service Specifications.
170003/S. Liver Transplantation
service (Adults)186
Pharmacological management 7.74% Derived from the median OS for
BSC from the NICE sorafenib
submission (TA47411)
Post transplant 1 1.39% Bellavance et al.122
Post transplant 2 1.39% Bellavance et al.122
Post transplant 3 1.39% Bellavance et al.122
No HCC (post transplant) 0.29% NHS Survival rates following
transplantation187
Note that one cycle is equal to 4 weeks.
Reproduced with permission from BTG Ltd.103
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TABLE 58 Adverse event rates: BTG CTT-eligible model
AE
Rate (%)
TheraSphere SIR-Spheres
Quirem
Spheres TACE DEB-TACE TAE
Aspartate aminotransferase level increase 0.0 0.0 0.0 0.0 0.0 0.0
Proteinuria 0.0 0.0 0.0 0.0 0.0 0.0
Blood bilirubin level increase 0.0 0.0 0.0 0.0 0.0 16.0
Diarrhoea 0.0 0.0 0.0 0.0 0.0 0.0
Fatigue 1.9 2.3 2.3 0.0 0.0 8.0
Gamma-glutamyl transferase level increase 0.0 0.0 0.0 0.0 0.0 26.0
Hypertension 0.0 0.0 0.0 0.0 0.0 0.0
Weight decrease 0.0 0.0 0.0 0.0 0.0 0.0
Platelet count decrease 0.0 0.0 0.0 0.0 0.0 0.0
Palmar–plantar erythrodysesthesia syndrome 0.0 0.0 0.0 0.0 0.0 0.0
Ascites 6.1 2.3 2.3 0.0 0.0 0.0
Cholecystitis 1.9 5.0 5.0 0.0 1.1 0.0
Hepatic encephalopathy 2.8 8.0 8.0 0.0 0.0 0.0
Post-procedural pain 1.9 1.2 1.2 18.2 0.0 21.0
Reproduced with permission from BTG Ltd.103
TABLE 59 Utility values: BTG CTT-eligible model
Health state Source utility Applied utilitya Source
Watch and wait 0.75 0.534 TA535154 (pre progression)
Pre transplant 0.75 0.534 TA535154 (pre progression)
Post transplant 1 0.69 0.474 Lim et al.125
Post transplant 2 0.69 0.473 Lim et al.125
Post transplant 3 0.69 0.473 Lim et al.125
No HCC post transplant 0.75 0.534 TA535154 (pre progression)
Pharmacological management 0.72 0.499 TA535154 (calculated as an
average of pre-progression
and post-progression utilities)
a Based on the age in the first cycle of the model.
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TABLE 60 Micro-costing of SIRT work-up assessment procedure: BTG CTT-eligible model
Work-up factors: costs included in the BTG analysis Cost
Band 6 technician: 30 minutes (unit cost per hour: £15.96) £7.98
Band 7 clinical scientist: 30 minutes (unit cost per hour: £19.06) £9.53
MAA body SPECTa £353.00
Lung shunt calculation – band 7 clinical scientist: 10 minutes (unit cost per hour: £19.06) £3.18
Volumetary – band 7 clinical scientist: 1 hour (unit cost per hour: £19.06) £19.06
Volumetary band radiologist: 1 hour (unit cost per hour: £75.16) £75.16
Total cost £467.91
Additional costs provided by BTG following the company submission
One radiologist: 2 hours (unit cost per hour: £75.16) £150.30
Two band 6 nurses: 3 hours (unit cost per hour: £23.82) £142.92
One band 6 radiographer: 3 hours (unit cost per hour: £23.82) £71.46
One band 4 co-ordinator: 1 hour (unit cost per hour: £16.30) £16.30
Blood work £11.35
Total cost £860.32
a There is not currently an NHS tariff for a MAA body SPECT. However, it is thought that a sum of the HRG codes
(from the National Tariff Payment System) for the following is suitable for the total cost of a MAA body SPECT:
a whole-body SPECT for one area [RN04A: £147 minus the agent cost (£26) = £121]; a whole-body SPECT for two
areas [£180 minus the agent cost (£22)= £158]; MAA consumable agent (£74).107
Reproduced with permission from BTG Ltd.103
TABLE 61 Unit costs of AEs: BTG CTT-eligible model
Item Unit cost Source
Aspartate aminotransferase
level increase
£615.76 National Schedule of Reference Costs 2017–2018.107 Hospitalisation.
Average non-elective short stay
Proteinuria £657.76 National Schedule of Reference Costs 2017–2018.107 Average non-elective
short stay (for hospitalisation) at £615.76
Plus a nurse visit (GP practice): £42 (PSSRU 2018106 – cost per hour
including qualifications)
Blood bilirubin level
increase
£886.56 National Schedule of Reference Costs 2017–2018.107 Average non-elective
short stay (for hospitalisation) at £615.76
Plus CT scan at £103.95. Weighted average of RD10Z–RD28Z. Adults
only. National Schedule of Reference Costs 2017–2018107
Plus £166.85: outpatient consultant-led, non-admitted face-to-face
attendance, follow up (medical oncology). Code WF01A. National Schedule
of Reference Costs 2017–2018107
Diarrhoea £561.30 National Schedule of Reference Costs 2017–2018107 – FD10K.
Non-Malignant Gastrointestinal Tract Disorders without Interventions,
with CC Score 6–10 – non-elective short stay
Fatigue £657.76 National Schedule of Reference Costs 2017–2018.107 Average non-elective
short stay (for hospitalisation) at £615.76
Plus a nurse visit (GP practice) £42 (PSSRU 2018106 – cost per hour
including qualifications)
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TABLE 61 Unit costs of AEs: BTG CTT-eligible model (continued )
Item Unit cost Source
Gamma-glutamyltransferase
level increase
£615.76 National Schedule of Reference Costs 2017–2018.107 Average non-elective
short stay
Hypertension £856.61 National Schedule of Reference Costs 2017–2018.107 Average non-elective
short stay (for hospitalisation) at £615.76
Plus 2 GP appointments (9.22 minutes) at £37 each (PSSRU 2018106 –
cost per hour including qualifications)
Plus £166.85: outpatient consultant-led, non-admitted face-to-face
attendance, follow up (medical oncology). Code WF01A. National Schedule
of Reference Costs 2017–2018107
Weight decrease £646.76 Hospitalisation: National Schedule of Reference Costs 2017–2018,107
average cost of non-elective short stay (£615.76)
Plus dietitian (PSSRU 2018106) – dietician band 4 cost per working hour (£31)
Platelet count decrease £615.76 National Schedule of Reference Costs 2017–2018.107 Hospitalisation.
Average non-elective short stay
Palmar–plantar
erythrodysesthesia
syndrome
£413.03 National Schedule of Reference Costs 2017–2018107 – JD07J Skin Disorders
without Interventions, with CC score 2–5 – non-elective short stay
Ascites £615.76 National Schedule of Reference Costs 2017–2018.107 Hospitalisation.
Average non-elective short stay
Cholecystitis £507.81 Weighted average of GA07C-E. Intermediate, Hepatobiliary or Pancreatic
Procedures, with CC Score 0–3+
Hepatic encephalopathy £615.76 National Schedule of Reference Costs 2017–2018.107 Hospitalisation.
Average non-elective short stay
Post-procedural pain £615.76 National Schedule of Reference Costs 2017–2018.107 Hospitalisation.
Average non-elective short stay
Adapted with permission from BTG Ltd.103
TABLE 62 Summary of unit costs: BTG CTT-eligible model
Item Unit cost Source
Treatment and aftercare costs
TheraSphere £8000 Clinician informed
QuiremSpheres £8000 Assumed the same as TheraSphere
SIR-Spheres £8000 NICE Medtech Innovation Briefing188
Sorafenib £3576.56 NICE BNF115
BSC £0.00 Assumed
Doxorubicin (loaded on to
DEB-TACE)
£109 Clinician informed
Drug-eluting beads
(DEB-TACE)
£550
Lipiodol (TACE) £250
Bland beads (TAE) £40
Ciclosporin
immunosuppressants
£68.28 NICE BNF115
continued
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TABLE 62 Summary of unit costs: BTG CTT-eligible model (continued )
Item Unit cost Source
Admissions and procedure costs
Hospitalisation (general) £1928 National Schedule of Reference Costs 2017–2018.107 Weighted average of
HRG GC12C–GC12K
Outpatient attendance £167 National Schedule of Reference Costs 2017–2018.107 Consultant-led: first
attendance non-admitted face to face. Code 105 hepatobiliary and
pancreatic surgery
Embolisation procedure £2790 National Schedule of Reference Costs 2017–2018.107 HRG code YR57Z
SIRT work-up £467.91 The Christie NHS Foundation Trust (personal communication)
Liver transplant procedure £17,340 National Schedule of Reference Costs 2017–2018.107 HRG code GA15A
Liver resection procedure £4994 National Schedule of Reference Costs 2017–2018.107 Weighted average of
HRG code GA06
Physician costs
Oncologist £166.85 National Schedule of Reference Costs 2017–2018.107 Code WF01A.
Non-Admitted Face-to-Face Attendance, Follow-up. Medical oncology
Hepatologist £262.40 National Schedule of Reference Costs 2017–2018.107 WF01A Consultant-led,
Non-Admitted Face-to-Face Attendance, Follow-up (hepatology)
Macmillan nurse £42 PSSRU Unit Costs of Health and Social Care 2018.106 Nurse (GP practice).
Cost per hour, including qualifications
Gastroenterologist £146.29 National Schedule of Reference Costs 2016/17.189 WF01A Consultant-led,
Non-Admitted Face-to-Face Attendance, Follow-up (gastroenterology)
Radiologist £152.27 National Schedule of Reference Costs 2016/17.189 WF01A Consultant-led,
Non-Admitted Face-to-Face Attendance, Follow-up (interventional radiology)
Clinical nurse specialist £42 PSSRU Unit Costs of Health and Social Care 2018.106 Nurse (GP practice).
Cost per hour, including qualifications
Palliative care physician/care £42
GP £37 PSSRU Unit Costs of Health and Social Care 2018.106 Cost per 9.22-minute
session, including qualifications
Laboratory tests
Full blood count £2.32 National Schedule of Reference Costs 2017–2018.107 Weighted average of
DAPS03, DAPS05 and DAPS08 (integrated blood services, haematology
and phlebotomy)
Liver function tests £20.07 National Schedule of Reference Costs 2017–2018.107 Weighted average of
DAPS01 and DAPS02
Alpha fetoprotein test £20.07
INR £2.32 National Schedule of Reference Costs 2017–2018.107 Weighted average of
DAPS03, DAPS05 and DAPS08 (integrated blood services, haematology
and phlebotomy)
Biochemistry £1.11 National Schedule of Reference Costs 2017–2018.107 DAPS04 (clinical
biochemistry)
Endoscopy £499.51 National Schedule of Reference Costs 2017–2018.107 FE50A (Wireless
Capsule Endoscopy, 19 years and over). Outpatient procedures
CT scan £103.95 National Schedule of Reference Costs 2017–2018.107 Weighted average of
RD10Z–RD28Z
Adults only
MRI scan £145.56 National Schedule of Reference Costs 2017–2018.107 Weighted average of
all MRI currency codes (adult only, excluding cardiac magnetic resonance
imaging) (RD01A, RD02A, RD03Z, RD04Z, RD05Z, RD06Z and RD07Z)
Ultrasound scan £52.06 National Schedule of Reference Costs 2017–2018.107 HRG codes RD40Z and
RD41Z
Ultrasound scan with duration < 20 mins, weighted average of cost
with/without contrast
Adapted with permission from BTG Ltd.103
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BTG model parameters: conventional transarterial therapy-ineligible model
TABLE 63 Health state costs: BTG CTT-eligible model
Item Cost per cycle
Total watch and wait £539.16
Total pre transplant £577.42
Total post transplant 0–1 £971.71
Total post transplant 1–2 £1049.22
Total post transplant 2–3 £516.42
No HCC post transplant £502.49
Resection £345.07
No HCC other £306.50
Pharmacological management £1308.57
Note that one cycle is equal to 4 weeks.
Reproduced with permission from BTG Ltd.103
TABLE 64 Utility values: BTG CTT-ineligible model
Health state Absolute utility Source Utility decrement
Progression free 0.75 Lenvatinib NICE submission12 0.26
Progressed 0.68 Lenvatinib NICE submission12 0.32
Reproduced with permission from BTG Ltd.103
TABLE 65 Drug acquisition costs: BTG CTT-ineligible model
Item Unit cost Source
Treatment and aftercare costs
TheraSphere £8000.00 Clinician informed
QuiremSpheres £8000.00 Assumed the same as TheraSphere
SIR-Spheres £8000.00 NICE Medtech Innovation Briefing188
Sorafenib £3576.56 NICE BNF115
Lenvatinib £1437.00
Regorafenib £3744.00
BSC £0.00 Assumed
Reproduced with permission from BTG Ltd.103
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TABLE 66 Health state costs and one-off progression costs: BTG CTT-ineligible model
Item Unit cost
Cost per cycle
Progression free Progressed
Physician visits
Oncologist £166.85 £115.51 £58.53
Hepatologist £262.40 £41.18 £121.11
Macmillan nurse £42.00 £19.38 £38.77
Gastroenterologist £146.29 £10.80 £0.00
Radiologist £152.27 £11.24 £0.00
Clinical nurse specialist £42.00 £19.38 £9.69
Palliative care physician/care £42.00 £5.04 £29.08
Laboratory tests
Full blood count £2.32 £1.61 £1.07
Liver function tests £20.07 £6.21 £4.63
Alpha fetoprotein test £20.07 £11.53 £7.04
INR £2.32 £0.72 £0.00
Biochemistry £1.11 £0.51 £0.26
Endoscopy £499.51 £38.04 £0.00
Radiological tests
CT scan £103.95 £23.12 £27.32
MRI scan £145.56 £12.42 £18.81
Hospitalisation
Hospitalisation £1928.00 £130.99 £341.70
Hospital follow-ups
Hepatologist £262.40 £60.55 £262.40
GP £37.00 £51.23 £37.00
Clinical nurse specialist £42.00 £67.85 £42.00
Total cycle costs £627.31 £999.40
Reproduced with permission from BTG Ltd.103
TABLE 67 One-off progression costs: BTG CTT-ineligible model
Resource item Mean cost
Physician visits £0.00
Laboratory tests £82.86
Radiological tests £12.46
Hospitalisation £0.00
Hospital follow-ups £0.00
Total £95.32
Adapted with permission from BTG Ltd.103
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TABLE 68 Treatment-related AE costs: BTG CTT-ineligible model
Intervention Total AE cost
TheraSphere £88.65
SIR-Spheres £111.33
QuiremSpheres £111.33
cTACE £112.07
DEB-TACE £5.59
TAE £483.88
Sorafenib £384.15
Lenvatinib £502.93
Regorafenib £559.69
Reproduced with permission from BTG Ltd.103
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Appendix 16 Model parameters and plots
independent economic assessment
TABLE 69 Proportion of patients downstaged to curative therapy
Population After SIR-Spheres After sorafenib
Base case (whole population)
Liver transplant 1.09% 0.46%
Resection 1.63% 0.00%
Ablation 3.26% 0.92%
Low tumour burden and ALBI 1
Liver transplant 2.25% 0.70%
Resection 4.50% 0.00%
Ablation 7.87% 1.40%
TABLE 70 Adverse event rates
Grade 3/4 AEs (significant/
≥ 5% of patients)
Rate (%)
SIR-Spheres TheraSphere QuiremSpheres Sorafenib Lenvatinib
Abdominal pain 3.0 3.0 3.0 6.0 0.0
Alopecia 0.0 0.0 0.0 0.0 0.0
Anaemia 0.0 0.0 0.0 0.0 0.0
Anorexia 3.0 3.0 3.0 5.0 0.0
Ascites 0.0 0.0 0.0 0.0 0.0
Aspartate aminotransferase level increase 0.0 0.0 0.0 0.0 5.0
Blood bilirubin level increase 4.0 4.0 4.0 4.0 6.5
Cardiac failure, congestive 1.0 1.0 1.0 5.0 0.0
Diarrhoea 1.0 1.0 1.0 14.0 4.2
Fatigue 9.0 9.0 9.0 19.0 3.8
Gamma-glutamyltransferase level increase 0.0 0.0 0.0 0.0 5.5
Haematological biological abnormalities 10.0 10.0 10.0 13.0 0.0
Haemorrhage 0.0 0.0 0.0 0.0 0.0
Hypophosphataemia 0.0 0.0 0.0 0.0 0.0
Hand–foot skin reaction 0.0 0.0 0.0 6.0 2.9
Hypertension 0.0 0.0 0.0 2.0 23.3
Liver dysfunction 8.0 8.0 8.0 13.0 0.0
Nausea/vomiting 0.0 0.0 0.0 0.0 0.0
continued
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TABLE 70 Adverse event rates (continued )
Grade 3/4 AEs (significant/
≥ 5% of patients)
Rate (%)
SIR-Spheres TheraSphere QuiremSpheres Sorafenib Lenvatinib
Other increased liver values 9.0 9.0 9.0 7.0 0.0
Platelet count decreased 0.0 0.0 0.0 0.0 5.5
Proteinuria 1.0 1.0 1.0 4.0 5.7
Rash/desquamation 0.0 0.0 0.0 0.0 0.0
Weight loss 0.0 0.0 0.0 3.0 7.6
Cholecystitis 0.0 0.0 0.0 0.0 0.0
Hepatic encephalopathy 0.0 0.0 0.0 0.0 0.0
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FIGURE 26 Kaplan–Meier plot of OS, for SIR-Spheres and sorafenib, from the pooled SARAH and SIRveNIB data set.
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FIGURE 27 Kaplan–Meier plot of PFS, for SIR-Spheres and sorafenib, from the pooled SARAH and SIRveNIB data set.
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TABLE 71 Summary of observed survival estimates for SIR-Spheres and sorafenib,
from the SARAH and SIRveNIB pooled data set
Survival SIR-Spheres Sorafenib
OS (weeks)
Median (95% CI) 42.86 (39.86 to 51.14) 44.38 (40.68 to 50.82)
Interquartile range 26.43–84.00 21.99–90.96
PFS (weeks)
Median (95% CI) 22.99 (19.00 to 26.77) 20.52 (16.29 to 23.73)
Interquartile range 12.76–41.14 12.09–39.49
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FIGURE 28 Log-cumulative hazard plot of OS, for SIR-Spheres and sorafenib, from the pooled SARAH and SIRveNIB data set.
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FIGURE 29 Log-cumulative hazard plot of PFS, for SIR-Spheres and sorafenib, from the pooled SARAH and SIRveNIB
data set.
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TABLE 72 Akaike information criterion and BIC: OS for SIR-Spheres and sorafenib, from the pooled SARAH and
SIRveNIB data set (survival analysis conducted by the AG)
Model
SIR-Spheres Sorafenib
AIC BIC AIC BIC
Generalised gamma 2343.50 2354.54 3146.87 3158.84
Weibull 2394.10 2401.46 3168.12 3176.10
Exponential 2412.02 2415.70 3173.08 3177.08
Log-logistic 2357.55 2364.91 3144.28 3152.26
Log-normal 2350.14 2357.50 3146.02 3154.00
Gompertz 2412.72 2420.08 3175.06 3183.04
TABLE 73 Akaike information criterion and BIC: PFS for SIR-Spheres and sorafenib, from the pooled SARAH and
SIRveNIB data set
Model
SIR-Spheres Sorafenib
AIC BIC AIC BIC
Generalised gamma 2225.88 2236.91 3120.26 3132.24
Weibull 2312.97 2320.33 3182.16 3190.15
Exponential 2337.34 2341.02 3195.35 3199.34
Log-logistic 2254.74 2262.10 3129.63 3137.61
Log-normal 2245.68 2253.04 3120.23 3128.21
Gompertz 2338.53 2345.89 3197.35 3205.33
TABLE 74 Fit statistics for the survival analyses of SARAH data (conducted by Sirtex)
Model
PFS OS
AIC BIC AIC BIC
Per-protocol population (SARAH19 only)
Log-normal 1881.7 1897.4 2181.2 2196.8
Exponential 1977.8 1985.6 2233.6 2241.4
Weibull 1953.4 1969 2213.8 2229.4
Generalised gamma 1874.7 1898.1 2183.9 2207.3
Gompertz 1976.3 1991.9 2231.3 2246.9
Log-logistic 1895.1 1910.8 2190 2205.6
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TABLE 74 Fit statistics for the survival analyses of SARAH data (conducted by Sirtex) (continued )
Model
PFS OS
AIC BIC AIC BIC
Low tumour burden and ALBI 1 subgroup
Log-normal 386.3 395.4 427.6 436.7
Exponential 394.4 398.9 442.6 447.1
Weibull 393.8 402.9 429.6 438.7
Generalised gamma 389.3 403 431.3 445
Gompertz 397.4 406.5 435.2 444.3
Log-logistic 389.4 398.5 428.4 437.5
No macrovascular invasion subgroup
Log-normal 783.4 795.3 846.2 858.1
Exponential 815.5 821.4 872.6 878.6
Weibull 805.6 817.6 855 866.9
Generalised gamma 786.2 804.1 848.8 866.7
Gompertz 817.1 829 866.8 878.8
Log-logistic 789.5 801.5 848.7 860.6
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FIGURE 30 Extrapolation of OS: low tumour burden and ALBI 1 subgroup – SIR-Spheres.
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FIGURE 31 Extrapolation of OS: no-MVI subgroup – SIR-Spheres.
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FIGURE 32 Extrapolation of OS: low tumour burden and ALBI 1 subgroup – sorafenib.
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FIGURE 33 Extrapolation of OS: no-MVI subgroup – sorafenib.
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FIGURE 34 Extrapolation of PFS: low tumour burden and ALBI 1 subgroup – SIR-Spheres.
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FIGURE 35 Extrapolation of PFS: no-MVI subgroup – SIR-Spheres.
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FIGURE 36 Extrapolation of PFS: low tumour burden and ALBI 1 subgroup – sorafenib.
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FIGURE 37 Extrapolation of PFS: no-MVI subgroup – sorafenib.
TABLE 75 Adverse event unit costs
AE
Unit cost
per episode Source
Abdominal pain £42.19 Sirtex submission102 (inflated from TA47411)
Alopecia £18.59 Sirtex submission102 (inflated from TA47411)
Anaemia £615.76 National Schedule of Reference Costs 2017–2018107
(hospitalisation) (TA535154)
Anorexia £657.86 Sirtex submission102 (inflated from TA535154)
Ascites £615.76 National Schedule of Reference Costs 2017–2018107
(hospitalisation) (TA535154)
Aspartate aminotransferase level increase £634.50 Sirtex submission102 (inflated from TA551124)
Blood bilirubin level increase £916.47 Sirtex submission102 (inflated from TA535154)
Cardiac failure, congestive £1979.71 National Schedule of Reference Costs 2017–2018107
Diarrhoea £605.13 Sirtex submission102 (inflated from TA551124)
Fatigue £677.68 Sirtex submission102 (inflated from TA551124)
Gamma-glutamyltransferase level increase £634.50 Sirtex submission102 (inflated from TA551124)
Haematological biological abnormalities £1713.98 Assumed same as anaemia (TA51413)
Haemorrhage £0.00 Sirtex submission102 (TA47411)
Hypophosphataemia £1297.52 Sirtex submission102 (inflated from TA551124)
Palmar–plantar erythrodysesthesia syndrome £897.98 Sirtex submission102 (inflated from TA535154)
Hypertension £888.12 Sirtex submission102 (inflated from TA551124)
Liver dysfunction £1207.13 Sirtex submission102 (inflated from TA535154)
Nausea/vomiting £82.18 National Schedule of Reference Costs 2017–2018107
(hospitalisation) (TA535154)
Other increased liver values £634.50 Sirtex submission102 (inflated from TA551124)
Platelet count decrease £634.50 Sirtex submission102 (inflated from TA551124)
Proteinuria £812.04 Sirtex submission102 (inflated from TA551124)
Rash/desquamation £71.09 Sirtex submission102 (inflated from TA47411)
Weight loss £665.35 Sirtex submission102 (inflated from TA551124)
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Appendix 17 Confidential information has
been removed
Confidential information has been removed.
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